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Abstract 
Mass spectrometry is a sensitive technique used to detect, identify and 
quantitate molecules based on their mass-to-charge (m/z) ratio in simple and 
complex mixtures. Originally developed almost 100 years ago to measure 
elemental atomic weights and the natural abundance of specific isotopes, MS 
was first used in the biological sciences to trace heavy isotopes through 
biological systems. 
The following PhD project was involved in the application of advanced 
methods of mass spectrometry in Multiple Reaction Monitoring ion mode 
(MRM) into different metabolomics and proteomics research areas. 
For the most part, the studies conducted over the past three years have had 
a single common thread: development and application of MRM mass 
spectrometry methods for the identification and quantification of targeted 
metabolites and/or proteins involved in inflammatory processes. 
It is clear that, for each project, we started from the study of the different 
biological matrices to find the most effective extraction strategy for the target 
analytes and subsequent steps have covered in-depth literature studies to 
identify the best condition to perform chromatographic separation and the 
subsequent optimization of instrumental parameters. 
The three main areas of application explored in these years concerned the 
following three points: 
1. MRM/MS analysis of metabolites 
In collaboration with Prof. Greco, Prof. Auricchio and Prof. Ruoppolo of 
the Department of Translational Medical Sciences and Department of 
Molecular Medicine and Medical Biotechnology of the University of Naples 
Federico II. 
The project provided for the development of a method that allow the 
investigation of the lipidomic profile of genetically predisposed children to 
celiac disease in order to identify potential molecular biomarkers for disease 
prediction, first of all, in genetically predisposed patients but also for subjects 
whose clinical history is unknown. 
Serum samples of two cohorts: 23 children who became coeliac and 23 
not yet (used as control), do share a similar genetic background, since they 
come from families with one celiac proband and bear the specific HLA 
haplotype (DQ2 or DQ8). It does appear that the genetic profile may not 
explain fully the great differences found between the two cohorts. The 
2 
 
developed MRM method allowed to monitor and quantify 83 different classes 
of analytes and allowed us to identify some classes of lipids as putative 
molecular biomarkers by comparing the results obtained from the analysis of 
the samples of serum collected at 4 months, before introduction of gluten, at 
12 months, with the introduction of gluten in the diet of the child and a t> 12 
months for children who have been diagnosed with celiac disease. 
2. MRM/MS analysis of proteins.  
A peculiar feature of a MRM method is the ability to monitor multiple 
precursor ion-product ion transitions. This greatly increase the selectivity and 
specificity of the analysis and this represents a huge advantage in the proteomic 
field because each target analyte, in this case peptide, it can be identified within 
complex mixtures (such as biological fluids) by monitoring transitions closely 
related to its own amino acid sequence. Different biological aspects were 
investigated: 
- The project, in collaboration with Prof. Piccoli and Dr. Arciello of the 
Department of Chemical Sciences of the University of Naples Federico 
II, involved the development and optimization of an MRM method for 
the quantification of proteins involved in inflammatory processes: TNF -
α, INF-γ, IL-8 and IL-10 in THP-I cell samples. In particular, 
differentiated cells have been treated with LPS, a well-known endotoxin, 
to stimulate the onset of an inflammatory process. A time course analysis 
was performed on differentiated and stimulated cells with LPS for 2h, 
4h, 6h, 9h and 24h. 
These analyses allowed to monitor the variation in protein expression 
during the whole inflammatory process, in both acute and late phase of 
the inflammation and the obtained data are consistent with published 
works. Quantitative analysis was conducted using the external standard 
method. In order to increase the selectivity and the specificity of the 
method, for each target protein, two or three peptides have been 
identified thanks to the aid of bioinformatic software which have a 
unique amino acid sequence and can be used as a stoichiometric 
representation of the protein in the quantitative analysis. 
- Project in collaboration with prof. Francisco Blanco and Dr. Cristina 
Ruiz-Romero of the INIBIC Biomedical Research Institute of A Coruña, 
Spain. At this research institute I spent six months for the foreign period 
of the PhD. 
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In these months I have worked on both the optimization of a SIS-
MRM/MS method for the quantification of proteins involved in 
rheumatoid arthritis (RA) pathogenesis and the application of this method 
to a cohort of 80 serum samples of subjects whom RA has been diagnosed. 
Quantitative analysis was performed using the internal standard 
method: stable isotope labelled standard peptides (SIS) were used. The 
target peptides belong to proteins that were statistically significant (p 
<0.05) in previous experiments of 8-plex iTRAQ and large-scale 
proteomics. RA diagnosis is complex and nowadays it is carried out by 
putting together radiographic data, DAS 28 and serum parameters such as 
C-reactive protein, rheumatoid factor (RF) and anti-citrullinated 
antibodies (ACPA) levels. The main problem in diagnostics is incurring 
false positives, as in the case of RF that shows the same trend also in other 
diseases like: chronic hepatitis, chronic viral infections, leukaemia, 
dermatomyositis, mononucleosis, scleroderma, Hashimoto's thyroiditis, 
systemic lupus erythematosus and Sjögren's syndrome. 
First step involved the development of the method, the validation of 
the selected transitions and the choice of the concentration of labelled 
peptides to be added to the real samples to obtain the best signal/noise 
ratio. Reverse calibration curves for each heavy target peptide were 
realized and analytical parameters Detection limit (LOD), Quantification 
limit (LOQ) and linearity range were calculated. 
The developed method was used for the identification and 
quantification of the 10 target proteins in a cohort of 80 samples of sera 
from RA patients subdivided into 4 sub-groups based on rheumatoid factor 
(RF) and anti-citrullinated antibodies (ACPA) values. The four sub-
groups were: RF-/ACPA-, RF-/ACPA+, RF+/ACPA- and RF+/ACPA+. 
Data analysis allowed to select some of the proteins monitored for the 
subsequent steps of method validation by using complementary 
techniques such as ELISA immunoassay. 
3. MRM/MS analysis for discovery. 
 
- An interesting application of mass spectrometry in MRM ion mode was 
in forensic field for the identification of biomarker proteins of biological 
fluids. This project was carried out in collaboration with Ten.Col. Peluso 
of the RIS department of the Carabinieri in Rome. The basic idea was to 
exploit the potential of mass spectrometry in MRM ion mode to identify 
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the nature of biological traces found at a crime scene from which the 
DNA was extracted. In this way it is possible to conduct complementary 
investigations on both the identity of the suspect and the sequence of 
events that lead to the crime. Presumptive and confirmatory tests are 
needed to be absolutely sure of the identity of the biological fluid found 
at a crime scene. These tests suffer from limitations due, above all, to 
poor specificity and to the necessity to conduct cascade tests to evaluate 
the nature of the trace. The developed MRM method allows to overcome 
these limitations as it allows to discriminate between four biological 
matrices: blood, saliva, seminal fluid and urine through a single analysis 
and through a single sample treatment, which involves hydrolysis with 
trypsin, to carry out the extraction DNA and the subsequent proteomic 
analysis.  
 
- Project in collaboration with Prof Nicosia from Department of Molecular 
Medicine and Medical Biotechnologies of the University of Naples 
Federico II for the identification of proteins in HCT116 cells (human 
colorectal tumour cells) deriving from alternative splicing processes and 
which could be closely related to the onset and progression of this type 
of cancer. Previous studies performed on mRNA have shown that such 
alternative splicing phenomena lead to proteins that have a mutated 
sequence to C-ter. This sequence was used for setting up of the MRM / 
MS method thanks to the high specificity and selectivity that derives 
from the use of mass spectrometry in this mode, but above all the high 
sensitivity to which it is possible to arrive (amol/μL). A method was 
developed to identify the presence of 5 mutated proteins using the 
mutated C-ter aminoacidic sequence as molecular target and it was 
possible to verify the presence of these mutated sequences confirming 
the translation of these proteins. 
Finally, for the method validation HT 29 and LS147T cell lines were 
used. The results seem promising, in all the selected cell lines the 
mutated proteins were detected. Further developments concern the 
implementation of the MRM / MS method developed with the use of 
isotopically labelled peptides to validate and perform quantitative 
analysis. 
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Results obtained in the present PhD thesis show the broad applicability of 
the MRM/MS methodology. This strategy was effective both during the 
discovery phase and for the quantitative analysis of metabolites and proteins, 
demonstrating high sensitivity, selectivity and specificity. The chance to 
simultaneously analyse a panel of numerous analytes allows to optimize 
analysis times and costs. 
Finally, the "multiple" ability of this method allows all methods to be 
implemented by inserting the characteristic transitions of heavy isotopically 
labelled standards that have the same chemical and physical properties of the 
target molecules but different m/z ratio. The use of an internal standard is 
fundamental to evaluate the matrix effect, the efficiency of an extraction 
methodology and the identification of an analyte in complex samples. 
Subsequent steps for the presented projects are mainly focused on the 
implementation of the developed MRM methods with isotopically labelled 
standards, the validation of the obtained results by complementary techniques 
(ELISA) and the development of kits that can be used in clinical practice for 
diagnostics or follow-up of patients suffering from various diseases or in 
forensic investigations. 
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Chapter 1 
1.1 Introduction 
1.1.1 Omics and system biology  
‘Omic’ technologies adopt a holistic view of the molecules that make up 
a cell, tissue or organism. They are aimed primarily at the universal detection 
of genes (genomics), mRNA (transcriptomics), proteins (proteomics) and 
metabolites (metabolomics) in different biological compartments such as 
whole blood, plasma and urine. The integration of these techniques is called 
systems biology1.  
Systems biology is based on the understanding that the whole is greater 
than the sum of the parts. It has been responsible for some of the most 
important developments in the science of human health and environmental 
sustainability2. It is a holistic approach to deciphering the complexity of 
biological systems integrating many scientific disciplines – biology, computer 
science, engineering, bioinformatics, physics and others – to predict how these 
systems change over time and under varying conditions, and to develop 
solutions to the world’s most pressing health and environmental issues.  
Components data yield information regarding the specific molecular 
content of the cell or system. Interactions data specify the connectivity that 
exists among the molecular species, thereby defining the network 'scaffold' 
within the cell or system. Finally, functional-states data reveal the overall 
behaviour, or phenotype, of the cell or system 3. 
This ability to design predictive, multiscale models enables our scientists 
to discover new biomarkers for disease, stratify patients based on unique 
genetic profiles, and target drugs and other treatments. Systems biology, 
ultimately, creates the potential for entirely new kinds of exploration, and 
drives constant innovation in biology-based technology and computation.4 
1.1.2 Components data  
Genomics. Genomics is defined as the study of the whole genome 
sequence and the information contained therein. It is clearly the most mature 
of the omics-sciences. Since 1995, nearly 300 genome-sequencing projects, 
with representative species from each of the three kingdoms of life, have been 
completed 5and hundreds more are underway.  
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The genomic sequence is used to study the function of the numerous genes 
(functional genomics), to compare the genes in one organism with those of 
another (comparative genomics), or to generate the 3-D structure of one or 
more proteins from each protein family, thus offering clues to their function 
(structural genomics).  
Genome annotation provide information about human and other major 
model organisms on complement of proteins and functional RNAs, 
transcription-factor-binding sites in genomic sequences and on complete set of 
translated open reading frames (ORFs) and the exon-intron structures from 
which they are assembled.  
Transcriptomics. The transcriptome is the total mRNA in a cell or 
organism and the template for protein synthesis in a process called translation. 
The transcriptome reflects the genes that are actively expressed at any given 
moment (Horgan RP 2011). Microarrays and serial analysis of gene expression 
(SAGE) represent the most well-used approaches and have been applied to 
many model systems, as well as to the study of genes that are predominantly 
expressed in stem cells, to classifying the molecular subtypes of human 
cancers, and to monitoring the host-cell transcriptional response to pathogens 
(Joyce A. R. 2006).  
Proteomics. The proteome is defined as the set of all expressed proteins 
in a cell, tissue or organism. Proteome analysis presents specialized analytical 
problems in two major areas: i) dynamic expression range and ii) diversity of 
protein expression (multiple protein forms). In order to clarify proteome–
phenotype relationships, several studies are dedicated to the development of 
new technology to explain the link between protein-expression profiles and 
distinct cellular processes or conditions6. In particular, one strategy that is 
being developed involves overcoming the problem of detecting only the most 
highly represented proteins in biological samples by focusing on unique 
characteristic peptides for each protein or protein isoform .3 
Metabolomics. The metabolome refers to the complete set of low 
molecular weight compounds in a biological sample. These compounds are the 
substrates and byproducts of enzymatic reactions and have a direct effect on 
the phenotype of the cell. Metabolites are the final products of the genome, 
transcriptome and proteome integration. The metabolome consists of 
molecules that have high chemical and physical heterogeneity. Metabolomics 
is fast becoming a popular tool for studying the cellular state of many systems, 
including plants, the human red blood cell and microbes, as well as in 
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metabolic-engineering applications, in pharmacology and toxicology and in 
human nutritional studies.3  
Lipidomics. Lipidomics is the systems-level analysis of lipids (fat 
molecules) and their interactions. It is a science still in its infancy but one that 
promises to revolutionize biochemistry. Lipids are grouped into eight 
categories that share common physical and chemical properties, and there are 
currently some 38,000 documented lipids7.  
Lipids that occur rarely or in small quantities are often the most effectual 
lipids in biological processes, meaning they are particularly important in 
disease diagnostics and in understanding pathology. Lipidomics can elucidate 
the pathology and treatment of many diseases such as cancer, diabetes, obesity, 
cardiovascular disease, arthritis, asthma, inflammatory bowel disease, 
Alzheimer's and others due to the associated disruption of lipid metabolic 
enzymes and pathways. A better understanding of lipidomics could 
significantly advance diagnostic medicine as well as provide novel treatment 
options8.  
1.2 Mass spectrometry  
Mass spectrometry is a reproducible methodology based on the 
determination of the molecular mass, which is not dependent on the 
experimental conditions. Most important features of mass spectrometry are: 
reproducibility, sensitivity, accuracy.  
Mass spectrometry is based on the production of gas phase ions. These 
ions can interact with an electric field and can be resolved following their 
electro-dynamic attitude, which is dependent on their mass-to-charge ratio.  
Today a wide variety of mass spectrometers is available, all sharing the 
capability to assign mass-to-charge values to ions, although the principles of 
operation and the types of experiments that can be done on these instruments 
differ greatly.  
Mass spectrometers have four essential parts:  
a) system for sample introduction  
b) source that produces gas phase ions from the sample  
c) one or more mass analyser to separate ions  
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d) ion detector.  
 
Sample under investigation is introduced into the ion source of the 
instrument where the sample molecules are ionized. These ions are extracted 
into the analyser region of the mass spectrometer where they are separated 
according to their mass-to-charge ratios (m/z). The separated ions are detected, 
and the generated signals sent to a data system where the m/z ratios are stored 
together with their relative abundance for presentation in the format of an m/z 
spectrum (Fig. 1.1).  
A class of mass spectrometers can be distinguished on its ionization 
system and on the type of analyser, that is an essential component to define the 
accessible mass range, sensitivity and resolution.  
All mass spectrometers are operated at very low pressure to prevent 
collisions of ions with residual gas molecules in the analyser during the flight 
from the ion source to the detector.  
The most widespread ionization methods in biochemical analyses are 
Electrospray Ionization (ESI) and Matrix Assisted Laser Desorption Ionization 
(MALDI). Mass analysers as quadrupoles (Q), ion traps (IT), time-of-flight 
(TOF), or combination of these in “hybrid instruments”, are commonly used 
for their good resolution and sensitivity. TOF analysers are typically used in 
combination with MALDI sources (MALDI-TOF MS instruments). However, 
both MALDI sources and TOF analysers can be used in different 
configuration.  
The coupling of Liquid Chromatography (LC) and tandem Mass 
Spectrometry (MS/MS) is a widely used analytical technique for quantitative 
Figure 1: Working process of a mass spectrometer, from sample 
introduction system to the mass spectrum display. 
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and qualitative analysis. Electrospray Ionization (ESI), Atmospheric Pressure 
Chemical Ionization (APCI), or Photo Ionization (APPI) allow the ionization 
of various semi-volatile, thermally labile, and polar to non-polar compounds, 
such as pharmaceuticals, pesticides, personal care products, steroids, 
explosives, drugs of abuse etc., in trace levels. Generated ions will be 
transferred after ionization through a vacuum interface into the mass analyser.  
1.2.1 Electrospray (ESI)  
Electrospray Ionization (ESI) has had a tremendous impact over the last 
few years on the use of mass spectrometry in biological research. ESI is well 
suited to the analysis of polar molecules ranging from less than 100 Da to more 
than 1,000,000 Da in molecular weight. In contrast to MALDI, in which the 
sample is a dried, crystalline admixture of protein/peptide sample and matrix, 
the peptides or proteins to be analysed by ESI are in aqueous solution. Proteins 
and peptides exist as ions in solution because they contain functional groups 
whose ionization is controlled by the pH of the solution.  
During standard electrospray ionization sample is dissolved in a polar, 
volatile solvent and pumped through a narrow, stainless steel capillary (Fig. 
1.2). A high voltage of 3 or 5 kV is applied to the tip of the capillary situated 
within the ionization source of the mass spectrometer and the sample emerging 
from the tip is dispersed into a spray of highly charged droplets, a process that 
is aided by a co-axially introduced nebulising gas flowing around the outside 
of the capillary.  
 
Figure 2:Diagram of electrospray ionization in positive mode 
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This gas, usually nitrogen, helps to direct the spray emerging from the 
capillary tip towards the mass spectrometer. The charged droplets diminish in 
size by solvent evaporation, assisted by a warm flow of nitrogen known as the 
drying gas which passes across the front of the ionization source. Eventually 
charged sample ions, free from solvent, are released from the droplets, some 
of which pass through a sampling cone or orifice into an intermediate vacuum 
region, and from there through a small orifice into the analyser of the mass 
spectrometer, which is held under high vacuum.  Electrospray is known as a 
“soft” ionization method (such as MALDI) as the sample is ionized by the 
addition or removal of a proton, with very little extra energy remaining to cause 
fragmentation of the sample ions. 
The peculiar aspect of this technique is the fact that it gives rise to multiply 
charged molecular-related ions such as (M+nH)n+ in positive ionization mode 
and (M-nH)n- in negative ionization mode. Because of the form assumed by 
the signal, this source is not useful to the analysis of complex mixtures. For 
this reason, RP-HPLC system is generally coupled to ESI-source. ESI source 
generally works with quadrupole and ion trap analysers.  
1.2.2 Quadrupole (Q) mass analyser  
Quadrupole mass analyser (Figure 3) has now become one of the most 
widely used types of mass analyser because of its ease of use, small size and 
relative low cost. It consists of four parallel rods that have fixed DC and 
alternating RF potentials applied to them. Ions produced in the source of the 
instrument are then focused and passed along the middle of the quadrupoles. 
Their motion will depend on the electric fields so that only ions of a particular 
m/z will be in resonance and thus pass through to the detector following a stable 
trajectory.  
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Figure 3:Quadrupole mass analyzer 
All other ions do not have a stable trajectory through the quadrupole mass 
analyser and will collide with the quadrupole rods, never reaching the detector. 
The RF is varied to bring ions of different m/z into focus on the detector and 
thus build up a mass spectrum.  
1.2.3 Tandem mass spectrometry  
Tandem mass spectrometry (MS/MS) is used to produce structural 
information about a compound by fragmenting specific sample ions inside the 
mass spectrometer and identifying the fragment ions. Tandem mass 
spectrometry also enables specific compounds to be detected in complex 
mixtures because of their characteristic fragmentation patterns. Tandem mass 
spectrometry uses two stages of mass analysis, one to preselect an ion and the 
second to analyse fragments. Generally, in a tandem mass spectrometer the two 
analysers are separated by a collision cell where an inert gas (e.g. argon, xenon) 
collides with the selected sample ions and brings about their fragmentation.  
1.2.4 Instruments for MS/MS analysis  
Instruments for tandem mass spectrometry can be classified as tandem in 
space or tandem in time (Figure 4). Tandem in space means that ion selection, 
ion fragmentation and fragments analysis, are events that occur in three 
different regions of the spectrometer; instruments of this type are the triple 
quadrupole (ESI-QqQ) and hybrid instruments such as ESI-Q-TOF, ESI-
QqLIT or MALDI-TOF-TOF. In tandem in time instruments, those three steps 
of analysis occur in the same region of the spectrometer but in different times; 
three-dimensional ion trap are instruments classified as tandem in time. 
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Figure 4:Schematic representation of tandem-in-space (A) and tandem-in-time (B) 
instruments. 
A commonly used instrument is the triple quadrupole, where two resolving 
quadrupoles mass filters are separated by a fragmentation cell. These are 
considered to be “beam-type” mass spectrometers because they are most often 
used with a continuous ion beam: when one of the mass filters is scanning, 
most of the ions are rejected by the instrument, resulting in poor sample use 
and low sensitivity, whereas when the mass filters are not scanning, but are 
transmitting a pre-selected ion, sensitivity and sample use are very high. 
MSMS mass spectrometer are Quadrupole ion Trap, Linear ion trap and triple 
quadrupole.  
1.2.5 Quadrupole ion trap (IT)  
The quadrupole ion trap is based on the same principle as the quadrupole 
mass filter, except that the quadrupole field is generated within a three-
dimensional trap. The trap consists of three electrodes, a ring electrode and two 
hemispherical end caps electrodes. These electrodes allow to trap ion in a small 
volume (Figure 5).  In IT, ions are dynamically stored in a three-dimensional 
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quadrupole ion storage device. The RF and DC potentials can be scanned to 
eject successive m/z ratios from the trap into the detector.  
 
Figure 5: Graphical representation of a Quadrupole Ion Trap geometry 
The advantages of the ion-trap mass spectrometer include compact size, 
and the ability to trap and accumulate ions to increase the signal-to-noise ratio 
of a measurement. For these reasons, ion traps are used in fragmentation 
experiments. Conventional ion trap mass spectrometers operate with a three-
dimensional (3D) quadrupole field, which confers to the analysis very high 
efficiency as regard the time to fill the ion trap and to generate a complete mass 
spectrum, but presents some problems as regard the trapping efficiencies, 
primarily due to their small volume. Thanks to the introduction of linear ion 
traps, characterized by a greater ion accumulation capacity and greater trapping 
efficiency, these problems have been overcome.  
1.2.6 Linear ion trap (LIT)  
Single quadrupole systems contain only one mass filtering quadrupole 
while triple quadrupole systems consist of three quadrupoles. Q1 and Q3 are 
working as mass filters while Q2 is acting as collision cell.  Quadrupoles can 
be used in scanning or filtering mode. During a mass scan, DC and RF voltages 
are ramped resulting in the acquisition of full scan mass spectra. Such spectra 
are typically used for qualitative data analysis. However, scanning a 
quadrupole suffers from low sensitivity and slow scan speed. Thus, 
quantitative studies are performed with quadrupoles working in filtering mode. 
The most selective mode to use a single quadrupole MS is called Selected Ion 
Monitoring (SIM). Hereby, a fixed set of DC and RF voltages is applied to the 
quadrupole and thus only a single m/z can pass. Ions with different m/z are 
filtered out. A fundamental understanding of the scan modes associated with 
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the TQMS is essential for understanding the MS and MS/MS capabilities of 
the instrument.9.  
Ion trapping can also be performed in linear 2D ion trap devices (LIT) (Le 
Blanc et al., 2003). The combination of triple quadrupole MS with LIT 
technology in a form of an instrument of configuration QqLIT, is particularly 
interesting because this instrument retains the classical triple quadrupole scan 
functions such as selected reaction monitoring (SRM), product ion (PI), neutral 
loss (NL) and precursor ion (PI) while also providing access to sensitive ion 
trap experiments. In addition, for peptide analysis, the enhanced multiply 
charged (EMC) scan allows an increase in selectivity, while the time- delayed 
fragmentation (TDF) scan provides additional structural information. The first 
commercially available instruments (Q-Trap TM) was manufactured by 
SCIEX and made available through the commercial area of Applied 
Biosystem.  
The linear ion trap combines the advantages of a triple quadrupole with 
that of the three-dimensional ion trap guaranteeing very selective scanning of 
precursor ions and high sensitivity. Additional benefits of LITs include 
increased ion storage capacity and improved trapping efficiency. In addition, 
there is no inherent low-mass cut-off in the product ion spectra because 
fragmentation and ion-trapping steps are spatially separated. 
Finally, in using Q3 as LIT it is possible to obtain MSn spectra. Moreover, 
Q3 is operated at a very low pressure (3 * 10-5 Torr) that insures that the ions 
entering the Q3 trap are collisionally cool enhancing and enhancing efficiency 
of MSn. 
Figure 6 summarize the different scan mode in which this instrument can 
operate.  
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Figure 6: Four different scan mode in which a LIT can operate. 
a) In the product or daughter ion scanning the Q1 is used to select user-
specified sample ions arising from a particular analyte; usually the molecular-
related (i.e. (M+H) + or (M-H) -) ions. These chosen ions pass into the q2, are 
bombarded by the gas molecules which cause fragment ions to be formed, and 
these fragment ions are analysed (i.e. separated according to their mass to 
charge ratios) by the Q3. All the fragment ions arise directly from the precursor 
ions specified in the experiment, and thus produce a fingerprint pattern specific 
to the compound under investigation. This type of experiment is particularly 
useful for generating peptide sequence information.  
b) In the precursor or parent ion scanning the Q1 allows the transmission 
of all sample ions, while the Q3 is set to monitor specific fragment ions, which 
are generated by bombardment of the sample ions with the collision gas in the 
q2. This type of experiment is particularly useful for monitoring groups of 
compounds contained within a mixture which fragment to produce 
characteristic fragment ions.  
c) In the constant neutral loss scanning both the Q1 and Q3 scan and 
collect data across the whole m/z range, but the two are off-set so that the 
second analyser allows only those ions which differ by a certain number of 
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mass units (equivalent to a neutral fragment) from the ions transmitted through 
the first analyser. This scan mode is used, for example, to identify 
phosphorylated peptides in a peptide mixture due to the typical fragmentation 
of these peptides consisting in loss of a phosphoric acid residue that correspond 
a mass shift of -98 Da.  
d) Selected Reaction Monitoring (SRM) is the most common mode of 
using a triple quadrupole MS/MS for quantitative analysis, allowing enhanced 
sensitivity and selectivity. The first quadrupole filters a specific precursor ion 
of interest. Ions generated in the ion source having a different m/z can not pass 
Q1. The collision cell is optimized to produce a characteristic product ion by 
collision of the precursor ion with a neutral collision gas, such as nitrogen. 
Generated product ions are transferred into the Q3 where only a specific m/z 
can pass. All other product ions are filtered out in Q3. In SRM mode, two 
stages of mass filtering are employed on a triple quadrupole mass 
spectrometer. In the first stage, an ion of interest (the precursor) is preselected 
in Q1 and induced to fragment by collisional excitation with a neutral gas in a 
pressurized collision cell (Q2). In the second stage, instead of obtaining full 
scan MS/MS where all the possible fragment ions derived from the precursor 
are mass analysed in Q3, only a small number of sequence-specific fragment 
ions (transition ions) are mass analysed in Q3 (Figure 7). 
 
Figure 7:Typical diagram showing the selected reaction monitoring experiment. In this triple 
quad, Q1 and Q3 act like a mass filter whereas Q2 acts as a collision cell for selected peptide 
ion.10 
Thus, SRM mode works like a double mass filter which drastically reduces 
noise and increases selectivity. Single quadrupole and triple quadrupole 
systems allow the detection of many SRM transitions, respectively. This 
enables quantitation of many targeted analytes in a single experiment. 
Typically, additional SRM transitions must be detected to perform 
identification of quantified compounds. Hereby, the most intense ion is called 
the ‘quantifier’ and all additional ions are called ‘qualifiers’.  
Selected reaction monitoring (SRM) coupled with stable isotope dilution 
mass spectrometry (SID-MS) using a triple quadrupole mass spectrometer is a 
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powerful method for quantitative measurement of target molecules. SRM 
methods, in principal, provide both absolute structural specificity for the 
analyte and relative or absolute measurement of analyte concentration when 
stable, isotopically-labelled standards are added to a sample in known 
quantities. When a synthetic, stable isotope labelled peptide is used as an 
internal standard, the concentration can be measured by comparing the signals 
from the exogenous labelled and endogenous unlabelled species. This can be 
done because they have the same physicochemical properties and differ only 
by mass. It has been a principal tool for quantification of small molecules in 
clinical chemistry for number of decades. MS-based quantitative assays have 
the necessary characteristics required for verification studies, namely: high 
specificity, sensitivity, multiplexing capability, and precision.  
1.3 Mass Spectrometry-based omics  
Dramatic technological advances in the biological sciences over the past 
few years have forged a new era of research including the emerging field of 
systems biology. Although the understanding of living organisms at the 
molecular system level is still in its infancy, it is evident that comprehensive 
investigations of the “omics cascade” with genomics, transcriptomics, 
proteomics, and metabolomics are important building blocks and will play a 
central role in this new science11. The integrative analysis of an organism’s 
response to a perturbation on the transcriptome, proteome, and metabolome 
levels will lead to a better understanding of the biochemical and biological 
mechanisms in complex systems.  
Many "omics" techniques have been developed for one goal: identification 
of specific target compounds involved in diagnosis, prognosis, therapeutic 
response prediction and population screening of human disease. For example, 
recent ‘‘omics’’ technologies have opened a new road to biomarker discovery 
and early detection of cancer. A biomarker is a biologically derived molecule 
in the body, which is indicative of the progress or status of a disease.  
Mass spectrometry (MS) is one of the key analytical technology on which 
the emerging ‘‘-omics’’ approaches are based. It may provide detection and 
quantization of thousands of proteins and biologically active metabolites from 
a tissue, body fluid or cell culture working in a ‘‘global’’ or ‘‘targeted’’ 
manner, down to ultra-trace levels. It can be expected that the high 
performance of MS technology, coupled to routine data handling, will soon 
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bring fruit in the request for a better understanding of human diseases, leading 
to new molecular biomarkers, hence affecting drug targets and therapies.  
1.3.1 Mass spectrometry-based metabolomics  
Mass spectrometry-based metabolomics aims at the comprehensive and 
quantitative analysis of wide arrays of metabolites in biological samples 
having very diverse physicochemical properties and occurring at different 
abundance levels.  
Consequently, comprehensive metabolomics investigations are primarily 
a challenge for analytical chemistry and specifically mass spectrometry has 
vast potential as a tool for this type of investigation. Metabolomics require 
special approaches for sample preparation, separation, and mass spectrometric 
analysis. It primarily focuses on metabolic fingerprinting, a technique that 
analyses all detectable analytes in each sample with subsequent classification 
of samples and identification of differentially expressed metabolites, which 
define the sample classes. 
Metabolome refers to the complete set of small-molecule metabolites 
(such as metabolic intermediates, hormones and other signalling molecules, 
and secondary metabolites) to be found within a biological sample, in a high 
dynamic range of concentrations, such as a single organism. Although the 
metabolome can be defined readily enough, it is not currently possible to 
analyse the entire range of metabolites by a single analytical method. Each type 
of cell and tissue has a unique metabolic ‘fingerprint’ that can elucidate organ 
or tissue-specific information, while the study of biofluids can give more 
generalized though less specialized information. Commonly used biofluids are 
urine and plasma, as they can be obtained non-invasively or relatively non-
invasively, respectively.  
A metabolite is usually defined as any molecule less than 1 kDa in size. In 
plant-based metabolomics, it is common to refer to "primary" and "secondary" 
metabolites. A primary metabolite is directly involved in the normal growth, 
development, and reproduction. A secondary metabolite is not directly 
involved in those processes, but usually has important ecological function. 
Examples include antibiotics and pigments. By contrast, in human-based 
metabolomics, it is more common to describe metabolites as being either 
endogenous (produced by the host organism) or exogenous. Metabolites of 
foreign substances such as drugs are termed xeno-metabolites. Global 
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metabolic fingerprinting and quantitative metabolite profiling represent two 
complementary strategies currently applied for metabolomic investigations11. 
In most cases, the first step in a metabolite profiling experiment is to 
extract metabolites from the biological matrix. Extracted metabolites are often 
separated using GC/MS, LC/MS, or CE/MS. Critical to all MS-based 
approaches is the efficient desorption and ionization of metabolites, where the 
resulting gas phase ions can be separated by mass analysers such as 
quadrupole, time-of-flight, and ion trap. Ions are typically detected using a 
microchannel plate and photomultiplier tube and identified through 
comparison of exact mass, retention time, and fragmentation information with 
genuine standards and spectral databases12.  
Nowadays, high throughput LC/SRM/MS allows simultaneous analysis of 
different class of small molecules, metabolites, or drugs in a short time, 
therefore enabling a quantitative profiling of hundreds to thousands of samples 
for target-based metabolite profiling13.  
Among different types of mass spectrometers, a triple quadruple mass 
spectrometer is optimal for targeted metabolomics, based on its high 
sensitivity, high specificity, and excellent quantitation ability. Two stages of 
mass selection reside in a triple quadrupole mass spectrometer: precursor ion 
(MS1) and a fragment of the precursor ion (product ion, MS2) that produce a 
molecular weight and structure specific sensitive measurement for a given 
analyte. The potential power of utilizing a triple quadrupole mass 
spectrometry-based quantitation technique, namely, Selected Reaction 
Monitoring (SRM), for metabolomics has not been fully recognized until 
recently. A triple quadrupole mass spectrometry-based quantitation for small 
molecules has been heavily used by analytical chemists for analysing drug 
metabolites, hormones, pesticides, and herbicides with great precision (CV < 
10%). To further increase selectivity and sensitivity of the triple quadrupole 
mass spectrometry-based quantitation assay, a front-end separation technique, 
such as LC, GC, or CE, is often added as the third dimension of separation. 
While a variety of separation techniques can be used to couple a triple 
quadrupole mass spectrometer, the polarity-based liquid chromatography (LC) 
stands out for its speed, simple sample pre-treatment, and numerous choices of 
types of commercially available columns based on different separation 
mechanisms such as reverse phase, normal phase, or hydrophilic interaction, 
etc14.  
Mass spectrometry-based metabolomics offers quantitative analyses with 
high selectivity and sensitivity and the potential to identify metabolites. 
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Combination with a separation technique reduces the complexity of the mass 
spectra due to metabolite separation in a time dimension, provides isobar 
separation, and delivers additional information on the physicochemical 
properties of the metabolites. However, mass spectrometry-based techniques 
usually require a sample preparation step, which can cause metabolite losses, 
and based on the sample introduction system and the ionization technique used, 
specific metabolite classes may be discriminated. Therefore, parallel 
application of several techniques, for example, GC-MS and LC-MS is desired 
to study the metabolome comprehensively15.  
1.3.2 Mass spectrometry-based proteomics  
Recent successes illustrate the role of mass spectrometry-based 
proteomics as an indispensable tool for molecular and cellular biology and for 
the emerging field of systems biology. Proteomics was defined as the study of 
“the expressed protein complements of a genome at a specific time” by Wilkins 
in 1994. The terms “proteomics” and proteome” mirror the terms “genomics” 
and “genome”. The drivers of genomic and proteomic analyses are the 
technological achievements of the past decade that enable the quantitative 
analysis of the DNA sequence, mRNA and protein expression inside cells and 
include tools such as DNA microarrays, two-dimensional gel electrophoresis 
(2D-GE) and mass spectrometry (MS).  
Nowadays proteomics can rely on powerful analytical protein-separation 
technologies (chromatography, electrophoresis), that serve to simplify 
complex protein mixtures to compare apparent differences in protein levels 
between two samples. However, the most powerful analytical tools for 
proteomic analysis is mass spectrometry (MS), whose instrumentation has 
undergone huge changes over the past years, culminating in the development 
of highly sensitive, robust instruments that can reliably analyse biomolecules, 
particularly proteins and peptides. The introduction of ES and MALDI 
(1980’s), in combination with the accessibility of genome sequence 
information, has revolutionized MS, thus allowing routine MS analysis of 
protein molecules. Two main strategies for protein ID by MS are currently used 
in proteomics: top-down and bottom-up proteomics. In top-down proteomics, 
intact proteins are introduced into a mass spectrometer and then subjected to 
gas-phase fragmentation16.  
However, the purpose to multiply charged product ions has always been a 
weak point of this approach, because it may prevent the determination of 
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product ion masses. With the introduction of the modern mass spectrometers 
with high mass measurement accuracy, this obstacle has been overcome (e.g., 
modern MALDI TOF/TOF instruments). Conversely, in bottom-up 
proteomics, the proteins are firstly separated by gel electrophoresis or 
chromatography, subsequently digested by specific enzymes (e.g., trypsin to 
cut lysine and arginine) and then introduced into the mass spectrometer. 
Bottom-up proteomics approach is represented by peptide mass fingerprinting 
(PMF) and tandem MS analysis. PMF has largely characterized the early years 
of the proteomic era; it relies on the acquisition of mass spectra from a tryptic 
digest of a protein sample and on the measure of tryptic peptide masses 
searched against a protein database such as UniProt, employing different 
database search engines and performing, for each protein, an in silico tryptic 
digest, hence generating a theoretical spectrum. The best overlap between the 
experimental and theoretical mass spectra then identifies the protein.  
The 1D- or 2D-SDS-PAGE-LC-MS/MS based proteomics, often called 
shotgun proteomics, is now the main bottom-up proteomics technological 
approach. The workflow provides the protein separation by 1D-SDSPAGE 
according to MW, followed by in-gel tryptic digestion, peptide analysis by 
nano-LC-MS/MS and protein ID by database searching, as above described17. 
While the application of shotgun proteomics workflows to tissues, cells, and 
organelles usually results appropriate, the analysis of body fluids (e.g., serum, 
blood, plasma, intestinal fluids, urine samples) is particularly difficult because 
of the complexity and of the high dynamic range of contained analytes.  
Recently, LC MS/MS in SRM ion mode has emerged as a promising 
technique for such precise quantification of targeted proteins. Originally 
applied to the measurement of small molecules (such as metabolites or drugs), 
where a capillary chromatography column is connected in-line to the 
electrospray ionization source of the mass spectrometer 18. SRM exploits the 
unique capability of triple quadrupole (QQQ) mass spectrometers to act as 
mass filters and to selectively monitor a specific analyte molecular ion and one 
or several fragment ions generated from the analyte by collisional dissociation. 
The number of such fragment ions that reach the detector is counted over time, 
resulting in a chromatographic trace with retention time and signal intensity as 
coordinates. Several such precursor–fragment ion pairs, termed SRM 
transitions, can be sequentially and repeatedly measured at a periodicity that is 
fast compared to the analyte's chromatographic elution, yielding 
chromatographic peaks for each transition that allow for the concurrent 
quantification of multiple analytes. This multiplexing capability has led to the 
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term multiple reaction monitoring (MRM), which is frequently used as a 
synonym of SRM. When applied to proteomics, SRM measures peptides 
produced by the enzymatic digestion of a proteome as surrogates of the 
corresponding proteins. Molecular ions within a mass range focused around 
the mass of the targeted peptide are selected in the first mass analyser (Q1), 
fragmented at the peptide bonds by collision-activated dissociation (in Q2) and 
one or several of the fragment ions uniquely derived from the targeted peptide 
are measured by the second analyser (Q3). A suitably chosen set of SRM 
transitions therefore constitutes a specific assay to detect and quantify a target 
peptide and, by inference, a target protein in complex samples19.  
The application of SRM to proteomics has been slow and not without 
complications. Proteins are large molecules and by themselves at present are 
not compatible with the technique. The ensuing questions of how many and 
which of the many peptides generated by tryptic digestion of each target 
protein constitute optimal inputs for SRM assays are therefore of critical 
importance. In addition, peptides generally yield more complex fragment-ion 
patterns than metabolites or drugs, thus complicating the choice of appropriate 
SRM transitions18. 
1.3.3 SRM in clinical applications  
The capability of SRM to quantify specific target compounds across a 
variety of samples appears particularly well suited for biomarker verification. 
Candidate biomarkers for their respective disease need to be verified across 
large sample sets to achieve enough statistical power, targeting easily 
accessible human specimens, such as serum or plasma20. Classically, 
biomarker verification relied on antibody-based assays, but recently SRM has 
emerged as an alternative because of its superior multiplexing capabilities of 
50–100 analytes, the shorter and cheaper assay development and the capability 
to discriminate between protein isoforms.  
Numerous examples of the application of SRM for the analysis of low 
molecular weight chemicals with biological relevance exist in the literature and 
these span a broad range of analytes including endogenous compounds, 
therapeutic agents and their metabolites, environmental toxicants and 
compounds of abuse or malicious intent. Recent examples of the use of SRM 
for analysing endogenous compounds in humans include the measurement of 
vitamins, steroids and neurotransmitters, multiple analyses of drugs and their 
metabolites are too numerous to list comprehensively, but include the 
measurement of therapeutic agents, such as warfarin, triazolam, nevirapine and 
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antibiotics, the measurement of drugs of abuse, such as heroin, cocaine and 
cannabinoids and the assay of performance enhancers, such as androgen and 
other stimulants. In addition, SRM has been utilised for the analysis of low 
molecular weight chemicals present in plants, fish and contaminated water 
courses, demonstrating the versatility and breadth of application of the 
technique for the routine quantification of low molecular weight products.21  
Over the last ten years, several studies that applied SRM to protein 
analysis increased exponentially and the subject of such studies is 
progressively shifting from technological advances to biological or biomedical 
applications, a development that attests to the increasing maturity of the 
technology.  A challenge in using SRM for candidate-biomarker verification 
is the required sensitivity for the quantification of low-abundance proteins, 
given a dynamic concentration range of plasma proteins over 12 orders of 
magnitude18. SRM has also been applied to study signalling pathways, for 
example, Wnt/β-catenin signalling, a system of high biological and biomedical 
importance given its deregulation in different types of cancer. Similarly, SRM 
has been used to quantitatively monitor linked to mammalian stem cell renewal 
and pluripotency in nuclear extracts from mouse embryonic stem cell22.  
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Chapter 2 
2.1 SRM method 
2.1.1 Analytical approach  
Targeted metabolomics and proteomics focus on the quantitative 
measurements of a specific subset of known analytes representative of 
biologically relevant processes by LC-MS/MS in Selected Reaction 
Monitoring scan mode. This approach was shown to be a valuable tool to 
identify altered pathways in pathological conditions and/or to define 
therapeutic modes of action.  
Aim of this project was the development of robust and versatile analytical 
procedures for the direct determination and quantification of proteins or 
metabolites in different biological samples.  
The methodological approach developed here are based on different steps: 
1) identification of a set of proteins and metabolites of interest capable of 
satisfying a specific biological or clinic request 2) selection of transitions 
maximizing sensitivity and selectivity 3) optimization of SRM transitions by 
tuning acquisition parameters of the mass spectrometer 4) validation of the 
transitions in biological matrix to account to unspecific contributions of 
fragment ions background 5) quantification by SRM.  
2.1.2 Identification of targeted analytes  
The first step of a targeted experiment is the selection of a set of 
compounds of interest. Depending on the sensitivity and accuracy required, 
hundreds and eventually up to 1000 analytes can be targeted in a single LC-
MS analysis after the transitions have been optimized. The selection of the 
metabolites and proteins set might be based on previous experiments or the 
scientific literature or to make possible in vitro and in vivo studies for specific 
disease.  
In particular, for proteins analyses specific peptides (proteotypic 
peptides)23. that are unique for target protein and easily detectable by mass 
spectrometry should be chosen. The uniqueness of a peptide sequence in a 
proteome can be determined, in principle, from the genomic information, but 
the true complexity of proteomes is generally difficult to predict. The choice 
of peptides with favourable mass spectrometry properties is thus crucial, as it 
determines the sensitivity of the assay. Nowadays, information from prior 
experiments conducted on natural proteomes are available in different database 
26 
 
as, for example, PeptideAtlas24, the Global Proteome Machine Database 
(GPMDB)25, that can be used for identification of peptides that can be 
reproducibly detected and are thus likely associated with the most intense 
signals.  
Numerous software tools for evaluating the best SRM peptides have 
emerged such as Skyline26. Among the parameters critical for predicting 
peptides were hydrophobicity, charge, energetic and structural properties.  
In general, short hydrophilic and long hydrophobic peptides should be 
avoided, whereas fully tryptic peptides with an average length of ~10 amino 
acids, devoid of residues prone to artefactual or post-translational 
modifications should be targeted, like peptide susceptible to undergo 
glycosylation, phosphorylation, etc. might to lead to bias as they can be present 
in various forms27. 
2.1.3 Selection of optimal transitions  
The combination of m/z settings for the first and third quadrupole is 
referred as “transition”, it is important to select transition ions that maximize 
sensitivity and specificity of the SRM experiment. Several in silico methods 
are available, and continue to be refined, which facilitate the choice of the 
transitions. Transitions can be selected from (1) libraries of previously 
collected MS/MS spectra in online repositories, (2) computational tools that 
predict fragmentation, (3) analysis of synthetic peptide standards. Several 
software tools, for facilitating transition selection have been described. The 
current practice is to select two transitions in metabolomic analysis and at least 
two to five most intense transitions per peptides for proteomic investigations.  
Skyline utilizes the ProteoWizard libraries 28to allow analysis of data from 
all MS instrument platforms, thus providing a vendor-neutral resource for 
sharing and creation of both methods and results across instrument platforms. 
Skyline facilitates the generation and refinement of proteomic peptide lists 
from protein sequences or database entries, both by utilizing online MS/MS 
spectral repositories and by supporting the generation of custom-built libraries 
based upon sets of locally acquired tandem spectral data.  
Skyline creates transition lists and vendor-specific instrument methods 
that can be imported directly into instrument control software for MS 
instruments from several vendors. Skyline also provides a platform for 
standardized analysis of SRM result files for peak integration and visualization 
and data quality assessment across multiple analyses. Finally, Skyline allows 
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the export of processed data in custom report formats compatible with 
subsequent statistical analyses, publication, and database deposition29. 
However, there is a physical limit to the number of transitions that can be 
measured in the same analysis. The SRM cycle time is the product of the 
number of transitions recorded in the cycle and the time spent on acquiring 
each transition signal (dwell time). A too long a cycle time, due to too many 
monitored transitions, hence an insufficient number of data points to 
reconstruct the chromatographic elution profile of the targeted peptide, 
compromising accurate quantification. Alternatively, this results in a low dwell 
time and a reduced signal-to-noise ratio, compromising the detection of low-
abundance components. This generates the well-known trade-off between the 
number of transitions and the limit of detection of an SRM experiment30. 
2.1.4 Optimization of SRM transitions  
In order to increase the limit of detection and quantification of the SRM 
assays mass spectrometry parameters that are molecule-dependent (such as 
declustering potential or cone voltage) or transition-dependent (for example, 
collision energy) needs to be optimized.  
In primis, ionization devices and experimental conditions, such as flow 
rate, solvents and background, can influence charge state distributions and the 
process of dissolvation and dissociation of ion clusters supported by a voltage 
potential (referred to as ‘declustering potential' (DP), ‘fragmentor voltage' or 
‘ion transfer capillary offset voltage' depending on the manufacturer) must be 
optimized.  
During fragmentation singly charged y ions are the predominant type of 
fragments generated by CID in a linear collision cell. Only small b ions are 
usually observed. Fragments with m/z values close to the precursor should be 
avoided as such transitions are usually noisy. Fragments with m/z values above 
the precursor generally display the highest selectivity, as the singly charged 
chemical background cannot result in fragments with higher m/z than the 
precursor. In contrast, tryptic peptide ions are predominantly doubly or triply 
charged with one charge at each terminus. Upon fragmentation, one charge is 
lost and therefore a part of the fragments has an m/z value bigger than the 
precursor value. A parameter that is of considerable importance is the collision 
energy, that is tuned to optimize the intensity of the fragment ions of interest: 
with increasing collision energy, a larger part of the precursor ions is 
fragmented, and fragment ion intensity increases until this increase is 
overcompensated by the losses due to secondary fragmentation events. The 
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optimal collision energy is approximately linearly correlated with the 
precursor mass for a given charge state. However, particular peptides or 
fragments deviate considerably from the predicted value.  
The easiest and most systematic way of optimizing ionization and 
fragmentation conditions is to test possible transitions in direct infusion mode 
and ramp the parameters. This process is partly automated by add-ons for the 
acquisition software.  
2.1.5 Validation of the transitions and matrix effect 
Transitions extracted for an SRM assay should be validated by addressing 
the likelihood that the chosen transitions and their intensity distribution are 
associated with the target peptide or metabolite. Each transition selected for a 
specific target should be evaluated in the context of the actual biological matrix 
to account for unspecific contributions of the fragment ions deriving from co-
eluting species with similar properties.  
Plasma is probably the most complex biological matrix, so it is important 
to evaluate the matrix effect that can affect the goodness of the analysis and 
the quality of the result obtained. Whilst this is readily achievable for low 
molecular weight markers, it provides a major challenge when looking for 
proteins or peptides. It has been estimated that human plasma contains proteins 
that span 10 orders of magnitude of concentration and includes resident plasma 
proteins (high and medium abundance) and signalling proteins such as 
hormones and cytokines (low abundance).  
Specifically, the matrix affects not only ion suppression, a major pitfall 
for the analyst, but also detection capability, repeatability and accuracy.  
The mechanism of the matrix effect in LC–MS, well described by Trufelli 
et al.201131, is not fully understood. One of the most important aspects is 
competition between an analyte and a co-eluting matrix component during 
ionization. As a result, there is a decrease in analyte ionization (ion 
suppression) or an increase in this ionization (ion enhancement). The matrix 
effect depends strongly on the type of ionization source. In ESI droplets are 
produced and a greater number of additives (from eluents or sample matrices) 
may lower evaporation efficiency and the ability of analytes to reach the gas 
phase.  
Reactions in the electrospray source depend on the properties of solvents 
and additives (like volatility, viscosity, pH or electrolyte concentration), the 
physicochemical properties of analytes (pKa, hydrophobicity, proton affinity 
or ion solvation energy) and the operating parameters of LC–MS instruments 
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(flow rate, temperature and voltage). Hence, all these variables make ionization 
a highly complex and changeable process. Furthermore, co-eluting 
components may produce similar ions in MS or MS/MS experiments, which 
leads to the erroneous interpretation of results, especially when these 
components are present at high concentrations in the extract and eluted in the 
same retention window as the target compounds.  
Several strategies have been put forward to eliminate the problems 
resulting from matrix 32,33. The most effective of them is exhaustive sample 
clean-up used immunoaffinity depletion of highly abundant plasma proteins in 
combination with peptide fractionation by strong- or mixed-mode cation 
exchange chromatography, which can help to remove interferents, and 
improves the LOQs to 1–10 ng ml− but it does run the risk of analyte loss. The 
second strategy is to improve chromatographic separation. This allows the 
analytes to be eluted in an appropriate period of time, in order to avoid co-
elution with matrix components. A third approach is to dilute the final extract 
several times so that fewer matrix components will be injected into the 
analytical system  
The matrix effect can be compensated for with appropriate calibration 
methods, firstly, by using calibration standards in pure solvents, and secondly, 
by using standards in the matrix 33. 
Finally, the standard-addition method is a much cheaper and useful 
approach when no blank matrix is available for the calibration. A known 
amount of analyte (spike) is introduced into aliquots of sample extracts 
containing the target compound, so that any co-extracted impurity is accounted 
for in the calibration; however, the volume of standard added must be small 
enough to prevent sample extract dilution. By using this methodology, the 
unknown concentration initially present in the sample can be calculated by 
extrapolation.  
At this point, for each analyte the recovery value (%) is estimated by 
measuring the concentration of analyte added to real samples (spiked samples) 
according to the following formula: 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) =
𝑐1 − 𝑐2
𝑐3
× 100  
Where: 
C1: analyte concentration measured after the addition  
C2: analyte concentration measured before the addition  
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C3: added concentration  
2.1.6 Quantification by SRM  
SRM-based quantification can be coupled to different strategies for 
relative or absolute protein quantification.  
The aim of relative quantification is to express the amount of a targeted 
compound in one state or sample relative to that of a second state or sample. 
Approaches to relative quantification that can be coupled to SRM include 
label-free or stable isotope–labelling methods. Isotope-labelling methods 
introduce stable isotope tags to proteins or peptides and rely on the 
concomitant mass spectrometry measurement of heavy and light or differently 
labelled peptides as an internal standardization, thus correcting for 
experimental and instrumental variability, downstream of the label-mixing 
step. Label-free approaches34 rely on the direct evaluation of mass 
spectrometry signal intensities of naturally occurring peptides contained in a 
sample. Although in principle each of these quantification methods can be 
coupled to SRM analysis to be noted that methods based on chemically added 
tags normally change peptide-fragmentation patterns as well as the precursor-
ion mass. In such cases, new SRM assays should be developed that are specific 
for the labelled peptides. In contrast, labels that conserve the chemical structure 
of peptides, such as metabolic labelling, also conserve their fragmentation 
patterns and thus the relative transition signal intensities. One can thus easily 
derive the assays for the heavy form of a peptide from the fragment-ion 
spectrum of the light peptide and the knowledge of the site and type of 
incorporation of the heavy label. A drawback of label-based methods is the 
introduction of additional sample-processing steps. An intermediate solution 
between the high precision of label-based approaches and the simplicity of 
label-free methods is the use of a single labelled peptide as a reference standard 
for all other measured endogenous peptides 35.  
The gold standard for absolute quantification is stable-isotope dilution. 
The most commonly used approach relies on isotopically labelled reference 
peptides that are chemically identical to the light native peptides (AQUA 
peptides) 36. The analytical precision of this method is high and can result in 
up to 5% errors in the estimation of the amount of peptide originally loaded 
onto the liquid chromatography system. However, issues such as incomplete 
digestion of the target protein, partial artefactual modification of the target 
peptide or partial loss of the synthetic peptide before addition can affect the 
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accuracy of this approach. For such reasons, the absolute quantification 
method is sometimes referred to as 'precise relative quantification18.  
In our SRM experiment, quantification was carried out by the external 
standard method with the realization of calibration curves, considering that 
areas subtended to peaks, for each transition, are proportional to concentration. 
The area under this curve is the extracted ion current (XIC) of a specific 
transition. XICs of peptides of interest are extracted from the original data file. 
Filters are used to correct baselines or to remove artefactual spikes. XICs are 
then smoothed with an average filter before performing a closing and an 
opening mathematical morphology operation with a small flat structuring 
element. The closing operation eliminates thin valleys and conserves the 
intensity of local maxima, while the opening operation eliminates thin peaks 
(i.e. remaining spikes) and conserves the intensity of local minima. Hence, 
detection of peak positions is performed on the closed profile, and the opened 
profile is used to eliminate remaining spikes. The peak boundaries are searched 
on the closed profile, and the peak area (i.e. the quantification value) is 
computed.  
Another important and critical procedure in protein quantification is data 
normalization. Linearity determines the highest measurable concentration 
within the specified conditions. The lower limit of detection (LLOD, often 
referred to as LOD) and the LOQ are defined, respectively, as the 
concentration level at which the analyte can be reliably detected in the sample 
under consideration and as the level at which the analyte can be detected and 
measured with enough precision. Several methods are used to determine LOD 
and LOQ 23,37,38. The simplest one consists in calculating LOD and LOQ for a 
given analyte as the amount of this analyte providing a signal corresponding 
to the mean value of repeated blank sample measurements +3 and +10 standard 
deviations, respectively.  
These strategies are simple and cost-effective and have demonstrated high 
reproducibility and linearity. 
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Chapter 3 
3.1 Introduction 
Lipidomics is the study of the structure and function of the whole set of 
lipids (the lipidome) produced in a given organism as well as their interactions 
with other lipids, proteins and metabolites. 
The importance in the study of lipidome lies in the many vital activities 
carried out within biological systems. Lipids act as: 
- an energy reservoir, 
- the major structural components of biological membranes (plasma 
membranes, membranes of intracellular organelles), 
- lipid transporters1, 
- chemical messengers in signal transduction, 
- interact with proteins to regulate their functions2, 
- important bioactive molecules in the body’s immune system against 
viral and bacterial infections3.  
In 2005, the LIPID MAPS consortium, the International Lipid 
Classification, and National Nomenclature Committee grouped lipids into 
eight categories based on lipids' chemical and biochemical properties: fatty 
acyls (FA), glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, 
prenol lipids, saccharolipids, and polyketides4. Lipids categories are further 
divided into subclasses that have diverse structural and chemical properties5. 
Lipidomics has experienced rapid progress, mainly because of 
continuous technical advances in instrumentation that are now enabling 
quantitative lipid analyses with an unprecedented level of sensitivity and 
precision. The still-growing category of lipids includes a broad diversity of 
chemical structures with a wide range of physicochemical properties6. 
Diet, genetic and disease context can alter levels of concentration and 
lipid composition in plasma. Plasma lipids are carried by lipoproteins in the 
body's circulation and changes in the number of lipoproteins, lipid 
composition and concentration, or a defect in lipid exchange among 
lipoproteins, reflect the functionality of lipoproteins and manifest signs of 
metabolic diseases. 
Numerous studies demonstrated the lipidome of lipoproteins is altered 
during disease development, like other metabolomic parameters7. As an 
example, 27-hydroxycholesterol a cholesterol metabolite, promotes 
atherosclerosis via estrogen receptor alpha-mediated pro-inflammatory 
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events. Plasma 27-hydroxycholesterol is the most commonly found oxysterol 
in human plasma and it increases with hypercholesterolemia and its level is 
also correlated with coronary artery disease.8 
3.1.1 Phospholipids and Phosphatidylcholine 
Phospholipids are the most abundant class of membrane lipids. They are 
amphipathic molecules with the apolar part (consisting of two saturated or 
unsaturated fatty acids with 16 or 18 C atoms), linked to glycerol and the 
polar part (consisting of the phosphate group, esterified with the choline, the 
ethanolamine, the serine or inositol) also linked to glycerol (Figure 1 and 
Figure 2). When many phospholipids line up, they form a double layer that is 
characteristic of all cell membranes. 
 
Figure 8: Schematization of a phospholipid structure. 
 
In addition to the structural function, as the main constituents of the 
plasma membrane, phospholipids are organized to form a semipermeable 
barrier which can be freely passed through fat-soluble molecules but is 
impenetrable from those that are water-soluble. Moreover, they develop an 
important metabolic function being a source of lipid mediators that can be 
mobilized in response to specific stimuli9. 
37 
 
Additionally, they are found in lung and joints, where they help lubricate 
cells. In pharmaceuticals, phospholipids are used as part of drug delivery 
systems, that promote the drug transport throughout the body to the area that 
it is meant to affect. Valium is an example of a medication that uses a 
phospholipid-based drug delivery system10.  In the food industry, 
phospholipids can act as emulsifiers, are found in high concentrations in many 
other animal and plant sources, such as soybeans, sunflowers, cotton seeds, 
corn, and even cow brains 11,12. 
3.1.2 Phosphatidylcholine biosyntesis 
Phosphatidylcholines are the most abundant phospholipids in animal 
tissues and typically contain palmitic, stearic, oleic, linoleic, or arachidonic 
acid. They usually have saturated fatty acids in the sn-1 position and 
unsaturated fatty acids at sn-2. 
The de novo pathways13 for phospholipid synthesis use cytidine 
triphosphate (CTP) for activation of intermediate species. The principle 
pathway (Figure 2) of phosphatidylcholine biosynthesis uses cytidine 
diphosphate (CDP-choline)14. Many reactions of phospholipid synthesis 
occur in the endoplasmic reticulum. Choline is phosphorylated by ATP to 
phosphocholine, which reacts with CTP to form CDP-choline, from which 
phosphocholine is transferred to sn-1,2-diacylglycerol. The rate-limiting step 
in this pathway is catalyzed by CTP phosphocholine cytidylyltransferase, 
which is activated by fatty acids.  
PC can also be generated endogenously in a second pathway via three 
sequential methylations of PE by phosphatidylethanolamine N-
methyltransferase (PEMT)15. The PEMT pathway is quantitatively significant 
only in the liver where it contributes approximately 30% of total hepatic PC 
synthesis15,16. Subcellular fractionation revealed that both PEMT and the final 
enzyme of the CDP-choline pathway16 reside on the endoplasmic reticulum 
(ER), underscoring the importance of this organelle in PC biosynthesis. 
Phosphatidylcholine is degraded by phospholipases that cleave 
preferentially at specific bonds. The choline released is phosphorylated by 
choline kinase and reutilized in phosphatidylcholine synthesis. However, in 
liver mitochondria, choline is also oxidized to betaine (N-trimethylglycine). 
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Figure 2: Main pathway for phosphatidylcholine in animals and plants. 
3.1.3 Celiac Disease 
Coeliac disease (CD) may be considered the most common chronic 
inflammatory condition since the estimated prevalence in Western Countries 
is near to one per cent17. CD is an autoimmune enteropathy caused by an 
abnormal immune response to dietary gluten that occurs in genetically 
susceptible individuals18.  
For the great majority of human beings, cereals represent an important 
source of nutrients, whereas for CD patients’ certain cereal products represent 
poisons that not only destroy small intestinal mucosa, as reported in Figure 
319, but also predispose to gastrointestinal malignancy20.  
 
 
 
 
 
 
 
 
These products constitute the storage protein fraction of the endosperm 
of the grains which, in the wheat, is classified into four classes depending on 
their solubility: albumins that are soluble in water, globulins soluble in salt 
solution, gliadins soluble in alcohol solution and glutenins insoluble in neutral 
aqueous or saline solution and ethanol.  
Gluten, which is provided by both gliadins and glutenins, is the product 
of a ball of wheat flour dough that has been exhaustively washed in tap water, 
Figure 3: Degeneration of intestinal villi. Normal villi were represented 
in the picture on the left and CD villi on the right. 
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and the baking qualities of the wheat depends on its ability to trap carbon 
dioxide in dough. 
The gluten peptides and the related prolamins are responsible for 
triggering mucosal lesions in CD patients21. Despite the recent progresses in 
understanding the molecular mechanisms of mucosal lesions, it remains 
unknown how increased amounts of gluten peptides can enter the intestinal 
mucosa to initiate the inflammatory cascade. Current knowledge indicates 
that different gluten peptides are involved in the disease processes as both 
‘toxic’ and ‘immunogenic’. The peptides defined as ‘toxic’ are able to induce 
mucosal damage either when added in culture to duodenal endoscopic biopsy 
or when administered in vivo, while those defined as ‘immunogenic’ are able 
to specifically stimulate HLA-DQ2- or DQ8-restricted T cell clones isolated 
from jejunal mucosa or peripheral blood of coeliac patients. These peptides 
can trigger two immunological pathways: one is thought to be a rapid effect 
on the epithelium that involves the innate immune response and the other 
represents the adaptive immune response involving CD4+ T cells in the 
lamina propria that recognize gluten epitopes processed and presented by 
antigen presenting cells. 
3.1.4 Aim of the study 
Celiac disease is a chronic inflammation of the small intestine. In 
presence of an inflammatory stimulus, enzymes belonging to the 
phospholipase class release arachidonic acid from membrane phospholipids 
such as: phosphatidylethanolamines (PE), phosphatidylcholines (PC), 
phosphatidylinositol (PI), phosphatidylserine (PS), phosphstidylglycerol 
(PG)(Figure 4)22. Arachidonic acid is the main precursor of eicosanoids, 
substances involved in the inflammatory response of the organism. 
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Figure 4: Structure of different classes of phospholipids: phosphatidylethanolamines 
(PE), phosphstidylglycerol (PG), phosphatidic acid (PA), phosphatidylserine (PS). 
The diagnosis of celiac disease is often delayed in time and it may take 
several months or years for the patient and the health care professional to 
think of it as the cause of many non-specific symptoms. History and physical 
examination may give direction as to the diagnosis. 
When the diagnosis is suspected, there is a two-step screening process to 
make the diagnosis. First a blood test for immunoglobulin A anti-tissue 
transglutaminase antibody (IgA TTG). Testing for antiendomysial antibody 
may also be considered. If the screening blood test is positive, then endoscopy 
and biopsy of the lining of the duodenum is requested. 
The aim of this project concerns the development and optimization of a 
simple method, based on mass spectrometry in Multiple Reaction Monitoring 
(MRM) ion mode to quantify 83 phospholipids in sera samples. 
In collaboration with Prof. L. Greco and R. Auricchio, from Dipartimento 
di Scienze Mediche Traslazionali from Federico II University of Naples, and 
Professor M. Ruoppolo from CEINGE of Naples the optimized method has 
been applied to sera from 23 CD children and 23 CTRL children. 
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In particular, it was explored the serum phospholipid profile of children 
at risk for celiac disease from the 4th month of life to look for a specific lipid 
profile that may predict the onset of celiac disease before the 6 years of age. 
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3.2 Material and Methods 
3.2.1 Material 
Chemials and reagents 
D-α-phosphatidylcholine, dipalmitoyl; L-α- phosphatidylethanolamine, 
dioleoyl were purchased from Avanti Polar Lipids. 
Acetonitrile (ACN) and methanol (MeOH) were purchased from Sigma-
Aldrich. Acetic acid (AcA) was purchased from Baker. Ammonium acetate 
(AA) was purchased from Carlo Erba. 
Samples cohorts 
This study was carried out in collaboration with Prof. Luigi Greco and 
Renata Auricchio from Dipartimento di Scienze mediche traslazionali of 
University of Naples Federico II. 
Frozen Serum samples from: 
23 Children, at risk for celiac disease, who became celiac (CD), sampled 
at 4, 12 and > 24months 
23 Children, at risk for celiac disease, who did not become celiac 
(CTRL), sampled at 4 and 12 months. 
All children were gradually introduced to gluten from the 6th months of 
life. None had received gluten at 4 months.  
3.2.2 Methods 
Extraction 
Aliquots of 100 µL human serum were diluted to 990 µL in 
chloroform/MeOH 17:1 v/v for metabolites extraction. After sonication the 
samples were centrifugated for 5 min at 13000 rpm. Once all the liquid phase 
has been removed, the pellets were diluted to 990 µL of chloroform/MeOH 
2:1 v/v and centrifugated for 10 min at 13000 rpm. The supernatant was 
recovered and stored at -20 ° C until the LC-MRM/MS analysis. 
Liquid chromatography and MRM mass spectrometry method set up 
The samples were analysed by liquid chromatography (Eksigent 
expressHT ultra, HPLC) coupled to electrospray ionization on an AB sciex 
QTrap 4000, operating with Analyst 1.6.2 (AB SCIEX). Chromatographic 
separation was achieved on a Halo C18 1.0 mm x 50 mm, 2.7 µm column 
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using a flow rate of 40 µL/min at 40 °C during 12 min gradient (0 min 70% 
A, 2min 50% A, 9min 5% A, 11 min 50% A, 12 min 70% A). 
5 µL of the extract was injected and each sample was analyzed twice. 
The auto sampler was cooled at 4 °C. Solvent composition was 
ACN/MeOH/AcA 97:2:1 v/v/v with AA 5mM for solvent A; and MeoH/AcA 
99:1 v/v with AA 5mM for solvent B.  The mass analysis was performed in 
both positive (ESI+) and negative (ESI-) mode. 
For each phospholipids compound, precursor ions, product ions and 
optimal collision energies were established for each MRM transition using 
the Analyst software. The instrument was operated with the following 
settings: CUR 20, CAD 5, IS 4500, TEMP 380, GS1 25, GS2 24. Two 
methods were set up to investigate the presence of different classes of 
phospholipids the first able to work in positive polarity and the second one in 
negative. Table 1 and 2 collected the instrumental parameters used to set up 
the two MRM/MS methods for the identification and quantitation of 83 target 
molecules.  
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Table 1: Parameters to set up the MRM Method 1 for the identification of LPC and PC 
phospholipid classes. The best transitions and Declustering Potential (DP), Collision Energy 
(CE) and Ectraction Potential (CXP) are reported. 
ANALYTES Q1 Q3 DP CE CXP 
LPC22:1 592,4 184,1 40 47 9 
LPC22:0 594,4 184,1 40 47 9 
LPC24:1 620,4 184,1 40 47 9 
LPC24:0 622,4 184,1 40 47 9 
LPC26:1 648,5 184,1 40 47 9 
LPC26:0 650,5 184,1 40 47 9 
PC28:2 674,5 184,1 40 47 9 
PC28:1 676,5 184,1 40 47 9 
PC28:0 678,5 184,1 40 47 9 
PC30:2 702,5 184,1 40 47 9 
PC30:1 704,5 184,1 40 47 9 
PC30:0 706,5 184,1 40 47 9 
PC32:2 730,5 184,1 40 47 9 
PC32:1 732,6 184,1 40 47 9 
PC32:0 734,6 184,1 40 47 9 
PC34:2 758,6 184,1 40 47 9 
PC34:1 760,6 184,1 40 47 9 
PC36:2 786,6 184,1 40 47 9 
PC36:1 788,6 184,1 40 47 9 
PC36:0 790,6 184,1 40 47 9 
PC40:4 838,6 184,1 40 47 9 
PC42:5 850,6 184,1 40 47 9 
PC(O-36:0) 776,6 184,1 40 47 9 
PC(O-38:3) 798,6 184,1 40 47 9 
PC(O-38:0) 804,6 184,1 40 47 9 
PC(O-40:6) 820,6 184,1 40 47 9 
PC(O-40:5) 822,6 184,1 40 47 9 
PC(O-40:1) 830,7 184,1 40 47 9 
PC(O-42:5) 864,6 184,1 40 47 9 
PC(O-42:3) 854,6 184,1 40 47 9 
PC(O-42:0) 860,7 184,1 40 47 9 
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Table 2: Parameters to set up the MRM Method 1 for the identification of PA, PE, PG, 
PS and PI phospholipid classes. The best transitions and Declustering Potential (DP), 
Collision Energy (CE) and Extraction Potential (CXP) are reported. 
ANALYTES Q1 Q3 DP CE CXP 
PA 28:1 
597,4 171,1 -180 -50 -13 
597,4 199,2 -180 -50 -13 
597,4 253,2 -180 -50 -13 
597,4 281,2 -180 -50 -13 
PA 28:0 
590,4 171,1 -180 -50 -13 
590,4 199,2 -180 -50 -13 
590,4 255,2 -180 -50 -13 
590,4 283,2 -180 -50 -13 
PA 30:1 
616,4 227,2 -180 -50 -13 
616,4 253,2 -180 -50 -13 
PA 30:0 
618,4 199,2 -180 -50 -13 
618,4 227,2 -180 -50 -13 
618,4 255,2 -180 -50 -13 
618,4 283,2 -180 -50 -13 
PA 32:2 642,4 253,2 -180 -50 -13 
PA 32:1 
644,4 227,2 -180 -50 -13 
644,4 253,2 -180 -50 -13 
644,4 281,3 -180 -50 -13 
PA 32:0 646,4 255,2 -180 -50 -13 
PA 34:2 
670,5 253,2 -180 -50 -13 
670,5 281,3 -180 -50 -13 
PA 34:1 
672,5 253,2 -180 -50 -13 
672,5 283,3 -180 -50 -13 
672,5 281,3 -180 -50 -13 
672,5 255,2 -180 -50 -13 
PA 36:2 698,5 281,3 -180 -50 -13 
PA 36:1 
700,5 281,3 -180 -50 -13 
700,5 283,3 -180 -50 -13 
PE 28:1 
631,4 199,2 -160 -48 -11 
631,4 253,2 -160 -48 -11 
PE 28:0 633,4 199,2 -160 -48 -11 
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633,4 255,5 -160 -48 -11 
PE 30:2 
657,5 225,2 -160 -48 -11 
657,5 253,2 -160 -48 -11 
PE 30:1 
659,5 199,2 -160 -48 -11 
659,5 227,2 -160 -48 -11 
659,5 253,2 -160 -48 -11 
659,5 281,3 -160 -48 -11 
PE 30:0 
661,5 199,2 -160 -48 -11 
661,5 227,2 -160 -48 -11 
661,5 255,2 -160 -48 -11 
661,5 283,2 -160 -48 -11 
PE 32:2 685,5 253,3 -160 -48 -11 
PE 32:1 
687,5 227,2 -160 -48 -11 
687,5 281,3 -160 -48 -11 
687,5 255,2 -160 -48 -11 
687,5 253,2 -160 -48 -11 
PE 34:2 
713,5 253,2 -160 -48 -11 
713,5 281,3 -160 -48 -11 
PE 34:1 
715,5 255,2 -160 -48 -11 
715,5 281,3 -160 -48 -11 
PE 36:2 741,5 281,3 -160 -48 -11 
PE 36:1 
743,5 281,3 -160 -48 -11 
743,5 283,3 -160 -48 -11 
PG 32:2 716,5 253,2 -130 -48 -11 
PG 32:1 
718,5 253,2 -130 -48 -11 
718,5 255,2 -130 -48 -11 
PG 34:2 
744,5 253,2 -130 -48 -11 
744,5 281,3 -130 -48 -11 
PG 34:1 
746,6 255,2 -130 -48 -11 
746,6 281,3 -130 -48 -11 
PS 32:3 729,5 253,2 -90 -60 -33 
PS 32:1 
731,5 227,2 -90 -60 -33 
731,5 253,2 -90 -60 -33 
731,5 255,2 -90 -60 -33 
731,5 281,3 -90 -60 -33 
PS 32:0 733,5 255,2 -90 -60 -33 
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PS 34:2 
757,6 253,2 -90 -60 -33 
757,6 281,3 -90 -60 -33 
757,6 255,2 -90 -60 -33 
PS 34:1 
759,6 255,2 -90 -60 -33 
759,6 281,3 -90 -60 -33 
PS 32:2 785,6 281,3 -90 -60 -33 
PS 36:0 789,6 283,3 -90 -60 -33 
PI 26:1 
722,5 171,1 -85 -62 -10 
722,5 253,2 -85 -62 -10 
PI 26:0 
724,5 171,1 -85 -62 -10 
724,5 199,2 -85 -62 -10 
724,5 227,2 -85 -62 -10 
724,5 255,2 -85 -62 -10 
PI 28:1 
750,6 199,2 -85 -62 -10 
750,6 225,2 -85 -62 -10 
750,6 227,2 -85 -62 -10 
750,6 253,2 -85 -62 -10 
PI 28:0 
752,6 171,1 -85 -62 -10 
752,6 199,2 -85 -62 -10 
752,6 227,2 -85 -62 -10 
752,6 255,2 -85 -62 -10 
752,6 283,3 -85 -62 -10 
PI 30:2 
776,6 253,2 -85 -62 -10 
776,6 225,2 -85 -62 -10 
PI 30:1 
778,6 199,2 -85 -62 -10 
778,6 225,2 -85 -62 -10 
778,6 227,2 -85 -62 -10 
778,6 253,2 -85 -62 -10 
PI 30:0 
780,6 199,2 -85 -62 -10 
780,6 227,2 -85 -62 -10 
780,6 255,2 -85 -62 -10 
780,6 283,3 -85 -62 -10 
PI 32:2 804,6 253,2 -85 -62 -10 
PI 32:1 
806,6 227,2 -85 -62 -10 
806,6 225,2 -85 -62 -10 
806,6 283,3 -85 -62 -10 
806,6 253,2 -85 -62 -10 
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PI 32:0 808,6 255,2 -85 -62 -10 
PI 34:2 
832,6 253,2 -85 -62 -10 
832,6 281,3 -85 -62 -10 
PI 34:1 
834,6 253,2 -85 -62 -10 
834,6 255,2 -85 -62 -10 
834,6 281,3 -85 -62 -10 
834,6 283,3 -85 -62 -10 
PI 34:0 
836,6 255,2 -85 -62 -10 
836,6 283,3 -85 -62 -10 
PI 36:2 860,7 281,3 -85 -62 -10 
PI 36:1 862,7 281,3 -85 -62 -10 
PI 36:0 864,7 283,3 -85 -62 -10 
 
As the Table 1 clearly show, all the monitored phosphatidylcholines 
report the same product ion (184,1 m/z). Indeed, for the identification of these 
molecules is peculiar the loss of choline due to the CID fragmentation in the 
collision cell. 
Solutions of known concentration of the standards were prepared to 
calculate the calibration curve in the range of concentration 0,1-250 µg/L for 
both D-α-Phosphatidylcholine, Dipalmitoyl and  L-α-
Phosphatidylethanolamine, Dioleoyl. 
The analyses were performed in triplicate for each point of the calibration 
curve. Recovery was estimated by measuring the concentration of standards 
added to real samples (spiked samples).  
 
𝑹𝒆𝒄𝒐𝒗𝒆𝒓𝒚 (%) = 
𝐶1−𝐶2
𝐶3
∗ 100 
where: 
C1: analyte concentration measured after the addition 
C2: analyte concentration measured before the addition 
C3: added concentration of the standard. 
 
3.2.3 Method validation 
The Limit of Detection (LOD) and the Limit of Quantification (LOQ) are 
defined, respectively, as the concentration level at which the analyte can be 
reliably detected in the sample under consideration and as the level at which 
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the analyte can be detected and quantified with sufficient precision. Several 
methods are used to determine LOD and LOQ23. Determination of the signal-
to-noise ratio is the simplest and is performed by comparing measured signals 
from samples with known low concentrations of analyte with those of blank 
samples and establishing the minimum concentration at which the analyte can 
be reliably detected. A signal-to-noise ratio between 3 or 2:1 is generally 
considered acceptable for estimating the detection limit, a typical signal-to-
noise ratio is 10:1 is acceptable for estimating the quantification limit 24. 
Possible matrix effects were evaluated by comparing standard and matrix 
matched calibration curves for each analyte. Standard solutions were prepared 
as described. The calibration curves were repeated three times. Matrix effects 
were evaluated by comparing five points standard and matrix-matched 
calibration curves. 
Measurement uncertainty was estimated according to the law of error 
propagation. The uncertainty contributions considered in the combined 
uncertainty were the uncertainties of the preparation of native standard 
solutions for instrument calibration, the uncertainty contribution deriving 
from instrument calibration, the uncertainty coming from the precision of the 
analyses and the uncertainty of bias. 
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3.3 Results and discussion 
3.3.1 Method set up 
5 ul of a mixture of targeted metabolites standard solution at different 
concentrations was separated in a single run by a LC-MSMS. The total ion 
current (TIC) chromatogram as a function of retention time was registered 
from detector, showing a good peak shape for each analyte.  
Identification and quantification are based on extracted ion 
chromatogram (XIC) signals of different transitions (Figure 5). Thanks to the 
external standard method, the two calibration curves for L-α-PC, dipalmitoyl 
and PE, dioleoyl were set up. 
 
 
Figure 5: MRM Chromatograms for the selected transitions 734.6→184.1 and 734,6→ 
734,6 recorded for D-α-Phosphatidylcholine, dipalmitoyl. 
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Figure 6: MRM Chromatograms for the selected transitions 744.6→199.2; 
744.6→281,3; 744.6→744.6 recorded for L-α-Phosphatidylethanolamine, Dioleoyl. 
Figures 5 and 6 showed the monitored transitions for the two standards; 
they are perfectly coeluted at 3.05 and 4.54 min respectively. For each 
standard a   quantifier transition was selected because it gave the best 
associated instrumental response and the absence of nonspecific signals (Dα-
Phosphatidylcholine, Dipalmitoyl: “734.6→184.1”,  L-α-
Phosphatidylethanolamine, Dioleoyl: “744.6→281.3”). 
The calibration curves were set up in a concentration range of 0,1-250 μg 
for both PC and PE; each point of the line was analysed in triplicate and the 
obtained curves are shown in Figure 6. 
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Figure 7 Calibration curves obtained from chromatogram peaks area integration of each 
transition as a function at different concentrations 
For the quantitative analysis of LPC and PC the calibration curve 
obtained by PC was used; while for the PA, PE, PI and PS the curve obtained 
for PE was used. 
The parameters of LOD, LOQ, recovery (%) and linearity are reported in 
Table 3. 
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3.3.2 Method validation on CD and CTRL infant sera samples 
As described in Materials and Methods section, serum samples of 
children genetically predisposed to celiac disease have been treated. 
The cohort of sera used for the validation of the MRM method is 
characterized by 23 genetically predisposed children for whom are available 
serum samples at 4 months, before the introduction of gluten in the diet, at 12 
months, following weaning and then with the introduction of gluten and 
finally a variable Td time (between 15 and 63 months) corresponding to the 
time of diagnosis of celiac disease. 
4-Months CD vs CTRL 
The treated 4-month CD and CTRL serum samples were analysed in 
duplicate using the previously shown MRM method and Table 1 in the 
Supporting Data summarize the results as averages of the two replicates with 
dev std and CV (%) values. 
Despite the high complexity of the analysed biological matrix, it was 
possible to identify and quantify many of the target molecules with a high 
reproducibility of the data. The data obtained were summarized in the 
following histograms one for each phospholipid class investigated (Figure 6). 
Data of children who developed celiac disease (CD) are indicated with blue 
bars while data of children who have not yet developed the pathology (CTRL) 
with orange bars. CTRL samples were used as control ones. 
Each bar in Figure 8 represents a class of target molecules. 
Standard Linear Range 
(pg/µL) 
Recovery 
(%) 
LOD 
(pg/µL) 
LOQ 
(pg/µL) 
PC 0,1-250 87 0,1 0,3 
PE 0,1-250 88 0,1 0,3 
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FFigura 8: Comparison of children's serum samples at 4 months before gluten introduction. The average data for CD children is shown in blue and the average data 
for CTRL children is shown in orange. 
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It can be seen how the PI 34: 1 and the molecules contained in the LPC, 
PC (3) and PS panels are increased in CD compared to CTRL already before 
the introduction of gluten in the child's diet. 
Therefore, it could be considered as a potential molecular signature for 
celiac disease in genetically predisposed children. Obviously subsequent 
studies on a higher samples number are necessary to evaluate both the dosage 
normal range of the target molecules and the use of this biomarker in normal 
clinical practice even in subjects whose family history is unknown. 
 12-Months CD vs CTRL 
CD and CTRL samples collected at 12 months were treated as described 
in the Materials and Methods section and analysed with the LC/MRM/MS 
method. Each sample was analysed in duplicate. 
The averages of the obtained results are collected in Table 3 of 
Supporting Data. This set of samples allows the evaluation of the trend of the 
target molecules following the introduction of gluten in the daily diet. In 
Figure 8 the average of the concentration of each target analyte and the 
associated standard deviation is reported as histogram. The blue bars 
correspond to CD children while the orange bars correspond to CTRL 
children, patients who have not yet developed the pathology. 
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Figura 9: Comparison of children's serum samples at 12 months after gluten introduction. The average data for CD children is shown in 
blue and the average data for CTRL children is shown in orange. 
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As can be expected, with the introduction of gluten in the child's diet, 
there is a variation in the production of some classes of lipids. LPC and PC 
panels represent some lipid classes that increase with gluten introduction, 
while other lipids, on the other hand, are diminished, like PGs or PEs. 
Interestingly that emerges from this study is that the change in some of 
these molecules is much more pronounced in individuals who have developed 
the disease (CD) than those who have not yet developed (CTRL). 
 4,12 and Time of Diagnosis (Td)  
Finally, the last sera analysed were those collected between 15 and 63 
months, called diagnosis time, or time span in which celiac disease was 
diagnosed for some of the selected subjects. 
  Table 4 of the supporting data contains the mean values, the standard 
deviation and the coefficient of variation (%) relative to the analyses carried 
out in duplicate on this series of sera. 
As an example, data comparing the concentration of monitored lipids for 
CD subjects (at T4, T12 and Td) are summarized in the histograms of Figure 
9. It is evident how, at the time of diagnosis, the monitored lipid values seem 
to settle around the values recorded at 12 months.  
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Figura 10: Comparison CD serum samples at 4, 12, and t >12 months after gluten introduction. In blue the mean results of 4-months samples, in orange 
the mean results of 12-months samples and in grey the mean value recorded at t < 12 months, the time of coeliac disease diagnosis. 
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3.4 Conclusions 
The simplicity of the quantification method allowed the analysis of 
eighty-three phospholipids in a single run of twelve min makes the developed 
method well suited not only for research work about but also for the 
measurement of clinical like of patients affected from celiac disease. 
The breakthrough of this technology is highlighted in its capability of 
providing a universal approach for developing assays of quantification for a 
wide spectrum of target molecules with minimum restrictions, and the ease 
of assembling multiplex detection in a single measurement. 
The children of the two cohorts do share a similar genetic background, 
since they come from families with one celiac proband and bear the specific 
HLA haplotype (DQ2 or DQ8). So, it does appear that the genetic profile may 
not explain fully the great differences found between the two cohorts. This 
investigation let to possible selection of a panel of molecules that can be used 
as putative serum biomarkers for coeliac disease to be investigated in further 
studies. 
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Chapter 4  
4.1 Introduction 
Inflammation is typically associated with secretion of specific 
cytokines and chemokines which coordinate cell and tissue activities. 1 
Toll-like receptors (TLRs) are receptors that have the prominent 
biological function to promote synthesis and release of cytokines to 
trigger inflammatory response2. TLR4 was the first identified 
mammalian TLR, belonging to cytomembrane type I transmembrane 
glycoprotein receptor, and can be activated by the lipopolysaccharides 
(LPS) of pathogenic microorganisms, lipoproteins and peptidoglycans, 
to promote cells to produce cytokines, chemokines, adhesion molecules 
and acute phase protein to regulate the inflammatory responses3.  
 
Figure 9:Schematization of inflammatory process.  The Aβ peptide produced 
by APP processing, form aggregates that activate microglia through TLRs and RAGE 
receptors. These receptors in turn, activate NF-κ B and AP-1 transcription factors, 
which induce the reactive oxygen species (ROS) production and the expression of 
inflammatory cytokines (IL-1, IL-6, TNF). These inflammatory factors directly acting 
on the neurons and also stimulate the astrocytes, which amplify the pro-inflammatory 
signals, inducing a neurotoxic effect. The inflammatory mediators generate by resident 
CNS cells, induce the production of adhesion molecules and chemokines, which recruit 
peripheral immune cells4. 
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Lipopolysaccharide (LPS) is one of the most powerful bacterial 
virulence factors in terms of proinflammatory properties5. Endotoxin, a 
cell wall component of Gram-negative bacteria, plays a central role in 
the pathogenesis of septic shock. By administering small doses of 
intravenous endotoxin to humans, a variety of acute inflammatory 
responses are induced which are qualitatively similar to those that occur 
during the early stages of septic shock. 
 
Figure 10: General chemical structure of LPS from Gram-negative bacteria. 
In this study mass spectrometry in Multiple Reaction Monitoring 
(MRM) Ionization mode has been used to develop a method able to to 
quantify relevant proteins which were found to be specifically induced 
in response to E.Coli LPS inflammatory activation in THP I 
differentiated cells. 
THP-1cells are monocytes derived from human monocytic 
leukaemia,and are currently predominantly used for the study of the 
pathogenesis of Streptococcus pneumoniae, Mycobacterium marinum 
and infection caused by others pathogenic agents6,7. 
Key advantages of MRM assays are the ability to target specific 
peptide sequences, including variants and modified forms, and the ability 
for multiplexing that allows analysis of hundreds of peptides during a 
single sample injection. The targeted approach of an MRM experiment 
provides an increase in sensitivity, selectivity and specificity8, avoiding 
the problems related to antibody availability for all target molecules and 
cross reactivity of immunoenzimatic assays. 
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In this paper, we report the development of MRM/MS assay to 
quantify Tumour Necrosis Factor-α (TNF-α), Interferon-γ (INF-γ), 
Interleukin-8 (IL-8) and Interleukin-10 (IL-10) in THP I differentiated 
cells after stimulation with E.Coli LPS to induce inflammation.  
A time course analysis has been performed after 2h, 4h, 6h, 9h and 
24 h E.Coli LPS stimulation to investigate the trend of expression of the 
four target proteins. 
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4.2 Material and Methods 
4.2.1 Chemicals and reagents 
Interleukin 8, Interleukin 10, Tumor Necrosis Factor-α and 
Interferon-γ standard proteins, guanidine, 
Tris(idrossimetil)amminometane chloridrate (TrisHCl), dithiothreitol 
(DTT); ethylendiaminetetraacetate (EDTA), trypsin, iodoacetamide 
(IAM), ammonium bicarbonate (AMBIC), trichloroacetic acid (TCA) 
were purchased from Sigma-Aldrich. Formic acid (HCOOH), methanol, 
chloroform, acetonitrile (ACN) are from J.T. Baker. Pipette tips C18 (zip 
tip) and centrifugal filter units were purchased from Merck Millipore. 
4.2.2 Cell culture 
THP-1 monocyte cells were from ATCC, Manassas, VA. Cells were 
cultured in RPMI-1640 (Sigma-Aldrich, Milan, Italy), supplemented 
with 10% foetal bovine serum (HyClone, GE Healthcare Lifescience, 
Chicago, IL), L-glutamine and antibiotics, in a 5% CO2 humidified 
atmosphere at 37 °C. THP-1 cells were differentiated by adding Phorbol 
12-myristate 13-acetate (PMA) (Sigma Aldrich, Milan, Italy) to 
macrophages. 
Lipopolysaccharides (LPS) 
Lipopolysaccharides from E. coli was purchased from Sigma-
Aldrich, Milan, Italy 
Antibodies 
Anti-IκB, anti-TNF-α and anti-β-actin primary antibodies where 
purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). 
4.2.3 Preparation of standard solutions and in solution digestion 
Stock solutions were prepared by following the procedures 
recomanded by Sigma and stored at −20˚C until in solution digestion and 
peptide mixture analysis. 
2μg of each standard protein were lyophylized and subsequently 
used to prepare the peptide mixture for the realization of the calibration 
curve by external standard method.  
Standard proteins were submitted to reduction, alkylation and tryptic 
digestion. Samples were dissolved in denaturant buffer (6M Urea, 300 
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mM Tris pH 8.0, 10 mM EDTA) containing DTT (10-fold molar excess 
on the Cys residues) at 37 °C for 2 h and then iodoacetamide (IAM) was 
added to perform carboamidomethylation using an excess of alkylating 
agent (5-fold molar excess on thiol residues). The mixture was then 
incubated in the dark at room temperature for 30 minutes. The product 
was purified by chloroform/methanol/water precipitation. Supernatants 
were removed, and the pellets were dried. Digestion of proteins mixture 
was carried out in 10 mM AMBIC using trypsin at a 50:1 protein:enzyme 
mass ratio. The samples were incubated at 37°C for 16 h and after 
acidification (10% HCOOH) they were dried.  
To eliminate any impurities the samples were suspended in 200 μL 
of 100 mM AMBIC, filtrated by centrifugal filter units (0.22 μm), and 
dried in a speed-vacuum concentrator. Peptide mixture was then 
resuspended in 0.1% HCOOH to a final concentration of 5 pmol/ μL. 
Standard solutions for each selected protein were prepared by serial 
dilution from stock solutions and used for calibration curves. Standard 
mixtures for each analyte at the following concentrations: 1, 10, 25, 50, 
100, 250, 500, 1000 fmol/μL for all the standard proteins were prepared. 
All standards were kept at -20˚C before LC-MRM/MS analysis. 
4.2.4 Sample preparation: In solution digestion of LPS stimulated 
THP1cellular extracts 
A total amount of 1 million of cells for both control THP1 samples 
and LPS stimulated THP1 cells were used for quantitative analysis of the 
selected proteins. The cellular extracts were lyophilized and then 
resuspended in denaturant buffer to reduction, carboamidomethilation 
and tryptic hydrolysis of proteins as previously described for standard 
proteins. 
After tryptic hydrolysis, purified peptide mixture was resuspended 
in 50 μL of 0.1% HCOOH and stored at -20°C until the LC-MRM/MS 
analysis. 
4.2.5 LC–MS/MS instrumentation and conditions: MRM targeted 
proteomic approach 
In order to set up a targeted MRM method, Skyline software (3.7, 
64-bit version MacCoss Lab Software, University of Washington, USA) 
was used for the in silico selection of peptides with unique sequence for 
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each selected protein. For each peptide, m/z precursor ion, m/z product 
ions and relative collision energy were provided by Skyline. 
Peptides with zero missed cleavages were considered and the best 
two to five transitions per peptide were selected from the top ranked y-
fragments. As a result, 9 peptides for the four selected proteins were 
selected and 29 transitions were monitored during a single analysis.  
Table 1 summarized the amino acid sequence for all the selected 
peptide for each protein and reported the best transitions, m/z precursor 
ion- m/z product ions, with the corresponding Collision energy (V) value 
to optimize the MRM-MS method.  
 
Table 1: List of selected protein reporting selected peptide 
sequence, precursor m/z, product ions m/z and Collision Energy (CE,V).  
Protein Peptide sequence 
Precursor Ion 
m/z 
Product Ions 
m/z 
Collision 
Energy 
(V) 
TNF-α 
R.ANALLANGVELR.D 
[108, 119] 
620,8540++ 
A[y10]1055,620+ 
L[y9]-984,5837+ 
L[y8]-871,4996+ 
A[y7]-758,4155+ 
N [y6]-687,3784+ 
20 
R.IAVSYQTK.V 
[158, 165] 
455,2556++ 
A[y7]-796,4199+ 
V[y6]-725,3828+ 
S[y5]-626,3144+ 
Y[y4]-539,2824+ 
15 
INF-γ 
K.SVETIK.E 
[91, 96] 
338,6974++ 
V[y5]-589,3556+ 
E[y4] -490,2871+ 
T [y3]-361,2445+ 
12 
K.FFNSNK.K 
[103, 108] 
378,6874++ 
F[y5]-609,2991+ 
N[y4]-462,2307+ 
11 
R.DDFEK.L 
[112, 116] 
327,1425++ 
D[y4]-538,2508+ 
F [y3]-423,2238+ 
11 
IL-8 
R.ELCLDPK.E 
[74, 80] 
437,7206++ 
L [y6]-745,3913+ 
C[y5]-632,3072+ 
L[y4] -472,2766+ 
14 
K.ENWVQR.V 
[81, 86] 
416,2090++ 
N[y5]-702,3682+ 
W[y4]- 88,3253+ 
11 
IL-10 
K.DQLDNLLLK.E 
[58, 66] 
536,3059++ 
Q[y8]-956,5775+ 
L[y7]-828,5189+ 
D[y6]-715,4349+ 
N[y5]-600,4079+ 
20 
K.ESLLEDFK.G 
[67, 74] 
490,7504++ 
S[y7]-851,4509+ 
L[y6]-764,4189+ 
L[y5]-651,3348+ 
E [y4]-538,2508+ 
18 
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Peptide mixture after purification was analyzed by LC-MS/MS 
analysis using a Xevo TQ-S (Waters) equipped with an IonKey UPLC 
Microflow Source coupled to an UPLC Acquity System (Waters). For 
each run, 1 μL peptide mixture was injected and separated on a TS3 1.0 
mm × 150 mm analytical RP column (Waters, Milford, MA, USA) at 
45°C with flow rate of 3 μl/min using 0.1% HCOOH in water (LC-MS 
grade) as eluent A and 0.1% HCOOH in ACN as eluent B. Peptides were 
eluted (starting 1 min after injection) with a linear gradient of eluent B 
in A from 7% to 95% in 55 min. The column was re-equilibrated at initial 
conditions for 4 min. The MRM mass spectrometric analyses were 
performed in positive ion mode. using an MRM detection window of 
0.5-1.6 min per peptide; the duty cycle was set to automatic and dwell 
times were minimal 5 ms. Cone voltage was set to 35V. 
4.2.6 Method validation Limit of detection and quantitation.  
The limits of detection (LODs) were defined as the lower limit of 
concentration below which the sample could not be revealed and were 
determined by making 10 replicate measurements of blank samples. 
Calculations were made according to the following formula: 
𝐿𝑂𝐷 = 3 × 𝑆𝐷  
where SD was the standard deviation of the Blank.  
The limit of quantitation (LOQ) is the lowest concentration at 
which the analyte can not only be reliably detected but also quantitated. 
The LOQ may be equivalent to the LOD or higher. Standard solutions 
were prepared by spiking known amount of IL-10, Il-8, INF-γ and TNF-
α in the control sample untreated with LPS. The proteins were 
hydrolysed and analysed by the LC-MRM/MS procedure. LOQ was 
determined as the analyte concentration giving a signal to noise ratio 
(S/N) of 3 times higher than the LOD.  
Matrix effect. Possible matrix effects were evaluated by comparing 
standard and matrix matched calibration curves for each analyte. 
Standard solutions were prepared as described. The calibration curves 
were repeated three times. Matrix effects were evaluated by comparing 
five points standard and matrix-matched calibration curves.  
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Specificity. The specificity of the assay was demonstrated by 
checking for interfering peaks at the retention time of the target analytes.  
Selectivity. Selectivity was evaluated by analyzing 20 blank 
samples. The blank samples were prepared by executing the whole 
analysis procedure without test sample and omitting the standards 
addition. Selectivity was defined acceptable when no peaks were 
detected in the chromatogram of the procedural blank sample at the 
retention time of the analytes ± 0.1 minute or, if present, peaks did not 
exceed 30% of the height of the native analyte in the chromatogram of 
the lowest calibration level.  
Linearity. The linearity of an analytical procedure is defined as its 
ability to obtain test results that are directly proportional to the 
concentration (amount) of analyte in the sample within a given range. 
Linearity was demonstrated directly on the standard solutions by dilution 
of a standard stock solution as described. Linearity was determined by a 
series of three injections of standards at different concentration levels. A 
linear regression equation was applied to the results. The linearity is 
evaluated graphically, by calibration curves, and by visually inspecting 
a plot of peak area as a function of analyte concentration. 
Recovery. Recovery values were calculated from the measurement 
of standards spiked in test samples. The average recoveries and their 
relative standard deviations were calculated from all the results obtained 
for each standard via response factors, which were determined from 
calibration solutions as follows:  
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑐1 − 𝑐2
𝑐3
× 100 
where: 
C1: analyte concentration measured after the addition 
C2: analyte concentration measured before the addition 
C3: added concentration 
Recovery values were not used for correction of analysis results. 
They were only used to monitor the yield of the sample preparation 
procedures.  
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4.3 Results 
Despite the occurrence of ELISA tests to quantify protein content in 
cellular extracts or biofluids, the development of an MRM/MS method 
is proposed as a comparative method, with high selectivity and 
specificity for identification and quantification of a panel of target 
proteins in a single analysis trying to overcome the problems of cross 
reactivity in the use of antibodies. 
Cells respond to an inflammatory stimulus primarily by activating 
signaling pathway which leads to cytokines and chemokines release 
which act as representatives for the occurring processes.  
The MRM method proposed in this work fulfils the request of a 
targeted approach with multiplexing capability to evaluate the 
inflammatory response, as a fingerprint of the cells state, at different time 
points. 
On the example of differentiated THP-1 cells stimulated with E. Coli 
LPS that the proposed MRM approach for quantification of TNF-α, INF-
γ, IL-8 and IL-10 with high accuracy, sensitivity, and robustness is a 
powerful tool to determine the inflammation state of cells. 
The best ionizing peptides per protein were easily determined and 
the best transitions precursor ion-product ions were indicated with the 
aid of the Skyline software, matrix interference could clearly be assessed 
by spiking samples and thus avoided. Therefore, the set-up of this MRM 
method did not require labeled peptides as references9 and the 
quantitative analysis has been performed by the external standard 
method by using standard proteins. 
4.3.1 THP-1 differentiation and LPS stimulation  
To differentiate THP-1 monocytes, cells were plated into 6 well 
plates (5x105 cells/well), and then 2 nM of PMA was added to the culture 
medium for 96 hrs at 37 °C. To induce the inflammatory process, the 
macrophages were stimulated by adding 100 ng/mL of LPS from E. coli 
for 40 min at 37 °C. Afterwards, we analysed the activation of NF-kB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), a key 
factor in regulating the immune response to infection, by following the 
phosphorylation of its inhibitor IκB. Upon phosphorylation and 
consequent degradation of IκB, the NF-κB complex is released and 
enters into the nucleus where it can 'turn on' the expression of specific 
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genes endowed with DNA-binding sites for NF-κB. The activation of 
these genes by NF-κB leads to the inflammatory or immune response. 
NF-κB turns on the expression of its own repressor, IκB. For this reason, 
IκB levels monitoring has to be performed in a specific time interval, in 
particular prior to its re-synthetisation (40 minutes at most)10. THP-1 
cells were stimulated with LPS and, subsequently, western blot analyses 
have been performed by using antibodies specifically recognizing IκB. a 
significant decrease (4.4 fold) of intracellular levels of IκB upon 
treatment of THP-1 cells with E. Coli LPS was found, strongly 
suggesting an activation of the NF-κB pathway (Figure 3). 
 
Figure 11: Western-blot analyses of intracellular levels of IκB activated by the 
treatment of differentiated THP-1 cells with LPS. Lane 1, total proteins extracted from 
untreated cells; lane 2, total proteins extracted from cells treated with 100 ng/mL of 
LPS (40 m minutes). Western-blot analyses have been performed by using antibodies 
specifically recognizing IκB. Endogenous β-actin was used as an internal standard. 
Upon induction of inflammation process, in order to evaluate the 
release of cytokines in the conditioned medium, another marker of 
inflammation was followed, such as tumour necrosis factor α (TNF-α). 
TNF-α is a cytokine playing a key role in systemic inflammation and is 
one of the cytokines involved in the acute phase reaction. It is mainly 
produced by activated macrophages11, but it is also produced by a broad 
variety of cell types including lymphoid cells, mast cells, endothelial 
cells, cardiac myocytes, adipose tissue, fibroblasts, and neurons. Large 
amounts of TNF-α are released in response to inflammation induced by 
cell exposure to lipopolysaccharide, bacterial products, and Interleukin-
1 (IL-1)12. 
To evaluate the release of this protein, cells were incubated with 1 
µg/mL of LPS from E. coli for 6 hrs and, subsequently, the conditioned 
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medium was analysed by western-blotting by using TNF-α as a marker 
of inflammation. It has to be noticed that, because of the low sensitivity 
of western-blotting methodology, no signal associated to TNF-α was 
observed (data not shown). For this reason, upon inflammation 
induction by treatment of cells with LPS (1 µg/mL) for 3 hrs at 37 °C, 
protein secretion was inhibited by co-treating cells with LPS (1 µg/mL) 
and brefeldin A (300 ng/mL) for further 3 hrs at 37 °C. By this way, 
TNF-α intracellular levels increase because of inflammation induction 
and concomitant block of protein secretion. In these experimental 
conditions, a significant increase of TNF-α levels (8.6 fold) has been 
observed upon inflammation induction (Figure 4). 
 
 
Figure 12: Analysis of TNF-α intracellular levels upon inflammation induction by 
treatment of differentiated THP-1 cells with LPS. Lane 1, total proteins extracted from untreated 
cells; lane 2, total proteins extracted from cells treated with 300 ng/mL of brefeldin (3 hrs); lane 
3, total proteins extracted from cells co-treated with 300 ng/mL of brefeldin A (3 hrs) and 1 
µg/mL of LPS (3 hrs). Western-blotting analyses were performed by using antibodies directed 
towards TNF-α. Endogenous β-actin was used as an internal standard. 
A kinetic analysis by stimulating macrophage cells (1x105 
cells/well) with 1 μg/mL of E.coli LPS for different lengths of time (2, 
4, 6, 9 and 24 hrs) was performed. This time range allowed the 
exploration of both “primary marker of inflammation” due to the 
immediate response of the immune system to the action of LPS, and the 
"late marker of inflammation" that generally occurs since 10 hours after 
the stimulation. The supernatants of the different time points were 
collected and subjected to MRM analysis. 
For the MRM analysis, the volume of conditioned medium analysed, 
has been normalized for the number of the cells (1*105 cells for each 
point). 
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4.3.2 MRM method set up 
 For each target protein the peptide showing the highest Total Ion 
Current for all the monitored transitions was assigned as Quantifier while 
the other/s monitored peptides were used as Qualifiers to enhance the 
specificity in protein recognition in a real sample. 
Linearity was studied using TNF-α, INF-γ, IL-8, IL-10 standard 
proteins. Solution at a known concentration (fmol/μL) were analyzed and 
the calibration curves were realized by plotting the sum of the peak areas 
for all the monitored transitions for the quantifier peptide versus the 
concentration of standard protein (fmol/μL) and linear functions have 
been applied to the calibration curves. The analyses were performed in 
triplicate for each point of the calibration curves to evaluate the 
reproducibility of the developed method. 
The coefficients of determination (R2) were greater than 0.99 and 
the calculated CV values were under the 10% for all the analytes. Figure 
6 the standard calibration curves obtained for the four analytes are 
reported (Figure 6). 
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Figure 5: Calibration Curves for TNF-α, INF-γ, IL-8 and IL-10. Total ion current 
is reported as function of concentration expressed as fmol/µL.  
In order to define the recovery in matrix and the LOQ, standard 
solutions were prepared by spiking known amount of standard proteins 
in mixture in THP I differentiated and non-stimulated cells samples. 
The matrix effect was calculated as the percentage of the matrix 
matched calibration slope (B) divided by the standard calibration slope 
(A) yielding a matrix effect (B/A x 100) of 11–15% for the four analytes. 
The limits of detection (LODs) were determined by making 10 
replicate measurements of blank samples spiked with low concentrations 
of each analyte and calculated as: LOD = 3SDBlank. 
The LODs values resulted to be 4,8 fmol/µL for TNF-α, 2,5 fmol/µL 
for INF-γ, 1,2 fmol/µL IL-8 and 3,2 fmol/µL for IL-10.  
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The LOQ values for each target protein were 14,4 fmol/µL for TNF-
α, 7,5 fmol/µL for INF-γ, 3,6 fmol/µL IL-8 and 9,6 fmol/µL for IL-10. 
One million of THP I differentiated cells were used as control 
samples to define the endogenous concentration of the target proteins in 
non-stimulated conditions. This control sample was treated as described 
in Material and Methods section to obtain the tryptic peptide mixture for 
LC-MRM/MS procedure using the conditions previously defined. 
The endogenous background of each analyte was corrected in Excel 
by calculating the non-spiked signal. LOQ, calculated as the analyte 
concentration giving a signal to noise ratio (S/N) of 10, resulted to be 40 
fmol/µL for TNF-α, 11433 fmol/µL for INF-γ, 3 fmol/µL IL-8 and 
760,97 fmol/µL for IL-10. 
Recovery was calculated by comparing the extraction yield before 
and after the addition of the different standard analytes into the control 
samples. Quantitation was achieved by using the calibration curves. 
Recovery for each analyte was better than 92,3%. 
4.3.3 MRM/MS method applied on LPS stimulated THP-1 cells 
The MRM/MS optimized procedure was applied to 1 million THP-
1 differentiated cells stimulated with E. Coli LPS to induce 
inflammation. The analyses were performed at different time point after 
LPS stimulation: 2, 4, 6, 9 and 24 hours.  
The MRM analysis were performed in triplicate to evaluate the 
reproducibility of the method in complex matrixes for each time point to 
evaluate the reproducibility of the analysis. 
The MRM TIC Chromatograms in Figure 7 showed the capability 
of the developed method to identify with high specificity and selectivity 
the ELCLDPK peptide from IL-8 protein without matrix interference 
(anomalous peaks derived from the matrix effect).  
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Figure 6: MRM TIC Chromatogram for ELCLDPK peptide from IL-8. Monitored 
transitions are perfectly coeluted at 3,2 min.  
All the results obtained by the MRM analysis of THP I cells 
differentiated and stimulated with E.Coli LPS are summarized in the 
following histograms (Figure 8). The graphs report the expression trend 
of each target protein, as average of the three replicates, at different 
time points after the induction of inflammation with E.Coli LPS. 
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Each point of the time-course analysis was related to a sample of 
THP I cells not stimulated with E.Coli LPS (CTRL) in order to indicate 
the content of each target protein at the baseline level. 
The following paragraphs show some information on the production 
and mechanism of action of selected proteins. 
4.3.4 TNF-α 
TNF-α is a proinflammatory cytokine which exerts multiple 
biological effect, it is a cell signalling protein (cytokine) involved in 
systemic inflammation and is one of the cytokines that make up 
the acute phase reaction. It is produced chiefly by 
activated macrophages, although it can be produced by many other cell 
types such as CD4+ lymphocytes, NK cells, neutrophils; mast cells, 
eosinophils, and neurons13. 
The primary role of TNF is in the regulation of immune cells. 
TNF, being an endogenous pyrogen, is able to induce fever, apoptotic 
cell death, cachexia, inflammation and to inhibit tumorigenesis and 
viral replication and respond to sepsis via IL1 & IL6 producing cells. 
Dysregulation of TNF production has been implicated in a variety 
of human diseases including Alzheimer's disease, cancer, major 
depression, psoriasis and inflammatory bowel disease(IBD). 
As it is possible to verify from the panel A of Figure 8, the 
production of TNF-α is increased immediately, after 2 h of 
inflammatory stimulation with LPS, and its production continues to 
increase up to 4h of stimulation of THP cells I. This confirming the 
pro-inflammatory action exerted by TNF-α in the recruitment of 
macrophages and giving rise to stimulation of complex signalling 
cascades that control various intracellular functions. 
This cytokine acts in synergy with IFN-γ, stimulates the migration 
of immune cells to the infection site, contributing to the granuloma 
formation, capable of controlling the disease progression. 
 
 
 
Figure 8: Graphical representation of target protein content in the time-course analysis. 
Protein content was expressed as fmol/µL for each sample of THP I cell stimulated with 
E.Coli LPS. Each sample was analysed in triplicate and the calculated standard deviation is 8-11%. 
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4.3.5 INF-γ 
Interferons (IFNs) are substances originally identified at cellular 
culture supernatants infected by virus and that appeared to interfere 
directly in the viral replication, hence its denomination IFN-γ. It was 
synthesized mostly by T lymphocytes and NK cells after this cells 
activation with immune and inflammatory stimuli, rather than viral 
infection and orchestrates a vast array of pathological responses.14 It 
upregulates expression of inflammatory mediators, especially the 
primary mediator such as TNF-α and interleukin (IL)-1, which induces 
alveolar macrophages to produce a large number of secondary 
inflammatory cytokines such as IL-6, IL-815. 
As reported in Figure 8 (B), INF-γ production is straightly related 
to TNF- α. In fact, it follows the same expression pathway but delayed 
in time. The maximum INF- γ levels were recorded after 4h and after 
24h of LPS stimulation according with the acute and late inflammation 
processes. 
4.3.6 IL-8 
IL-8, is secreted by monocytes/macrophages and epithelial cells. It 
promotes the accumulation and activation of inflammatory cells, the 
release of inflammatory mediators and aids in neutrophil chemotaxis to 
sites of inflammation to regulate the inflammatory response16. 
IL-8, a pro-inflammatory factor, has been shown to promote cancer 
progression not only by directly stimulating cancer cell proliferation, 
survival, and migration but also by increasing angiogenesis17 18 
According to these data, IL-8 secreted levels by THP-1 cells were 
significantly increased after 2h of E.Coli LPS stimulation and these 
decrease slowly in time until it became about 1/3 after 24h. 
4.3.7 IL-10 
Due to its ability to inhibit the T lymphocyte production of 
cytokines, IL-10 was originally described as a cytokine synthesis 
inhibitory factor (CSIF). IL-10 acts inhibiting the production of pro-
inflammatory cytokines (IFN-γ, TNF-α and IL-12) and the action of 
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antigen presenting cells, blocking the activation of T lymphocytes 
through the inhibition of expression of MHC class II molecules.  
Unlike TNF-α and IFN-γ, IL-10 is considered primarily an 
inhibitory cytokine, important to the adequate balance between 
inflammatory and immunopathological responses6,19. 
Evidences of this behaviour are reported in panel D of Figure 8: the 
main increase in IL10 level by LPS is recorded after 24 h of LPS 
stimulation. Otherwise, the concentration of this protein remains almost 
constant or equal to the THP I non-stimulated sample.  
To investigate the sensitivity of TNF alpha detection by using 
antibody, a pool of serum samples from patients affected by different 
inflammatory diseases was submitted to TNF-α test by using specific 
antibody as previously described. Figure 8 showed absence of positive 
signal of the target protein in serum sample (lane 3). Thus, different 
aliquot of TNF-α standard protein at known concentration were loaded 
in order to define the limits of the range of detection by using this 
methodology. 
As shown in this figure, the limit od detection is around 6,25 ng 
corresponding to about 35 fmol/µL. Thus, taking in account that the limit 
of detection of TNF-α by MRM method was set up at 4,8 fmol/µl, this 
method seems to be promising for the detection and quantification of 
these inflammatory proteins in sera.  
 
Figure 13: Analysis of TNF-α levels in the serum of patients with inflammatory 
diseases. Lane 1, pre-stained protein markers; lane 2, pure TNF-α protein (200 ng); lane 
3, control serum; lane 4, serum from patients with inflammatory disease; lane 5, pre-
stained protein markers; lane 6, pure TNF-α protein (100 ng); lane 7, pure TNF-α 
protein (50 ng); lane 8, pure TNF-α protein (25 ng); lane 9, pure TNF-α protein (12,5 
ng); lane 10, pure TNF-α protein (6,25 ng). Western-blotting analyses were performed 
by using antibodies directed towards TNF-α protein 
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4.4 Conclusions 
SRM and MRM strategies appear as an excellent match to the 
requirements of systems biology, not only allowing quantitative analysis 
of low-abundant proteins, but also delivering reliably quantitative data 
when proteins are analysed across multiple samples20. 
Cytokines are molecules that mediate mainly the intercellular 
communication in the immune system, being produced by different cell 
types. Cytokines have pleiotropic and regulatory effects and participate 
in the host defence and in inflammatory and tissue reparation processes. 
The aim of this work was the development of a mass spectrometry 
method in MRM mode that allowed the simultaneous monitoring of four 
proteins TNF-α, INF-γ, IL8 and IL10. The developed method was used 
for the study of the expression trend of these proteins in THP I 
differentiated and stimulated samples to induce inflammation with E. 
coli LPS. 
The method shows interesting characteristics: high specificity and 
selectivity, but also sensitivity comparable to immunoenzymatic assays, 
is a robust method with good reproducibility. 
The differentiated THP cells, were treated with a well-known 
endotoxin to induce the inflammatory process, and in order to study how 
the system reacts to stimulation, a time-course analysis has been 
performed. Samples were collected at 2h, 4h, 6h, 9h, 24h after 
stimulation with LPS. Each sample was then analysed in triplicate to 
evaluate the reproducibility of the instrumental response. 
The results obtained from the MRM analysis allowed us to draw an 
expression profile for each of the target proteins that goes well with the 
data reported in the literature. 
The immune system's response to LPS is an increase in TNF-α 
production that triggers a cascade process mechanism that leads to the 
production of INF-γ and IL-8. Il-10 remains almost constant throughout 
the process and around 24 hours after stimulation with LPS there is an 
increase in its expression, supporting its action of anti-inflammatory 
cytokine. 
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Chapter 5 
5.1 Introduction 
5.1.1 Rheumatoid Arthritis: etiology, gender distribution and social 
impact. 
Rheumatoid arthritis (RA) is a polygenic and multifactorial syndrome, 
believed to be caused by a combination of genetic1,2, and environmental 
factors. Once triggered, the pathological process has the synovial joints as the 
main target, in which both inflammatory (acute and chronic) and destructive 
phenomena are identifiable (Figure 1). 
 
Figure 14: Comparison between a normal joint and one suffering from Rheumatoid 
Arthritis. 
Many complex immunological and genetic interactions are involved in the 
outcome of the clinical disease. In the articular joints RA involves a 
multicellular inflammatory process; infiltration of lymphocytes and 
granulocytes into the articular cartilage, proliferation of synovial cells, 
leukocyte extravasation, and, neo-vascularization of the synovial lining 
surrounding the joints3.  
This proliferative process not only induces swelling, erythema, and pain 
of multiple joints, but also progresses to the destruction and loss of cartilage 
and bone architecture. Many cellular components (macrophages, dendritic 
cells, synovial cells, mast cells, neutrophils, T cells, and B cells), cell surface 
molecules (co-receptors, adhesion molecules, and integrins), signalling 
components (ZAP70, PTPN22, JAK, MAPK and Stat1), metabolic 
components, and humoral mediators (antibodies, cytokines, chemokines, 
metalloproteinases, serine proteases, and aggrecans) interact and aid in the 
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disease progression, leading to the digestion of extracellular matrix and the 
destruction of articular structures4. 
RA has a significant impact on the lives of those affected: about 90% of 
the subjects have some degree of disability within 20 years from the onset. In 
22% of cases the patient is forced to abandon all types of work and 10% need 
continuous assistance. It is not only the quality of life that is compromised but 
also the life expectancy decreases on average 4 years in men and 10 in women 
if the disease is not adequately treated. The prevalence of RA is higher in 
females than males, the incidence is 4–5 times higher below the age of 50, but 
above 60–70 years the female/male ratio is only about 25. The prognosis is 
worse in patients suffering from severe illness or presenting extra-articular 
symptoms. In fact, the social costs increase exponentially with the aggravation 
of the affliction. The control of the disease, therefore, preserves from the 
increase of the financial burden. Given the chronic and potentially disabling 
nature of the disease, it is essential to consider RA not only from a medical but 
also a social point of view.  
It has been estimated that in Italy RA affects about 0.5% of the general 
population: 0.6% of women and 0.25% of men in adulthood. Although the 
prevalence of RA is significantly lower than other conditions, such as 
osteoarthritis, the frequent severity of the clinical picture and the high potential 
for disability make it a disease with a significant socio-economic impact in 
terms of costs, disability and loss of productivity6. 
5.1.2 Rheumatoid Arthritis diagnosis 
The RA diagnosis arises through a specialized assessment of symptoms 
and clinical signs. These signs have a wide range of severity degrees, and there 
are several inflammatory and arthritic conditions that manifest similar 
symptoms. This makes RA diagnosis very difficult. 
Therefore, the patient must undergo numerous medical, laboratory and 
radiographic tests. 
Physical exam. The detailed chronology of the beginning and severity of 
symptoms as well as the family history of RA or other autoimmune disorders. 
It investigates the affected swollen, inflamed and painful joints and other 
joints, including the hands, upper limbs, knees and feet. 
Health assessment questionnaires. The HAQ was developed as a 
comprehensive measure of outcome in patients with a wide variety of 
rheumatic diseases, including RA, osteoarthritis, juvenile RA, lupus, 
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scleroderma, ankylosing spondylitis, fibromyalgia, and psoriatic arthritis. It 
has also been applied to patients with HIV/AIDS and in studies of normal 
aging. It should be considered a generic rather than a disease-specific 
instrument. Its focus is on self-reported patient-oriented outcome measures, 
rather than process measures7.  
Laboratory tests. Laboratory tests can help to differentiate this pathology 
from other diseases and disorders that impair joint functioning. Several blood 
tests are necessary: Erythrocyte Sedimentation Rate (ESR), C-Reactive protein 
(CRP)8 and Rheumatoid Factor. 
Radiographic analysis. Several imaging studies that examine the affected 
joints may help in the diagnosis of RA. The presence of two or more eroded 
and destroyed joints is significant in rheumatoid arthritis. Radiography can be 
very useful in diagnosis but does not show any abnormality in the early stages 
of the disease (3-6 months). On the contrary, the use of articular echography is 
more and more relevant to check for decreased space within the joint's bones 
and damage to the cartilage and soft tissues, much more sensitive than 
traditional radiography (especially in the initial phase) and cheaper than 
Magnetic Resonance Imaging, MRI, in documenting the synovial membrane 
hypertrophy and the intensity of the joint and peri-articular inflammation. 
DAS 28 test. The Disease activity score 28 (DAS28) combines 28 
inflamed joints and 28 holds (hands, arms and knees) and the patient's 
perception of his inability. It also includes blood tests such as erythrocyte 
sedimentation rate. DAS28 has a complicated mathematical evaluation and 
now a simplified version is used combining 28 tender and swollen joint 
assessments of doctors' and 'counts' patients, and C-Reactive protein levels. 
5.1.3 Serum biomarkers and RA diagnosis 
A biomarker is a characteristic that can be objectively measured as an 
indicator of normal or pathologic biological processes, or as an indicator of 
response to therapy9. A biomarker is a diagnostic indicator of a clinical 
endpoint and often is a reporter of early-stage disease development. Biomarker 
selection is likely to be most beneficial when focused on early-stage 
mechanisms and changes in the disease process.  
Biomarkers have the potential to aid clinical diagnosis when symptoms 
are present or to provide a means of detecting early signs of disease when they 
are not. Some biomarkers can serve as early surrogates of eventual clinical 
outcomes or guide therapeutic decision making by enabling identification of 
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individuals likely to respond to a specific therapy. Using biomarkers might 
reduce the costs of drug development by enabling individuals most likely to 
respond to be enrolled in clinical trials, thereby minimizing the number of 
participants required10. 
In early RA stages a biomarker may help the diagnosis particularly during 
acute flare-ups where arthritic joints become hot swollen and tender. 
Radiographic image features correlate very poorly with symptoms and a 
biomarker test may assist with evaluation and selection of patients for join 
replacement surgery. The biomarker response may also be of benefit in 
assessment of post implantation responses. Persistent pain, functional 
impairment, infection and implant loosening are a few of the common effects 
of surgery, and a biomarker may be of use in determining the physiological 
aspects of these problems as opposed to purely mechanical ones11. In the 
diagnosis of RA, rheumatoid factor values have been historically used to 
support the medical examination and radiographic data. 
Rheumatoid factor 
Rheumatoid factors (RFs), a class of immunoglobulins (Igs) that have 
different isotypes and affinities, were first detected more than 70 years ago, but 
there is still much to discover about the mechanisms underlying their 
production, physiological role, and pathological effects. In 1948, Rose 
described these antibodies in patients with rheumatoid arthritis (RA), and in 
1952 they were finally christened RFs because of their association with RA. 
Rheumatoid factor (RF) is an antibody against the Fc portion of IgG, but 
in clinical practice is measured as IgM. The role of RF in disease is not clear 
but may be related to the binding by RF on B-cells to immunoglobulins 
attached to antigens for antigen presentation, resulting in amplification of the 
humoral response. The sensitivity of RF for rheumatoid arthritis varies, 
depending on the patient population. RF is associated with more severe disease 
with greater extra-articular features. In general, the sensitivity of RF for RA is 
around 50 to 85%, increasing over time, as some people with rheumatoid 
arthritis are initially RF negative and later seroconvert. However, RF alone 
cannot make a diagnosis of rheumatoid arthritis, as roughly 5% of a young 
healthy population can be RF positive, and this rate increases with age. 
Although mostly associated with rheumatoid arthritis, RF can also be seen in 
Sjögren’s syndrome, mixed connective tissue disease, mixed 
cryoglobulinemia, SLE, and polymyositis, as well as in  non-rheumatic 
disorders such as chronic infections, inflammatory disorders, and malignancy. 
Only 50% of early rheumatoid demonstrate RF positivity. 
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Furthermore, around 15% of patients with RA will never have RF 
positivity. Therefore, this test should only be ordered where the diagnosis of 
RA is strongly suspected: namely, in the setting of obvious joint swelling, 
synovitis, or effusions. Another setting would be the finding of erosive changes 
radiologically12. RFs can also interfere with other laboratory tests, including 
those designed to detect anticardiolipin antibodies (especially if IgM levels are 
in the low positive range), anti-2GPI antibodies, anti-HCV antibodies, 
antirubella antibodies, thyroid assays, and tests for carbohydrate antigen 19–9 
and various cytokines13. 
Anti-CCP antibodies 
Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been around 
for decades but have recently been gaining popularity. These were first 
described as markers for RA in 1964. It was because of very exacting technical 
requirements that anti-CCP antibodies never gained wide-spread acceptance, 
despite their specificity for RA. Some research suggests that citrullinated 
extracellular fibrin in synovium is a significant autoantigen involved in the 
immune response in rheumatoid arthritis. It has similar sensitivity for RA (50 
to 85%) but higher specificity (90 to- 95%)14-17 
Up to two-thirds of patients with RA harbor ACPA, as has been known 
for many years18. However, the underlying mechanism linking ACPA with a 
more severe disease progression with increased joint destruction is 
incompletely elucidated. Recent data suggest that ACPA influences bone 
resorption by directly activating osteoclasts19. Serological status has become 
an important factor in diagnosis and prognosis of the disease. Patients with 
seropositive RA share certain genetic and environmental risk factors and have 
been shown to have a more severe disease course. Less is known about 
seronegative RA, but evidence of genetic associations for ACPA-negative RA 
has been found20. The clinical presentation and disease course of seronegative 
RA are usually reported as less severe than for seropositive RA, although 
studies are conrtoversial21,22. 
5.1.4 Aim of the study 
Blood tests would offer a powerful, minimally invasive method for early 
diagnosis of RA. However, no reliable biomarkers for RA are presently 
available. The aim is to develop a multiple reaction monitoring (MRM)‐based 
quantification method to select a panel of candidate biomarkers. 
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5.2 Materias and Methods 
5.2.1 Samples 
80 serum samples of patient with RA were provided from Complejo 
Hospitalario Universitario de Santiago de Compostela (CHUS), Spain. Age, 
sex, ACPA and RF status were known for all patients. According to the RF 
and ACPA values these samples were divided into four distinct sub-groups of 
20 sera samples each: RF+/ACPA+, RF+/ACPA-, RF-/ACPA+ and RF-
/ACPA-.  
5.2.2 Materials 
13C/15N-labeled lysine and arginine, formic acid (FA), methanol 
(MeOH), acetonitrile (ACN), were purchased from Thermo Fisher (Waltham, 
USA). Urea, thiourea, dithiothreitol (DTT), iodoacetamide (IAM), sodium 
ammonium bicarbonate (AMBIC), trypsin, trifluoroacetic acid (TFA), water 
(H2O), Stage Tip C18 47mm, Empore were purchased from Sigma-Aldrich 
(Saint Louis, USA). 
5.2.3 Selection of target peptides 
Previous studies on this and other RA cohorts, based on 8plex iTRAQ and 
LC-MALDI/TOF/TOF analysis, showed a statistical relevant modulation (p-
value<0.05) of 10 proteins. According to LC-MALDI/TOF/TOF identification 
and Skyline selection, 26 proteotypic peptides were selected to be appropriate 
for use in MRM-based assays.  
Quantitative analysis was performed by internal standard method: 26 
synthetic isotopically labelled peptides were purchased from Thermo Fisher 
(Waltham, USA). 
5.2.4 Design of multiple reaction monitoring (MRM) methods 
Skyline software v1.3 (MacCoss Lab Software, Seattle,WA, USA)23 was 
used to set up and optimize the best peptides for the target proteins with several 
filters. Proteotypic peptides with the highest spectral counts, only fully tryptic 
peptides, with no missed cleavages, with a length between 8 and 30 amino 
acids and devoid of methionine and cysteine residues, if possible, were chosen 
for MRM assays development. In addition, sequences that may cause 
incomplete digestion, such as continuous sequences of arginine (R) or lysine 
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(K) and a proline (P) at the C-terminal side of R or K were also excluded since 
partial tryptic hydrolysis at the peptide bond is often observed in MS/MS. 
The top transitions were selected for method development based on the 
presence of abundant y ions at m/z greater than that of the precursor. In the 
absence of high-m/z y ions, the most abundant fragment b ions were selected. 
All the monitored peptides, transitions for the light and heavy peptides and 
collision energy that were included in the MRM method developed herein, are 
detailed in Supporting Data Table 1. 
 
5.2.5 Sample Processing 
100 μg of protein content were treated with 6 M urea/2M Thiourea. 
2 μL of diluted serum was denaturized by adding 1,25 μL of 50mM DTT 
and 3 μL of 25 mM AMBIC for 1h at 37 °C. The alkylation step was then 
performed by adding 6,5 μL of IAM solution (100 mM) and further incubated 
at room temperature for 45 min in the dark.  
The samples were diluted with 10 μL of 25 mM AMBIC prior to the 
addition of 0,5 μL of trypsin solution (1 μg/ μL) for overnight digestion at 37 
°C. The amount of trypsin in the digest was calculated for a 1:20 enzyme to 
substrate ratio. Digests were then acidified with 10 μL of 2% TFA and 
combined with 10 μL of solutions containing varying SIS peptide 
concentrations (250, 100, 50, 25 fmol/ μL), depending on the ionization 
capability of every synthetic peptide.  
The sample clean-up was performed by using homemade C18 StageTip. 
After filter activation (50 μL x2 times MeOH, 50 μL x2 times of 80% 
ACN/0.5% TFA and 50 x 3 0,5% TFA), the sample was loaded two times on 
the filter and centrifuged for 2 min at 4000 rpm. Salts were eluted with 50 μL 
0,5% TFA and 50 x2 0,5% formic acid. The elution was performed with 30 μL 
x2 80% ACN/0,5% FA. 
Samples were dried under vacuum and rehydrated in 20 μL of 98% 
H2O/2% ACN/ 0.1% FA prior to injection, to give a final serum protein 
concentration of 0,5 μg/μL.  
5.2.6 Calibration Curves and SIS Peptide Mixtures 
In order to determine in which concentration range the instrumental 
response is linear for all the selected peptides and which is the best 
concentration of heavy peptides to be used in the serum samples, an equimolar 
mixture of all 26 peptides was prepared. 
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An 11-point dilution curve (from 0.1 to 12000 fmol/μL) containing all the 
heavy peptides in FA was prepared. These stock solutions were diluted 1:10 
and spiked into 10 μg of a pool of digested human plasma protein to prepare 
the reverse calibration-curve in the range of concentrations from 0.01 to 1200 
fmol/μL. The endogenous amount of target peptides was detected by injecting 
three times the only digested pool of serum (Blank). Each concentration level 
was processed in technical triplicate.  
All the reverse calibration curves, reporting the peak area ratio heavy/light 
as function of the heavy concentration (fmol/μL) are reported in Supporting 
Data Figure 1. 
Limit of detection (LOD) was calculated as three times the standard 
deviation of the average area of the blank sample and the limit of quantification 
(LOQ) was calculated as 10 times the standard deviation value.  
5.2.7 LC-MS/MS Methods 
Digested samples (2 μL of injection volume) were separated by reversed 
phase on a nano LC Eksigent system equipped with a Trapping column TRAP 
Acclaim pepmap 100A nanoviper C18 100µm x 2cm x 5µm and a column 
Acclaim pepmap 100A C18 75µm x 15cm x 5µm. 
Mobile phases A and B consisted of 98% H2O, 2% ACN, 0.1% FA and 
5% H2O, 95% ACN, 0.1% FA respectively. The flow rate was 300 nL/min 
throughout the following 70 min multistep gradient: 0 min: 5%B, 5 min: 
15%B, 45 min: 35%B, 46 min: 95%B, 56 min: 95%B, 57 min, 5%B, 70 min: 
5%B. The nano LC Eksigent system was interfaced to an AB Sciex 5500 
QTRAP mass spectrometer via a nanospray ESI source. The capillary voltage 
was set to 2600 V and the temperature was fixed to 150°C, the Curtain Gas 
(Cur) was 30 Bar and Ion Source Gas (GSI) was set to 25 l/min. The EP and 
CXP potentials were set to 10 and 15 V respectively and both Q1 and Q3 were 
set to unit resolution. 
Data were acquired in the positive dynamic MRM mode, using a cycle 
time of 900 ms for a minimum dwell time of 15 ms. The equivalent three 
optimized transitions were used to monitor the isotopologue of each peptide: 
light (endogenous) peptide. 
5.2.8 Data Processing 
The .raw data was processed, and the integration was performed with 
Skyline software 25 version 4.1.0.11796. Quantitation was performed via 
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regression analysis of peptide standard curves (1/x weighting), realized for all 
transitions that were found to be interference free and detectable across the 
entire concentration range. Statistical analysis was performed using GraphPad 
Prism 7 version 7.04. Distributed data were analysed using the non-parametric 
Mann–Whitney U test and statistical significance was set at a p value below 
0.05.  
Kruskal–Wallis and Mann–Whitney U test and the box plot graphs were 
performed using GraphPad Prism 5.01 software (La Jolla, CA, USA). 
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5.3 Results 
Rheumatoid arthritis is a chronic disease that causes pain, swelling and 
joint stiffness, limiting the range of movement and function of the affected 
joints. Although the joint is the part of the organism most involved, 
inflammation can also develop in internal organs (such as lungs, kidneys, heart, 
nervous system, blood vessels, eyes). 
Although they owe their name to their first detection in RA patients, RFs 
are found in patients with other autoimmune and nonautoimmune diseases, as 
well as in healthy subjects. It has been demonstrated that low-affinity RFs 
appear to be key player in immune responses to many infectious organisms, 
and high-affinity RFs indicate more severe and persistent disease in patients 
with RA. RFs are probably the result of the immune response to inflammation 
(depending on genetic background) and may have regulatory effects on Ig 
production by controlling B cell activation13. Both rheumatoid factor (RF) and 
anti-cyclic citrullinated peptide antibodies (ACPA) are associated with poor 
radiologic outcomes in patients with rheumatoid arthritis (RA). general, RA 
patients positive for RF or ACPA (SPRA) are considered to manifest an 
aggressive disease course compared with seronegative RA patients (SNRA). 
However, the relationship between seropositivity and measures of disease 
severity other than radiologic outcome is disputed. In addition, it plays an 
important role in the pathogenesis of RA and is significantly associated with 
radiographic progression 24. In order to obtain a panel of proteins that can be 
used, in the common clinical routine, to evaluate both the course of the disease 
and the effectiveness and the response of the body to pharmacological 
treatments, it is important to have an optimized method for the patients follow 
up. 
The mayor advantage of the MRM approach is the ability to monitor and 
quantify, at the same time, all the target peptides with high selectivity and 
specificity. In contrast, the immunoenzymatic tests (as ELISAs), are more time 
consuming and do not allow the chance to multiplex the analysis of all the 
selected proteins. 
5.3.1 Assay development 
Quantitative analysis was conducted by Internal Standard Method, by 
using as internal standards 26 target peptides with an isotopically labelled 
Arginine o Lysine. (Δm= +10 Da, Δm= +8 Da). 
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First, assay concentration ranges were established by running dilution 
curves of the SIS peptides in a human plasma digest. The range of 
concentration used for the calibration curves was 0.5-1200 fmol/µL. The 
analyses were performed in triplicate and the results are summarized in Table 
1 in which the calculated LOD, LOQ are also reported. 
Table 1: Reverse curve parameters for all selected peptides used to set up 
the MRM/MS method. 
   Curve parameters 
Labelled Peptide LOD [fmol/µL] LOQ [fmol/µL] Slope (x10+3) Intercept (x10+3) 
ALG 5,44±0,45 10,68±0,77 7,48E+00 -2,86E+00 
TLD 6,50±0,66 7,25±0,47 4,85E+03 6,05E+04 
DLL 1,24±0,89 3,92±0,41 2,06E+02 3,31E+01 
ATF 135,03±10,2 150,50±9,83 8,64E+01 -6,05E+04 
IPS 10,40±0,99 12,01±1,1 1,35E+03 1,65E+01 
TSS 17,29± 1,88 18,06±1,92 1,85E+02 -2,42E+05 
GVT 26,91±2,33 43,21±3,66 3,82E+01 3,79E-01 
LED 11,55±1,15 11,89±1,02 7,61E+03 -7,92E+06 
WEL 0,60±0,05 3,33±0,14 1,28E+01 -2,51E-02 
VIP 6,71±0,31 7,07±0,43 8,07E+02 2,20E+06 
EAQ 1,48±0,09 5,31±0,05 8,24E+01 3,63E-02 
YWG 7,42±0,66 8,75±0,65 4,81E+03 -5,50E+07 
LLN 1,08±0,09 19,61±1,8 1,48E+00 -2,29E-03 
YTF 4,52±0,45 8,82±0,99 2,84E+05 2,10E+08 
HLS 16,11±1,78 17,82±1,44 5,10E-01 -9,52E-03 
VLE 3,25±0,33 3,59±0,49 4,92E+04 4,88E+06 
YVG 7,20±0,98 9,05±1,01 7,95E-01 -3,56E-02 
EQL 8,78±0,56 10,28±0,78 1,85E+05 2,81E+07 
SDVV 0,76±0,05 15,42±1,45 8,22E-02 7,09E-03 
EHV 0,21±0,001 2,56±0,07 1,31E+06 5,49E+07 
EQL 12,10±1,11 20,05±1,98 1,03E-02 -1,16E-03 
SDVM 2,55±0,54 4,34±0,37 7,02E+06 -8,59E+07 
EIG 0,29±0,06 0,89±0,05 6,16E-02 -2,33E-02 
AVL 37,57±2,66 65,71±5,23 8,25E+04 2,87E+06 
VGY 11,89±1,44 17,53±1,77 1,14E+00 -2,31E-01 
VTS 5,01±0,61 5,25±0,48 1,58E+05 3,40E+06 
 
 
Linearity of results for at least 4 orders of magnitude, reproducibility of 
analyses and low values of CV (<20%) for the standard heavy peptides spiked 
in human serum were observed. 
To minimize the matrix effect that can negatively affect the quantification 
of the target proteins, a known amount of SIS peptides was added to the 
samples following enzymatic digestion (Supporting Data Table 2), but before 
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the desalting phase. In this way, endogenous and heavy peptides are subject to 
the same purification treatment and therefore to the same loss.  
 
5.3.2 Analysis of RA serum samples 
As described in Material and Methods, 80 sera samples were analysed. 
These samples were divided into 4 subgroups related to the RF and ACPA tests 
value as follows: RF+/ACPA+, RF+/ACPA-, RF-/ACPA+ and RF-/ACPA-.  
The digested samples were analysed in duplicate by using the MRM 
developed method and .raw data were analysed with Skyline software to 
evaluate the perfect coelution of the monitored transitions for endogenous and 
heavy peptides and to check the peak area integration as reported in Figure 2. 
Two technical replicates were measured, leading to peak area ratios between 
the endogenous and heavy peptide (SIS) with good coefficients of variation (% 
CVs < 20). 
 
Figure 15: Target peptides VTS (A), EHV (B), DLL (C) and YTF (D).  Coelution of 
Light (red) and heavy (blue) transitions at 16,3, 15,7, 23,0 and 15,0 min respectively. 
Quantitative analyses on real sera samples were conducted using SIS 
peptides in the single point calibration method. Single-point calibration 
consists of calculating the ratio between a known amount of SIS peptide and 
the analyte. The analyte/SIS peptide ratio is then multiplied by the 
concentration of the SIS peptide spiked in the sample. The molecular weight 
of the protein was used to calculate protein concentrations, as previously 
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described25. This calibration method assumes that the calibration curve in the 
range that includes the concentration of the SIS peptide and the analyte is 
linear, that the slope is 1, and that the intercept goes through the origin as 
previously observed in the spiked sera26. 
The obtained results for the 80 sera in the following tables are shown 
(Table 2A-D). The protein concentration is expressed as µg/mL showing 
values in good agreement with published data26,27. 
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Table 2 A-D: Quantitative data for the four sub-groups RF-/ACPA- (A), RF+/ACPA+ (B), RF+/ACPA- (C) and RF-/ACPA+ (D). Standard deviation of approximately 10% was recorded. 
  RF-/ACPA- 
2A 
Sample  
ID 
128 140 150 153 161 163 171 177 190 191 198 203 207 210 212 214 221 224 227 231 
Protein Peptide µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
1 
ALG 26,0 25,3 25,8 12,2 15,7 40,0 38,6 25,2 9,2 11,2 20,6 33,9 27,8 16,8 12,1 14,1 13,1 21,3 18,9 14,7 
TLD 135,6 42,6 44,4 33,5 88,8 94,4 73,2 64,9 27,5 28,8 51,2 65,6 48,5 27,5 18,8 29,0 24,2 38,3 37,1 23,9 
DLL 18,2 17,3 21,8 9,9 13,9 39,4 32,0 21,9 12,1 16,1 28,4 31,1 25,9 14,0 9,9 14,7 12,4 20,2 18,7 11,4 
2 
ATF 4753,8 997,7 2034,8 399,5 2300,1 1092,4 1406,8 2226,1 1184,6 676,4 560,7 999,1 1125,6 934,5 1066,1 1672,2 763,3 1174,8 935,7 1620,9 
IPS 5288,5 1564,3 3129,2 604,7 1791,1 1675,7 2231,5 3966,3 1223,1 854,8 769,7 1826,8 2896,8 1510,7 1885,1 3439,4 1548,2 2475,9 1806,9 2664,6 
TSS 4337,0 587,2 1240,8 796,8 2096,1 868,3 837,4 1435,3 1028,7 694,5 642,7 751,6 954,9 710,1 774,7 1036,3 463,1 821,0 552,9 804,5 
3 
GVT 1286,4 344,9 613,5 249,3 795,6 810,3 330,3 582,1 16,8 425,7 350,6 545,2 584,9 317,9 384,1 379,8 102,0 470,3 317,5 133,2 
LED 263,7 100,3 143,6 40,0 139,6 183,1 75,3 137,8 1,7 104,8 96,0 140,6 157,3 91,8 113,2 124,3 32,4 132,4 124,6 29,4 
4 
WEL 1803,4 576,1 1485,7 529,2 1030,3 1425,2 1423,5 1175,6 677,7 657,6 710,3 867,2 1184,9 895,9 939,2 1001,4 618,5 1209,8 1025,8 1021,3 
VIP 448,1 110,7 288,4 134,4 176,4 296,1 315,7 228,0 149,1 142,2 174,5 157,1 232,6 159,8 158,2 194,9 116,4 247,5 178,4 175,7 
EAQ 311,7 128,3 300,5 111,1 174,4 261,2 237,4 213,6 118,6 117,1 127,3 142,5 197,4 134,0 137,9 172,8 95,8 195,3 166,2 157,1 
5 
YWG 172,9 29,2 101,6 23,7 47,0 50,4 80,7 42,9 35,8 27,6 19,2 42,3 42,4 43,3 48,1 43,0 33,4 46,7 36,4 41,6 
LLN 2703,7 367,3 1212,2 356,8 936,8 872,3 945,0 711,0 371,3 253,0 168,9 366,8 223,1 352,9 352,9 369,3 299,9 446,8 273,0 301,9 
6 
YTF 324,9 156,1 348,7 130,3 283,6 300,2 359,8 248,4 119,0 128,9 91,2 216,8 258,0 211,3 150,9 162,7 120,0 265,1 187,8 214,1 
HLS 926,4 366,3 793,0 352,1 781,1 696,8 898,4 597,8 367,3 463,5 378,1 477,7 560,3 472,3 352,2 339,3 252,5 542,3 342,6 439,2 
VLE 252,1 161,5 271,9 125,2 232,7 289,1 308,8 222,5 143,0 150,1 124,2 190,6 222,8 172,2 127,0 145,4 102,1 234,2 154,5 184,2 
7 
YVG 677,8 278,5 418,9 234,4 370,7 806,3 350,1 357,7 162,7 199,0 288,7 522,6 340,9 170,3 228,6 274,2 128,2 291,8 130,5 293,9 
EQL 1054,0 360,1 511,1 293,1 797,0 1000,6 381,1 456,3 188,5 202,4 245,0 540,2 277,7 185,5 215,8 312,1 141,3 295,5 152,9 368,5 
SDVV 907,8 707,3 1044,9 174,9 656,3 1544,4 770,0 437,5 305,7 355,5 478,4 1187,9 692,8 428,5 552,4 662,2 373,1 648,5 418,1 933,6 
8 
EHV 291,8 144,7 252,7 120,5 179,2 291,5 248,4 165,3 137,6 114,7 92,7 238,2 190,5 141,7 146,9 161,6 89,2 191,4 100,9 114,2 
EQL 58,2 1602,8 3747,8 2933,3 7633,3 9802,0 6475,6 4893,3 2179,8 1551,6 1159,1 2868,4 1752,7 1495,3 1677,7 2391,5 1380,4 2838,9 1277,4 1367,0 
SDVM 454,6 256,6 507,0 382,6 286,2 489,1 427,6 676,8 184,3 166,8 120,9 441,8 390,3 280,5 302,2 336,0 182,2 372,0 236,7 263,9 
9 
EIG 159,4 142,4 231,7 108,6 167,7 309,1 178,9 153,5 77,4 120,6 157,0 213,6 156,5 111,3 85,9 112,0 36,9 147,4 104,1 77,4 
AVL 6710,7 3007,5 5406,2 3256,0 6383,7 7023,6 4494,3 3511,3 1612,1 2890,7 3611,5 5209,0 3622,7 2336,3 1620,7 2344,0 847,7 2950,8 2072,1 1627,8 
10 
VGY 1119,4 1352,5 2543,0 1078,4 1324,1 2571,3 986,4 1105,6 320,4 859,3 1283,5 2128,4 1087,3 900,9 1080,9 1120,8 693,6 1363,4 440,3 1111,9 
VTS 1196,7 1399,7 2755,2 1229,8 1525,9 2865,1 1001,0 1119,4 299,8 932,5 1511,1 2478,5 1084,5 942,9 1178,0 1178,8 666,5 1355,0 430,0 1171,0 
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  RF+/ACPA+ 
2B Sample ID 130 131 132 135 137 138 139 144 148 149 156 158 159 160 162 165 167 169 170 176 
Protein Peptide µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
1 
ALG 48,0 41,0 21,7 28,7 31,7 13,8 37,2 20,8 38,7 13,5 14,8 15,4 12,4 19,5 6,6 23,6 25,7 20,3 24,6 33,5 
TLD 119,7 122,6 51,0 72,3 108,6 32,1 40,1 51,2 82,0 32,3 42,6 28,8 19,5 28,9 13,0 38,1 47,8 42,4 43,2 62,6 
DLL 48,2 43,8 21,5 27,5 32,1 13,5 18,0 21,8 41,5 16,9 19,0 12,8 9,4 17,4 7,3 24,1 24,3 20,7 24,4 31,4 
2 
ATF 1406,2 2635,2 2311,3 1768,2 701,5 173,4 1326,8 1585,7 2638,2 815,5 877,4 811,6 729,2 770,3 464,2 1450,6 1352,6 950,4 2679,5 1690,2 
IPS 2200,4 4052,7 3822,5 2248,5 1003,5 603,0 2421,0 2654,9 4547,4 982,7 1410,7 1454,1 1665,6 1882,6 581,1 2703,3 2817,3 2088,3 5529,5 3807,8 
TSS 663,2 1346,2 1285,7 1256,7 1163,8 469,4 811,6 1081,8 1614,1 884,0 714,9 663,1 535,6 674,3 315,6 807,6 827,9 544,9 1495,5 1083,6 
3 
GVT 533,1 658,5 619,7 497,1 498,0 284,0 447,4 567,2 787,2 427,1 331,9 277,3 215,1 292,2 186,8 382,1 500,5 412,9 562,7 864,7 
LED 124,6 155,0 140,0 103,4 106,3 60,9 120,7 142,1 209,2 124,6 100,4 75,3 58,7 100,6 49,9 114,0 159,7 133,5 168,0 292,4 
4 
WEL 679,0 1394,5 823,9 932,0 1360,8 492,7 1114,9 1159,6 1592,1 946,5 738,2 718,4 792,2 821,9 338,4 985,0 998,9 973,5 1358,9 1552,0 
VIP 121,0 283,8 280,7 205,4 279,0 125,1 190,5 204,1 299,4 185,3 162,6 155,1 175,0 158,9 70,4 194,0 191,1 188,0 259,9 248,3 
EAQ 124,7 214,7 257,9 174,7 218,6 86,6 181,0 173,8 241,7 153,6 114,7 123,0 133,6 118,8 51,5 148,1 145,3 150,5 195,1 209,1 
5 
YWG 15,8 80,7 74,6 41,0 54,5 13,9 35,9 48,9 59,8 46,0 38,3 26,8 40,4 37,6 26,7 53,5 63,3 47,0 56,4 77,1 
LLN 185,8 1125,5 995,3 686,8 1020,9 145,5 536,7 533,3 735,0 227,3 231,7 311,5 259,4 309,6 181,6 369,5 522,4 381,2 458,3 600,9 
6 
YTF 193,5 336,5 319,9 258,5 338,2 112,6 218,2 219,2 290,6 161,9 137,1 138,6 176,9 149,5 59,9 208,0 227,8 219,0 295,7 284,3 
HLS 418,2 787,8 790,6 640,0 937,5 296,1 579,4 504,3 662,0 541,6 417,9 364,4 414,8 355,0 150,4 505,0 484,1 489,7 635,8 550,2 
VLE 122,1 343,6 287,1 189,2 290,5 93,9 189,9 195,0 264,3 181,9 144,5 126,7 148,5 128,8 54,8 170,3 188,4 191,7 264,7 239,7 
7 
YVG 500,2 621,1 421,8 529,5 905,3 365,9 413,2 441,0 442,5 163,3 260,8 268,3 232,2 408,4 129,8 448,2 459,0 432,4 366,5 541,6 
EQL 601,4 676,1 515,9 663,1 1149,2 380,6 470,5 484,1 545,2 156,0 274,6 265,6 246,8 356,3 109,0 409,4 475,4 413,8 411,7 656,9 
SDVV 1249,5 1409,5 1066,0 1181,9 1514,8 666,6 810,1 1000,1 901,6 340,7 537,6 494,8 630,9 873,8 206,6 1007,6 470,3 952,0 843,5 1668,7 
8 
EHV 113,9 303,8 318,9 155,2 273,2 152,0 202,7 238,0 232,5 116,4 130,6 89,5 91,2 183,0 43,3 217,2 174,9 139,9 126,7 272,0 
EQL 1833,6 4924,0 4223,0 3863,3 8066,3 2416,5 4992,7 6269,1 5556,6 1553,2 2259,9 1499,9 1012,5 2250,1 457,0 2113,3 2854,6 2217,3 1807,2 4135,9 
SDVM 232,0 575,7 616,7 259,3 368,5 239,1 323,9 425,7 424,4 186,3 202,4 146,4 184,5 360,2 68,2 403,7 974,1 264,1 247,9 673,4 
9 
EIG 209,9 275,2 173,2 184,9 464,1 119,4 213,9 202,0 209,1 79,3 118,1 97,8 95,1 163,8 62,7 163,1 168,4 202,6 160,3 323,2 
AVL 4286,4 7050,9 3852,8 4282,5 12553,8 2535,5 4895,2 4551,1 5859,3 1868,5 2435,8 2375,7 2385,5 3824,5 1313,2 3460,5 3441,9 4065,2 3103,2 6445,0 
10 
VGY 1808,2 2165,9 1596,9 1863,9 2026,6 1143,5 942,0 1322,3 1548,4 826,7 1218,2 968,0 1120,8 1348,9 432,0 1731,5 1776,7 1057,8 1945,9 2626,6 
VTS 2046,4 2498,4 1659,8 1980,6 2388,4 1399,7 973,8 1383,1 1601,0 884,8 1366,1 953,4 1232,2 1560,9 451,5 1923,9 1987,3 1055,3 2053,0 2861,5 
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  RF+/ACPA- 
2C Sample ID 133 136 141 168 175 199 206 243 276 286 289 290 293 303 314 322 329 332 337 347 
Protein Peptide µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
1 
ALG 39,2 20,2 24,4 19,7 14,9 13,0 28,6 30,9 47,7 27,3 165,6 1474,1 3,0 12,3 5,2 8,7 1,5 8,4 9,1 66,1 
TLD 33,8 36,0 45,2 31,1 23,4 20,9 52,7 49,4 47,2 51,6 23,5 24,5 33,6 24,3 21,8 51,2 81,2 59,9 65,7 85,9 
DLL 20,0 17,3 22,8 19,6 11,8 11,0 25,3 29,6 23,8 24,7 16,2 12,9 19,4 12,8 12,7 30,1 43,8 28,5 34,4 44,9 
2 
ATF 1802,6 1636,1 1574,5 1283,5 861,0 760,8 1107,6 1962,8 768,4 617,2 765,3 471,9 1114,7 882,8 1134,0 966,6 1365,9 1242,7 1764,4 891,3 
IPS 3354,3 3428,4 3706,9 2982,1 1865,7 1366,2 1874,0 4133,9 1316,8 962,5 1489,7 912,0 2145,1 1736,9 2110,0 2027,3 2809,3 2590,8 3268,4 1607,0 
TSS 1135,2 984,8 1055,4 1356,7 957,3 828,6 675,7 2034,3 708,2 760,5 772,4 508,6 1182,2 817,4 934,5 819,0 962,3 835,1 1245,8 614,9 
3 
GVT 629,7 387,3 372,4 153,6 325,5 382,8 469,2 574,6 502,5 576,3 201,2 247,0 442,0 459,5 397,8 449,4 511,7 150,6 594,0 444,5 
LED 238,7 164,3 144,7 5,1 88,8 90,5 120,8 154,4 124,4 159,2 38,4 64,0 90,9 116,9 106,6 109,4 214,1 26,7 223,1 185,1 
4 
WEL 1580,5 1069,5 1147,9 2001,5 1172,3 1050,6 1515,0 2233,1 957,5 1357,0 1038,9 921,8 1561,9 1498,2 1093,2 2145,0 1945,0 2067,8 1812,4 1202,8 
VIP 281,7 145,5 206,1 308,1 199,2 165,0 239,8 330,8 196,5 243,2 172,6 159,1 262,7 214,3 148,8 295,8 223,8 252,8 242,4 149,9 
EAQ 253,4 143,2 177,0 232,1 164,0 144,0 139,0 240,2 129,2 163,7 115,3 118,1 220,8 216,3 110,3 244,1 185,8 223,7 203,3 138,7 
5 
YWG 85,6 38,6 55,2 97,5 57,3 33,8 34,7 78,5 47,0 55,7 31,4 35,3 46,2 55,9 39,1 71,1 53,2 47,0 63,5 36,4 
LLN 659,1 298,9 395,1 434,0 276,1 200,9 159,2 361,5 255,0 233,6 193,2 221,9 215,5 261,4 167,3 303,3 289,8 273,5 318,2 165,7 
6 
YTF 322,8 255,0 231,7 264,7 180,8 157,9 158,3 305,6 140,6 166,9 155,7 122,8 229,5 256,3 161,8 301,0 298,9 365,7 295,1 225,3 
HLS 674,1 497,4 437,0 690,1 450,2 399,5 432,3 821,6 385,1 425,2 408,8 336,4 572,9 633,3 370,5 704,4 670,4 818,9 623,4 454,5 
VLE 249,7 223,6 216,0 221,8 169,8 136,0 134,8 261,4 137,5 162,1 119,2 113,7 210,6 233,1 129,2 231,1 234,4 299,5 250,7 175,9 
7 
YVG 348,3 296,2 342,7 440,8 202,5 188,0 475,6 370,1 517,7 529,1 197,6 158,6 373,1 237,4 232,5 579,4 377,1 178,2 530,7 546,4 
EQL 375,4 404,9 370,1 289,7 186,2 169,9 416,8 303,2 382,9 436,5 163,1 127,3 315,8 194,5 224,8 445,4 427,1 193,8 632,0 620,5 
SDVV 1187,3 1034,4 1026,2 970,6 499,2 438,7 1062,9 1194,6 1090,3 1316,5 435,3 370,8 781,0 462,3 657,8 1397,2 1273,7 773,5 1536,1 1720,2 
8 
EHV 147,3 211,4 115,5 235,5 133,0 84,0 194,8 237,2 192,3 175,0 119,8 94,4 176,3 181,1 137,5 211,4 207,6 114,3 256,8 238,1 
EQL 1875,0 2689,8 1477,4 2269,7 1277,4 719,4 2462,0 2930,6 2067,1 1716,4 1602,8 1280,2 2036,6 2035,1 1608,4 2001,4 3430,0 1801,0 3700,5 3016,1 
SDVM 336,6 467,5 266,4 473,5 247,8 154,5 414,5 502,6 382,5 392,3 204,6 132,7 278,8 305,9 252,8 398,7 520,4 261,5 643,1 571,2 
9 
EIG 144,2 211,7 144,2 92,8 120,3 105,3 273,0 163,1 181,7 298,0 130,5 77,9 123,3 142,2 95,7 166,8 172,6 147,8 254,5 327,6 
AVL 2660,3 4343,1 2922,6 5071,3 2866,9 2653,4 5777,3 3642,3 4358,2 6543,9 2951,0 1797,9 2663,0 3117,1 2058,1 4114,4 3069,3 2849,2 4899,7 7373,9 
10 
VGY 1731,8 1196,7 984,0 1142,5 555,5 1196,0 1279,5 1189,5 1716,7 2832,2 463,7 449,7 713,6 1486,7 1144,4 2126,1 2520,1 1195,3 2092,3 1374,2 
VTS 1880,4 1212,1 975,6 1166,2 563,7 1239,4 1342,0 1223,1 1587,1 2644,6 500,1 471,0 708,4 1529,6 1295,3 2172,3 2571,8 1167,5 2038,8 1366,6 
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  RF-/ACPA+ 
2D Sample ID 125 134 143 152 172 174 230 240 256 258 261 269 280 288 304 313 336 341 356 357 
Protein Peptide µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml 
1 
ALG 18,0 10,6 27,1 12,7 31,7 11,9 28,0 75,0 83,2 24,3 10,9 279,5 0,0 1,2 1,3 1,7 1,4 10,0 4,0 6,9 
TLD 29,5 16,7 42,9 20,4 56,5 21,8 55,2 36,6 21,4 69,9 26,9 34,9 44,9 27,3 35,0 52,2 33,9 52,2 39,7 121,3 
DLL 14,6 8,7 22,3 8,2 29,4 11,9 30,5 17,1 13,5 42,7 14,6 17,9 19,3 12,0 19,8 23,3 16,4 26,7 19,1 61,4 
2 
ATF 1810,1 623,1 2056,6 1178,2 1390,0 865,0 1958,3 608,3 940,6 1241,9 516,3 1097,2 1673,6 498,8 1000,8 2532,2 1195,3 1368,9 1366,8 3300,6 
IPS 1991,4 1014,3 3006,5 1876,4 2028,1 1237,4 3130,0 1210,2 1761,2 2472,5 878,0 2234,9 2810,9 848,1 1974,7 4428,2 2368,6 2538,7 2355,3 5223,0 
TSS 954,7 552,1 1279,9 673,8 678,8 571,7 1107,7 400,9 612,8 885,9 787,6 770,9 1399,9 806,9 992,6 1618,1 997,6 1012,6 885,3 1613,2 
3 
GVT 355,9 234,2 430,2 300,8 604,4 30,2 70,5 137,1 531,6 531,3 442,4 403,5 662,8 324,6 511,4 528,6 527,1 459,6 162,2 911,2 
LED 89,2 66,8 128,4 73,4 155,9 2,3 13,8 22,6 127,6 138,9 91,0 127,6 123,6 71,5 134,6 165,5 167,7 164,0 47,1 444,6 
4 
WEL 1524,0 755,6 1739,2 935,0 1269,4 1056,2 1900,7 810,1 1172,4 1853,9 1235,4 1322,5 1931,7 458,8 1463,0 2220,8 2078,2 1515,7 1565,5 2899,4 
VIP 195,6 100,2 257,1 123,5 172,6 137,5 266,9 122,0 172,3 295,5 179,0 210,1 376,3 77,5 206,5 299,1 230,0 167,0 167,2 277,5 
EAQ 175,8 91,7 218,9 105,1 138,4 120,2 191,8 111,1 169,2 243,2 171,7 164,5 252,7 181,3 175,8 288,0 225,3 184,6 172,0 324,6 
5 
YWG 51,5 30,8 63,4 50,2 63,0 33,0 96,1 34,8 36,7 74,2 43,0 38,3 64,8 5,7 59,5 77,6 49,3 22,3 42,7 38,2 
LLN 256,8 179,6 401,4 366,6 415,6 181,2 660,7 200,7 251,6 389,0 255,2 192,1 383,9 11,5 299,8 424,3 296,2 84,4 282,6 253,4 
6 
YTF 241,6 120,4 280,6 164,8 178,3 117,7 222,5 236,3 195,9 264,6 128,8 204,1 257,7 185,3 207,6 292,1 261,8 257,2 216,2 449,9 
HLS 601,6 291,7 634,6 399,9 542,5 332,1 661,5 711,3 490,9 708,9 507,9 544,5 748,9 495,9 538,9 726,7 608,3 612,3 439,0 880,4 
VLE 217,4 106,0 254,4 139,7 185,0 117,1 245,8 255,7 171,5 243,2 203,4 192,2 209,6 184,3 179,6 298,0 222,1 217,8 182,0 387,5 
7 
YVG 278,8 130,5 293,6 243,9 613,1 216,5 665,8 194,9 396,4 743,2 288,7 344,1 482,6 159,1 356,4 385,1 255,3 295,1 235,1 535,2 
EQL 292,9 121,9 283,5 223,5 578,3 179,4 485,8 166,2 345,7 646,5 162,0 320,2 346,0 44,6 318,5 444,7 273,2 320,5 262,2 813,6 
SDVV 717,6 313,8 827,2 614,0 1336,1 915,8 4647,0 342,1 953,8 1623,6 450,2 823,3 980,3 611,0 457,5 1320,3 851,8 1010,4 789,1 2241,9 
8 
EHV 174,4 81,5 221,6 137,8 297,9 117,2 164,0 136,2 128,1 380,2 183,3 116,7 308,3 117,1 147,6 299,2 206,8 176,3 168,3 294,2 
EQL 1726,9 729,3 2293,5 1437,1 3233,3 1416,3 1654,0 1508,0 1277,7 3653,7 1256,4 1111,2 3150,8 497,5 1540,6 3730,8 2168,3 2128,4 1747,9 3177,0 
SDVM 376,5 170,4 462,1 306,6 614,6 330,0 361,5 198,1 207,3 607,7 229,1 208,2 477,4 194,2 650,8 668,4 461,9 424,8 404,7 842,5 
9 
EIG 109,1 92,6 184,2 122,3 340,8 90,3 256,1 110,7 194,1 352,9 132,6 178,9 154,2 119,0 139,8 199,9 136,2 217,6 158,6 420,8 
AVL 2311,6 1893,5 3114,0 2442,6 7192,6 1746,9 5563,5 2767,0 4287,8 5893,1 2501,5 3770,8 2823,7 2450,1 2817,8 4110,5 2720,3 4091,8 2781,9 7125,1 
10 
VGY 894,8 794,3 1883,9 1099,2 2228,4 632,2 1733,9 868,1 1610,1 2500,1 499,9 914,7 746,9 132,8 593,7 2847,2 1863,5 2119,0 852,8 2303,2 
VTS 928,7 804,0 1863,9 1096,4 2368,4 553,8 1809,4 906,8 1637,3 2548,6 508,7 915,3 833,4 153,0 634,5 2722,0 1847,6 2133,9 861,1 2323,1 
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As it is clear from Tables 2A-D, with the same protein but considering different 
peptides, different concentration values of the target protein are obtained. This 
phenomenon is due to several factors such as the non-total protein hydrolysis with 
trypsin, the different intrinsic ease of ionization and fragmentation efficiency of 
peptides28 and, above all, the suppression of ionization effect due to the matrix 
complexity. 
This unique method allows to quantify the ten target proteins simultaneously 
in a single analysis, overcoming the problems of multiplex analyses that occur with 
enzyme immunoassays, such as ELISAs. In addition, without fractionation or 
enrichment strategies, MRM assays allow for the quantitation of protein in the low 
μg/mL or high ng/mL concentration range, whereas immunoaffinity depletion of 
abundant blood proteins and minimal protein fractionation can enable quantitation 
in the low ng/mL range. 
5.3.3 Prism analysis 
In this section the statistical analysis results are reported. Non-parametric 
Mann-Whitney tests, on peak area ratio (endogenous/heavy) obtained from sera 
sample analyses, were performed by using Prism GraphPad version 7.  
The RF-/ACPA- sub-group, also called serum negative condition (SNRA) 
condition, was selected as Control condition, as published data reports, because a 
low percentage of subjects with rheumatoid arthritis is classified as serum negative. 
SNRA patients manifested more active disease at baseline but showed a better 
response to treatment compared with SPRA. SNRA does not appear to be a benign 
subtype of RA24.  
In addition, patients with this condition present a long-term minor damage 
compared to those who are seropositive for RF only and these in turn presenting a 
lesser degree of detriment than those in which the RA is diagnosed with positive 
ACPA14.  
Several peptides were identified that show a statistically significant modulation 
(p <0.05) as indicated in Figures 3, 4 and 5. All the figures show the ratio of the 
area of the endogenous peptide to its standard in relation to the conditions of study. 
In Figure 3, the comparison of the RF+/ACPA+ condition versus the control 
(RF-/ACPA-) is shown. 9 peptides, belonging to proteins 1, 7, 9 and 10, are 
significantly increased in RF+/ACPA+. 
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Figura 3:  Modulated peptides (P-value <0.05) in the comparison of RF+/ACPA+ condition versus the 
control (RF-/ACPA-). Peptides: ALG, DLL (protein 1), YVG, EQL, SDV (protein 7), EIG, AVL (protein 
9), and VGY, VTS (protein 10). 
In the RF+/ACPA- condition (Figure 4), there are 7 statistically modulated 
peptides. These peptides belong to proteins 4, 5, 6, 7 and 9. All are increased, except 
those belonging to protein 5. 
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Figura 4: Modulated peptides (P-value <0.05) in the comparison of the RF+/ACPA- condition versus the control 
(RF-/ACPA-). Peptides: WEL, VIP (protein 4), LLN, YWG (protein 5), YTF (protein 6), SDV (protein) and EIG 
(protein 9). 
Finally, Figure 5 shows the 9 statistically enhanced peptides obtained in the 
comparison of the RF-/ACPA+ condition and the control. These belong to proteins 
4, 5, 6, 7, 8 and 9 and, as in the previous case, they are all increased except for the 
peptides of protein 5. 
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Figura 5: Modulated peptides (P-value <0.05) in the comparison of the RF-/ACPA+ condition versus the control 
(RF-/ACPA-). Peptides: WEL, EAQ (protein 4), HLS, VLE (protein 6), EHY, SDV (protein 9), LLN (protein 5), 
SDV (protein 7) and EIG (protein 9). 
The statistical analysis allowed us to observe that, of the 26 peptides analysed, 
significant differences were found in 19 of them (Table 3). 
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Table 3: This table summarized all the statistically significant peptides (p<0,05) for the three 
conditions RF+/ACPA+, RF-/ACPA+ and RF+/ACPA- against the selected control condition RF-
/ACPA-. 
Protein Peptide RF+/ACPA+ RF+/ACPA- RF-/ACPA- 
1 
ALG X   
DLL X   
4 
WEL  X X 
EAQ   X 
VIP  X  
5 
LLN  X X 
YWG  X  
6 
HLS   X 
VLE   X 
YTF  X  
7 
YVG X   
EQL X   
SDVV X X X 
8 
EHV   X 
SDVM   X 
9 
EIG X X X 
AVL X   
10 
VGY X   
VTS X   
 
All proteins are overexpressed except for protein 5, which appears diminished 
in the second and third comparisons. This protein is involved in the vitamin A 
transport regulation through blood plasma from the deposit located in the liver to 
peripheral tissues. This vitamin is essential for growth, cell differentiation and bone 
development, so its low expression could influence the lack of bone recovery in 
patients suffering degradation due to RA. In addition, the SDV and EIG peptides, 
belonging to proteins 7 and 9 respectively, appear increased under all conditions. 
This could indicate that those two proteins are closely related to each other.  
All the proteins that are modulated participate in the immune response of the 
organism and are characterized by increasing their levels during the acute phase 
response. Their functions are also related to inflammatory processes, regulation of 
angiogenesis, cell proliferation and maintenance of soft and bone tissues. In 
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addition, some of them are responsible for transporting other proteins through the 
bloodstream or in the protein storage, hence an alteration in their levels can be very 
harmful to the body. 
Sokolove et al.17, evaluate the interaction and possible relationship of RF and 
ACPA with RA. Comparing the group RF+/ACPA+, with RF-/ACPA-, they 
observed a higher activity of the disease, as well as higher levels of ESR and CRP 
than normal, which can be related to inflammatory processes, in this case derived 
from the RA. In addition, the finding of high levels of several cytokines compared 
to control supports the possible relationship between these biomarkers and the 
disease. 
Aletaha et al.29 revealed that the lowest DAS is associated to seropositive 
patients only for ACPA, while the highest DAS reaches the patients RF+/ACPA+ 
or RF+/ACPA-. These data suggest that high DAS are related to the positivity of 
rheumatoid factor. In addition, they compared the groups avoiding the positive 
double and, apart from obtaining again greater activity in the RF+ group, greater 
activity was seen in the ACPA- group than in the ACPA+, which supports that the 
RF+ is associated with higher DAS and, also, the possibility that ACPA+ is 
associated with less activity. 
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5.4 Conclusion 
The social impact of RA as personal disability, inability to work and costs of 
health urges us to look for serum biomarkers that, together with radiographic data, 
tests of the Rheumatoid Factor and ACPA allow to early diagnose this pathology in 
order to promptly intervene with a therapy that is, as much as possible, ad personam 
and that allows the follow-up of the patient. 
The present work fits perfectly into the research context of potential new 
protein biomarkers for RA diagnostics. 
MRM mass spectrometry guarantees high specificity and selectivity, increased 
by using SIS peptides and allows to overcome the limits of multiplex analysis of 
ELISA enzymatic assays, maintaining, however, comparable sensitivities. 
In this study 80 serum samples of patients with RA were analysed. The samples 
were divided into four sub-groups based on the RF and ACPA values. 
Targeted analysis involved the monitoring and quantification of a panel of ten 
proteins that, from previous large-scale proteomic studies, were significantly 
modulated. These proteins are related to RA because they are involved in the acute 
phase of inflammation, in bone mineralization and in the immune system response. 
Validation of the protein panel in larger cohorts of healthy patients and patients 
with other diseases is necessary to confirm the specificity of these proteins for RA. 
This validation is pending to be carried out by ELISA immunoassays. 
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5.6 Supporting Data 
 
SD Table 1: MRM/MS method. List of selected proteins reporting selected 
peptide sequence, precursor m/z, product ions m/z, Declustering Potential (DP, 
V) and Collision Energy (CE, V).  
Protein 
Peptide 
sequence 
 Precursor ion 
m/z 
Product ion 
 m/z 
Ion type DP (V) CE (V) 
1 ALG 
Light 576,81 
774,41 +2y7 73.2 29.6 
661,33 +2y6 73.2 29.6 
546,3 +2y5 73.2 29.6 
Heavy 581,81 
784,42 +2y7 73.2 29.6 
671,33 +2y6 73.2 29.6 
556,31 +2y5 73.2 29.6 
1 TLD 
Light 1019,05 
1166,68 +2y10 105.4 45.5 
1053,59 +2y9 105.4 45.5 
823,5 +2y7 105.4 45.5 
Heavy 1024,05 
1176,69 +2y10 105.4 45.5 
1063,6 +2y9 105.4 45.5 
833,51 +2y7 105.4 45.5 
1 DLL 
Light 590,34 
838,48 +2y7 74.2 30.1 
725,39 +2y6 74.2 30.1 
342,2 +2b3 74.2 30.1 
Heavy 595,34 
848,49 +2y7 74.2 30.1 
735,4 +2y6 74.2 30.1 
342,2 +2b3 74.2 30.1 
2 ATF 
Light 612 
813,48 +3y7 75.7 30.9 
714,41 +3y6 75.7 30.9 
617,36 +3y5 75.7 30.9 
Heavy 615,33 
823,49 +3y7 75.7 30.9 
724,42 +3y6 75.7 30.9 
627,37 +3y5 75.7 30.9 
2 IPS 
Light 523,31 
835,47 +2y7 69.3 27.7 
748,44 +2y6 69.3 27.7 
649,37 +2y5 69.3 27.7 
Heavy 527,31 
843,48 +2y7 69.3 27.7 
756,45 +2y6 69.3 27.7 
657,38 +2y5 69.3 27.7 
2 TSS Light 808,95 1010,59 +2y9 90.1 38 
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896,55 +2y8 90.1 38 
783,46 +2y7 90.1 38 
Heavy 812,96 
1018,6 +2y9 90.1 38 
904,56 +2y8 90.1 38 
791,48 +2y7 90.1 38 
3 GVT 
Light 913,99 
1055,56 +2y9 97.7 41.8 
472,32 +2y4 97.7 41.8 
1143,58 +2b11 97.7 41.8 
Heavy 919 
1065,57 +2y9 97.7 41.8 
482,33 +2y4 97.7 41.8 
1143,58 +2b11 97.7 41.8 
3 LED 
Light 797,4 
777,45 +2y7 89.2 37.6 
664,37 +2y6 89.2 37.6 
577,33 +2y5 89.2 37.6 
Heavy 801,4 
785,46 +2y7 89.2 37.6 
672,38 +2y6 89.2 37.6 
585,35 +2y5 89.2 37.6 
4 WEL 
Light 544,76 
773,4 +2y6 70.8 28.5 
660,31 +2y5 70.8 28.5 
500,28 +2y4 70.8 28.5 
Heavy 549,77 
783,41 +2y6 70.8 28.5 
670,32 +2y5 70.8 28.5 
510,29 +2y4 70.8 28.5 
4 VIP 
Light 885,96 
1020,51 +2y9 95.7 40.8 
933,48 +2y8 95.7 40.8 
Heavy 890,97 
1030,52 +2y9 95.7 40.8 
943,49 +2y8 95.7 40.8 
4 EAQ 
Light 570,82 
812,49 +2y7 72.7 29.4 
699,4 +2y6 72.7 29.4 
329,15 +2b3 72.7 29.4 
Heavy 574,82 
820,5 +2y7 72.7 29.4 
707,42 +2y6 72.7 29.4 
329,15 +2b3 72.7 29.4 
5 YWG 
Light 599,82 
849,48 +2y8 74.8 30.5 
693,39 +2y6 74.8 30.5 
622,36 +2y5 74.8 30.5 
Heavy 603,82 857,5 +2y8 74.8 30.5 
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701,41 +2y6 74.8 30.5 
630,37 +2y5 74.8 30.5 
5 LLN 
Light 1032,99 
1178,55 +2y10 106.4 46 
1107,51 +2y9 106.4 46 
742,39 +2y6 106.4 46 
Heavy 1037,99 
1188,56 +2y10 106.4 46 
1117,52 +2y9 106.4 46 
752,4 +2y6 106.4 46 
6 YTF 
Light 458,23 
752,39 +2y6 64.5 25.4 
651,35 +2y5 64.5 25.4 
504,28 +2y4 64.5 25.4 
Heavy 463,24 
762,4 +2y6 64.5 25.4 
661,35 +2y5 64.5 25.4 
514,29 +2y4 64.5 25.4 
6 HLS 
Light 418,91 
590,33 +3y5 61.7 20.4 
489,28 +3y4 61.7 20.4 
376,19 +3y3 61.7 20.4 
Heavy 422,25 
600,33 +3y5 61.7 20.4 
499,29 +3y4 61.7 20.4 
386,2 +3y3 61.7 20.4 
6 VLE 
Light 400,25 
700,42 +2y6 60.3 23.3 
458,3 +2y4 60.3 23.3 
Heavy 404,26 
708,44 +2y6 60.3 23.3 
466,31 +2y4 60.3 23.3 
7 YVG 
Light 584,99 
982,62 +3y8 73.8 29.4 
835,55 +3y7 73.8 29.4 
764,51 +3y6 73.8 29.4 
Heavy 588,33 
992,63 +3y8 73.8 29.4 
845,56 +3y7 73.8 29.4 
774,52 +3y6 73.8 29.4 
7 EQL 
Light 871,91 
1186,56 +2y9 94.7 40.2 
1039,49 +2y8 94.7 40.2 
876,42 +2y7 94.7 40.2 
Heavy 876,91 
1196,56 +2y9 94.7 40.2 
1049,5 +2y8 94.7 40.2 
886,43 +2y7 94.7 40.2 
7 SDV Light 556,77 910,47 +2y7 71.7 28.9 
113 
 
811,4 +2y6 71.7 28.9 
401,2 +2b4 71.7 28.9 
Heavy 560,77 
918,48 +2y7 71.7 28.9 
819,41 +2y6 71.7 28.9 
401,2 +2b4 71.7 28.9 
8 EHV 
Light 412,24 
798,5 +3y6 61.2 20 
661,44 +3y5 61.2 20 
548,36 +3y4 61.2 20 
Heavy 415,58 
808,51 +3y6 61.2 20 
671,45 +3y5 61.2 20 
558,36 +3y4 61.2 20 
8 EQL 
Light 705 
1046,51 +3y8 82.5 35.9 
933,43 +3y7 82.5 35.9 
818,4 +3y6 82.5 35.9 
Heavy 708,33 
1056,52 +3y8 82.5 35.9 
943,44 +3y7 82.5 35.9 
828,41 +3y6 82.5 35.9 
8 SDV 
Light 572,75 
942,44 +2y7 72.9 29.5 
843,37 +2y6 72.9 29.5 
712,33 +2y5 72.9 29.5 
Heavy 576,76 
950,45 +2y7 72.9 29.5 
851,38 +2y6 72.9 29.5 
720,34 +2y5 72.9 29.5 
9 EIG 
Light 531,3 
819,46 +2y7 69.8 28 
633,4 +2y5 69.8 28 
520,31 +2y4 69.8 28 
Heavy 535,3 
827,48 +2y7 69.8 28 
641,41 +2y5 69.8 28 
528,33 +2y4 69.8 28 
9 AVL 
Light 954,48 
1134,56 +2y12 100.7 43.2 
1005,52 +2y11 100.7 43.2 
718,41 +2y8 100.7 43.2 
Heavy 958,49 
1142,58 +2y12 100.7 43.2 
1013,54 +2y11 100.7 43.2 
726,42 +2y8 100.7 43.2 
10 VGY Light 490,75 
824,4 +2y7 66.9 26.5 
661,34 +2y6 66.9 26.5 
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562,27 +2y5 66.9 26.5 
Heavy 495,76 
834,41 +2y7 66.9 26.5 
671,35 +2y6 66.9 26.5 
572,28 +2y5 66.9 26.5 
10 VTS 
Light 602,32 
916,49 +2y7 75 30.5 
803,4 +2y6 75 30.5 
675,35 +2y5 75 30.5 
Heavy 606,33 
924,5 +2y7 75 30.5 
811,42 +2y6 75 30.5 
683,36 +2y5 75 30.5 
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SD Figure 1: Calibration curves for each heavy standard peptide.  
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SD Table 2: SIS spiked peptides concentration in sera 
samples. 
 
Labelled Peptide 
Spiked SIS peptides 
concentration (fmol/µL) 
ALG 50 
TLD 100 
DLL 25 
ATF 100 
IPS 50 
TSS 100 
GVT 250 
LED 100 
WEL 250 
VIP 250 
EAQ 100 
YWG 100 
LLN 250 
YTF 100 
HLS 250 
VLE 100 
YVG 250 
EQL 250 
SDVV 250 
EHV 250 
EQL 250 
SDVM 250 
EIG 250 
AVL 250 
VGY 250 
VTS 250 
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Chapter 6 
6.1 Introduction 
In the last three decades the link between forensic investigations and 
scientific disciplines, such as Chemistry and Biology, Biology, has been 
enormously strengthened by the application of new tools for a detailed 
characterization of the crime scene starting from trace evidence. In particular, 
DNA testing is fundamental to identify the individuals involved in a crime often 
leading the investigators to define a unique genetic profile1. 
However, the detection and identification of the type and origin of 
biofluids at a crime scene are just as important as DNA test to link the nature of 
the biofluid, the criminal act and the dynamics of the crime. For example, blood 
stains can indicate some form of physical altercation, whereas detection of 
semen or vaginal fluid can indicate the involvement of some form of sexual 
encounter or assault. Moreover, identification of the specific fluid or tissue from 
which the DNA sample was recovered is fundamental in correctly reconstructing 
the criminal event and the effective role of the donor. 
The most common biofluids found at crime scenes are blood, semen, and 
saliva, but others such as vaginal fluid, urine, and sweat can also be found. Each 
of these fluids has one or more presumptive tests that are initially used to give 
some indication as to the identity of the substance; blood is quickly detected by 
means of luminol or benzidine2, whereas traces of semen, saliva, sweat, urine 
and other biological fluids are detected by ultraviolet light or by other light 
sources at specific wavelengths3. Confirmatory tests, based on biochemical, 
spectroscopic and microscopy methods, and immunochemical techniques, are 
necessary to give a legal value to the trace evidence4-9. 
However, these identification methods suffer from several limitations 
including instability of assayed biomolecules and low selectivity and specificity. 
As an example of the latter issue, it is not possible to discriminate between alpha-
amylase 1 (present in saliva) and 2 (present in semen and vaginal secretion)10. 
Moreover, biochemical assays are specific only for one biological matrix and 
several cascade tests might then be needed before the biological nature of a 
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certain stain is uncovered. This is even more challenging when the sample is a 
mixture of different biological matrices thus greatly increasing the complexity, 
the cost and the time of the analytical procedures. Finally, some confirmatory 
tests very often cause sample loss and they are not compatible with downstream 
individual identification by DNA analysis. 
For all these issues, forensic science is looking for a universal confirmatory 
test for the analysis of unknown stains which will be able to unambiguously 
identify the type and nature of any biofluids that might be present at a crime 
scene. The method should be applicable to mixtures, and, more importantly, 
should preserve the samples for subsequent DNA analysis. Since biofluids have 
evolved to perform different functions, they contain different proteins, or 
different combinations of proteins, providing each biological matrix with a 
unique protein signature that can be used to distinguish among the various 
biofluids11-13. Recently, untargeted proteomics have been introduced for the 
determination of biological matrices in forensic science based on the 
identification of the most prominent proteins present in biofluids11,14. However, 
these methods can give poor or uncertain results when high amounts of non-
specific proteins occur in the samples, i.e. when low amounts of a particular fluid 
are present in combination with high amounts of other matrices or when the 
sample is contaminated by other tissues. 
This paper reports a universal method alternative and complementary to 
"traditional" tests currently used in forensic investigation to identify an unknown 
stain of biofluids occurring at a crime scene. The method is based on a targeted 
proteomic approach that makes use of tandem mass spectrometry in multiple 
reaction monitoring (MRM) mode to selectively monitor a number of specific 
peptides belonging to proteins biomarkers of individual biological fluids. First, 
the most prominent and highly specific protein biomarkers for each biological 
matrix were identified by both conventional LC-MS/MS analyses and 
comparison with literature data. Specific peptide markers of each protein were 
then selected on the basis of their mass spectrometric behavior together with 
their specific precursor ion-product ion transitions as defined by their unique 
amino acid sequence. Then, a single MRM method was devised to detect the 
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occurrence of the target peptides within the sample leading to the unambiguous 
discrimination among the different biological matrices in a single analysis due 
to its high sensitivity, selectivity and accuracy. The optimized method was tested 
and validated on specimens consisting of four biological matrices (blood, saliva, 
semen and urine), or mixtures of matrices, spotted on different substrates like 
cloth, wood, plastic, plaster and paper. Finally, a combined strategy allowing 
both DNA analysis and biofluids identification on the same sample was 
developed and demonstrated to be effective in forensic investigation by the 
analysis of real specimens collected at a crime scene. 
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6.2 Materials and methods 
Control biofluids (blood, saliva, urina, semen) were provided by a private 
chemical laboratory. Guanidine, Tris(idrossimetil)amminometano cloridrato 
(TrisHCl), dithiothreitol (DTT), ethylendiaminetetraacetate (EDTA), trypsin, 
iodoacetamide (IAM), ammonium bicarbonate (AMBIC), trichloroacetic acid 
(TCA) were purchased from Sigma-Aldrich. Bovine serum albumin (BSA), 
formic acid (HCOOH), methanol, chloroform, acetonitrile (ACN) are from J.T. 
Baker. Bradford staining solution was from Bio-Rad. Pipette tips C18 (zip tip) 
and centrifugal filter units were purchased from Merck Millipore.  
6.2.1 In-solution digestion of proteins from biological matrices  
Different protocols were performed to improve the number of identified 
proteins and thus to provide the higher sequence coverage for blood, urine, 
semen and saliva. A protocol of protein precipitation by using 
chloroform/methanol/water15 was carried out for each biofluids. After 
precipitation, protein concentration was determined by Bradford assay using 
BSA as standard16. Samples were submitted to reduction, alkylation and tryptic 
digestion. Samples were dissolved in denaturant buffer (urea 6 M, Tris 300 mM 
pH 8.0, EDTA 10 mM) containing DTT (10-fold molar excess on the Cys 
residues) at 37 °C for 2 h and then iodoacetamide (IAM) was added to perform 
carboamidomethylation using an excess of alkylating agent (5-fold molar excess 
on thiol residues). The mixture was then incubated in the dark at room 
temperature for 30 minutes. The product was purified by 
chloroform/methanol/water precipitation. Supernatants were removed, and the 
pellets were dried. Digestion of proteins mixture was carried out in AMBIC 10 
mM using trypsin at a 50:1 protein:enzyme mass ratio. The samples were 
incubated at 37°C for 16 h and after acidification (10% HCOOH) they were 
dried. To eliminate any impurities the samples were suspended in 200 μL of 
AMBIC 100 mM, filtrated by centrifugal filter units (0.22 μm), and dried in a 
speed-vacuum concentrator. Finally, samples were suspended in 20 μL of 
HCOOH 1% and purified by reverse phase chromatography using ZipTip C18 
cartridges (Millipore). Samples were evaporated and suspended in 10 μL of 
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HCOOH 0.1% and analysed by nanoLC-MS/MS and then by LC-MRM/MS as 
described below. 
In order to improve the number of identified proteins from blood by LC-
MS/MS, a step of depletion of abundant proteins was carried out using 
ProteoPrepR 20 Plasma Immunodepletion KitProteoprep® 20 Plasma 
Immunodepletion Kit (Sigma Aldrich, Milan, Italy) able to deplete twenty highly 
abundant proteins from human plasma or serum. Dried extracted proteins were 
subjected to reduction, carboamidomethylation, chloroform/methanol/water 
precipitation protocol and tryptic hydrolysis as described above. 
Protein precipitation from urine was also performed using cold acetone 
followed by the same steps of tryptic digestion as described above. Cold acetone 
at -20°C (400 μL) was added to urine (100 μL) and incubated at -20°C for 2h. 
After centrifugation at 12,000 rpm for 15 min the pellet was collected and dried 
under vacuum. 
Protein precipitation from semen was also carried out using TCA. Semen 
was centrifuged (13,000 rpm, 30 min) to remove cellular material, and the 
proteins were precipitated (4°C, 60 min) using an equal volume of cold TCA at 
final concentration of 10%. Following further centrifugation (10,000 rpm, 30 
min), the supernatant was removed and the protein pellet washed with cold 
acetone (three times) to remove residual TCA. 
Therefore, a unique precipitation/sample preparation procedure based on 
chloroform/methanol/water was adopted for all the samples because the origin 
or matrix of casework samples. 
6.2.2 Test Specimens 
Twenty test forensic samples were prepared by drying different biological 
fluids (100 µl) or mixture of them on various substrates: cloth, wood, plastic, 
plaster and paper. Cloths were put directly in a plastic tube while the samples on 
the other substrates were recovered by a cotton-swab (Agilent Technologies, 
Palo Alto, CA). Samples were collected in plastic tubes and 2 ml of AMBIC 50 
mM were added for 16 h under gentle agitation. Samples were then sonicated for 
20 min and submitted to chloroform/methanol/water precipitation. After 
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precipitation, reduction, alkylation and tryptic digestion were performed as 
previously described. The resulting peptide mixtures were analysed by LC-
MRM/MS as described below. 
6.2.3 Analysis of real samples 
Real samples consisting of traces of unknown biological fluids on cloths, 
paper and stubs collected at a crime scene (Sample1, Sample 2, Sample 3) were 
provided by RIS Laboratory in Rome. Samples were treated as described above 
(see Test Specimens section) and submitted to tryptic digestion. Then, gDNA 
was extracted from the samples using the robotic platform Qiagen Biorobot EZ1 
Advanced XL using the Qiagen EZ1 DNA Investigator kit17. The DNA was then 
washed and eluted in water. DNA degradation and quantification level were 
evaluated by multiplex RT-PCR using the Quantifiler™ Trio DNA 
Quantification Kit (Applied Biosystems, CA, USA) on a 7500 Real-Time PCR 
System (Applied Biosystems)18. Results showed a total DNA amount of 
0.081ng/µl for Sample 1, 0.71 ng/µl for Sample 2 and 1.05 ng/µl for Sample 3. 
Samples were also tested for possible DNA degradation showing a good quality 
with a degradation index of about 1.0 for all samples.  
DNA profiling was obtained by multiple amplification of 17 polymorphic 
regions comprising the D3S1358, vWA, FGA, D8S1179, D21S11, D18S51, 
TH01, D16S539, D2S1338, D19S433, ACTBP2 (SE33), D1S1656, D2S441, 
D10S1248, D12S391, D22S1045 and Amelogenin STR loci using the 
Investigator ES Splex SE Plus Kit Qiagen (Qiagen, Hilden, Germany)18. 
Amplified DNA was analysed by automated DNA sequencing on an Applied 
Biosystems 3500xL Genetic Analyzer19-21. Data were collected and elaborated 
using the 3500 Series Data Collection Software v. 2.0and the Gene Mapper ID-
X Software v.1.4 (Life Technologies, Carlsbad, CA, USA). 
6.2.4 LC-MS/MS analysis 
Peptide mixture were analyzed by LC-MS/MS on a 6520 Accurate-Mass 
Q-TOF LC/MS system (Agilent Technologies) equipped with a 1200 HPLC 
system and a chip cube (Agilent Technologies). After loading, the peptide 
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mixture (1 μL) was concentrated and desalted at flow rate of 4 μL/min in a 40 
nL enrichment column (Agilent Technologies chip) with 0.1% HCOOH as 
eluent. The sample was then fractionated on a C18 reverse phase capillary 
column (75 μm*43 mm in the Agilent Technologies chip) at flow rate of 400 
nL/min, with a linear gradient of eluent B (0.1% HCOOH in 95% acetonitrile) 
in A (0.1% HCOOH in 2% acetonitrile) from 5% to 80% in 50 min. Peptides 
analysis was performed using data-dependent acquisition of one MS scan (mass 
range m/z 300-2400) followed by MS/MS scan of the five most abundant ions in 
each MS scan. MS/MS spectra were measured automatically when the MS signal 
was greater than the threshold of 50000 counts. Doubly- and triply- charged ions 
were preferably isolated and fragmented over singly charged ions. Data were 
acquired through Mass Hunter software (Agilent Technologies). The acquired 
data, containing MS and MS/MS spectra, were transformed in .mgf format and 
used for protein identification with a licensed version of Mascot Software 
(www.matrixscience.com). 
Mascot search parameters included: NCBInr as database; Trypsin as 
enzyme, allowed number of missed cleavage 3; Homo-Sapiens as taxonomy; 
carbamidomethyl, C as fixed modifications; oxidation of methionine (oxidation 
(M));, Gln pyro-Glu (N-term Q) as variable modifications; 10 ppm MS tolerance, 
0.6 Da MS/MS tolerance and peptide charge, from +2 to +3.  
6.2.5 MRM targeted proteomic approach 
In order to build up a targeted MRM method, Skyline software (3.7, 64 bit 
version MacCoss Lab Software, University of Washington, USA) was used for 
the in silico selection of peptides with unique sequence for each selected protein. 
For each peptide, m/z precursor ion, m/z product ions and relative collision 
energy were provided by Skyline. Peptide mixture was analysed by LC-MS/MS 
analysis using a Xevo TQ-S (Waters) equipped with an IonKey UPLC 
Microflow Source coupled to an UPLC Acquity System (Waters). For each run, 
1 μL peptide mixture was injected and separated on a TS3 1.0 mm × 150 mm 
analytical RP column (Waters, Milford, MA, USA) at 45°C with flow rate of 3 
μl/min using 0.1% HCOOH in water (LC-MS grade) as eluent A and 0.1% 
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HCOOH in ACN as eluent B. Peptides were eluted (starting 1 min after 
injection) with a linear gradient of eluent B in A from 7% to 95% in 55 min. The 
column was re-equilibrated at initial conditions for 4 min. The MRM mass 
spectrometric analyses were performed in positive ion mode using MRM 
detection window of 0.5-1.6 min per peptide; the duty cycle was set to automatic 
and dwell times were minimal 5 ms. Cone voltage was set to 35 V.  
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6.3 Results 
6.3.1 Selection of protein biomarkers of biological matrices 
Four biological matrices, blood, saliva, urine and semen, representative of 
biofluids recovered at crime scenes, were analysed to identify specific protein 
biomarkers candidates for each matrix. Different procedures for sample 
preparation were investigated (Material and Methods section). As an example, 
results obtained for blood with the only chloroform/methanol/water precipitation 
followed by tryptic hydrolysis, are shown in Table 1A where GI number, the 
name of identified proteins, the number of peptides and the corresponding 
sequence coverage are reported. 
The unsatisfactory number of identified proteins in the original assay 
severely limited the choice of specific protein biomarkers for blood candidates 
for the MRM method because the dominant abundance of unselective blood 
proteins. Thus, a different sample preparation procedure was then explored by a 
depletion step from the most abundant proteins to improve protein identification 
(Table 1B). A significantly higher number of peptides were identified for each 
protein leading to a much larger sequence coverage.  
 
Table 1A. List of the identified proteins following the chloroform/methanol/water 
precipitation protocol applied to human blood sample. Table 1B. List of the identified proteins 
following the depletion step previous to the chloroform/methanol/water precipitation protocol. 
The Gi number, the number of peptides, the corresponding Mascot score and sequence 
coverage are reported for human blood sample. 
Table 1A 
GI number Identification MascotScore 
Number 
of 
Peptides 
Sequence 
Coverage 
(%) 
Gi|3212456 
Chain A, Crystal 
Structure Of Human 
Serum Albumin 
1186 35 24 
Gi|90108664 
Chain A, Crystal 
Structure Of Lipid-Free 
602 18 22 
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Human Apolipoprotein 
A-I 
Gi|2765421 
Immunoglobulin Kappa 
Heavy Chain 
192 4 34 
Gi|28637 Alpha-1 Antitrypsin 188 5 5 
Gi|386789 Hemopexin Precursor 178 7 10 
Gi|28810 
Beta-2-Glycoprotein  
Apolipoprotein H 
160 6 1 
Gi|4557871 Serotransferrin Precursor 146 6 5 
Gi|38026 Zn-Alpha2-Glycoprotein 75 2 5 
Gi|112910 Alpha-2-HS-Glycoprotein 71 2 4 
Table 1B 
Gi number Identification MascotScore 
Number 
of 
Peptides 
Sequence 
Coverage 
(%) 
Gi|1431650 Chain β Of Hemoglobin 156 6 20 
Gi|229751 Chain α of Hemoglobin 138 4 15 
Gi|3212456 
Chain A, Crystal 
Structure Of Human 
Serum Albumin 
1995 48 34 
Gi|194383506 Serum Transferrin 1012 34 29 
Gi|90108664 
Chain A, Crystal 
Structure Of Lipid-Free 
Human Apolipoprotein 
A-I 
562 22 27 
Gi|177870 Alpha-2-Macroglobulin 485 17 7 
Gi|13787109 Alpha-1-antitrypsin 337 12 14 
 
Improved results were also obtained in saliva, semen, and urine analysis 
by using the chloroform/methanol/water precipitation protocol. Table S-1 in 
Supplementary information (SI) reports the lists of the different proteins 
identified for the other matrices, including the GI number, the number of 
peptides and the Mascot score. 
Proteins identified for each biofluids by LC-MS/MS were then compared 
with literature data11 to eventually select the most specific protein biomarkers 
for each biological matrix. Following this procedure, proteins listed in Table S-
2 were chosen as representative for each biological fluid. 
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6.3.2 Development of MRM methods specific for each biological matrix 
and a single MRM method for all the matrices 
Several unique peptides belonging to the target proteins characteristic of 
individual biological matrix were selected by in silico analysis using the Skyline 
software that provided the predicted best transitions and collision energy to 
generate maximal fragment intensities. The in silico data of the selected peptides 
were then compared with the experimental fragmentation spectra obtained by 
the LC-MS/MS analyses. Peptides defined by Skyline analysis and showing the 
best signal to noise ratio in the experimental fragmentation spectra were selected 
for developing MRM methods for each biological fluid. These methods 
contained all the precursor ion- product ions transitions and collision energy 
associated with the selected peptides from the defined target proteins 
constituting the protein signature of each individual biofluids in Table S-2. 
As an example, two peptides from α-globin, three from β-globin, and 
Hemopexin, five from Haptoglobin and six from α-2-macroglobulinfor a total of 
25 peptides and 106 transitions were selected to monitor the presence of blood 
and to build the MRM method for this biological matrix. 
The Total Ion Current chromatogram (A) and the MRM TIC analysis of 
the three peptides 132-143, 82-94 and 30-39 from β-globin (B) are shown in 
Figure 1. Panel C displays the MRM TIC chromatogram of the three transitions, 
m/z 409.72 to 507.29, m/z 409.72 to 604.34 and m/z 409.72 to 719.37, used to 
monitor the α-globin (92-98) peptide. The different transitions perfectly co-
eluted at a retention time of 5.24 min thus indicating that they belong to the same 
precursor ion. 
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Figure 16: Identification of all the protein of blood fluid by LC-MS/MS analysis and 
MRM/MS data of the defined target proteins constituting the protein signature of blood. 
Panel A: Total Ion Current (TIC) as a function of time (min.). LCMSMS analysis allowed 
the identification of protein content on blood tryptic peptide mixture. Panel B: BPI 
Chromatograms for β-globin 132-143, 82-94, 30-39 peptides eluted at 6.18, 11.46 and 16.91 
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min respectively. Panel C: MRM TIC Chromatograms extracted for α-Globin (92-98) 
peptide. The monitored transitions for this peptide: m/z 409.72 to 719.37, m/z 409.72 to 
604.34 and m/z 409.72 to 507.29 are perfectly co-eluted at 5.24 min as an unambiguous 
identification of blood detection. 
Similar MRM methods were developed for the other biological matrices (Table 
S-2). For urine, as an example, Figure S-1 shows the Total Ion Current 
chromatogram (A) and the MRM TIC analysis of the two peptides (507-605) and 
(204-211) from Uromodulin (B). Panel C displays the TIC chromatogram of the 
three transitions for the Uromodulin (204-211) peptide. The different transitions 
perfectly co-eluted at a retention time of 2.99 min thus indicating that they all 
originated from the same precursor ion. 
Some of the MRM TIC chromatograms of the selected peptides for the specific 
detection of proteins from saliva and semen were reported in SI (Figure S-2, 
FigureS-3).  
Once the optimized MRM methods were developed for each individual 
biological fluid, the next step involved the development of a single MRM 
method able to detect all the biological fluids in a single analysis. For each 
selected protein biomarker, all the selected peptide sequences, m/z precursor ion, 
m/z product ions and the optimized collision energy were tabulated in Table S-
3. 
As the mass spectrometer was able to handle a very large number of 
transitions per run, the single MRM method was built up by using a total of 46 
peptides and 212 transitions. 
6.3.3 Analysis of test specimens 
For all the test specimens samples, the MRM chromatograms solely 
showed the mass transitions associated to the target peptides belonging to the 
specific proteins constituting the unique signature of the defined matrix. No 
transitions related to peptides from proteins characteristic of other biological 
fluids were detected for all the analysed samples. As an example, Figure 2A 
shows the MRM TIC chromatogram of the three transitions, m/z 637.86 to 
687.35, m/z 637.86 to 850.42, m/z 637.86 to 949.49, m/z 637.86 to 1048.56 and 
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m/z 637.86 to 1161.64 used to monitor the β-globin (30-39) peptide form a blood 
sample spotted on plaster. Panel B showed the corresponding MRM 
chromatogram for the (1075-1086) peptide from Mucin-6, a protein specific of 
semen, illustrating the absence of any non-specific transition of interfering 
proteins. This result clearly demonstrates that the specific signature of blood 
could be easily monitored whereas no interference from cross transitions of 
peptides belonging to other biological matrices was detected. 
 
 
Figure 2. MRM/MS analysis of test specimens: blood spotted on plaster. Panel A: MRM 
TIC Chromatograms extracted for β-Globin (30-39) peptide. The best five monitored 
transitions m/z 637.87 to 687.36 m/z, 637.87 to 850.42, m/z 637.87 to 949.49, m/z 637.87 to 
1048.56, m/z 637.87 to 1161.64 are reported in figure eluted at 16.73 min. Panel B: MRM 
TIC chromatogram extracted for (1075-1086) peptide from Mucin-6 a protein specific of 
semen, illustrating the absence of any non-specific transition (m/z 785.38 to 960.42, m/z 
785.38 to 1057.48, m/z 785.38 to 1307.62). 
 
Similar results were obtained on all the other spotted samples and are 
summarized in Table 2. Each biological matrix could be unambiguously 
identified by the developed MRM method even on different substrates. No cross 
transitions were observed whatsoever with the exception of urine where peptides 
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from PSA and PAP proteins, a specific signature of semen, was also detected. 
However, the presence of seminal proteins in urine is somehow expected and 
provides further information on the origin of the sample that was obviously from 
a male donor. 
 
Table 2. List of proteins detected in each test specimen prepared by drying different 
biological fluids on various substrates: cloth, wood, plastic, plaster and paper. matrix 
spotted on substrates.  
X is reported when the unique peptides belonging to the target proteins characteristic 
of individual biological matrix were identified by MRM analysis. 
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To test the MRM optimized method capability to unambiguously define 
the occurrence of individual biofluids when occurring in a 50:50 ratio mixture, 
blood-semen, blood-urine and semen-urine were spotted onto different 
substrates. The negative controls, for a total of 5 sample, consisted of the 
exclusive use of substrates: cloth, wood, plastic, plaster and paper. As shown in 
Table S-4, each individual component of the binary mixture was unambiguously 
identified by the specific transitions of the unique peptide signature; whenever 
urine was present, specific peptides from semen proteins were also detected. 
6.3.4 Analysis of real crime scene samples 
The developed procedure was then applied to real samples collected at a 
crime scene by the RIS Laboratory in Rome. Samples were prepared according 
to the procedure described above and following enzymatic hydrolysis, DNA was 
extracted from each sample according to the normal procedure performed at the 
RIS Laboratory. DNA extracts were quantified, the degradation level was 
evaluated and the DNA profiling obtained as described in Materials and Methods 
section. The resulting genotypic profile of Sample 1 is shown in Figure S-4 and 
was identified as a male genotype profile called "Profile A". The quality of the 
data exceeded the minimum quality requirements established by internal 
validation procedures for this Lab for comparative procedures to be used for 
personal identification purposes. 
Following DNA analysis, the remainder of the samples containing the 
mixture of tryptic peptides was submitted to the developed MRM analytical 
procedure. Figure 3 shows the TIC analysis of the three peptides 30-39, 82-94, 
and 132-143 monitored for the human β-globin and two peptides 92-98 and 127-
138 monitored for the human α-globin (A). Panel B displays the MRM TIC 
chromatogram corresponding to four transitions, m/z 637.87 to 687.35, m/z 
637.87 to 850.42, m/z 637.87 to 949.48 and m/z 637.87 to 1048.55, used to 
monitor the β-globin (30-39) peptide. 
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Figure 3. MRM/MS analysis of real crime scene samples after DNA extraction. Panel A: 
BPI Chromatograms for α-Globin 92-98 and 127-138 peptides eluted at 5.26 and 14.91 min 
respectively and BPI Chromatograms for β-Globin 132-143, 82-94, 30-39 peptides eluted at 
11.40, 11.50, 16.62 min respectively. Panel B: MRM TIC Chromatogram corresponding to 
four transitions, m/z 637.87 to 687.35, m/z 637.87 to 850.42, m/z 637.87 to 949.48 and m/z 
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637.87 to 1048.55 perfectly co-eluted at 16.59 min, used to monitor the β-globin (30-39) 
peptide. 
 
 As shown in Table 3, the MRM analysis was able to unambiguously 
define individual protein component occurring in the different samples by their 
unique peptide signature even after DNA extraction and analysis. Therefore, this 
combined procedure led to both DNA profiling analysis and the unambiguous 
identification of blood indicating the biological fluid the DNA was collected 
from. 
Table 3. Identification of the biomarker proteins by MRM analysis in three samples got from 
RIS laboratories after DNA extraction and analysis. 
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K.VYHLPYYEACVR.D [1075, 
1086]  x  
S
E
M
 I
I 
K.GHYQNVVDVR.E [217, 226]  x  
K.DIFTTQDELLVYNK.N [251, 
264]    
K.ISYQSSSTEER.H [345, 355]  x  
K.QDLLSHEQK.G [534, 542]  x  
P
S
A
 
R.IVGGWECEK.H [20, 28]  x  
K.HSQPWQVLVASR.G [29, 40]  x  
R.LSEPAELTDAVK.V [121, 132]  x  
K.FMLCAGR.W [190, 196]  x  
P
A
P
 
R.SPIDTFPTDPIK.E [47, 58]  x  
K.DFIATLGK.L [185, 192]  x  
R.ELSELSLLSLYGIHK.Q [236, 
250]  x  
S
E
M
 1
 
R.LWVHGLSK.E [165, 172]  x  
K.VQTSLCPAHQDK.L [233, 244]  x  
K.DVSQSSIYSQTEEK.A [307, 
320]    
138 
 
K.GESGQSTNR.E [404, 412]  x  
 
U
R
IN
E
 
O
st
e
o
p
o
n
ti
n
 K.QNLLAPQTLPSK.S [51, 62]    
R.GDSVVYGLR.S [145, 153]    
R.ISHELDSASSEV.- [287, 298]    
U
r
o
m
o
d
u
li
n
 
R.STEYGEGYACDTDLR.G [185, 
199]    
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K.INFACSYPLDMK.V [420, 431]    
R.VGGTGMFTVR.M [449, 458]    
R.VLNLGPITR.K [597, 605]    
X is reported when the unique peptides belonging to the target proteins 
characteristic of individual biological matrix were identified by MRM 
analysis. 
6.5 Discussion 
Knowledge of the nature of biofluid discovered at a crime scene can 
influence the outcome of a case. Identification of a suspect's DNA on a victim is 
quite different if it comes from saliva, suggesting intimate contact, wither 
consensual or forced, or from blood or seminal fluid, indicating a physical 
struggle or a sexual assault. However, this is not always an easy task, since many 
biofluid stains are either invisible to the naked eye or similar in appearance to 
other fluids or substances. Even when the identity of a stain may seem obvious 
to a forensic investigator, absolute confirmation is necessary to give a legal value 
to the trace evidence to either prove or disprove a fact in a case lawsuit. This is 
especially important with the possible occurrence of mixtures as single stain 
could contain multiple biofluids.  
Most biochemical and immunologic tests which have been used for 
presumptive or confirmatory methods suffer from several limitations leading to 
sample destruction resulting in sample loss for subsequent DNA analysis or to 
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incompatibility with downstream individual identification assays, i.e. DNA 
profiling. Moreover, most of the current methods are designed to detect a single 
biofluid forcing the investigators to decide which test to perform in the presence 
of a limited amount of sample.  
Contrary to DNA, proteins were rarely considered and scarcely used as 
sources of useful biological traces in crime scene investigations. Proteins tend to 
be less stable than DNA and are easily degraded making their identification by 
immunological methods unfeasible. Moreover, the amount of available samples 
cannot be amplified by “PCR–like” procedures thus requiring the use of 
analytical techniques with extremely high sensitivity22. 
More recently, proteomics strategies have been applied to the 
identification of biofluids that overcome most of the previous difficulties. In 
proteomic approaches, proteins are identified by their peptide fragments making 
the degradation no longer a problem. Moreover, contrary to DNA, proteins are 
tissue-specific providing a unique signature to identify biological tissues and 
fluids. Finally, the tiny amount of trace evidence usually recovered at a crime 
scene is matched by the extraordinary sensitivity of modern mass spectrometers. 
Untargeted proteomic approaches demonstrated to be effective in the definition 
of biofluids in traces from crime scenes by identification of specific proteins 
belonging to individual biological sample5. However, severe limitations in 
sensitivity, in the analysis of mixed traces and, more important, in preserving the 
samples for subsequent DNA analysis still exist. A recent study has greatly 
overcome this drawback by MALD IMS imaging directly on a blood fingermark 
leaving the ridge detail completely preserved10. Even though the proposed 
method is as destructive as the other approaches, the great compatibility between 
DNA extraction and MS strategy protocols allows to limit the destruction of the 
entire trace evidence. Indeed, a combined strategy to provide both DNA analysis 
profiling by RIS laboratory and identification of the corresponding biological 
fluid(s) on the same sample collected at real crime scenes has been developed. 
Samples were deproteinised by treatment with trypsin instead of the commonly 
used non-specific proteases, i.e. pronase, proteinase K, etc. DNA was then 
extracted from the digested samples and analysed according to the usual 
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procedure, yielding optimal DNA profiles. Moreover, the proposed bottom-up 
approach makes this method valid also on old traces that have undergone 
degradation. Another advantage from the current approach is the unambiguous 
identification of all target proteins allowing us to univocally discriminate among 
the different fluids, even in mixture by a single MRM run of less than one hour.  
Indeed, four proteins, α-globin, β-globin, Haptoglobin and Hemopexin 
have been selected for blood signature, four for saliva (α-amylase 1, Mucin-5, 
Annexin A1 and Cystatin S), five for semen (Semenogelin I and II, PSA, PAP 
and Mucin-6) and two proteins determined for urine (Uromodulin and 
Osteopontin). For each protein biomarker, a number of unique tryptic peptides 
(proteotypics) has been selected with the use of bioinformatics tools and the best 
precursor ion-fragments transitions employed to set up a single MRM method 
able to identify any of the four biofluids in unknown stains. The MRM LC-
MS/MS analysis recognizes the specific peptides by their unique transitions. The 
identified proteotypic peptides have been correlated to each set of selected 
protein biomarkers that in turn unambiguously defined the biological fluid(s) 
under investigation.  
The MRM method optimized on pure samples of the four matrices, blood, 
urine, semen and saliva, is resulted to have good specificity and selectivity for 
each biofluid with no cross-contamination observed whatsoever. A single 
contamination was detected in the urine samples spotted on different surfaces 
that showed the occurrence of small amount of seminal fluid. However, this 
presence was somehow expected and contributed to indicate a male donor. Then 
in a proof of concept, prepared test samples consisting of different fluids spotted 
on various substrates have been analysed by using the single optimized MRM 
method.  
The current results demonstrated that the developed strategy based on the 
MRM LC-MS/MS method could be a useful substrate in forensic science due to 
its capability of providing a universal approach for the identification of unknown 
stains recovered at crime scenes with high selectivity and specificity. Moreover, 
this approach can be carried out on the same samples used for DNA profiling 
revealing the nature of the tissue or fluid the DNA had been recovered from. 
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6.7 Supplementary Data 
Table S-1. Identified Proteins By Different Pretreatment of each 
biological matrix with relative Gi Number, Molecular weight, Number 
of peptides and Mascot Score. Chloroform/Methanol/Water 
precipitation protocol showed the best results and it was selected for 
building up the experimental strategy to apply for real samples 
treatment. 
Urine 
Code Identification 
Mascot 
Score 
Numbero of 
Peptides 
Gi|3212456 
Chain A, Crystal Structure  Of Human 
Serum Albumin 
832 29 
Gi|340166 Uromodulin 542 13 
Gi|157835127 
Chain A, Crystal Structure Of Human 
Apolipoprotein D (Apod) In Complex 
With Progesterone 
223 8 
Gi|4502067 Protein Ambp Preproprotein 142 5 
Gi|480312171 
Chain H, Crossfab Binding To Human 
Angiopoietin 2 
140 2 
Gi|229585 Ig A1 Bur 132 4 
Gi|238236 Transmembrane Secretory Component 121 4 
Gi|4504893 Kininogen-1 Isoform 2 Precursor 118 5 
Gi|29470 
Human Basement Membrane Heparan 
Sulfate Proteoglycan Core Protein 
118 3 
Gi|178585 Alpha-Amylase 111 2 
Gi|4557871 Serotransferrin Precursor 92 3 
Gi|3297879 
  
Masp-2 84 2 
Gi|256397 
Urine Protein 1, Up1=Clara Cell 10 Kda 
Protein Homolog 
Ù {N-Terminal} [Human, Urine, Peptide 
Partial, 53 Aa] 
83 3 
Gi|4759166 Osteopontin Isoform Opn-B Precursor 81 4 
Gi|532598 Ig J-Chain, Partial 78 2 
Gi|307151 Mac25 75 2 
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Gi|15489339 Vasn Protein, Partial 70 2 
Gi|5803023 
Vesicular Integral-Membrane  Protein 
Vip36 Precursor 
69 1 
Gi|180550 
Plasma Serine Protease Inhibitor 
Precursor 
67 1 
Gi|62738629 
Chain A, Crystal Structure Of Human 
Peptidoglycan Recognition Protein 
(Pgrp-S) 
64 2 
Gi|261745 
1.14 Beta-Trace=23.5 Kda Glycoprotein 
{N-Terminal} [Human, Cerebrospinal 
Fluid, Peptide Partial, 19 Aa] 
57 1 
Gi|31075 E-Cadherin 48 1 
Gi|292870 Tyrosine Kinase Receptor 45 1 
Gi|6563042 
Leukocyte-Associated Ig-Like Receptor 
1b 
43 1 
Gi|4502719 Cadherin-13 Isoform 1 Preproprotein 40 1 
Gi|310942621 
Chain D, The Crystal Structure Of Pcsk9 
In Complex With 1d05 Fab 
40 1 
Gi|189524 
 
Prostate Specific Antigen Precursor, 
Partial 
40 1 
Gi|186651 Kallikrein 36 1 
Gi|179617 C1-Inhibitor, Partial 31 1 
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Saliva 
Code Identification Mascot 
Score 
Numbero 
of 
Peptides 
 Gi|131412225 Keratin, Type I Cytoskeletal 13 1020    21 
Gi|114644568 Keratin, Type II Cytoskeletal 6A 818      20 
Gi|82654947   Keratin, Type II Cytoskeletal 4 779     21 
Gi|178585 Alpha-Amylase 458   15 
Gi|4502101  Annexin A1 415    10 
Gi|375314779  Keratin 1  397   5 
Gi|157057089   Mucin 5AC, Oligomeric Mucus/Gel-
Forming  
247      7 
Gi|238236   Transmembrane Secretory Component 201 6 
Gi|28336   Mutant Beta-Actin (Beta'-Actin) 158     5 
Gi|229585  Ig A1 Bur 132     5 
Gi|21669481 Immunoglobulin Kappa Light Chain VLJ 
Region  
126 2 
Gi|240102 Cystatin SN  116    2 
Gi|609412460 Chain A, Crystal Structure Of Human 
Lnkh2b-H2a.Z-Anp32e 
115     2 
Gi|17942573  Chain A, G48a Human Lysozyme 85 2  
Gi|7706635  Cornulin 75  3  
Gi|662841  Heat Shock Protein 27 68 2 
Gi|359513  Cystatin SA 123     4  
Gi|4503109    Cystatin-S Precursor 68     1 
Gi|38026 Zn-Alpha2-Glycoprotein 64 2  
Gi|186833 Lactoferrin 81 5 
 
  
146 
 
Semen 
Code Identification Mascot 
Score 
Numbero 
of 
Peptides 
Gi|122920512     Chain A, Human Serum Albumin 
Complexed With Myristate And Aspirin 
 1581    39 
Gi|187122     Lactoferrin  1367 30 
Gi|578840955 PREDICTED: Mucin-6 Isoform X1  1069 21 
Gi|4506883    Semenogelin-1 Preproprotein 1048 26   
Gi|6382064 Prostatic Acid Phosphatase Isoform PAP 
Precursor  
860   23 
Gi|31397     Fibronectin Precursor 946  25 
Gi|38026     Zn-Alpha2-Glycoprotein 855  18 
Gi|62089422 Membrane Alanine Aminopeptidase 
Precursor Variant 
741 18 
Gi|189524     Prostate Specific Antigen Precursor, 
Partial 
613  12 
Gi|178855     Apolipoprotein J Precursor 613  14 
Gi|38648667  Fatty Acid Synthase 546 15 
Gi|83699649   Heat Shock 90kda Protein 1, Alpha 494  10 
Gi|180550 Plasma Serine Protease Inhibitor 
Precursor 
427 10 
Gi|4505821 Prolactin-Inducible Protein Precursor 418  9 
Gi|219517850  Membrane Metallo-Endopeptidase 410   9 
Gi|180570     Creatine Kinase 376 8 
Gi|4503009    Carboxypeptidase E Preproprotein 346 10 
Gi|177836     Alpha-1-Antitrypsin Precursor 336 9 
Gi|5031863    Galectin-3-Binding Protein Precursor 329 8 
Gi|1353350    Prostate-Specific Transglutaminase 313  8 
Gi|337760     Cerebroside Sulfate Activator Protein 295 9 
Gi|4505763 Phosphoglycerate Kinase 1 294  6 
Gi|4507953    14-3-3 Protein Zeta/Delta  287 7 
Gi|183129     Gamma-Glutamyltransferase 1 (EC 
2.3.2.2)  
284 5 
Gi|4557305    Fructose-Bisphosphate Aldolase A 
Isoform 1 
281 5 
Gi|3641398    NADP-Dependent Isocitrate 
Dehydrogenase 
272 8 
147 
 
Gi|4505591 Peroxiredoxin-1 258 7 
Gi|693933     2-Phosphopyruvate-Hydratase Alpha-
Enolase 
239 5 
Gi|386785     Heat Shock Protein 269  7 
Gi|1488324 Extracellular Matrix Protein 1 238   7 
Gi|4758638    Peroxiredoxin-6 238  6 
Gi|226529917  Triosephosphate Isomerase Isoform 2 230  4 
Gi|15620780   Glutamate Carboxypeptidase 223 8 
Gi|4826870    Nucleobindin-2 Precursor  223 7 
Gi|4826643 Annexin A3 215 4 
Gi|496078     L-Iditol-2 Dehydrogenase  198 5 
Gi|1246085    Acidic Epididymal Glycoprotein 
Homolog 
191 5 
Gi|4759000    Ras-Related Protein Rab-3D 189 4 
Gi|4557727    Lipoprotein Lipase Precursor 186  5 
Gi|4503273 Angiotensin-Converting Enzyme Isoform 
1 Precursor 
184 4 
Gi|5174735    Tubulin Beta-4B Chain 186  6 
Gi|190215 Placental Protein 14 177 4 
Gi|4502101    Annexin A1 153   4 
Gi|181387     Cystatin C 148 3 
Gi|31645     Glyceraldehyde-3-Phosphate 
Dehydrogenase 
148 4 
Gi|235948     Cystatin SA-III=Potential Precursor Of 
Acquired Enamel Pellicle 
146 4 
Gi|189998     M2-Type Pyruvate Kinase 145 3 
Gi|1931577    Rab27a 143 4 
Gi|662841 Heat Shock Protein 27  138 4 
Gi|558379     FALL-39 Peptide Antibiotic 138 4 
Gi|9857661 Cell Surface Receptor 134 3 
Gi|181250 Cyclophilin, Partial 132 3 
Gi|31615558     Chain A, X-Ray Crystal Structure Of 
Cyclophilin AHIV-1 Ca N- Terminal 
Domain (1-146) M-Type H87a Complex. 
130 4 
Gi|37492 Alpha-Tubulin 128 3 
Gi|4826898    Profilin-1  121 3 
Gi|19923082   Prostate And Testis Expressed Protein 1 
Precursor 
121 3 
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Gi|45594240   Limbic System-Associated Membrane 
Protein Preproprotein 
111  4 
Gi|5453678 Epididymal Secretory Protein E1 
Precursor 
106 3 
Gi|62089124 Angiotensinogen Precursor Variant 89 3 
Gi|291191130 Chain A, Crystal Structure Of Human 
Seminal Plasma Protein Psp94 
79 2 
Gi|5031857 L-Lactate Dehydrogenase A Chain 
Isoform 1 
78 2 
Gi|36038 Rho GDP Dissociation Inhibitor (GDI) 78 2 
Gi|307110     Lysosomal Membrane Glycoprotein-2 75 2 
Gi|35830 Ubiquitin Activating Enzyme E1 75 2 
Gi|386789     Hemopexin Precursor, Partial 73 3 
Gi|3777541 Major Sperm Fibrous Sheath Protein 
Precursor 
72 2 
Gi|31075 E-Cadherin 67 2 
Gi|5901956 Follistatin-Related Protein 1 Precursor 59 2 
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Table S-2. List of proteins selected as representative for each 
biological matrix by matching  LC-MS/MS analysis and literature 
data. 
Matrix Protein Biomarkers 
Blood Chain A of Hemoglobin 
Chain B of Hemoglobin 
Hemopexin 
Haptoglobin 
Complement C3 
Alfa-1-Antitrypsin 
Alfa-2-Macroglobulin 
Alpha-2-HS-Glycoprotein 
Saliva Α- Amylase 
Annexin 
Mucin 5 Ac 
Cystatin S 
Transmembrane Secretory Complement 
Mutant Beta Actin 
Urine Osteopontin 
Uromodulin 
AMBP Protein 
Kininogen 
Semen Epididymal Secretory Protein E1 
Mucin-6 
Semenogelin I 
Semenogelin II 
Prostate Specific Antigen (PSA) 
Galectin-3-Binding  Protein 
Prostatic Acid Phosphatase (PAP) 
Prostate- Specific Transglutaminase 
Prostate And Testis Expressed Protein 1 
Beta-Microseminoprotein/ Crystal Structure Of Human Seminal 
Plasma Protein Psp 94 
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Table S-3.  MRM method optimized for each biological fluid 
reporting protein, selected peptide sequence, precursor m/z, product 
ions m/z and Collision Energy (V). 
BLOOD 
 Peptide Precursor m/z Products m/z 
Collision 
Energy (V) 
C
h
a
in
 α
 o
f 
H
em
o
g
lo
b
in
 
R.VDPVNFK.L 
[92, 98] 
409,72 
719,37 
604,34 
507,29 
14 
K.FLASVSTVLTSK.Y 
[127, 138] 
626,86 
992,56 
921,52 
834,49 
735,42 
648,39 
22 
C
h
a
in
 β
 o
f 
H
em
o
g
lo
b
in
 
R.LLVVYPWTQR.F 
[30, 39] 
637,86 
1161,64 
1048,55 
949,48 
850,42 
687,35 
23 
K.GTFATLSELHCDK.L 
[82, 94] 
 
739,85 
1173,55 
1102,51 
1001,47 
888,38 
801,35 
26 
K.VVAGVANALAHK.Y 
[132, 143] 
575,34 
951,53 
880,50 
823,47 
724,41 
653,37 
20 
A
lp
h
a
 2
-
g
ly
co
p
ro
te
in
 
K.EHAVEGDCDFQLLK.
L 
[106, 119] 
830,88 
1323,62 
1224,55 
1095,51 
1038,49 
923,46 
30 
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K.FSVVYAK.C 
[124, 130] 
407,22 
666,3821 
579,3501 
480,2817 
14 
K.CNLLAEK.Q 
[218, 224] 
424,22 
687,4036 
573,3606 
460,2766 
15 
H
em
o
p
ex
in
 
R.ELISER.W 
[82, 87] 
373,70 
617,36 
504,27 
391,19 
13 
R.QGHNSVFLIK.G 
[101, 110] 
571,81 
1014,57 
957,55 
820,49 
706,44 
619,41 
20 
K.VDGALCMEK.S 
[401, 409] 
511,73 
923,39 
808,36 
751,34 
680,31 
567,22 
18 
H
a
p
to
g
lo
b
in
 
K.AVGDK.L 
[77, 81] 
 
245,13 
418,22 
319,16 
262,13 
8 
K.DIAPTLTLYVGK.K 
[156, 167] 
645,86 
1062,61 
991,58 
894,52 
793,48 
680,39 
23 
R.VMPICLPSK.D 
[202, 210] 
 
522,78 
945,48 
814,44 
717,39 
604,31 
18 
R.NANFK.F 
[227, 231] 
297,15 
479,26 
408,22 
10 
K.YVMLPVADQDQCIR.
H [238, 251] 
854,41 
1314,64 
1201,56 
1104,51 
1005,44 
934,40 
31 
A
l
p
h a
-
1
-
A
n
ti
tr
y
p
s
in
 
K.QINDYVEK.G 504,75 
880,44 
767,35 
18 
152 
 
[155, 162] 
 
653,31 
538,28 
R.DTVFALVNYIFFK.G 
[178, 190] 
788,92 
1261,69 
1114,62 
1043,59 
930,50 
831,44 
28 
R.SASLHLPK.L 
[282, 289] 
426,75 
765,46 
694,42 
607,39 
494,30 
15 
A
lp
h
a
-2
-M
a
cr
o
g
lo
b
u
li
n
 
K.NEDSLVFVQTDK.S 
[123, 134] 
697,84 
1151,59 
1036,56 
949,53 
836,45 
737,38 
25 
K.FEVQVTVPK.I 
[228, 236] 
523,79 
899,51 
 770,47 
671,40 
543,35 
18 
K.GVPIPNK.V 
[375, 381] 
362,72 
667,41 
568,34 
471,29 
12 
K.GHFSISIPVK.S 
[521, 530] 
542,81 
 
1027,59 
890,53 
743,46 
656,43 
543,35 
19 
K.AIGYLNTGYQR.Q 
[1003, 1013] 
628,32 
1184,60 
1071,52 
1014,50 
851,43 
738,35 
22 
K.MVSGFIPLKPTVK.M 
[1384, 1396] 
708,91 
1186,71 
1099,68 
1042,66 
895,59 
782,51 
25 
153 
 
URINE 
 Peptide 
Precursor 
m/z 
Products 
m/z 
Collision 
Energy (V) 
O
st
eo
p
o
n
ti
n
 
K.QNLLAPQTLPSK.S 
[51, 62] 
655,37 
1067,64 
954,56 
841,47 
770,44 
673,38 
23 
R.GDSVVYGLR.S 
[145, 153] 
483,25 
908,48 
793,45 
706,42 
607,35 
508,28 
17 
R.ISHELDSASSEV.- 
[287, 298] 
637,29 
1160,50 
1073,47 
 936,41 
807,37 
694,28 
23 
U
ro
m
o
d
u
li
n
 
R.STEYGEGYACDTDLR.G 
[185, 199] 
 
 
868,85 
1419,58 
1256,52 
1199,49 
1070,45 
 1013,43 
31 
 
R.FVGQGGAR.M 
[204, 211] 
 
396,2116 
644,34 
545,27 
488,25 
14 
 
K.VFMYLSDSR.C 
[356, 364] 
     
 
559,27 
1018,46 
871,39 
740,35 
577,29 
20 
K.INFACSYPLDMK.V [420, 
431] 
 
729,84 
1231,54 
1084,48 
1013,44 
853,41 
766,38 
26 
154 
 
R.VGGTGMFTVR.M 
 [449, 458] 
     
 
512,76 
868,43 
811,41 
710,36 
653,34 
522,30 
18 
R.VLNLGPITR.K 
[597, 605] 
     
 
491,80 
883,53 
770,45 
656,40 
543,32 
17 
 
P
ro
te
in
 A
M
B
P
 P
re
p
ro
p
ro
te
in
/A
lp
h
a
-1
-
M
ic
ro
g
lo
b
u
li
n
 
K.GVCEETSGAYEK.T 
[88, 99] 
     
 
665,28 
1272,54 
1173,47 
1013,44 
884,40 
755,36 
24 
R.ETLLQDFR.V 
[158, 165] 
     
 
511,26 
892,48 
791,44 
678,35 
565,27 
18 
R.EYCGVPGDGDEELLR.F 
[334, 348] 
854,87 
 
1416,64 
1256,61 
1199,59 
1100,52 
1003,46 
946,44 
31 
 
K
in
in
o
g
en
-1
 I
so
fo
rm
 2
 P
re
cu
rs
o
r
 
K.AATGECTATVGK.R [101, 
112] 
 
583,28 
1094,51 
1023,47 
922,42 
865,40 
736,36 
21 
K.ENFLFLTPDCK.S 
 [208, 218] 
 
692,33 
 
1254,61 
1140,57 
993,50 
880,42 
733,35 
519,22 
25 
R.IASFSQNCDIYPGK.D [240, 
253] 
 
800,37 
 
1415,62 
1328,59 
1181,52 
1094,49 
966,43 
29 
155 
 
 
  
852,39 
301,18 
K.DFVQPPTK.I 
[254, 261] 
 
466,24 
 
816,46 
669,39 
570,32 
442,26 
345,21 
16 
K.ESNEELTESCETK.K [330, 
342] 
 
778,32 
 
1426,60 
1339,56 
1225,52 
1096,48 
967,44 
854,35 
28 
156 
 
SALIVA 
 Peptide Precursor m/z Products m/z 
Collision 
Energy (V) 
α
- 
A
m
y
la
se
 
R.TSIVHLFEWR.W 
[25, 34] 
644,34 
1186,63 
1099,60 
986,52 
887,45 
750,39 
23 
R.WVDIALECER.Y 
[35, 44] 
645,81 
1104,53 
1005,46 
890,44 
777,35 
706,31 
23 
K.SSDYFGNGR.V 
[258, 266] 
501,71 
915,39 
828,36 
713,33 
550,27 
17 
R.ALVFVDNHDNQR.G 
[306, 317] 
714,35 
1243,58 
1144,51 
997,44 
898,37 
783,34 
25 
A
n
n
ex
in
 1
 
K.GVDEATIIDILTK.R 
[58, 70] 
694,38 
1116,65 
987,60 
916,57 
815,52 
702,43 
25 
R.SEIDMNDIK.A 
[303, 311] 
532,75 
977,46 
848,41 
735,33 
620,30 
19 
K.ILVALCGGN.- 
[337, 345] 
458,75 
803,41 
690,32 
591,25 
520,21 
16 
T
ra
n
sm
e
m
b
ra
n
e 
S
ec
re
to
r
y
 
C
o
m
p
le
m
en
t R.TVTINCPFK.T 
[146, 154] 
540,28 
978,51 
879,43 
778,39 
19 
157 
 
665,30 
551,26 
R.ILLNPQDK.D 
[296, 303] 
470,77 
827,46 
714,37 
601,29 
487,25 
16 
R.LVSLTLNLVTR.A 
[525, 535] 
614,88 
1115,67 
1016,61 
929,57 
816,49 
715,44 
22 
 
M
u
ta
n
t 
B
et
a
-A
ct
in
 
 (
B
et
a
'-
A
ct
in
) 
K.AGFAGDDAPR.A 
[18, 27] 
488,72 
905,41 
848,38 
701,32 
630,28 
573,26 
17 
R.GYSFTTTAER.E 
[196, 205] 
566,76 
1075,50 
912,44 
825,41 
678,34 
577,29 
20 
K.EITALAPSTMK.I 
[315, 325] 
581,31 
1032,57 
919,49 
818,44 
747,40 
634,32 
20 
M
u
ci
n
 5
 A
C
 
K.GVQLSDWR.D 
[1335, 1342] 
480,74 
903,46 
804,39 
676,34 
563,25 
17 
K.SEQLGGDVESYDK.I 
[2212, 2224] 
713,82 
1082,50 
969,41 
912,39 
855,37 
740,34 
25 
R.AQAQPGVPLR.E 
[2999, 3008] 
518,79 
965,55 
837,49 
766,45 
638,39 
541,34 
18 
158 
 
 
  
K.SMDIVLTVTMVHGK.E 
[5478, 5491] 
765,90 
1197,70 
1084,61 
985,54 
872,46 
771,41 
27 
C
y
st
a
ti
n
 S
 K.QLCSFEIYEVPWEDR.
M [115, 129] 
985,95 
1482,69 
1335,62 
1206,57 
1093,49 
35 
R.MSLVNSR.C 
[130, 136] 
403,71 
675,37 
588,34 
475,26 
14 
159 
 
SEMEN 
 Peptide Precursor m/z Products m/z 
Collision 
Energy (V) 
E
p
id
id
y
m
a
l 
S
ec
re
to
ry
 P
ro
te
in
 E
1
 
K.SGINCPIQK.D 
[94, 102] 
508,76 
 
929,48 
872,46 
759,38 
 645,33 
18 
K.SEYPSIK.L 
[116, 122] 
412,21 
736,38 
607,34 
444,28 
14 
M
u
ci
n
-6
 I
so
fo
rm
 X
1
 
K.VTNEFVSEEGK.F 
[182, 192] 
619,79 
1139,52 
1038,47 
924,43 
 795,38 
648,31 
22 
R.ETDPCSMSQLNK.V  
[573, 584] 
705,30 
1179,51 
1064,48 
967,43 
807,40 
720,37 
25 
R.GVLLWGWR.S 
[646, 653] 
493,78 
929,53 
 830,46 
 717,38 
604,29 
17 
K.VYHLPYYEACVR.D 
[1075, 1086] 
785,38 
1307,62 
1170,56 
1057,47 
 960,42 
797,36 
28 
S
em
en
o
g
el
in
 I
I K.DIFTTQDELLVYNK.N 
[251, 264] 
849,93 
1323,67 
1222,63 
1121,58 
993,52 
878,49 
30 
K.ISYQSSSTEER.H 
[345, 355] 
643,79 
1173,50 
1086,46 
923,40 
22 
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795,34 
708,31 
K.QDLLSHEQK.G 
[534, 542] 
549,28 
969,50 
854,47 
741,38 
628,30 
19 
P
S
A
 
R.IVGGWECEK.H 
[20, 28] 
 
539,25 
964,41 
865,35 
808,32 
751,30 
565,22 
19 
R.LSEPAELTDAVK.V 
 [121, 132] 
636,83 
1072,55 
943,51 
846,45 
775,41 
646,37 
22 
K.FMLCAGR.W 
[190, 196] 
427,70 
707,33 
576,29 
463,20 
15 
G
a
le
ct
in
-3
-B
in
d
in
g
 
P
ro
te
in
 
R.ELSEALGQIFDSQR.G 
[137, 150] 
796,89 
1263,63 
1134,59 
1063,55 
950,46 
893,44 
28 
R.IDITLSSVK.C 
[216, 224] 
488,2897 
862,48 
747,46 
634,37 
533,32 
17 
P
ro
st
a
te
 A
n
d
 
T
es
ti
s 
E
x
p
re
ss
ed
 
P
ro
te
in
 1
 
R.GICTATTEEACMVGR.M 
[64, 78] 
828,3629 
1325,5824 
1224,5347 
1153,49 
1052,45 
951,40 
30 
B
et
a
-
M
ic
ro
se
m
in
o
p
ro
te
in
 
K.TCSVSEWII.- 
[85, 93] 
547,7630 
993,47 
833,44 
746,41 
647,34 
560,30 
19 
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R.LWVHGLSK.E 
[165, 172] 
 
470,27 
826,45 
 640,37 
541,31 
16 
K.GESGQSTNR.E 
[404, 412] 
468,21 
878,39 
749,35 
662,32 
605,30 
477,24 
16 
162 
 
Table S-4: List of selected protein biomarkers, reporting selected 
peptide sequence, precursor m/z, product ions m/z and Collision 
Energy (V). 
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BLOOD 
C
h
a
in
 α
 o
f 
H
em
o
g
lo
b
in
 
Peptide 
Precursor 
m/z 
Products 
m/z 
Collision 
Energy (V) 
K.VGAHAGEYGAEALER.M 
[16, 30] 
765,37 
1302,60 
1165,54 
1094,51 
1037,48 
908,44 
27 
R.VDPVNFK.L 
[92, 98] 
409,72 
719,37 
604,34 
507,29 
14 
K.FLASVSTVLTSK.Y 
[127, 138] 
626,86 
992,56 
921,52 
834,49 
735,42 
648,39 
22 
C
h
a
in
 β
 o
f 
H
em
o
g
lo
b
in
 
R.LLVVYPWTQR.F 
[30, 39] 
637,87 
 
1161,64 
1048,55 
949,48 
850,42 
687,35 
23 
K.GTFATLSELHCDK.L 
[82, 94] 
739,85 
1173,55 
1102,51 
1001,47 
888,38 
801,35 
26 
K.VVAGVANALAHK.Y 
[132, 143] 
575,34 
951,53 
880,49 
823,47 
724,41 
653,37 
20 
H
em
o
p
ex
in
 R.ELISER.W 
[82, 87] 
373,70 
617,36 
504,27 
391,19 
13 
K.VDGALCMEK.S 
[401, 409] 
511,74 
923,39 
808,36 
751,34 
18 
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680,31 
567,22 
H
a
p
to
g
lo
b
in
 K.DIAPTLTLYVGK.K 
[156, 167] 
645,87 
1062,61 
991,58 
894,52 
793,48 
680,39 
23 
R.VMPICLPSK.D 
[202, 210] 
522,78 
945,48 
814,44 
717,39 
604,31 
18 
URINE 
O
st
eo
p
o
n
ti
n
 
K.QNLLAPQTLPSK.S 
[51, 62] 
655,38 
1067,64 
954,56 
841,47 
770,44 
673,38 
23 
R.GDSVVYGLR.S 
[145, 153] 
483,26 
908,48 
793,46 
706,42 
607,36 
508,29 
17 
R.ISHELDSASSEV.- 
[287, 298] 
637,30 
1160,50 
1073,47 
 936,41 
807,37 
694,28 
23 
U
ro
m
o
d
u
li
n
 R.STEYGEGYACDTDLR.G 
[185, 199] 
868,86 
1419,58 
1256,52 
1199,49 
1070,45 
1013,43 
31 
K.VFMYLSDSR.C 
[356, 364] 
     
 
559,27 
1018,46 
871,39 
740,35 
577,29 
20 
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K.INFACSYPLDMK.V  
[420, 431] 
729,84 
1231,54 
1084,48 
1013,44 
853,41 
766,38 
26 
R.VGGTGMFTVR.M  
[449, 458] 
512,77 
868,43 
811,41 
710,36 
653,34 
522,30 
18 
R.VLNLGPITR.K 
[597, 605] 
491,81 
883,53 
770,45 
656,40 
543,32 
17 
SALIVA 
α
 A
m
y
la
se
 
R.WVDIALECER.Y 
[35, 44] 
645,81 
 
1104,53 
1005,46 
890,44 
777,35 
706,31 
23 
K.SSDYFGNGR.V 
[258, 266] 
501,72 
 
915,39 
828,36 
713,33 
550,27 
17 
A
n
n
ex
in
 1
 
K.GVDEATIIDILTK.R  
[58, 70] 
694,39 
1116,65 
987,60 
916,57 
815,52 
702,43 
25 
R.SEIDMNDIK.A  
[303, 311] 
532,75 
977,46 
848,41 
735,33 
620,30 
19 
K.ILVALCGGN.- 
[337, 345] 
458,75 
803,40 
690,32 
591,25 
520,21 
16 
166 
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u
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n
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A
C
 
K.GVQLSDWR.D  
[1335, 1342] 
480,75 
903,46 
804,39 
676,34 
563,25 
17 
R.AQAQPGVPLR.E  
[2999, 3008] 
518,80 
965,55 
837,49 
766,45 
638,39 
541,34 
18 
C
y
st
a
ti
n
 S
 K.QLCSFEIYEVPWEDR.M 
[115, 129] 
985,95 
1482,69 
1335,62 
1206,57 
1093,49 
35 
R.MSLVNSR.C  
[130, 136] 
403,71 
675,37 
588,34 
475,26 
14 
SEMEN 
M
u
ci
n
 6
 I
so
fo
rm
 X
1
 
K.VTNEFVSEEGK.F  
[182, 192] 
619,80 
1139,52 
1038,47 
924,43 
 795,38 
648,31 
22 
R.ETDPCSMSQLNK.V 
[573, 584] 
705,31 
1179,51 
1064,48 
967,43 
807,40 
720,37 
25 
R.GVLLWGWR.S  
[646, 653] 
493,78 
929,53 
 830,46 
 717,38 
604,29 
17 
K.VYHLPYYEACVR.D  
[1075, 1086] 
785,38 
1307,62 
1170,56 
1057,47 
 960,42 
797,36 
28 
167 
 
S
em
en
o
g
el
in
 I
I 
K.GHYQNVVDVR.E 
 [217, 226] 
593,80 
1129,57 
992,51 
829,45 
701,39 
21 
K.DIFTTQDELLVYNK.N 
 [251, 264] 
849,93 
1323,67 
1222,63 
1121,58 
993,52 
878,49 
30 
K.ISYQSSSTEER.H  
[345, 355] 
643,80 
1173,50 
1086,46 
923,40 
795,34 
708,31 
23 
K.QDLLSHEQK.G 
 [534, 542] 
549,28 
969,50 
854,47 
741,38 
628,30 
19 
P
ro
st
a
te
 S
p
ec
if
ic
 A
n
ti
g
en
 P
r
e
cu
rs
o
r
 
(P
S
A
) 
R.IVGGWECEK.H 
 [20, 28] 
539,26 
964,41 
865,35 
808,32 
751,30 
565,22 
19 
K.HSQPWQVLVASR.G  
[29, 40] 
704,38 
1270,69 
1183,65 
1055,59 
958,54 
772,46 
29 
R.LSEPAELTDAVK.V 
 [121, 132] 
636,84 
1072,55 
943,50 
846,45 
775,41 
646,37 
22 
K.FMLCAGR.W  
[190, 196] 
427,70 
707,33 
576,29 
463,20 
15 
 P
A
P
 R.SPIDTFPTDPIK.E 
 [47, 58] 
665,85 
1146,60 
1033,52 
918,49 
24 
168 
 
 
  
817,44 
670,37 
K.DFIATLGK.L  
[185, 192] 
432,74 
749,45 
602,38 
489,30 
15 
R.ELSELSLLSLYGIHK.Q  
[236, 250] 
851,47 
1372,78 
1243,74 
1130,65 
1043,62 
930,54 
31 
S
em
en
o
g
e
li
n
-1
 P
re
p
ro
p
ro
te
in
 
R.LWVHGLSK.E 
 [165, 172] 
470,27 
826,45 
 640,37 
541,30 
16 
K.VQTSLCPAHQDK.L  
[233, 244] 
692,34 
1156,54 
1055,49 
968,46 
855,37 
695,34 
25 
K.DVSQSSIYSQTEEK.A  
[307, 320] 
800,87 
1299,60 
1171,54 
1084,51 
997,48 
884,39 
30 
K.GESGQSTNR.E  
[404, 412] 
468,21 
878,39 
749,35 
662,32 
605,30 
477,24 
16 
169 
 
Table S-5. Specificity test of MRM method in the identification of biomarker proteins when biological 
fluids were mixed on cloth.  
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S
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I 
Semen and 
Blood 
X X X X       X X X  X 
Semen and 
Urine 
    X X     X X X X X 
Blood and 
Urine 
X X X X X X     X X    
X is reported when the unique peptides belonging to the target proteins characteristic of individual biological matrix 
were identified by MRM analysis. 
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Figure S-1. Total Ion Current chromatogram (A) and the TIC chromatograms 
analysis of two peptides 507-605 and 204-211 from Uromodulin (B) (396.21 → 
644.34 m/z, 396.21 → 545.27 m/z, 396.21 → 488.25 m/z). MRM chromatograms 
of three transitions for the (204-211) Uromodulin peptide (C). The different 
transitions perfectly co-eluted at a retention time of 2.99 min thus indicating that 
they all originated from 
the same precursor ion 
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Figure S-2. TIC chromatograms analysis of two peptides 35-44 and 258-266 
from α-amylase at retention time of 11.59 min, 3.35 min, respectively (A). MRM 
TIC chromatogram of three transitions (403.71 → 675.37, 403.71 → 588.34, 403.71 
→ 475.26) used to monitor the (130-136) Cystatin S peptide (Panel B). 
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Figure S-3. TIC chromatograms analysis of three peptides 81-91, 165-172, 404-
412 from Semenogelin 1 at retention time of 15.55 min, 8.31 min and 6.03 min, 
respectively (A). MRM TIC chromatograms of three transitions (427.7 →707.33, 
427.7→ 576.29, 427.7 →463.2) used to monitor the (190-196) PSA peptide (Panel 
B).  
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Figure S-4. DNA profiling. DNA profiling obtained by multiple amplification 
of 17 polimorphic regions comprising the D3S1358, vWA, FGA, D8S1179, D21S11, 
D18S51, TH01, D16S539, D2S1338, D19S433, ACTBP2 (SE33), D1S1656, 
D2S441, D10S1248, D12S391, D22S1045 and Amelogenin STR loci using the 
Investigator ESSplex SE Plus Kit della Qiagen (Qiagen, Hilden, Germany). 
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Chapter 7 
7.1 Introduction 
7.1.1   Human Colorectal Carcinoma  
Colorectal cancer (CRC) is the third most common cancer in men and 
the second most common cancer in women. More than 1.2 million new 
cases of colorectal cancers are diagnosed globally, with more than 
600,000 related deaths in 2008.  Both genomic and epigenetic alterations 
are common in CRC and are the driving forces of tumourigenesis1.This 
cancer develops as a result of the pathologic transformation of normal 
colonic epithelium to an adenomatous polyp and ultimately an invasive 
cancer. The multistep progression requires years and possibly decades 
and is accompanied by a number of recently characterized genetic 
alterations. Mutations in two classes of genes, tumour-suppressor genes 
and proto-oncogenes, are thought to impart a proliferative advantage to 
cells and contribute to development of the malignant phenotype2. 
7.1.2 Dna Mutations 
Cancer is a result of mutations that inhibit certain gene functions, 
leading to uncontrollable cell growth. A mutation, which may arise 
during replication and/or recombination, is a permanent change in the 
nucleotide sequence of DNA. Damaged DNA can be mutated either by 
substitution, deletion or insertion of base pairs. Mutations, for the most 
part, are harmless except when they lead to cell death or tumour 
formation. Because of the lethal potential of DNA mutations cells have 
evolved mechanisms for repairing damaged DNA3. 
There are three types of DNA Mutations:  
➢ Base Substitutions 
Single base substitutions are called point mutations, recall the point 
mutation Glu -> Val which causes sickle-cell disease (Figure 1). Point 
mutations are the most common type of mutation. 
➢ Deletions 
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A deletion, resulting in a frameshift, results when one or more base 
pairs are lost from the DNA. If one or two bases are deleted the 
translational frame is altered resulting in a garbled message and 
nonfunctional product. A deletion of three or more bases leave the 
reading frame intact (Figure 1). A deletion of one or more codons results 
in a protein missing one or more amino acids. This may be deleterious 
or not. 
➢ Insertions 
The insertion of additional base pairs may lead to frameshifts 
depending on whether or not multiples of three base pairs are inserted 
(Figure 1). 
 
 
 
 
 
 
 
 
Figure 1: Three types of DNA mutations, base substitutions, deletions and 
insertions. 
7.1.3 HCT116 Tumor Line 
Genetic studies carried out on the HCT116 tumor line (studies 
conducted on mRNA in collaboration with Professor A. Nicosia from the 
University of Naples Federico II) have demonstrated that mutations of 
DNA were transcribed in mRNAs determining the modification of some 
proteins involved in tumorigenesis, which are reported in Table 1.These 
mRNAs encodes the following hypothetically mutated proteins that 
shows a mutated amino acid sequence at C-ter (showed in Table 1 ) :  
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Protein MUTATED SEQUENCE * 
1 
13 AA 
2 
18 AA 
3 
31 AA 
4 
44 AA 
5 34 AA 
6 10 AA 
7 
187 AA 
8 
32 AA 
9 
38 AA 
10 
22 AA 
11 
66 AA 
12 
62 AA 
13 
43 AA 
14 
62 AA 
Table 1: Sequences mutated at the C-terminal of proteins encoded by mRNA. 
Protein target are protected by secrecy agreement until publication 
Studies conducted on these proteins show how their mutation is 
related to the onset of colon cancer, for example Protein 1 is involved in 
innate immune response by recognizing cytosolic double-stranded DNA 
and inducing caspase-1-activating inflammasome formation in 
macrophages. Defects in Protein 1 may be a cause of microsatellite 
unstable colon cancers4. Protein 3 mutation may enhance 
genomic instability in some colorectal cancers5. 
Starting from genetic studies that identified mRNAs, the aim of this 
study was to understand if: 
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• mRNAs are translated into proteins or degraded; 
• in the case they are not degraded, the mutated proteins are 
released by the cell or are immediately degraded. 
From the analytical point of view, the mutated C-terminal sequence 
of these proteins may be useful in detecting and analyzing them in the 
protein extract of the HCT116 cell line. The analytical strategy for the 
identification of these proteins is based on the development and 
optimization of a method based on Mass Spectrometry in Multiple 
Reaction Monitoring (MRM) mode which appears to be more specific, 
selective and faster than traditional methods such as the ELISA test.  
The main part of the method development was to identify for each 
amino acid sequence peptides that are unique and characterizing the 
proteins in order to obtain a high specificity and selectivity for MRM 
analysis. Methods ‘optimization was carried out by using a triple 
quadrupole instruments in MRM ion mode. The first analyzer only 
selects the values of m/z relative to the precursor ions, the second acts as 
a collision cell (CID) fragmenting the precursor and the third identifies 
the specific fragment. Thus, the optimized LC-MRM-MS method was 
unique for all proteins to be analyzed and for the peptide sequences 
selected, fast because in a single analysis the simultaneous identification 
of all the selected protein is allowed and highly selective and specific 
because all transitions monitored are derived from target peptides. The 
validation step was carried out by testing the MRM method on other two 
tumor cell lines LS174T and HT 29. The identification of these mutated 
proteins in colorectal carcinoma can be considered a preclinical 
exploratory study required to optimize the search of cancer biomarkers 
and to make it possible targeted drug therapy. 
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7.2 Materials and Methods  
8 samples from HCT 116, LS174T and HT 29 cell lines respectively 
were purchased from Prof. Nicosia Laboratory.  
7.2.1 Sample Treatment 
Proteins extracts obtained from the HCT116 tumour line were 
submitted to in solution hydrolysis protocol that provides the following 
steps: 
• Reduction (RED) and carboamidomethylation (CAM); 
• Precipitation of proteins with CHCl3, MeOH and H2O; 
• Tryptic digestion. 
Dried proteins were dissolved in denaturation buffer: 6M Guanidine, 
0.3M Tris HCl, 10mM EDTA at pH 8.0. Reduction was carried out by 
using a 10:1 DTT: cysteine molar ratio. After incubation at 37°C for 2 h, 
iodoacetamide was added to perform carboamidomethylation using an 
excess of alkylating agent of 5:1 respect to the moles of thiolic groups. 
The mixture was then incubated in the dark at room temperature for 30 
minutes. The alkylation reaction was stopped with 10 µL of 10% 
HCOOH, in order to achieve an acid pH. 
Alkylated proteins were purified by a precipitation step conducted by 
adding 400 µL of MeOH, 100 µL of CHCl3 and 300 µL of H2O. The 
resulting solution was centrifuged for 5 minutes at 12000 rpm. The 
proteins will be precipitated at the interface organic-inorganic phases. 
The supernatant was removed and was added 300 µL of MeOH. The 
solution was centrifuged for 5 minutes at 12000 rpm and it was clearly 
visible a protein pellet. The supernatant was removed, and samples was 
dried under vacuum.  
Protein digestion was carried out in 10 mM AMBIC using trypsin at 
a 50:1 protein:enzyme mass ratio. The sample was incubated at 37°C for 
16 h. Then sample was dried under vacuum and stored at -20°C until the 
LC-MRM/MS analysis. 
7.2.2 Development of LC-MRM-MS method 
For the LC-MRM-MS method optimization was necessary to perform 
a sequence alignment to identify target peptides, related to the mutated 
sequence at the C-terminal, that uniquely identifies the mutated protein. 
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Sequence alignment between mutated protein sequences (Table 1) and 
corresponding non-mutated proteins and all human proteins was 
performed using the Align function of the UniProt database6. This step 
was necessary to select targeted peptides unique in terms of sequence. 
From sequence alignment it has been shown that not all proteins 
provided by Prof Nicosia have been identified as unique peptides; 
therefore, for the MRM method, only the following mutated proteins 
listed Table 2 were selected. After the alignment of the sequence, for all 
mutated proteins Skyline showed a list of target peptides, which uniquely 
identify the mutated protein, with its precursor-product ion transitions 
and relative collision energies (Table 2). 
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Table 2: MRM Method contains for selected mutated HCT116 proteins, the specific 
transitions precursor-product ion selected by Skyline, for all target peptides 
corresponding to mutated sequence at C terminal. Protein target are protected by 
secrecy agreement until publication 
Protein Peptide 
Precursor 
ion m/z 
Product ion 
m/z 
Collision 
Energy 
(V) 
1  
HRE 334.6956++ 
531.3249+ 
375.2238+ 
11 
EVK  266.1661+ 
402.2823+ 
303.2139+ 
9 
3  
LCL  430.7548++ 
747.4182+ 
587.3875+ 
474.3035+ 
15 
TLL  387.2420++ 
672.4291+ 
559.3450+ 
446.2609+ 
13 
4  LTW 417.7182++ 
721.3450+ 
620.2973+ 
434.2180+ 
14 
6  KPG  640.8188++ 
1152.5354+ 
1055.4826+ 
998.4612+ 
897.4135+ 
810.3815+ 
697.2974+ 
23 
14 
QIL  365.2163++ 
601.3668+ 
488.2827+ 
375.1987+ 
12 
EYF 350.1892++ 
570.3286+ 
407.2653+ 
12 
AMT 453.2417++ 
834.4390+ 
703.3985+ 
602.3508+ 
503.2824+ 
16 
AVS 527.3244++ 
982.6044+ 
883.5360+ 
796.5039+ 
683.4199+ 
555.3613+ 
442.2772+ 
18 
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7.3 Results and Discussion 
Regulation of eukaryotic gene expression is crucial in 
pathophysiological responses to extracellular and intracellular signals in 
the context of homeostasis maintenance and cellular differentiation or in 
stress response and cell survival. Damaged DNA can be mutated either 
by substitution, deletion or insertion of base pairs. Mutations, for the 
most part, are harmless except when they lead to cell death or tumour 
formation. Post-transcriptional control of mRNA trafficking and 
metabolism plays a critical role in the actualization and fine tuning of the 
genetic program of cells, both in development and in differentiated 
tissues. We started from prof. Nicosia data related to the presence, in 
HCT 116 cells, of mutated mRNA belonging to the proteins presented in 
Table 1. The project's focus point was to verify, with an MRM mass 
spectrometry method, the translation of these mRNAs into the 
corresponding proteins with the C-ter mutation. In this case was 
exploited, on one hand, the possibility of conducting multiplex analyses 
with high specificity and sensitivity deriving from a targeted analysis 
and, on the other hand, the considerable time and cost saving of the 
method optimization compared to the immunoenzymatic assays or 
fluorescence techniques. To set up the MRM method, the main step 
involved the selection of the peptides to be monitored. Sequence 
alignments of the mutated protein with the WT protein and all the 
proteins contained in the UniProt Database belonging to Human was 
carried out and the selection of peptides with a unique amino acid 
sequence, the so-called proteotypic peptides, was realized. From 
sequence alignment not all proteins provided by Prof Nicosia have been 
identified as unique peptides; therefore, for the MRM method, only the 
mutated proteins listed in Table 2 Next step was defining the best 
precursor ion-product ion transitions and other instrumental parameters 
(dwell time and collision energy), subsequently, samples of the HCT 116 
cell line were treated. The eight samples were subjected to a classical 
protocol of hydrolysis with trypsin, as reported in Materials and 
Methods. To evaluate the robustness of the method, peptides’ mixture 
were analysed in triplicate and as an example, Figure 2 shows the MRM 
TICs Chromatogram for TLL and LCL of protein 2 are reported. 
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Figure 2: Enlargment of MRM TIC Chromatogram for TLL and LCL 
respectively.  All the monitored transitions are coeluted at 4 and 3,4 min respectively. 
Thanks to MRM analysis it was possible to verify the production of 
the target protein. This kind of analysis is qualitative, the perfect 
coelution of the monitored transitions for each target peptide allowed the 
identification, but it also gave a trend of mutated protein expression in 
the sample. Figure 3 shows, in the form of histograms, the average of the 
total ionic currents recorded for each target peptide for each analysed 
sample, underline the behaviour of each protein. From the strictly 
analytical point of view, the collected data showed a good reproducibility 
with coefficients of variation lower than 20
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Figure 3: Mutated proteins trend in HCT 116 samples. The histograms showed the average of the total ion current recorded for each 
transition of each target peptide belonging to the mutated C-ter. 
PROTEIN 13
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Figure 3 clearly shown that sample 5 has a higher amount of 
mutated protein in comparison to the others. 
From a biological point of view, it was possible for the first time to 
demonstrate the translation of the target proteins with the mutation of the 
C-ter due to alternative splicing processes. The presence of proteins that 
are involved in DNA mismatch repair mechanisms it is possible to 
hypothesize that the mutated protein, if produced and if functioning, 
could negatively influence the regulation of mRNA translation which 
may contain defects and therefore lead to malfunction of the whole cell. 
Damaged DNA can be repaired by several different mechanisms like 
Mismatch Repair mechanism that is a system for recognizing and 
repairing erroneous insertion, deletion, and mis-incorporation 
of bases that can arise during DNA replication and recombination, as well 
as repairing some forms of DNA damage. Mismatch repair is strand-
specific. During DNA synthesis the newly synthesized (daughter) strand 
will commonly include errors. In order to begin repair, the mismatch 
repair machinery distinguishes the newly synthesized strand from the 
template (parental). However, in other prokaryotes and eukaryotes, the 
exact mechanism is not clear. Subsequent functional studies will support 
the idea that this mutated protein can not fully perform its function or 
that due to the mutation is sent to the proteasome or migrate into other 
cellular compartments compromising the proper functioning of the cell. 
The last phase of the work involved the validation of the results obtained 
for the HCT 116 cell line with two other cell lines: HT 29 and LS174T. 
These two cell lines are commonly used for the study of 
adenocarcinomas or colon tumours7. Therefore, eight samples were 
provided for each cell line that were treated as previously reported for 
HCT 116 and analysed in triplicate using the same LC-MRM / MS 
method. Similar results, as reported for HCT 116, have been obtained 
and are shown in Figures 4 and 5. 
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Figure 4: Mutated proteins trend in LS 147T samples. The average of the total ion current recorded for each transition of each target peptide is 
reported in histogram form.
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Figure 5: Mutated proteins trend in HT29 samples. The histograms showed the average of the total ion current recorded for each transition of each 
target peptide belonging to the mutated C-ter.
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Figure 4 shows the trend of the mutated proteins in the LS174T 
tumour line. We can see an increase from sample 1 to sample 8, 
especially for proteins 13 and 6. For the HT 29 (Figure 5) we can note 
similar trend for Protein 6 and Protein 4.  
The identification of these mutated proteins in these colon carcinoma 
lines can be considered a preclinical exploratory study required to 
optimize the search of cancer biomarkers and to make it possible drug 
therapy targeted. The analyzes carried out on the three HCT 116, HT29 
and LS174T cell lines are qualitative analysis. They are to be considered 
as demonstrations of the existence of proteins with the C-ter mutation 
and of the expression trend of these proteins within the eight samples. 
Future developments include the implementation of the MRM method 
developed with internal standards, isotopically labeled peptides, which 
confirm the presence of target peptides and allow to perform a 
quantitative analysis of the same. 
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        7.4 Conclusion  
Genetic studies carried out on the HCT116 tumour line (in 
collaboration with Prof. A.Nicosia  of the University of Naples Federico 
II) have demonstrated that mutations of DNA were transcribed in 
mRNAs. Such mutations involve hypothetical translation of truncated 
proteins with respect to WT proteins and having a mutated amino acid 
sequence at C-ter. This thesis was based on the development and 
optimization of a MRM-based method of MS ion mode to identify within 
a cell line extract of the HCT 116 line a series of mutated proteins 
produced by gene mutations with a mutated sequence at C-ter. The main 
part of the method development is to identify for each amino acid 
sequence peptides that are unique and characterizing the protein under 
study in order to obtain a high specificity and selectivity for MRM 
analysis. These peptides were subjected in silico analysis by Skyline 
providing specific output precursor -product ions transitions and 
instrumental parameters (collision energy) needed for optimizing the 
method. Methods ‘optimization was carried out by using a triple 
quadrupole instruments in MRM ion mode. Thus, the optimized LC-
MRM-MS method was unique for all proteins to be analysed and for the 
peptide sequences selected, fast because in a single analysis the 
simultaneous identification of all the selected protein is allowed and 
highly selective and specific because all transitions monitored are 
derived from target peptides. This project showed that the translation 
phase of some of hypothetical mutated proteins takes place and that are 
not immediately degraded are produced. Mutated C-terminal sequence 
of these proteins was useful in detecting and analysing them in the 
protein extract of the HCT116 cell line. From qualitative analysis of LC-
MRM-MS results, mutated proteins in HCT116 samples are 1, 3, 4, 6, 14 
and they increase in sample 5. The developed LC-MRM-MS method has 
also been tested on other two tumour lines LS174T and HT29. The 
identification of these mutated proteins in colorectal carcinoma can be 
considered a preclinical exploratory study required to optimize the 
search of cancer biomarkers and to make it possible drug therapy 
targeted. 
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8. Conclusion 
8.1 SRM compared to other quantification techniques 
Targeted metabolomics and proteomics by SRM have shown the 
potential of becoming the technique of choice for the identification and 
quantification of specific compounds in biological matrices. Several methods 
can produce metabolic signatures of biomaterials, including nuclear magnetic 
resonance (NMR), gas chromatography-mass spectrometry (GC-MS), liquid 
chromatography-mass spectrometry (LC-MS), capillary electrophoresis- 
mass spectrometry (CE-MS), and so on. GC coupled to MS has been 
extensively used in metabolome analysis because of its high separation 
efficiency and the easy interfacing of GC with MS. It can be used to analyse 
a wide range of volatile compounds and semi-volatile compounds through 
chemical derivatization. LC coupled to MS is useful tool for metabolomics 
studies. They can resolve and quantify multiple components in crude 
biological extracts in the nanomole to picomole and even femtomole range 
from as little as sub microliter volumes. LC-UV-MS is routinely used for 
metabolites quantification based on the peak area associated with UV signals. 
Currently LC-MS/MS is considered the workhorse of metabolites detection 
because the derivatization of polar/on-volatile metabolites for GC-MS 
analysis is both time consuming and require fewer material compared to LC. 
Analytical methods based on affinity reagents, such as antibodies, have been 
routinely used in biological and biomedical research to measure the presence 
and/or quantity of target proteins by exploiting the antibody specificity and 
the direct or indirect detectability of a tag such as radioisotopes, enzymes and 
fluorophores. The methods with the lowest limit of detection have the 
potential to detect, in principle, low-abundance compounds, down to 
zeptomole detection limits. However, the development of reagents of suitable 
specificity and affinity to support the unambiguous measurement of the target 
protein in a complex background remains challenging, expensive and 
arduous. A step toward increased multiplexing of affinity reagent–based 
assays was the development of protein arrays in which microarrays, chips or 
beads allow for the parallel, multiplexed screening of large numbers of 
proteins, in an automated manner, and with minimal consumption of sample 
and reagents.  
Another used technique is the direct tagging of the target protein with a 
detectable and quantifiable label such as a fluorescent protein and its 
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quantification by flow cytometry or microscopy techniques. The 
multiplexing capabilities are normally limited, and the introduced tag can 
potentially affect the localization, function, stability and expression of the 
target protein. These fusion proteins offer the possibility to quantify the 
amount of the target protein in single cells, thus revealing the cell-to-cell 
variability in expression and to provide information about the subcellular 
localization of proteins. Other techniques to quantify specific proteins in 
single cells are immunofluorescence, which can be applied to cells or tissue 
sections, and mass cytometry, which expands the multiplexing capabilities of 
single-cell probes using multiatom elemental tags. However, both techniques 
rely on antibodies and thus have limitations associated with their use. 
8.2 Advantage of SRM 
In recent years there has been a rapid increase of targeted proteomics and 
metabolomics using SRM methods. As demonstrated in this thesis project, 
SRM offers several advantages, such as specificity, sensitivity, linearity and 
it ideally suits for multiple quantitative analysis. The selective nature of SRM 
reduces the likelihood of interference from matrix and other target 
compounds, allowing the rapid analysis of more compounds in a single run. 
In addition, the ability of monitoring more transitions simultaneously allows 
greater specificity in the identification of specific target compound, reducing 
false positive. LC-SRM measurements showed that the range of analytes 
concentration accessible by direct LC-SRM is 4–5 orders of magnitude and 
that limits of detection at the low attomole level can be routinely reached, 
even in complex samples at high reproducibility and throughput.  
Another important advantage is that the SRM analysis does not require 
a laborious step of sample pre-treatment or a detailed chromatographic 
separation offering the possibility of reducing the time analysis, including the 
extraction and data processing.  
SRM analysis are not limited to a single application area but it is a 
versatile analytical approach. Laboratories working in food safety, 
environmental monitoring and bioanalysis can all benefit from the 
advantages of a SRM analysis. Therefore, costly sample preparation 
procedures can be optimized to deliver an efficient lab oratory workflow.  
Moreover, one can measure 50–100 analytes in parallel in the same LC-
SRM run if a reasonable duty cycle for accurate quantification and a 
sufficient dwell time to maintain a low limit of detection are applied. Upon 
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identity confirmation, the primary transitions are used to quantify the analyte. 
This approach has the potential to dramatically increase the multiplexing 
capabilities of SRM. 
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The manufacture of biodegradable and renewable containers from bitter vetch seed protein-based
“bioplastics” was investigated. A bitter vetch seed protein concentrate was prepared and analyzed for
proteins, carbohydrates, phenols, other several organic compounds and multi-elements. Protein film
forming solutions were cast in the presence of two different glycerol concentrations and the film con-
taining higher plasticizer amount was laminated with an additional corn zein layer. Both lamination
process and lower glycerol concentration led to reduce film moisture content, total soluble matter and
elongation at break, while both film tensile strength and water vapour barrier properties resulted
enhanced. The obtained bioplastics were then processed by a new laboratory plastic moulding equip-
ment specifically designed and fabricated to convert protein-based films to shaped containers. The use of
either lower plasticizer concentration or corn zein lamination gave rise to potentially satisfactory vacuum
thermoformed containers with acceptable resistance and stability.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
The dramatic increase in production and lack of biodegradability
of commercial polymers, particularly commodity plastics used in
packaging industry and agriculture, focused public attention on a
potentially huge environmental accumulation and pollution prob-
lem that could persist for centuries. In fact, petroleum-based syn-
thetic polymers occur in the ecosystem as industrial waste products
generating multiple serious problems, e.g. visual pollution,
blockage of drains, livestock deaths and threat to aquatic life
(Shimao, 2001). There is, thus, an increasing interest toward bio-
based polymers to produce eco-friendly materials. In fact, a
future extensive use of renewable and biodegradable plastics
would allow to avoid the petroleum dependence, as well as the
incineration and landfill pitfalls, making these “bioplastics” stra-
tegic for a sustainable development. There are three main ways to
produce bioplastics: i) by starting from bio-based monomers ob-
tained by fermentation or conventional chemistry and polymer-
izing them in a second step (e.g. polylactic acid), ii) by producingbio-based polymers directly in microorganisms or in genetically
modified crops (e.g. polyhydroxyalkanoates), iii) by using different
natural polymers (e.g. polysaccharides and proteins). Natural
polymers are oftenmodifiedmechanically, physically or chemically,
as well as combined with plasticizers or further polymeric addi-
tives, to overcome several problems of different origin. Therefore,
most of the raw material converted to bioplastics may come from
the nature, green plants and microorganisms, or even from eatable
vegetables. Two examples are sugarcane and wheat straw, annually
renewable resources, the by-products of which (bagasse and straw
waste) can be turned into several articles normally made from
plastic or paper. Further widely used biomaterials are polylactic
acid, polybutylenes succinate, poly3-hydroxybutyrate, poly-
caprolactone, starch- and cellulose-based biopolymers (Smith,
2005).
Among the possible natural biomacromolecules, proteins offer a
valid alternative to the mentioned biopolymers (Arcan &
Yemenicioglu, 2011; Bambdad, Goli & Kadivar, 2006; Borreani &
Tabacco, 2015; Giosafatto et al., 2014; Peelman et al., 2013;
Razavi, Amini, & Zahedi, 2015; Tang, Xiao, Chen, & Yang, 2011).
Numerous potential applications for protein-based bioplastics are
imaginable, from biodegradable containers to packaging materials,
from agricultural mulching films to food service utensils. However,
A. Arabestani et al. / Food Hydrocolloids 60 (2016) 232e242 233to date only few commercial products have been made by using
proteins as raw material, even though different vegetable and an-
imal proteins have been suggested for obtaining edible coatings
and biodegradable packages (Anderson& Lamsal, 2011; Cho, Lee, &
Rhee, 2010; Cuq, Gontard & Guilbert, 1998; Peelman et al., 2013).
Among these, whey and soy proteins represent a biodegradable and
reproducible resource and, exhibiting an acceptable biocompati-
bility and processability, show an interesting potential mostly in
both food and agricultural biotechnology (Di Pierro et al., 2013 and
Mariniello et al., 2003). Some applications of whey and soy protein-
based materials, especially for food preservation and packaging
technology, have been reported (Di Pierro, Sorrentino, Mariniello,
Giosafatto, & Porta, 2011; Grewell, Schrader, & Srinivasan, 2014;
Rossi Marquez, Di Pierro, Esposito, Mariniello & Porta, 2014;
Song, Tang, Wang & Wang, 2011). Also zein, a protein extracted
from corn (Zeamays L.) during the wet-milling process (Shukla &
Cheryan, 2001) has many properties that make it an appealing
bioplastic feedstock, being an ethanol hydrophobic by-product and,
thus, quite water resistant (Anderson & Lamsal, 2011; Arcan &
Yemenicioglu, 2011; Ghanbarzadeh et al., 2006; Helgeson, Graves,
Grewell, & Srinivasan, 2009). Some species of leguminous family
are cheap protein sources, generally used only for animal feeding
(Saki et al., 2008). One of these, bitter vetch (Vicia ervilia; BV), is
widely cultivated throughout the temperate areas of Europe,
western and central Asia, north Africa and Americas for the utili-
zation of its seeds and hay. BV seeds contain up to 25% of protein
(Larbi, El-Moneim, Nakkoul, Jammal, & Hassan, 2011; Pastor-
Cavada, Juan, Pastor, Alaiz, & Vioque, 2011; Reisi, Zamani, Vatank-
hah, & Rahimiyan, 2011; Sadeghi, 2011) and, therefore, were
recently analyzed as sustainable alternative source to produce
biodegradable films, edible coatings and, potentially, properly
shaped biodegradable containers (Arabestani, Kadivar, Shahedi,
Goli, & Porta, 2013; Porta et al., 2015). Therefore, the specific
objective of the present work was to develop biodegradable con-
tainers made of BV seed proteins using a simple laboratory equip-
ment newly designed and fabricated. For this purpose a BV protein
concentrate (BVPC) was prepared and its content in proteins, car-
bohydrates, as well as in multi-element, phenolic and other organic
compounds, preliminarly analyzed.
2. Materials and methods
2.1. Materials
BV seeds were obtained from a local market in Isfahan, Iran. Zein
powder (containing 90% protein dry weight) was purchased from
Suvchem (India). Ethanol (96%) was supplied from Sepahan Teb
Company (Isfahan, Iran) and polyethylene glycol 400 from Serva
Electrophoresis GmbH (Heidelberg, Germany). Sodium hydroxide,
hydrochloric acid (37%) and glycerol (about 87%) were purchased
from the Merck Chemical Company (Darmstadt, Germany). All re-
agents for multi-element, organic compound, carbohydrate and
protein analyses were from Sigma Chemical Company (St. Louis,
MO).
2.2. Preparation of BV seed proteins and BVPC
Proteins were extracted from BV seeds according to Monsoor
and Yusuf (2002) by milling the seeds to a fine powder (40 mesh)
and soaking the latter in distilled water (1:10, w/v) brought at pH
10 by 0.1 N NaOH. After stirring (IKA® RH basic 2, Germany) at
medium speed for 1 h at 25 C, the mixture was centrifuged at
3200 g for 10 min and the precipitate discarded. The pH of the
supernatant was then adjusted to pH 5.4 by 0.1 N HCl addition and
the resulting precipitate, collected after centrifugation at 3200 g for10min, was finally dissolved by adding 0.1 N NaOH until pH 7.0 was
reached and the obtained solution dried in a vacuum oven at 40 C.
The obtained dry concentrate of BV proteins was finally minced in a
coffee grinder.
Protein content of both BV seeds and of the derived final BVPC
was determined by the Kjeldahl's method (AACC, 2003), using a
nitrogen conversion factor of 6.25.
2.3. BV protein identification
In gel trypsin digestion and protein identification. Proteins
contained in BVPC sample were analyzed by 12.5% SDS-PAGE. The
gel (1.5 mm) was run at constant 25 mA for 1 h, then stained with
colloidal Coomassie, and the blue-stained protein bands excised
from the gels and analyzed as follows. Gel particles were first
separately washed with acetonitrile and with 0.1 M ammonium
bicarbonate, then incubated with 10 mM DTT for 45 min at 56 C
and, finally, the cysteine residues alkylated by 5 mM iodoacetamide
treatment for 15 min at room temperature in the dark. After
washing with ammonium bicarbonate and acetonitrile, an enzy-
matic digestion was carried out by incubating the sample in the
presence of trypsin (10 ng/mL) in 50 mM ammonium bicarbonate
buffer, pH 8.5, at 4 C for 2 h to allow the enzyme to enter the gel.
The solution was then removed and a new aliquot of buffer was
added and the incubation continued for 18 h at 37 C. A minimum
reaction volume, sufficient for a complete gel rehydration, was
used. At the end of the incubation the peptides were extracted by
washing the gel particles with 0.1% formic acid in 50% acetonitrile at
room temperature and the sample freeze-dried.
Mascot identification. The sample was analyzed by LCMSMS on
a 6520 Accurate-Mass Q-TOF LC/MS System (Agilent Technologies,
Palo Alto, CA) equipped with a 1200 HPLC system and a chip cube
(Agilent Technologies). After loading, the peptide mixture was first
concentrated and washed in 40 nL enrichment column (Agilent
Technologies chip), with 0.1% formic acid in 2% acetonitrile as
eluent. The sample was then fractionated on a C18 reverse-phase
capillary column (Agilent Technologies chip) at a flow rate of
400 nL min1, with a linear gradient of eluent B (0.1% formic acid in
95% acetonitrile) in eluent A (0.1% formic acid in 2% acetonitrile)
from 5 to 80% in 50 min. Peptide analysis was performed using
data-dependent acquisition of one MS scan (mass range from 300
to 1800 m/z) followed by MS/MS scans of the five most abundant
ions in each MS scan. MS/MS spectra were measured automatically
when the MS signal surpassed the threshold of 50,000 counts.
Double and triple charged ions were preferably isolated and frag-
mented. The acquired MS/MS spectra were transformed in Mascot
generic format (.mgf) and used for protein identification in the
unreviewed set of protein entries that are present in the NCBInr
database for all bacteria, with a licenced version of Mascot software
(http://www.matrixscience.com) version 2.4.0. Additional Mascot
search parameters were: peptide mass tolerance 10 ppm, fragment
mass tolerance 0.6 Da, taxonomy Viridiplantae (Green Plants,
2,907,072 sequences) allowed trypsin missed cleavages up to 3,
carbamidomethylation of cysteines as fixed modification, oxidation
of methionine, pyro-Glu N-term Q, as variable modifications. Only
doubly and triply charge ions were considered. Ions score was 10
log(P), where P is the probability that the observed match is a
random event. Individual ion scores > indicated identity or exten-
sive homology (P < 0.05).
2.4. Analysis of low MW carbohydrates and other organic
compounds
1 mg of BVPC was dissolved in 500 mL of 1 M methanolic-HCl at
80 C for 16 h. The re-N-acetylation of the monosaccharide mixture
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50 mL of acetic anhydride at room temperature for 15 min. Sugars
were finally trimethylsilylated in 200 mL of N, O-bis(trimethylsilyl)
acetamide at 70 C for 45 min. The sample was dried down under
nitrogen, dissolved in 50 mL of hexane and centrifuged to remove
the excess of solid reagents. The hexane supernatant (1 mL) was
used for the GCMS analysis (Agilent 6890 Series GC, coupled to a
detector MS 5973, Agilent Technologies) by using a fused silica
capillary column (30 m, 0.5 mm ID, 0.25 mm ft) from Supelco. The
injection temperature was 250 C. For sugar analyses the oven
temperature was increased from 25 C to 90 C in 1 min and held at
90 C for 1 min before increasing to 140 C at 25 C/min, to
200 C at 5 C/min and finally to 300 C at 10 C/min. Conversely,
the temperature gradient used for fatty acid analysis was as fol-
lows: from 60 C to 150 C at 15 C/min or 20 C/min and then to
280 C at 3 C/min or 7 C/min. Electron ionisation mass spectra
were recorded by continuous quadrupole scanning at 70eV ion-
isation energy.
For the analysis of other organic compounds BVPC sample was
subjected to extraction step by using equal volume of dichloro-
methane and hexane and directly analyzed by GCMS with the in-
jection system in splitless mode. The DB-5ms capillary columnwas
30 m long, 0.25 mm I.D., and carried a film of stationary phase
0.25 mm thick. The stationary phase used consisted of poly-
dimethylsiloxane containing 5% of a phenyl derivative. Heliumwas
used as carrier gas at a flow-rate of 1.0 mL/min. Volatiles were
desorbed in the GC injector at 230 C for 3 min. The gradient pro-
gram for the GC analysis was as follows: 45 C for 3 min, 12 C/min
to 150 C, 18 C/min to 230 C, 19 C/min to 250 C. The GC detector
employed was maintained at a temperature of 250 C. The ioniza-
tion energy was set at 70 eV and the resulting fragment ions were
analyzed in the mass range m/z. 30-450.
2.5. Isolation and derivatization of oligosaccharide chains
BVPC tryptic digestion was carried out in 0.4% ammonium bi-
carbonate, pH 8.5, at 37 C overnight using an enzyme to substrate
ratio of 1:50 [w/w]. N-linked glycans were released from the pep-
tide mixture by treatment with 0.1 enzyme unit of peptide-N-(4)-
(N-acetyl-beta-glucosaminyl)asparagine amidase A (PNGase A) in
50 mM ammonium citrate, pH 6.5, overnight at 37 C. Total N-
linked oligosaccharides released by PNGase A were separated from
peptides by reverse phase chromatography on prepacked Sep-pak
cartridges (Waters) equilibrated with 5% acetic acid. Peptides
were retained on the cartridge and elutedwith 5% acetic acid in 40%
propanol, whereas the oligosaccharides were eluted in the aqueous
phase, collected, freeze-dried and, finally, permethylated. Briefly,
0.5e1 mL of dimethyl sulfoxide/NaOH slurry (prepared by grinding
five pellets of sodium hydroxide with approximately 3 mL of
dimethyl sulfoxide) was added to the oligosaccharide sample fol-
lowed by 0.5 mL of methyl iodide. The mixture was shaken for
10 min at room temperature and then quenched with 1 mL of
distilled water; the products were extracted into chloroform, which
was washed several times with distilled water. The chloroform
layer was finally dried under a stream of nitrogen and the residue
was dissolved in methanol for MALDIMS analysis.
2.6. Phenol determination
10 g of BVPC were suspended in 100 mL methanol and the
mixture, stirred for 24 h at room temperature, was finally centri-
fuged at 10,000  g for 10 min at 4 C. The obtained pellet was
washed three times with additional 20 mL methanol. The obtained
supernatants (160 mL) were pooled and analyzed for both quanti-
tative (unbound phenol content) and qualitative phenoldetermination. The final pellet was redissolved in distilled water at
pH 12 and analyzed for bound phenol content. Both bound and
unbound phenol BVPC content was determined using the Folin-
Ciocalteau method described by Rocha and Morais (2002). Gallic
acid was used to prepare a standard curve to determine the amount
of phenols (2e12 mg). Phenols were expressed as mg of gallic acid
equivalents/g BVPC.
Unbound phenol identification was carried out by drying 1 mL
BVPC methanol extract and resuspending the obtained powder in
0.5 mL of 5% acetic acid solution. The sample was chromatographed
through a Sep-Pak C18 classic cartridge (360 mg sorbent per car-
tridge, 55e105 mm particle size, 50/pk) equilibrated with 5% acetic
acid/40% isopropanol and the elution was then carried out with
3 mL of 5% acetic acid/40% isopropanol and 3 mL of isopropanol.
The two fractions were dried and the derived powders then
resuspended in 0.1% formic acid for MALDIMS analysis. Positive
reflectron MALDI spectra were recorded using a MALDI-TOF
Voyager-DE STR (Applied Biosystems, Framingham, MA, USA). The
MALDI matrices were prepared by dissolving 20 mg of 2,5-
dihydroxybenzoic acid (DHB) in 1 mL acetonitrile/water (90:10 v/
v). Typically, 1 mL of matrix was applied to the metallic sample plate
and 1 mL of analyte was added. Thus, 1 mL of extract was directly
mixed with the matrix on the metallic sample plate and MALDI
analysis was performed, avoiding any fractionation or enrichment
step. The analyses were performed in the positive ion mode, setting
the instruments in the reflector mode in the mass range m/z
100e700. A laser pulse voltage power of 3500 V was applied to
improve the detection of high molecular weight compounds in the
MS spectra. A total of 1500 laser shots at 337 nmwere summed for
each spectrum. Raw data were analyzed by using the Data Explorer
Software (version 4.9, build 115; Applied Biosystems, Framingham,
MA, USA) and reported as monoisotopic masses. In all cases, MALDI
mass spectra are dominated by cations Mþ.
2.7. Multi-element determination
Minute sub-samples of BVPC were analyzed by ICPMS. BVPC
(1 mg) was suspended in 1 mL of Milli-Q water in a teflon vessel
and digested in amicrowave oven (Milestone Ethos 900-Mega II) by
adding a mixture of 4 mL of 67% HNO3, 2 mL of 40% HF and 1 mL of
37% HCl. HNO3 and HCl were Super Purity Solvent grade (Romil,
Cambridge, UK). Mineralization was achieved with the following
microwave oven program: 20 min to reach 220 C at 1400 W;
15 min at 220 C and 1400 W; ventilation for 30 min. The solution
was then quantitatively transferred into polystyrene liners and
stored at 4 C until the ICPMS analysis was performed. The analyses
were carried out in triplicate on an Agilent 7700 ICP-MS, equipped
with a frequency-matching RF generator and 3rd generation
Octopole Reaction System (ORS3), operating with helium as cell gas
on diluted samples (1:10 v/v Milli-Q water). The parameters were
set as follows: radiofrequency power 1550 W, plasma gas flow
14 Lmin1; carrier gas flow 0.99 Lmin1; He gas flow 4.3 mLmin1.
The Octopole Reaction System was activated to improve the metal
quantification because of the interferences by polyatomic species
produced by a combination of isotopes coming from plasma, re-
agents and matrix. 103Rh was used as an internal standard
(50 mg mL1 final concentration). Multi-element calibration stan-
dards were prepared in 5% HNO3 at four different concentrations (1,
10, 50, and 100 mg L1). The standard addition approach for cali-
bration on four concentration levels was used in order to keep the
matrix-induced variations to a minimum. At least three replicates
of each calibration standard were run. Intra-day repeatability was
determined by the measurements of sample three times on the
same day. Inter-day repeatability was determined by the analysis of
a similar digested solution on three different days over a period of
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drifts, 103Rh was added as internal standard to all the samples and
calibration standards. Relative SD was calculated for both series of
analyses. Reagent blanks run together with matrices.2.8. Film preparation
BVPC powder (5 g) was dispersed under constant stirring in
100 mL distilled water and, then, glycerol was added to obtain
either 30% or 50% (w/w) concentrations. The pH was adjusted to a
pH value of 10 and the film forming solutions were heated for
30 min at 80 C in a water bath under constant stirring. The film
forming solutions were then cooled at room temperature,
degassed, and finally cast on teflonecoated glass plates
(30  30 cm) at 30 C for 24 h. In addition, some BVPC films ob-
tained in the presence of 50% glycerol were laminated with an
additional corn zein layer to obtain bilayer films. To this aim, corn
zein (2 g) and polyethylene glycol 400 (0.5 g) were mixed in 30 mL
ethanol. The mixture was stirred for 10 min at medium speed and
then heated at 80 C until zein was completely dissolved. The so-
lution was then cooled and poured onto a dried BVPC film and
allowed to stand for 30 min at 25 C before drying for 30 min at
85 C. Finally, the obtained bilayer film was stored overnight at
25 C before using.
All the films were manually peeled off and, prior to be tested,
were conditioned at 50% RH and 25 C by placing them in a
desiccator over a saturated solution of Mg(NO3)26H2O for 48 h.
Film thickness was measured with a micrometer (Electronic digital
micrometer, DC-516, sensitivity 0.001 mm) at different positions of
each film specimen. At least five thickness measurements were
performed for each film and the mean values were considered in
the different tests.2.9. Moisture and total soluble matter determination
Three samples (2  2 cm) were cut from each film, weighed
(±0.0001 g) into aluminum dishes and dried in an oven at 105 C for
24 h. The moisture content values were determined as the per-
centage of initial film weight lost during drying. Conversely, to
determine total soluble matter (TSM) content, same amounts of
film samples were directly immersed in distilled water at 25 C.
After 24 h the film samples were removed, rinsed with distilled
water and dried at 105 C for 24 h. Film initial dry matter values
were inferred from moisture content measurements of the same
film. TSM percentage of each film was calculated by using the
following equation (Tang, Jiang, Wen, & Yang, 2005):
%TSM ¼ Initial dry wt: Final dry wt:
Initial dry wt:
 1002.10. Mechanical properties
Following the ASTM Standard Test Method D 882e91 (ASTM,
1996) each film strip (2.5  10 cm) was mounted between the
grips of the texture analyzer (Zwick 1446e60, Germany) and tested
with initial grip separation of 5 cm and cross-head speed of 1mm/s.
Tensile strength (TS) was calculated by dividing themaximum force
by the initial cross-sectional area of the specimens. Percentage of
elongation at break (EB) was calculated as the percentage of change
in the length of the specimen compared to the original length be-
tween the grips.2.11. Water vapor permeability
Film water vapor permeability (WVP) was determined gravi-
metrically (Bamdad et al., 2006). Circular steel cups with a diameter
of 5.1 cm and a depth of 5.4 cm were filled with 3 g of anhydrous
calcium chloride and then covered with protein films. Cups were
weighed with their contents, then placed in a desiccator containing
1 L of purewater at 22 C, and finally weighed every 24 h for aweek.
WVP was calculated according to the following equation (Kaya &
Kaya, 2000):
WVP ¼ ðDm=DtÞ xL=SDP
Where Dm/Dt is the weight of moisture gain per unit of time (g/
h), L is the average film thickness (mm), S is the cup test mouth area
(m2) andDP is thewater vapor pressure difference between the two
sides of the film (KPa).2.12. Scanning electron microscopy
Film cross section was examined by a Phillips XL30 scanning
electron microscope (The Netherlands). At first, the film samples
were fractured in liquid nitrogen. Then, for cross-sectional analysis,
fractured films were rested vertically on the sides of a rectangular
aluminum piece and fixed on stubs using double sided adhesive
tape, coated with gold (300 s, 20 mA), and finally observed at a
magnification of 1000  . An acceleration potential of 20 kV was
used during micrograph.2.13. Container production
About 0.12e0.18 mm thick-walled containers of the same shape
and size (1.5 cm height, 6.0 cm small diameter and 9.0 cm large
diameter) were made starting from 5 g of BVPC. The prepared films
were moulded around the outside of a round teflon laboratory
device, having an outer diameter of 18.0 cm and a height of 17.5 cm,
by IR heating and under vacuum suction. The obtained containers
were then removed from moulds and stored at room temperature
for 18 months. The teflon laboratory device, designed for
manufacturing protein-based containers, is illustrated in Fig. 1. The
device consists of a heat source, constituted by a IR lamp along with
lamp holder connected to power supply 1, a circular film support 2,
a suction chamber provided with both a hole 3 through which
vacuum is applied and a bowl 4 presenting nine little holes (1 mm)
to give concave plate shape to the sucked films (Panel A). The
section images of the device was showed in the Panel B of Fig. 1.
Protein film samples (30  30 cm) were mounted between the grip
of the two rings (18 cm diameter) of the device and then fixed by
three screws to the circular support. After that heat generated by
the IR lamp conferred an appropriate flexibility to the film, vacuum
was applied through the suction chamber hole (3.5 cm diameter)
by a 2000 W domestic cleaner until the desired shape of the
container was obtained. Finally, redundant edges around the
container were cut using scissors and the final product was stored
at 25 C.2.14. Statistical analysis
All determinations were carried out in triplicate and mean
values with standard deviations were calculated. The results were
analyzed using the SAS package (version 9.1). The least significant
difference test was used to describe means at 5% significance level.
3.
Fig. 1. . Laboratory device for producing protein-derived containers. Panel A: IR lamp (1), circular film support (2), suction chamber hole for vacuum application (3), concave plate
(4). Panel B: device sectional images.
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3.1. BVPC protein identification
The detected protein content values from ground BV seeds
(flour), ranging from 27 to 28% (db), were found similar to the
amounts previously reported (Haddad, 2006; Pastor-Cavada et al.,
2011; Sadeghi, Pourreza, Samei, & Rahmani, 2009). The obtained
BVPC, containing 86.45% (db) proteins, was analyzed for protein
identification by a preliminary SDS-PAGE separation and staining
with colloidal Coomassie Blue. Most intense protein bands were
excised from the gels, digested with trypsin and the resulting
peptide mixtures fractionated by nano HPLC and sequenced by
tandem mass spectrometry generating sequence information onindividual peptides. LCMSMS spectrawere used to search for a non-
redundant sequence against UniprotSprot databases using the in-
house Mascot software, taking advantage of the specificity of
trypsin and of the taxonomic category of the samples. The number
of measured masses matching within the given mass accuracy was
recorded and the proteins showing the highest number of peptide
matches were examined leading to the identification of the protein
components. As further selection criteria, only the proteins iden-
tified by Mascot search with at least three peptides, and found
exclusively in the replicates, were selected. The list of proteins
identified by this experimental approach (Table 1) showed the
occurrence of the same six proteins (convicilin, legumin A2, legu-
min B, alcohol dehydrogenase, glyceraldehyde-3-phosphate dehy-
drogenase and allergen Len c 1.0101) in the ten different bands
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teolytic processing of the different proteins.3.2. BVPC phenol, multi-element, carbohydrate and other organic
compound content
It has been recently reported that the total phenol content of BV
seed aqueous extract corresponds to about 60 mg gallic acid
equivalents/g (Mirzaei, Satarifar, & Zadeh, 2014). Our quantitative
determination of the phenol content in BVPC methanol extract
(unbound phenols) indicated a value of 1.2 mg gallic acid equiva-
lents/g, whereas the large majority of phenol compounds (20.3 mg
gallic acid equivalents/g) was detected in the methanol unsoluble
BVPC fraction being, thus, probably protein-bound.
Although MALDIMS is a well known powerful method for the
identification of several different molecules, only recently it has
been used for the analysis of condensed tannins or simple flavonols.
In fact, it has been demonstrated that it is possible to simulta-
neously detect numerous molecules of this class of compounds in
the mass spectra where Mþ cations dominate (Carpentieri, Marino,
& Amoresano, 2007; Nunes-Miranda et al., 2012). Therefore, BVPC
methanol extract was also analyzed by MALDIMS in order to
identify the different unbound phenols and Table 2 summarizes the
fingerprinting obtained by the analysis carried out on the BVPC
methanol soluble fraction. Each peak of the MALDIMS spectrum
was assigned to the corresponding species on the basis of literature
data and fragmentation spectra, the most abundant compounds
resulting 4-methyl-epicatechin-3’-glycoside (m/z, 496.35), malvi-
din-3-O-glycoside (m/z, 515,23), petunidin-3-(6’-acetyl)-glycoside
(m/z, 520.36), spinatoside-4-O-glucuronide (m/z, 522.38) andTable 1
BVPC protein identification by LCMSMS analysis of the main SDS-PAGE protein bands.
ID NCBI Protein
BAND 1 gij164512566 Convicilin
gij479104 Legumin B
gij126161 Legumin A2
BAND 2 gij164512566 Convicilin
gij479104 Legumin B
gij113361 Alcohol dehydrogenase 1
gij29539109 allergen Len c 1.0101
gij126161 Legumin A2
BAND 3 gij164512566 Convicilin
gij479104 Legumin B
BAND 4 gij29539109 allergen Len c 1.0101
gij164512566 Convicilin
gij479104 Legumin B
BAND 5 gij29539109 allergen Len c 1.0101
gij164512566 Convicilin
gij479104 Legumin B
gij126161 Legumin A2
BAND 6 gij479104 Legumin B
gij126161 Legumin A2
gij462138 Glyceraldehyde-3-phosphate
BAND 7 gij126161 Legumin A2
gij164512566 Convicilin
gij462138 Glyceraldehyde-3-phosphate
gij479104 Legumin B
gij29539109 allergen Len c 1.0101
gij113361 Alcohol dehydrogenase 1
BAND 8 gij29539109 allergen Len c 1.0101
gij164512566 Convicilin
gij479104 Legumin B
gij126161 Legumin A2
BAND 9 gij29539109 allergen Len c 1.0101
gij164512566 Convicilin
gij479104 Legumin B
BAND 10 gij479104 Legumin B
gij126161 Legumin A2cyanidin-3-O-(6-O-p-coumaroyl)-pentoside (m/z, 565.18).
Furthermore, ICPMS analysis of BVPC let us to identify and
quantify up to fifty-three different metal ions in a single run, even
though only thirteen resulted to have a value higher than the ICP
limit of detection. Among these, only one element occurred at a
value higher than 5 ppm (Mg, 7.17), two elements at values be-
tween 1 and 2 ppm (Fe, 1.85; Zn, 1.14) and four at values between
0.1 and 0.5 ppm (Al, 0.50; Cu, 0.24; Mn, 0.18; B, 0.15), whereas only
traces of Cr, Cu, Sr, Mo, Ba and Pb were detected.
Monosaccharides and other low MW carbohydrates were
instead determined by mild hydrolysis of BVPC sample followed by
GCMS analysis of the obtained trimethylsilyl derivatives. The re-
sults reported in Table 3 show a high percentage of the mono-
saccharides glucose (22.1%) and mannose (8.3%), as well as of the
disaccharides saccarose (25.3%) and maltose (19.3%). In addition,
several other organic compounds like squalene and a eketobutirric
acid (11.2%), as well as tocopherol and oleic alcohol acetate (8%),
were identified in BVPC by using a liquid phase extraction proce-
dure coupled to GCMS (Table 3). Additional informations about the
possible protein-bound glycosidic structures were obtained by
digesting the BVPC sample with trypsin and by releasing the intact
N-linked oligosaccharides from the obtained peptides with PNGase
A treatment. The glycans were separated from the peptides by a
Sep-pack reverse phase chromatographic step, then permethylated
and finally analyzed by MALDIMS. The obtained spectra displayied
a high heterogeneous glycoform mixture. In particular, two
different classes of N-linked glycans were detected: high-mannose
structures, representing the most abundant components, and
fucosylated complex structures. The m/z of permethylated oligo-
saccharides released by BVPC and the hypothesized molecularMW (kDa) Number of peptides
62.7 12
54.6 15
59.3 5
62.7 45
54.6 7
41.1 6
47.7 7
59.3 5
62.7 12
54.6 13
47.7 15
62.7 13
54.6 5
47.7 15
62.7 14
54.6 4
59.3 3
54.6 10
59.3 9
dehydrogenase 36.6 8
59.3 12
10
dehydrogenase 36.6 8
54.6 7
47.7 8
41.1 7
47.7 13
62.7 9
54.6 4
59.3 4
47.7 7
62.7 5
54.6 4
54.6 8
59.3 5
Table 2
MALDIMS fingerprinting of phenols occurring in methanol soluble fraction of BVPCa.
Compound m/z
Cis-Resveratrol-3-O-glycoside þ Na 411.16*
Cis-Resveratrol-3-O-glycoside þ K 427.13*
Pelargonidin-3-O-glycoside 433.12*x
Epicatechin-3-O-gallate 441.00*
Cyanidin-3-O-monoglicoside/Kaempferol-3-glycoside 449.13*
Taxifolin-deoxy-hexoside B/A 450.10x
Peonidin-3-O-monoglycoside 463.00*
Delphinidin-3-O-monoglicoside/Quercetin-3-glycoside 465.16*
Isorhamnetin-3-O-glicoside/Quercetin-3-O-glycoside 478.36x
Myricetin-3-glycoside 481.12*
4-Methyl-epicatechin-3’-glycoside 496.35*§
Acetone derivate of Peonidin-3-glycoside 501.01*
Delphinidin-3-O-(6-O-acetyl)-monoglycoside 507.30x
Malvidin-3-O-glycoside þ Na 515.23§
Petunidin-3-(6’-acetyl)-glycoside 520.36*§
Spinatoside-4-O-glucuronide 522.38*§
Peonidin-3-(600-malonyl)-glicoside 549.22*
Cyanidin-3-O-(6-O-p-coumaroyl)-pentoside 565.18*
Crisoeriol-7-O-(6’-malonyl-glycoside)þ Na 570.36x
Delphinidin-3-glicoside-4-vinylphenol adduct 581.17*
Cyanidin-3-O-(6-O-p-coumaroyl)-pentoside þ Na 587.17*
Cyanidin-3-O-monoglicoside-(6-O-p-coumarate)/Petunidin-3-O-glycoside-4-vinylphenol adduct 595.19*
Malvidin-3-O-glycoside Pyruvate/Vitisin A þ K 599.44x
Malvidin-3-(6-O-acetyl-glycoside) piruvate 603.14*
Malvidin-Cyanidin (fragment) 617.18*x
Pinotin A/Peonidin-3-(6-O-caffeoyl)glycoside/Peonidin-3,5-O-diglycoside/Malvidin-3-O-glycoside-4-vinyl catechin 625.47x
Delphinidin-3,5-diglucoside 627.22*
Malvidin-Peonidin (fragment) 631.43x
Malvidin-3-O-(6-O-p-coumaroyl) monoglycoside 639.00x
Acetyl Pigment A/Malvidin-3-acetyl-4-vinylphenol adduct 651.19*
Malvidin-3,5-O-diglycoside/Malvidin-caffeoyl-glucoside 655.44x
Malvidin-3-acetyl-glycoside-4-vinylcatechol adduct 667.18*
Acetyl Pigment A/Malvidin-3-acetyl-4-vinylphenol adduct þ Na 673.18*
Malvidin-3-acetyl-glycoside-4-vinylguaiacol adduct 681.20*
MalvidineMalvidin þ K (fragment) 685.00x
Acetyl Pigment A/Malvidin-3-acetyl-4-vinylphenol adduct þ K 689.16*
Delphinidin -3-O-(6-O-P-Coumaroyl) glycoside Pyruvic Acid 701.40*
Malvidin-3-(6-O-P-Coumaroylglicoside)Pyruvate/A Type Vitisin Of Malvidin-3-P-Coumaroyl glycosilate 707.22x
Delphinidin-3-p- Coumaroyl-glycoside-4- vinylphenol adduct 727.28*
Epicatechin-epicatechin-3-O-galactoside 738.55x
(epi)catechin-Peonidin-3-O-glycoside 751.33*
Delphinidin-catechin-glycoside 753.48x
Catechin-ethyl-cyanidin-glycoside 765.33*
Catechin-Petunidin-glycoside 767.00*
Malvidin-Cyanidin-glycoside/Peonidin-3-glycoside-ethylcatechin 779.23*x
Delphinidin-3-sporoside-5-glycoside 789.29*
Malvidin-3-(6-O-p-coumaroyl)-5-O-diglycoside 801.47x
Malvidin-3-glycoside-4-vinylcatechin 805.26*
Malvidin-Malvidin-glucoside (fragment)/Catechin-Malvidin-acethylglicoside 823.52*
P3/Procyanidin (T2,T3,T4) 866.67x
Malvidin-3-(6-O-p-coumaroyl-glycoside)-epicatechin 927.68x
Malvidin-3-p-coumaroyl-glycoside-4-vinylcatechin 951.37*
Patuletil-3-o-(200-feruloylglycosyl)-apiosilglycoside 964.33x
Trimer 1G þ Na A seriesb 1039.72x
Trimer 1G þ Na B seriesb 1041.73x
a Phenols eluted by either 5% acetic acid/40% isopropanol (*) or isopropanol (x); the most abundant phenols are reported in bold.
b G, galloyl ester; A and B series refer to inter phalanic bonds.
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The obtained BVPC resulted suitable for the preparation of
flexible brown films, sufficiently strong to be easily handled. With
the aim to obtain biodegradable finely shaped containers, we pre-
pared three different BVPC films, two of them containing different
glycerol concentrations (30 and 50%) whereas the third, containing
50% glycerol, was laminated with a thin layer of zein, the prolamine
fraction of corn proteins widely used in bilayer film production. It is
known that the amount of plasticizer occurring in the film formingsolution is critical for obtaining films with desired flexibility (Vieira,
Silva, Santos, & Beppu, 2011) whereas the lamination with another
film layer may produce films with improved mechanical and bar-
rier characteristics (Ghanbarzadeh & Oromiehi, 2008, 2009) as a
result of the combined properties of the different layers
(Rakotonirainy & Padua, 2001; Gonzales, Strumia & Igarzabal,
2011). In fact, zein has a high hydrophobic amino acid content
and produces films with lower water vapor permeability and
higher tensile strength in comparison with other protein-based
films (Cho, Park, & Rhee, 2002; Cho et al., 2010; Ghanbarzadeh
et al., 2006; Ghanbarzadeh & Oromiehi, 2009).
Table 5 shows the characteristics of the three different films
Table 3
Low MW carbohydrates and other organic compounds occurring in
BVPCa.
Compound %
Arabitol 0.9%
Cellobiose 0.9%
Fruttose 0.7%
Galactose 0.6%
Glycerol 0.6%
Glucose 22.1%
Maltose 19.3%
Mannobiose 0.2%
Mannose 8.3%
Myo-inositol 0.6%
NAcetylGalactosamine 0.1%
Pinitol 0.3%
Ribitol 0.3%
Saccarose 25.3%
Sorbitol 0.3%
Talose 0.7%
Turanose 0.4%
Dimethylheptane 1.3%
Diossane 3.0%
Isopropyllaurate 4.5%
Metan-3-one semicarbazone 1.5%
Methyl palmitate 0.4%
Methylottane 0.8%
Oleic alchool acetate 8.6%
Squalene 11.1%
Ter-buthylphenol 0.6%
Tocopherol 8.0%
Toluene 1.7%
Trimethyldodecane 0.2%
a eKetobutirric acid 11.2%
a The most abundant compounds are reported in bold.
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glycerol, as well as that of the zein-laminated films, markedly
decreased with respect to the one of the films containing 50% of
plasticizer (33% and 45%, respectively). These results were probably
due to the hydroscopic properties of glycerol that, by forming
hydrogen bonds, is able to effectively retain water molecules into
the film matrix (Vieira et al., 2011) while, conversely, the zein high
hydrophobic amino acid content contributes to repulse water from
the laminated BVPC film network. As a consequence, also the TSM
values resulted reduced (of about 25%) both in films containing a
lower concentration of glycerol and in the zein-laminated ones
depending on their minor hydrophilic characteristics.
Concerning the film mechanical properties, both BVPC films
containing 30% glycerol and zein-laminated films exhibited a
higher TS (3.5-fold) and a markedly lower EB (20- and 33-fold,
respectively) compared to BVPC films prepared in the presence of
50% glycerol (Table 5). Numerous studies showed that high plasti-
cizer concentrations decrease protein film TS and increase their EB
by reducing the intermolecular forces along the polypeptide chains
(Vieira et al., 2011). In particular, the increase in mechanical resis-
tance and the decrease in deformability of protein films prepared in
the presence of lower glycerol concentrations were previously re-
ported (Choi & Han, 2001; Saremnezhad, Azizi, Barzegar, Abbasi, &
Ahmadi, 2011). A similar trend was also observed when soy (Cho
et al., 2010) or whey protein (Vieira et al., 2011) films, as well as
caseinate/whey protein films (Cho et al., 2002), were laminated
with corn zein layers.
Moreover, BVPC film containing 30% glycerol and laminated
BVPC/zein bilayer film exhibited also a significantly lower WVP
(about 25%) with respect to the monolayer BVPC films containing
50% glycerol. Increase in glycerol concentration is known to
enhance permeability to water vapor as a consequence of inter-
molecular space enlargement inside the film network, whereas thehigh content of hydrophobic amino acids occurring in zein may
explain the more effective water vapor barrier activity observed in
laminated bilayer BVPC films.
Finally, also film morphology observed in scanning electron
microscopy images shown in Fig. 2 was markedly affected, the
different microstructures being able to explain the changes of
properties of the three different films.
3.4. Developed containers and stability studies
Proteins are considered promising biopolymers to replace
petroleum-based commodity plastics, even though they generally
exhibit poor mechanical properties regarding processability and
end-use application. In fact, protein film brittleness exhibited
during thermoformation limits their potential industrial use. To
overcome this problem, plasticizers and/or additional film layers
could be utilized to provide the needed protein-based film work-
ability. Fig. 3 shows three different representative containers ob-
tained with the three different BVPC films prepared, respectively, at
two different glycerol concentrations or after lamination with corn
zein of BVPC film containing 50% glycerol, by using a new specific
designed device for container manufacture. The containers derived
from the BVPC film prepared in the presence of 30% glycerol (Fig. 3,
panel B) and the one produced with zein-laminated film (Fig. 3,
panel C) were more easily prepared since the originating films
showed both resistance and deformability properties more suitable
with respect to the BVPC film prepared in the presence of a higher
concentration of glycerol (Fig. 3, panel A). Furthermore, the
container derived from bilayer film exhibited a stability, shown as
structural integrity and mechanical resistance, greater than that of
the other two BVPC containers during storage at 25 C. In fact, no
visible changes occurred in the structure and shape of the BVPC/
zein bilayer container during 18 months of its storage, while some
cracks were evident on the surface of the container prepared with
BVPC film obtained in the presence of 30% glycerol following 3
months of storage, and the container derived from 50% glycerol
containing film lost its shape only few days after its production
because of its excessive flexibility.
4. Discussion
The results of the present study highlight BVPC, easily obtain-
able from BV seeds, as a promising raw material candidate for the
production not only of films but also of biodegradable containers.
BV seed proteins were preliminarly identified and BVPC carbohy-
drate, metal ion, phenolic and other organic compound content
also determined. Convicilin, legumins A2 and B, allergen Len c
1.0101 and two oxydoreductase, alcohol dehydrogenase 1 and
glyceraldehyde-3-phosphate dehydrogenase, were identified by
analysing the ten main protein bands obtained by SDS-PAGE of the
BVPC sample. The first four proteins generally occur in the seeds of
many leguminous and non-leguminous plants and are known as
globulins functioning as protein storage, whereas the two enzymes
are certainly related to the embryo development. Moreover, the
performed analyses showed the presence in the BVPC of a high
content of phenol compounds, the large majority of which was
detected in the methanol unsoluble fraction being, thus, probably
covalently bound to macromolecules during BVPC preparation. An
interesting result was the determination of two different classes of
N-linked glycans, i.e. high mannose and fucosylated complex
structures, All these findings suggest the occurrence in the BVPC of
a complex macromolecular network, probably constituted by
polysaccharide/protein complexes with different phenol com-
pounds covalently linked, potentially suitable for the preparation of
films with improved mechanical features. The films obtained by
Table 4
Hypothesized structures and m/z of permethylated oligosaccharides released from BVPC by PNGase A treatment.
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added with 30% glycerol, as well as with 50% glycerol and then
laminated by zein, a high TS and a low EB, becoming capable to be
processed to obtain moulded solid containers. In addition, theobtained bilayer BVPC/zein container exhibited a marked stability
since no change in its structure and shape and no cracks were
observed during 18 months of storage at 25 C. Moreover, a further
result of the present study was the manufacture of a laboratory
Table 5
Properties of different BVPC films used for container preparation*.
Film Thickness (mm) Moisture content (%) WVP (gmm/mhKPa) TSM (%) TS (MPa) EB (%)
BVPC þ 50% glycerol 0.10 ± 0.02a 27.69 ± 1.18a 0.71 ± 0.02a 36.57 ± 2.08a 5.04 ± 0.81b 118.01 ± 18.71a
BVPC þ 30% glycerol 0.11 ± 0.02a 18.60 ± 0.30b 0.52 ± 0.06a 27.52 ± 0.45b 17.82 ± 1.69a 5.79 ± 0.64b
BVPC/zein þ 50% glycerol 0.14 ± 0.04a 15.42 ± 0.34c 0.55 ± 0.03a 27.33 ± 0.96b 18.03 ± 0.95a 3.54 ± 0.59b
*Values superscripted with dissimilar letters (a,b,c) are significantly different (p < 0.05).
Fig. 2. . Scanning electron microscope images of BVPC films prepared in the presence of 30% glycerol (A), 50% glycerol (B) or 50% glycerol and then zein-laminated (C). Experimental
details are given in the text.
Fig. 3. . Representative BVPC-based bioplastic containers. The containers were obtained by using BVPC films prepared in the presence of 50% (A) or 30% (B) glycerol, or by
lamination with corn zein of BVPC films prepared in the presence of 50% glycerol (C). Experimental details are given in the text.
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without using the conventional thermoplastic processing tech-
niques generally unsuitable to mould protein-based materials. In
fact, it has been demonstrated that BVPC-derived films can be easily
transformed into small bowls through a new simple device
equipped with only a tunable IR heater lamp and a vacuum unit.
However, the obtained biodegradable protein-derived containers
were made by hand and, therefore, had sidewalls that were not as
uniform as would be expected for those of machine-moulded
containers obtainable from a commercial manufacturer. Slight
variations in thickness of the walls, in fact, may worsen the struc-
tural properties and longevity of the obtained containers, while the
commercially fabricated ones might have better features simply
due to their uniformity. However, further strategies to increase
container stability deserve to be explored, as well as the feasibility
of producing BVPC-based bioplastic containers by either modifying
standard moulding techniques or refining the device described in
the present paper.
In conclusion, although the obtained container made of BV seed
protein-based sustainable plastics represents only a promising
prototype, the reported results should be considered the first
insight concerning the possibility of using BV proteins to fabricate
biodegradable articles. Future efforts will be mainly addressed to
structurally improve the product with the aim to confer to it the
characteristics of durability typical of conventional plastic articles
suitable for different uses, and there are several possibilities for
improving the BVPC container performance. One of these is
applying a coating on its inner walls for reducing the rate of itsdegradation. In fact, if the container is layered with a protective
material, BV protein degradation might be certainly delayed.
Moreover, further research should be addressed to examine how
the addition of either plasticizers other than glycerol (Vieira et al.,
2011), nanoparticles (Kadam et al., 2013) or chemical/enzymatic
cross-linking agents (Porta, Di Pierro, et al., 2011; Porta, Mariniello,
et al., 2011) may affect the properties of such protein-based bio-
plastics as well as container longevity and relative costs. Other
physical changes could also be determined by the use of fillers to
create new composite materials. Corn stover, as well as lignin and
cellulosic fibres, are among the numerous possible additives to
incorporate into BVPC films to improve the structural properties of
the derived containers. Being many of these potential components
underutilized by-products of other processes, their recycle might
also partially contribute to offset the current high price of the
existing protein-based biodegradable containers.
5. Conclusions
BVPCwas easily obtained, analyzed for its protein, carbohydrate,
multi-element, phenolic and other organic compound content, and
then utilized in manufacturing of films and biodegradable con-
tainers by using a new designed and realized plastic moulding
equipment. The reported results showed that either the addition of
30% glycerol to BVPC film forming solution or corn zein lamination
of bitter vetch protein-based films gave rise to potentially satis-
factory vacuum thermoformed containers with acceptable resis-
tance and stability. These findings open new perspectives in using
A. Arabestani et al. / Food Hydrocolloids 60 (2016) 232e242242BV proteins as a sustainable alternative to fossil fuel based plastics
to produce a variety of properly shaped biodegradable articles.
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ABSTRACT
Chronic inflammation can result from inadequate engagement of resolution mechanisms, mainly
accomplished by specialized pro-resolving mediators (SPMs) arising from the metabolic activity of
lipoxygenases (ALOX5/15) on v-6 or v-3 essential polyunsaturated fatty acids (PUFA). We previously
demonstrated that formyl peptide receptor 1 (FPR1) suppresses gastric cancer (GC) by inhibiting its
inflammatory/angiogenic potential. In this study, we asked whether FPR1 exploits inflammation resolution
pathways to suppress GC angiogenesis and growth.
Here, we demonstrate that genetic or pharmacologic modulation of FPR1 in GC cells regulated ALOX5/
15 expression and production of the SPMs Resolvin D1 (RvD1) and Lipoxin B4 (LXB4). SPM treatment of GC
cells abated their angiogenic potential. Genetic deletion of ALOX15 or of the RvD1 receptor GPR32
increased the angiogenic and tumorigenic activity of GC cells thereby mimicking FPR1 loss. Deletion/
inhibition of ALOX5/15 or GPR32 blocked FPR1-mediated anti-angiogenic activities, indicating that
ALOX5/15 and GPR32 are required for FPR1’s pro-resolving action. An v-3- or v-6-enriched diet enforced
SPM endogenous production in mice and inhibited growth of shFPR1 GC xenografts by suppressing their
angiogenic activity. These data implicate that FPR1 and/or pro-resolving pathway components might be
used as risk/prognostic markers for GC; v-6/3-enriched diets, and targeting FPR1 or SPM machinery may
be exploited for GC management.
KEYWORDS
Angiogenesis; formyl peptide
receptors; gastric cancer;
lipoxin B4; pro-resolving
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Introduction
Prolonged inflammation underlies the pathogenesis of vari-
ous diseases including cancer.1 Recent years have seen a
paradigm shift in our understanding of the etiopathogenesis
of inflammation whereby chronic inflammation may not
result only from persistence of inflammatory mechanisms,
but may also arise from an inadequate engagement of the
resolution mechanisms.2 Resolution is an active process
brought about by a series of cellular mechanisms that are
activated to restore tissue homeostasis.3 Lipid specialized
pro-resolving mediators (SPMs), which are the main effec-
tors of resolution, derive from the effects exerted by lipoxy-
genases (ALOX5 and 15) on v-6 arachidonic acid (AA), or
on v-3 eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), which are essential polyunsaturated fatty acids
(PUFA)3 (Fig. 1A). Recent evidence associates a deficit in
pro-resolving pathways with the establishment of various
inflammatory-related disorders (e.g., asthma, fibrosis, and
autoimmune diseases).4 However, whether and how defects
in resolution mechanisms affect cancer initiation and
progression, and what signals control pro-resolving path-
ways in this context is unknown.
Formyl peptide receptors (FPR1, 2, and 3) are pattern recogni-
tion receptors (PRR) of the G-protein-coupled (GPCR) family
that recognize both exogenous and endogenous “danger” signals,
and trigger inflammation and immune responses.5 FPRs can also
trigger inflammation resolution, depending on the environmental
context and on the specific ligand.6 We recently showed that
genetic ablation of FPR1 in AGS gastric cancer (GC) cells, which
constitutively express high levels of the receptor, increased their
angiogenic and tumorigenic potential. Accordingly, enforced
expression of FPR1 in MKN45 GC cells, which constitutively
express low levels of the receptor, dramatically impaired GC cell
xenograft angiogenesis and growth in immunodeficient mice.7
Since genetic deletion of FPR1 in GC cells increased angio-
genesis and enhanced the response to pro-inflammatory cyto-
kines,7 which is a phenotype suggestive of unresolved
inflammation, we asked whether, at the gastric level, FPR1
might actively sustain pro-resolving pathways to inhibit GC
angiogenesis and growth.
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Here, we show that, in GC cells, FPR1 expression/activa-
tion levels directly correlate with ALOX expression, and
with SPM Resolvin D1 (RvD1) and Lipoxin B4 (LXB4) (3)
production (Fig. 1A). The increased angiogenic potential of
GC cells lacking FPR1, previously reported,7 was reverted
by RvD1 or LXB4 treatment. Genetic ablation of ALOX15
or of GPR32 (an RvD1 receptor)8 induced a pro-angiogenic
phenotype in GC cells similar to that induced by FPR1
deletion. ALOXs and GPR32 are required for FPR1-medi-
ated anti-angiogenic activity in GC cells. Consistently,
administration of v-3 or v-6 PUFA-enriched diets, which
enforces endogenous production of SPMs,9 inhibited xeno-
graft growth of FPR1-silenced GC cells by ablating their
angiogenic activity.
Figure 1. Relation between FPR1 expression and SPM biosynthesis machinery. (A) Schemes of arachidonic acid-AA, docosahexaenoic acid-DHA, and eicosapentaenoic
acid-EPA metabolism. (B) AGS shFPR1 cl 15 cells produced significantly lower amounts of RvD1 and LXB4 compared to AGS shCTR cells, while MKN45 cells overexpressing
FPR1 (MKN45 FPR1 cl 4) released higher amounts of RvD1 and LXB4 compared to empty vector transfected cells (MKN45 pcDNA), as evaluated by EIA assays. Data are
represented as mean § SD of five independent experiments. p < .05 compared to the relative control. (C) Increased release of PGE2 and LTB4 from shFPR1 AGS cells
and from MKN45 pcDNA cells compared to the relative control cells, assessed by EIA. Data are represented as mean § SD of three independent experiments. p < .05
compared to the relative control. (D) AGS shFPR1 cl 15 expressed significantly lower levels and MKN45 FPR1 cl 4 significantly higher levels of ALOX5, ALOX15A, and
ALOX15B mRNAs compared to relative controls (dotted line), as assessed by real-time PCR. Data are represented as mean § SD of three independent experiments.
p < .05 compared to the relative control. (E) ALOX5, ALOX15A, and ALOX15B protein levels were lower in AGS shFPR1 vs. AGS shCTR, and in MKN45 pcDNA vs. MKN45
FPR1 cells, as evaluated by cytofluorimetric analysis. One representative experiment out of three is shown.
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Our data indicate that FPR1 signaling activates a pro-resolv-
ing program in GC cells that inhibits angiogenesis and growth.
Results
FPR1 controls ALOX5 and ALOX15 expression and the
production of SPMs in GC cells
To study whether pro-resolving pathway components are
involved in the FPR1-mediated anti-angiogenic and tumor sup-
pressor activity of GC, we used our previously generated GC
cell lines, namely, FPR1-silenced AGS (AGS shFPR1) and
MKN45 ectopically expressing FPR1 (MKN45 FPR1) or their
relative controls (AGS shCTR and MKN45 pcDNA).7
RvD1 and LXB4 levels were significantly lower in AGS
shFPR1 cells than in AGS shCTR cells. Consistently,
MKN45 cells overexpressing FPR1 released higher amounts
of RvD1 and LXB4 than did empty vector-transfected cells
(Fig. 1B). RvD1 and LXB4 syntheses were reduced in
shFPR1 but not in shFPR2 or shFPR3 AGS cells (not
shown), which indicates that FPR1 plays a non-redundant
role in controlling SPM production, as already observed for
Figure 2. Effects of FPR1 pharmacologic modulation on SPM biosynthesis. (A) EIA assays showing that fMLF (agonist to FPR1-10¡9 M) treatment of AGS significantly
increases RvD1 and LXB4 release compared to untreated cells (dotted line). In contrast, CsH (inverse agonist to FPR1-800 nM) treatment significantly reduced RvD1 and
LXB4 release compared to controls (dotted line). Data are represented as mean § SD of three independent experiments. p < .05 compared to untreated cells. (B) fMLF
induced, whereas CsH inhibited, ALOX5, ALOX15A, and ALOX15B mRNA expression in AGS and MKN45 cells. Data are represented as mean § SD of three independent
experiments. p< .05 compared to untreated cells (dotted line). (C) fMLF induced, whereas CsH inhibited, ALOX5, ALOX15A, and ALOX15B protein expression in AGS cells,
as evaluated by cytofluorimetric analysis. One representative experiment out of three is shown. (D) fMLF inhibited, whereas CsH induced, pro-angiogenic molecule mRNAs
expression in AGS and MKN45 cells. Data are represented as mean § SD of three independent experiments. p < .05 compared to untreated cells (dotted line).
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its tumor suppressor function.7 We evaluated the lipidomic
profiles of controls and FPR1-depleted/overexpressing GC
cell supernatants by liquid chromatography tandem-mass
spectrometry (LC-MS/MS) (Fig. S1). Compared to controls,
AGS shFPR1 cells produced significantly lower levels of
SPMs, including 18-HEPE, a resolvin precursor, and LXB4
(Fig. S1A). MKN45 FPR1 cells released significantly higher
levels of RvD3 and LXB4 than did control cells (Fig. S1A).
LXA4 levels did not differ significantly among GC cells
expressing different levels of FPR1 (Fig. S1B). SPM expres-
sion parallels the downregulation of pro-inflammatory eico-
sanoids.4 Consistently, AGS shFPR1 cells synthesized
significantly higher amounts of LTB4 and PGE2 compared
to shCTR cells, whereas MKN45 FPR1 cells released lower
levels of PGE2 compared to empty vector transfected cells,
as assessed by EIA (Fig. 1C).
The levels of the enzymes involved in SPM synthesis
(ALOX5, ALOX15A, and ALOX15B)10,11 were significantly
lower in FPR1-silenced GC cells than in shCTR cells, both
at mRNA (Fig. 1D) and protein (Fig. 1E) level. The expres-
sion of SPM receptors GPR32, ChemR23, and BLT18 was
lower in AGS shFPR1 cells than in controls (Fig. S1C and
D). On the other hand, MKN45 FPR1 cells produced signif-
icantly higher levels of pro-resolving enzymes (Fig. 1D and
Figure 3. Anti-angiogenic effects of SPMs in GC. (A) RvD1 (1 nM) and LXB4 (1 nM) treatment significantly reduced mRNA expression of pro-angiogenic molecules (VEGF-A,
-B, -C, -D, Ang1, and CXCL1) in AGS shCTR and shFPR1 cells. Data are represented as mean § SD of three independent experiments. p < .05 compared to the relative
untreated control (dotted line). (B) Reduction of spontaneous and WKYMVm-induced VEGF-A release upon RvD1 treatment of the indicated GC cells. Data are represented
as mean § SD of three independent experiments. p < .05 vs. the relative untreated control (dotted line). (C) RvD1 and LXB4 treatment significantly induced the mRNA
expression of the enzymes (ALOX5, ALOX15A, and ALOX15B) and receptors (BLT1, GPR32, and ChemR23) involved in pro-resolving pathways in AGS shCTR and shFPR1
cells. Data are represented as mean § SD of three independent experiments. p < .05 vs. the relative untreated control (dotted line). (D) RvD1 treatment significantly
induced ALOX5, ALOX15A, and ALOX15B protein expression in AGS shCTR and shFPR1 cells, as evaluated by cytofluorimetric analysis. One representative experiment out
of three is shown. (E) RvD1 treatment significantly induced GPR32, ChemR23, BLT1 protein expression in AGS shCTR and shFPR1 cells, as assessed by cytofluorimetric anal-
ysis. Data are represented as mean § SD of three independent experiments. p < .05 compared to the relative untreated control (dotted line).
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E) and of SPM receptors (Fig. S1C and D). These data were
reproduced on one more clone and a mass population of
both AGS shFPR1 and MKN45 FPR1 GC cells (Fig. S2).
To approach the FPR1-SPMs association from a pharmaco-
logic standpoint, we treated AGS and MKN45 cells with fMLF
(10¡9 M), which is an FPR1 agonist, or with cyclosporine H
(CsH 800 nM), which is an FPR1 inverse agonist12 and verified
their ALOX5/15 expression, SPM release, and synthesis of pro-
angiogenic mediators (VEGF-A, -B, -C, -D, Ang1, and
CXCL1). The release of RvD1 and LXB4 was significantly
higher in AGS treated with fMLF (12 h) than in untreated cells.
In contrast, RvD1 and LXB4 release was significantly lower in
cells treated with CsH (12 h) than in controls (Fig. 2A). fMLF
induced, whereas CsH reduced, ALOX5, ALOX15A, and
ALOX15B mRNA expression in AGS and MKN45 cells
(Fig. 2B). These observations were confirmed at the protein
level (Fig. 2C). mRNA levels of pro-angiogenic molecules were
significantly reduced by fMLF and induced by CsH treatment
(Fig. 2D).
SPMs inhibit the production of pro-angiogenic factors and
restore the expression of ALOX5/15 and of SPM receptors
in GC cells
To assess whether SPMs (RvD1 and LXB4) block the pro-
angiogenic activity of GC cells, we treated or not AGS cells
with RvD1 (1 nM) or LXB4 (1 nM), and evaluated the lev-
els of pro-angiogenic factor mRNAs. RvD1 and LXB4 sup-
pressed pro-angiogenic factor mRNA expression in GC cells
(Fig. 3A). RvD1 treatment of GC cells significantly reduced
VEGF-A release both in basal conditions and upon
WKYMVm stimulation (pro-inflammatory FPR2/3 ligand)
(Fig. 3B)7 Similar results were obtained with LXB4 (not
shown). This effect was significantly more efficient in GC
cells expressing low levels of FPR1 (AGS shFPR1 and
MKN45 pcDNA) (Fig. 3A and B). Interestingly, RvD1 treat-
ment restored, and in some cases increased above basal lev-
els, the expression of ALOX5, ALOX15A, ALOX15B, and
the SPM receptors (GPR32, ChemR23, and BLT1) at
Figure 4. ALOXs and GPR32 involvement in GC angiogenic response. (A) Tumor growth curves of AGS shCTR, shALOX5 (three clones) and shALOX15 (three clones) xeno-
grafts in immunodeficient mice. p < .05 compared to shCTR xenografts. (B) Representative images and quantification (five fields/sample) of the proliferation index
(Ki-67), vessel density (CD31), and apoptotic rate (Cleaved Caspase 3), assessed by immunohistochemistry, of shCTR, shALOX5, and shALOX15 cell xenografts harvested
28 d post-inoculation. p < .05 compared to shCTR xenografts. (C) ALOX15 and ALOX5 mRNA expression levels of 295 patients affected by gastric adenocarcinoma strati-
fied for disease-free and overall survival status. p < .05 between the two groups. (D) Tumor growth curves of AGS shCTR and shGPR32 xenografts (average of three
clones) cells in immunodeficient mice p< .05 compared to shCTR xenografts. (E) Representative images of the vessel density (CD31), assessed by immunohistochemistry,
of shCTR and shGPR32 AGS cell xenografts harvested 28 d post-inoculation.
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mRNA (Fig. 3C) and protein level (Fig. 3D and E) thereby
triggering a positive feed-forward loop. These responses of
AGS shCTR to RvD1 were significantly less efficient than
that of AGSshFPR1 cells (Fig. 3C). Similar results were
obtained with LXB4 (not shown).
ALOX15- and GPR32-silencing increase angiogenesis and
tumorigenesis of GC cells thereby mimicking the FPR1-
silencing phenotype
To evaluate whether SPM pathway components are necessary
to control the angiogenic activity of GC cells, we stably trans-
fected AGS cells with vectors expressing shRNAs targeting
ALOX5, ALOX15, GPR32, or control non-targeting shRNAs
(shCTR). ALOX5-silencing induced a specific reduction of
ALOX5 mRNA levels in AGS cells. However, AGS shALOX5
cells overexpressed ALOX15A and ALOX15B mRNAs
(Fig. S3A). Transfection of shRNAs targeting ALOX15 signifi-
cantly reduced ALOX15A and ALOX15B levels in AGS cells,
but did not modify ALOX5 mRNA (Fig. S3A). The effects of
shRNAs were confirmed at the protein level (Fig. S3B). shA-
LOX15 and, to a lesser extent shALOX5, impaired AGS cell
growth and survival, as did FPR1 silencing7 (not shown). shA-
LOX5 and shALOX15 AGS cells (three clones/each) constitu-
tively produced lower amounts of RvD1 and increased
amounts of PGE2 and LTB4 versus controls, as did shFPR1
cells. LXB4 release was reduced in shALOX15, but not in shA-
LOX5 cells (Fig. S3C). GPR32 and ChemR23 protein expres-
sions were lower in AGS shALOX5 and shALOX15 cells than
in controls (not shown). AGS shALOX5 and shALOX15 cells
constitutively synthesized higher levels of VEGF-C and VEGF-
D mRNAs and released increased amounts of VEGF-A than
did controls (Fig. S3D).
To evaluate their tumorigenic potential, we injected AGS
shCTR cells or ALOX-silenced clones subcutaneously in
athymic mice. AGS shCTR and shALOX5 tumors reached a
volume of about 1 mm3 at day 7, and regressed thereafter
(Fig. 4A). In contrast, AGS shALOX15 cells formed larger
non-regressing tumors, i.e., 2.8 mm3 (Fig. 4A), again repli-
cating the phenotype of FPR1-silenced cells.7 The tumor
growth advantage of shALOX15 cells was due to their
higher vessel density compared to controls (Fig. 4B). No
differences were detected in Ki-67C and cleaved caspase 3C
cells, evaluated far from the necrotic areas, among shCTR,
shALOX5, and shALOX15 cell xenografts (Fig. 4B). Our in
vivo observations are corroborated by data, publicly avail-
able in the cBioPortal for Cancer Genomics database
(http://www.cbioportal.org),13,14 reporting the RNAseq analy-
sis of 295 human GC samples. These data show that enhanced
mRNA expression of ALOX15, but not of ALOX5, was signifi-
cantly associated with overall survival status and disease-free
status15 in GC patients (Fig. 4C).
To analyze the effects of GPR32 silencing on the GC
cell phenotype, we selected various AGS shGPR32 clones.
The low levels of GPR32 were associated with a significant
reduction of growth ability and with an increased apopto-
tic rate of GC cells in culture (not shown). The reduced
level of GPR32 in AGS GC cells caused a significant reduc-
tion of ALOX5 and ALOX15A/B expression levels
(Fig. S3E) and an increased expression of pro-angiogenic
mediators at mRNA (Fig. S3E) and protein (Fig. S3F) level
vs. shCTR cells. RvD1 did not reduce angiogenic factor
mRNAs in shGPR32 cells (Fig. S3G). When xenotrans-
planted into nude mice, AGS shGPR32 formed signifi-
cantly larger tumors than formed by shCTR cells
(Fig. 4D). Consistently, the vessel density of shGPR32 xen-
ografts was significantly higher than that of controls
(Fig. 4E). No differences were detected in Ki-67C and
cleaved caspase 3C cells in shCTR and shGPR32 xenografts
(not shown).
FPR1-mediated suppression of angiogenesis in GC cells
requires ALOX5, ALOX15, and GPR32
To assess whether FPR1-mediated suppression of angiogenesis
requires ALOX5 and/or ALOX15, we stimulated with fMLF
(10¡9 M) GC cells in which ALOX expression/activity was
abolished. As shown in Fig. 5A, fMLF significantly reduced the
mRNA levels of pro-angiogenic factors (VEGF-B, VEGF-C,
and CXCL1) in AGS shCTR, but not in shALOX5 and shA-
LOX15 AGS cells. Similar results were obtained in AGS cells in
which ALOXs were pharmacologically inhibited by 10 mM nor-
dihydroguaiaretic acid-(NDGA) (Fig. 5B).16 These observations
suggest that ALOX5 and ALOX15 are required to trigger the
anti-angiogenic activity of FPR1 in GC cells.
To verify the requirement of the RvD1 pathway for FPR1-
mediated anti-angiogenic activity, we stimulated parental GC
cells with fMLF in the presence or absence of a GPR32-neu-
tralizing antibody. fMLF (10¡9 M) induced ALOX5 and
ALOX15A mRNA expression and concomitant VEGF-B and
CXCL1 mRNA downregulation in AGS. These effects were
reverted by the GPR32-blocking antibody (5 mg/mL)
(Fig. 5C). Similar results were obtained in MKN45 cells
(Fig. S4A). Consistently, fMLF did not induce ALOXs or
suppress pro-angiogenic mediators in AGS shGPR32 cells
(Fig. 5D), although shCTR and shGPR32 cells released com-
parable amounts of RvD1 both in basal conditions and upon
fMLF stimulation (not shown). We then assessed the
involvement of FPR2, the other RvD1 receptor.8 fMLF stim-
ulation of AGS shFPR2 cells induced ALOX5 and ALOX15A
mRNA expression, and VEGF-B and CXCL1 downregula-
tion, and these effects were reverted by the anti-GPR32
blocking antibody (Fig. 5E). Taken together, these results
indicate that RvD1, by binding GPR32, but not FPR2, medi-
ates FPR1’s anti-angiogenic effects in GC cells.
We then asked which signaling pathways were involved
in the anti-angiogenic response of GC cells to RvD1 and
whether differences can be detected in FPR1-lacking cells
compared to controls. We found that Akt, MAPK, JNK,
and p38 signaling pathways were induced in GC cells
treated with RvD1 (1 nM) for different times (15 min–
12 h) without significant differences in the activation kinetic
and strength between AGS shCTR and shFPR1 cells, or
MKN45 pcDNA and FPR1 cells (Fig. 5F). In contrast,
RvD1 treatment induced a significant STAT3 and SRC acti-
vation only in AGS shFPR1 and MKN45 pcDNA cells
expressing lower levels of FPR1 compared to the relative
control cells (Fig. 5F). RvD1-mediated reduction of VEGF-
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A release was reverted by pre-treatment of AGS shFPR1
cells with the two STAT3 inhibitors FLLL31 (10 mM) and
5–15DPP (15 mM)17,18 (Fig. 5F). Similar results were not
detectable in AGS shCTR cells (Fig. 5F). STAT3 inhibition
reverted RvD1 effects on CXCL1 and Ang1 mRNAs levels
(Fig. S4B). Instead, when MAPK [U0 126 (25 mM)] or Akt
[LY294002 (15 mM)] inhibitors7 were used, no effects on
VEGF-A release were observed (Fig. S4C).
v-6 and v-3 diets reduce the tumorigenic potential of
shFPR1 GC cells in vivo
Dietary interventions based on differential PUFA v-3 or v-6
intake affect AA-, EPA-, and DHA metabolism and the derived
SPM endogenous production in mice (Fig. 1A).9 To assess the
effects exerted by v-6- or v-3-enriched diets on GC cell
growth, we xenotransplanted AGS shCTR or shFPR1 cells in
Figure 5. ALOXs and GPR32 are required for FPR1 tumor suppressor role. (A) VEGF-B, -C, and CXCL1 mRNA synthesis was inhibited in shCTR, but not in shALOX5 or shA-
LOX15 AGS cells upon fMLF (10¡9 M) treatment. Data are represented as mean § SD of three independent experiments. p < .05 vs. the relative untreated cells (dotted
line). (B) Pre-treatment of AGS cells with NDGA (ALOX inhibitor) reverted the ability of fMLF to inhibit the mRNA synthesis of pro-angiogenic molecules. Data are repre-
sented as mean § SD of three independent experiments. p< .05 compared to fMLF treated cells. (C) In AGS cells, fMLF induced ALOX5 and ALOX15A mRNA overexpres-
sion and concomitant VEGF-B and CXCL1 mRNA downregulation. These effects were reverted by a neutralizing GPR32 antibody. An isotype-matched antibody was used as
a control. Data are represented as mean § SD of three independent experiments. p < .05 compared to untreated cells (dotted line). xp < .05 compared to isotype-
matched control. (D) fMLF significantly induced ALOX5, ALOX15A, and ALOX15B mRNA levels and significantly reduced the mRNA levels of pro-angiogenic mediators in
AGS shCTR, but not in shGPR32 cells. Data are represented as mean § SD of three independent experiments. p < .05 compared to shCTR cells. (E) A neutralizing GPR32
antibody inhibited fMLF-induced ALOX5 and ALOX15A mRNA overexpression and concomitant VEGF-B and CXCL1 mRNA downregulation in AGS shFPR2 cells. An iso-
type-matched antibody was used as a control. Data are represented as mean § SD of three independent experiments. p < .05 compared to untreated cells (dotted
line). xp < .05 compared to isotype-matched control. (F) Activation kinetics of AKT, MAPK, JNK, p38, STAT3, and SRC in AGS shCTR, AGS shFPR1, MKN45 pcDNA, MKN45
FPR1 cells assessed by western blot for their phosphorylated forms. Two STAT3 inhibitors (5-15 DPP and FLLL31) reverted the anti-angiogenic effects of RvD1 in AGS
shFPR1 cells. Data are represented as mean § SD of three independent experiments. p < .05 compared to untreated cells (NT). xp < .05 compared to RvD1 treated cells.
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immunocompromised mice randomly fed a classic, an v-6/v-3
balanced (grape seed-colza oils 50/50%, CTRL), an v-6
enriched (grape seed oil 100%, v-6), or an v-3 enriched (colza/
fish oils 80/20%, v-3) diet, 2 weeks before and 4 weeks after
xenotransplantation. No differences were detected between ani-
mals fed a classic diet and those fed a balanced diet (not shown)
demonstrating that a 5% PUFA-enriched diet did not change
the tumorigenic potential of GC cells. As shown previously,7
AGS shCTR cells formed small tumors that regressed in mice
fed a balanced, v-3-, or v-6-enriched diet, without statistical
differences among groups (Fig. 6A). In contrast, AGS shFPR1
cells formed tumors that progressively increased in size
(Fig. 6A).7 Both v-3 and v-6-enriched diets significantly sup-
pressed AGS shFPR1 xenograft growth. However, growth inhi-
bition was significant at day 7 post-injection in v-6-fed mice
vs. day 14 in v-3-fed mice (Fig. 6A). The administration of an
v-3 or v-6 enriched diet to AGS shFPR1 xenotransplanted
mice abolished statistical differences in tumor growth curves
between shFPR1 and shCTR cells.
Vessel density was higher in shFPR1 xenografts than in
shCTR xenografts (Fig. 6B); v-6 and v-3 diets reverted this
difference (Fig. 6B). Vessel density was unchanged in shCTR
xenografts irrespective of the diet administered (Fig. 6B). Both
v-6 and v-3 diets significantly reduced Ki-67 staining of
shFPR1, and, to a lesser extent, of shCTR excised tumors
(Fig. 6C). Diet composition did not affect apoptotic rate as
assessed by cleaved caspase-3 evaluation (not shown).
To investigate the effect of dietary intervention on mouse
serum lipid composition, we profiled fatty acids by LC-MS/
MS. Concentrations of AA were significantly higher in mice
fed an v-6 diet than in those fed a balanced or an v-3 diet
(Table 1). Consistently, EPA ad DHA concentrations were
higher in v-3-fed mice than in the other two groups of
mice (Table 1). The concentrations of LXB4 were signifi-
cantly higher in the sera of v-6-fed mice than in controls.
Concentrations of RvD1, RvD3, and RvE2 were significantly
higher in the serum of mice fed an v-3 diet than in con-
trols. Interestingly, the v-3 diet significantly reduced PGE2,
LTB4, and TXB2 serum concentrations vs. controls
(Table 1). Lipid serum concentrations did not differ among
mice fed the same diet but xenotransplanted with shCTR or
shFPR1 AGS cells (not shown).
Figure 6. Effects of v-6 and/or v-3 increased consumption on GC growth/angiogenesis in a xenotransplantation mouse model. (A) Tumor growth of AGS shCTR and
shFPR1 xenografts in CD1 nu/nu mice fed an v-6/v-3 balanced (grape seed/colza oils 50/50%, CTRL), an v-6 enriched (grape seed oil 100%, v-6), or an v-3 enriched
(colza/fish oils 80/20%, v-3) diet. p < .05 vs. CTRL diet. (B) Vessel density (CD31) assessed by immunohistochemistry of shCTR and shFPR1 cell xenografts harvested 28 d
post-inoculation from mice fed the three diets as in panel A. Representative images and the relative quantifications (five fields/sample) are shown. p< .05 vs. the relative
CTRL diet. (C) Proliferation index (Ki-67) assessed by immunohistochemistry of shCTR and shFPR1 cell xenografts harvested 28 d post-inoculation from mice fed with the
three diets. Representative images and the relative quantifications (five fields/sample) are shown.p < .05 vs. the relative CTRL diet.
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To assess whether the effects exerted by an v-3 or v-6 diet
on the proliferation rate of GC xenografts was a direct event or
whether it was indirectly due to differences in tumor vasculari-
zation levels, we studied the effects of RvD1 (1 nM), LXB4
(1 nM), AA (20 mM), DHA (20 mM), and EPA (20 mM) on
AGS shCTR and shFPR1 cell proliferation in vitro. We found
no difference in BrdU incorporation between treated and
untreated cells at the concentrations of lipids above mentioned
(Fig. S5). AA, DHA, and EPA significantly reduced GC cell via-
bility when used at higher concentrations (50 mM), as already
reported by others.19-21 However, these concentrations were
never reached in vivo in diet-fed mice.9,22 (Table 1).
Discussion
The role of FPR1 in cancer is complex. In certain cancer types,
FPR1 exerts tumor-promoting activities by stimulating the
motility and growth of cancer cells23-26 However, in mouse liver
and colon, FPR1- or FPR2-genetic deletion abolishes epithelial
homeostasis, increases inflammation after injury and, in
colonic mucosae, increases tumorigenesis.27,28 Recent studies
showed that decreased FPR1 concentrations in tumor-infiltrat-
ing antigen-presenting cells compromise chemotherapy-
induced antitumor immunity.29,30 In human GC, high FPR1
expression, evaluated by immunohistochemistry, has been cor-
related with advanced tumor stage and poor overall survival.31
However, an FPR1 polymorphism linked to reduced FPR1
activity has been associated with an increased risk of stomach
cancer in humans.32,33
Here, we provide evidence that FPR1, expressed by GC cells,
plays a tumor suppressor role by constitutively activating an
inflammation resolution program that includes the expression
of ALOX5/15, SPMs (RvD1 and LXB4), and SPM receptors
(BLT1, ChemR23, and GPR32). FPR1 loss/inhibition sup-
presses this program and induces an inflammatory/angiogenic
phenotype in GC cells. Interestingly, the GC-associated FPR1
polymorphism was also associated with periodontitis,34 a dis-
ease whose pathogenesis has been linked to defective pro-
resolving pathways and in which SPMs exert protective
effects.35-38
We demonstrate that the anti-angiogenic potential of SPMs,
already reported in other contexts,39 was more evident in cells
expressing low levels of FPR1, despite their lower levels of SPM
receptors (BLT1, GPR32, and ChemR23), vs. controls. This
effect might be due to constitutively high levels of RvD1 and
LXB4 produced by control cells, which could saturate/desensi-
tize their receptors thereby rendering these cells less responsive
to exogenous SPM stimulation.
Various studies have recognized that ALOXs exert tumor-
promoting or tumor-suppressive activities.40 Our study intro-
duces a new concept in this field, namely, that another com-
ponent of pro-resolving pathways, i.e., the Resolvin D1
receptor GPR32,8 can exert tumor suppressor activity in GC.
The LXB4 receptor remains unidentified; consequently, we
were unable to investigate its role in GC. We demonstrate
that the ALOX enzymes and GPR32 are induced by FPR1 and
necessary for FPR1-mediated SPM production and anti-angio-
genic activity in GC. In vivo, vessel density and tumor growth
were higher in shALOX15 and shGPR32, but not in shA-
LOX5, xenografts than in controls, despite their comparable
angiogenic potential in culture. This discrepancy could be
explained by the compensatory upregulation of ALOX15
expression in shALOX5 cells that enabled the production of
other SPMs, including LXB4. Thus, qualitative or quantitative
differences in SPM production between shALOX5 and shA-
LOX15 cells and/or their interaction with tumor stroma might
result in a different angiogenic potential in vivo. Be that as it
may, in line with our data, an RNAseq analysis showed that
higher ALOX15, but not ALOX5, mRNA expression was sig-
nificantly associated with better overall survival of GC patients
(TCGA, http://www.cbioportal.org).13-15
Several studies have demonstrated that v-3 PUFA plays a
direct anti-tumor or an adjuvant role in various cancers41,42
by modulating cell proliferation or apoptosis43-45 in the
high micromolar range.13,19,20 We believe that, in our sys-
tem, the effects of an v-3 or v-6 diet on xenograft growth
were predominantly due to differences in vessel density
rather than to a direct effect on cell proliferation. In fact, in
the low micromolar range, which corresponds to the con-
centrations we found in vivo upon dietary modification,7,22
we found that PUFA suppressed the angiogenic response
but did not directly affect GC cell proliferation in culture.
In the present study, vessel density in shCTR xenografts did
not differ among mice fed different diets, although cell pro-
liferation was slightly, albeit significantly, reduced in mice
fed an v-3 or v-6 diet. We ascribe this phenomenon to the
very low in vivo angiogenic potential and to the massive
presence of necrotic areas in these tumors.7 However, it
should be noted that since PUFA administration induces
the production of many intermediate metabolites that exert
anti-angiogenic and anti-proliferative effects in vivo,46 we
cannot exclude the possibility that in the xenograft micro-
environment, these intermediates, together with PUFA,
could reach a concentration sufficient to induce xenograft
growth inhibition by directly modulating cell proliferation.
Table 1. Lipidomic profile of mice fed v-6 and/or v-3 enriched diets.
DIET
CTRL v-6 v-3
AA 6353.6 § 1444.1 16991 § 925.8 5677.2 § 1295
PGD2 281 § 43.9 237.3 § 33.3 327 § 75.1
PGE2 183.5 § 45.1 172 § 66.7 92.7 § 20
PGF2a 76 § 33 57 § 23 47.5 § 14.7
TXB2 740.8 § 64.1 911.4 § 147.1 466 § 148.7
LTB4 740.8 § 141.2 775 § 145.9 355.8 § 109.8
LXA4 5748.6 § 258.5 5012.6 § `185.1 5017 § 230.5
LXB4 134.3 § 20.9 318.7 § 33.4 183.4 § 21.5
EPA 1476.2 § 280.6 2167.8 § 671.3 5028.1 § 462.8
RvE1 108.3 § 29.9 32.6 § 17.1 130.8 § 26.4
RvE2 3251.5 § 532.2 3797 § 474.2 8862.7 § 576.1
RvE3 213.4 § 44.6 162.3 § 42.5 249.7 § 73.6
DHA 8886.4 § 1586.2 10220.2 § 1364.6 17447.5 § 772
RvD1 45.8§ 19.5 52.3 § 4.7 95.7 § 12.5
RvD2 46.6§ 14.6 47.5 § 4.9 86 § 29.4
RvD3 2664.7 § 365.9 3252 § 446.5 5101.1 § 380.3
RvD5 30.5§ 5.9 20 § 8.2 46.7 § 18.2
RvD6 56.7§ 15.8 40.7 § 17.4 98.2 § 25.6
PD1 56.6§ 6.3 39.5 § 6.3 56.5 § 28
Lipid concentration in serum of mice fed the indicated diets (10 mice/group). Val-
ues are reported as nM.
p < .05 vs. the CTRL diet group.
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Pattern recognition receptors trigger inflammation,47 but
can also promote its resolution.12,48,49 This is particularly
important for the gastrointestinal tract, which, being continu-
ously exposed to food- and microbioma-derived antigens, is
subject to a chronic low-level of mucosal inflammation50 that
must be counteracted to avoid tissue damage. In injured mouse
colonic mucosa, FPR1 promotes tissue restitution by recogniz-
ing the endogenous N-terminal-derived annexin A1 (Ac2-26)
peptides51,52 or specific commensal microbiota strains.53 Our
data suggest that FPR1 is constitutively active in GC cells,
which implies the presence of an endogenous ligand endowed
with pro-resolving activity. A possible candidate ligand is pep-
tide Ac2-26 that derives from AnxA1, which, as we previously
showed, is constitutively expressed in GC cells.7
In conclusion, we describe a novel molecular mechanism in
GC, actively controlled by FPR1, that links PUFA metabolism
and SPM biosynthesis with angiogenesis. This raises the possi-
bility of new prognostic tools and therapeutic interventions for
GC. It is feasible that FPR1 and/or components of pro-resolv-
ing pathways may represent novel risk factors or prognostic
markers of GC. Administration of SPMs or pharmacologic
stimulation of FPR1, ALOX15, or GPR32 could suppress GC
angiogenesis and growth. Lastly, as SPM production can be
largely determined by diet, increasing v-3 or v-6 consumption
might be a tool in the management of GC.
Materials and methods
Cell culture
The AGS and MKN45 cell lines derived from poorly differenti-
ated human gastric adenocarcinoma were grown as previously
described.7 To generate AGS cells stably expressing ALOX5,
ALOX15, or GPR32 shRNA, we used pools of five constructs
(Qiagen, Valencia, CA, USA) containing 21-mer short hairpin
RNAs (shRNA) directed to various coding regions of each tar-
get gene. Transfectants were selected in medium with 500 ng/
mL puromycin.
RNA isolation and real-time PCR
Total RNA was isolated and retrotranscribed according to
the manufacturer’s instructions (Promega, Madison, WI,
USA). Real-time quantitative PCR was performed on the
CFX96 system (Bio-Rad, Hercules, CA, USA) using the PE
SYBR Green PCR kit (Applied Biosystems, Grand Island,
NY, USA). The target-specific primers used for real-time
PCR are listed in Table S1. No-reverse transcribed mRNA
samples served as a negative control. The expression levels
of each target were calculated relative to that of control
cells, arbitrarily considered equal to 1. Results were normal-
ized to b-actin mRNA levels.
Flow cytometric analysis
Cells were incubated (30 min at 4C) with specific or isotype
control antibodies (Abs). ALOX5, ALOX15A, and ALOX15B
Abs were from Santa Cruz Biotechnology (Dallas, TX, USA),
anti-GPR32 was from Acris (Herford, Germany), anti-BLT1
from LSBio (Seattle, WA, USA), and anti-ChemR23 from
MyBiosource (San Diego, CA, USA). Cells were analyzed with
an FACS Calibur cytofluorimeter using CellQuest software (BD
Biosciences, Mississauga, ON, Canada). When necessary, we
performed cell membrane permeabilization using the Cytofix/
Cytoperm kit (BD Biosciences).
Protein studies
Protein extractions, immunoblotting, and immunoprecipita-
tion were carried out according to standard procedures. Anti-
phospho-MAPK, -Akt, -p38, -JNK, -STAT3, -SRC antibodies
(Abs) were from Cell Signaling Technology (Danvers, MA,
USA). Anti-tubulin was from Sigma-Aldrich (St. Louis, MO,
USA), and secondary anti-mouse and anti-rabbit Abs coupled
to HRP were from Bio-Rad.
Xenografts in mice
Each group of 10 mice (4-week-old female CD1 nu/nu mice,
Charles River, Wilmington, MA) was inoculated subcutane-
ously with shCTR, shFPR1, shALOX5, shALOX15, shGPR32
AGS cells (1£107 cells/mouse). Tumor diameters were mea-
sured at regular intervals with a caliper. Tumor volumes (V)
were calculated with the formula: V D A£B2/2 (A D axial
diameter; B D rotational diameter). This study was conducted
according to Italian regulations for experimentation on ani-
mals; the study protocol was approved by the Italian Ministry
of Health. Paraffin-embedded tumors were analyzed by immu-
nohistochemistry with anti-Ki-67 antibody from Biocare Medi-
cal (Concord, CA), anti-cleaved caspase 3, and anti-CD31 from
R&D Systems (Minneapolis, MN).
Fatty composition of diets
The three isocaloric diets containing 5% fat (w/w) were
designed as previously described.9,22 Pellets were prepared by
Mucedola (Milan, Italy). We used grape seed and colza oils
(50/50%) to prepare the pellets for the control diet (CTRL),
grape seed oil (100%) for the v-6 (v-6), and colza oil/fish oils
(80/20%) for an v-3 fatty acid-enriched diet (v-3). The oils
were obtained from Sigma-Aldrich (St. Louis, MO). Pellets
were stored under vacuum at ¡20C. The diets were changed
twice a week in each animal cage to avoid oxidative degradation
of lipids.
ELISA and EIA assays
VEGF-A contents in culture supernatants were measured in
duplicate determinations with a commercially available ELISA
(R&D Systems). RvD1, LTB4, PGE2, and LXB4 contents in cul-
ture supernatants were measured in triplicate determinations
with a commercially available EIA (Cayman Chemical, Ann
Arbor, MI).
LC-MS/MS instrumentation and conditions
To extract the lipids, 120 mL samples (mice serum or cell cul-
ture supernatants), together with deuterated internal standards,
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were loaded onto solid phase extraction Waters Oasis HLB car-
tridges (60 mg sorbent, 30 mm particle size), and eluted with
2 mL methanol and 2 mL ethyl acetate into polypropylene
tubes containing 6 mL of a glycerol solution (30% in methanol).
The SPE eluates were dried and residues were then reconsti-
tuted in 100 mL methanol. 5 mL of methanol extract were ana-
lyzed by using a 4000QTrap mass spectrometer (Applied
Biosystems) coupled to a 1,100 nanoHPLC system (Agilent
Technologies, Waldbronn, Germany). The lipids were sepa-
rated by using a micro-C18 column (10 cm x 1.0 mm, 5u). The
mobile phase was generated by mixing eluent A (0.1% acetic
acid) and eluent B (acetonitrile/isopropanol 50/50) and the
flow rate was 30 nL/min. Starting condition was 20% to 95% B
in 5 min. Tandem mass spectrometry was performed using a
turbo ion spray source operated in a negative mode (curtain
gas 20psi, GS 1/2 50/50psi, ion spray voltage ¡5,500 V, DP,
¡60 V; Dwell 25 ms and temperature of 550C), and the multi-
ple reaction monitoring mode was used to detect a unique
product ion arising from collision-induced fragmentation of
the protonated parent compound as reported in Table S2.
Statistical analysis
Values from groups were compared by using the paired Student
t test or the Duncan test. A p value < 0.05 was considered sta-
tistically significant.
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A B S T R A C T
UV-A radiations are known to induce cellular oxidative stress, leading to premature skin aging. Consumption of
açai fruit (Euterpe oleracea Martius) is known to have many health benefits due to its high level of antioxidants.
Herein, we analyzed the ability of phenolic compounds extracted from this fruit to attenuate UV-A-induced
oxidative stress in immortalized fibroblast.
A methanol/water açai extract was fractionated by HPLC and each fraction tested for anti-oxidant stress
activity. Immortalized fibroblasts were pre-incubated with açai fractions and then exposed to UV-A radiations.
Açai extract was found to be able to strongly protect cells from oxidative stress. In particular, reactive oxygen
species (ROS) production, GSH depletion, lipid peroxidation and no increase in the phosphorylation levels of
proteins involved in the oxidative stress pathway was observed in cells pre-incubated with the extract and then
irradiated by UV-A. Mass spectrometry analyses of HPLC fractionated extract led us to the identification of
malvidin and cyanidin derivatives as the most active molecules able to counteract the negative effects induced
by UV-A irradiation.
Our results indicate, for the first time, that açai fruit is a valuable natural source for malvidin and cyanidin to
be used as anti-stress molecules and represent good candidates for dietary intervention in the prevention of age
related skin damage.
1. Background
In the last few years, an increasing attention has focused on age-
related diseases, including skin aging. Oxidative stress caused by aging
is considered a general initiating factor of neurodegeneration and
carcinogenesis [1]. Indeed, it is known that the skin is constantly
exposed to oxidative stress induced by reactive oxygen species (ROS),
generated by endogenous (i.e. enzyme activities) or exogenous sources
[2,3].
UV radiation from sunlight is one of the most important health-
related environmental factors because of its hazardous effects, which
include generation of skin cancer, suppression of the immune system,
and premature skin aging [2]. In particular, UV-A (400–315 nm)
radiations are weakly absorbed by DNA, but rather excite endogenous
chromophores, leading to DNA damage. This occurs through the
production of reactive singlet oxygen that specifically reacts with
guanine within the DNA molecule [4,5]. UV-A radiations may also
promote the formation of hydroxyl radicals via the photosensitized
production of superoxide anions. Because of their high reactivity and
low specificity, hydroxyl radicals likely induce a wide range of DNA
damage [6]. Fibroblasts, cells of the dermis, are continuously exposed
to UV-A radiations, which are able to penetrate deeply in the skin. The
cellular antioxidant defense system is composed of endogenously
produced antioxidant molecules, but the intrinsic mechanism for
antioxidant defense is gradually impaired with aging, resulting in an
inability to deal with ROS generation [7]. A continuous and regular
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intake of vitamins, trace metals, polyunsaturated fatty acids, and
polyphenols from food sources contributes to counteract oxidative
stress [8,9] and in preventing or retarding age-related diseases
[10–12]. As an example, we recently report the beneficial effects of
tomato extracts in counteracting oxidative stress in different cell lines
[13,14]. Therefore, a continuous search for natural extracts highly rich
in antioxidant molecules is needed to identify and provide novel natural
drugs against aging-associated diseases.
Açai (Euterpe oleracea Martius) tree is a large palm found in the
Amazon flood plain. The fruit of this palm is a small purple-black berry
which reaches about 10 mm in diameter and is usually consumed in all
states of Brazil since it is rich in α-tocopherol, fibers, lipids, polyphenols
(including anthocyanins), and mineral ions [15,16]. The high poly-
phenol content, mostly composed of anthocyanins and flavones, is
thought to confer to açai fruit several health-promoting effects, includ-
ing anti-inflammatory, immunomodulatory, antinociceptive, and anti-
oxidant properties [17–25]. In particular, açai extracts were shown to
increase plasma antioxidant capacity [21], to decrease oxidative stress
in endothelial cells [26], to attenuate tumor growth in mice affected by
esophageal cancer [27] and to lower the level of blood cholesterol in
animal models for hypercholesterolemia [28].
A positive role of açai in modulating ROS production and activating
antioxidant genes expression in rat liver was also reported [29] and,
more recently, Peixoto and colleagues demonstrated the beneficial
effect of açai extract in counteracting oxidative stress and aging in C.
elegans [18].
Although several reports on the spectrum of health benefits of açai
have been reported, only few studies are available so far on the
identification of the antioxidant molecules responsible for the reported
beneficial effects on human health.
Here, a methanol/water extract from Euterpe oleracea fruits was
analyzed for its antioxidant activity on fibroblasts exposed to UV-A-
induced insults. A combined approach of bioassays and mass spectro-
metry analyses led to the identification of açai bioactive compounds.
2. Methods
2.1. Açai Extracts
Methanolic extracts from açai fruit were obtained as reported by
Rigano et al. [30], starting from commercially available dried powder
(2 g, Tuialimentos, Brasil). The mixture was dried in a rotovapor (R-
210, Buchi), and dissolved in 5% dimethyl sulfoxide (DMSO) in PBS
(1 mL).
2.2. Antioxidant Compounds Determination and Antioxidant Activity
Analysis
Total phenols content was determined in the whole açai extract
according to the method of Singleton et al. [31] modified as reported by
Rigano et al. [30]. Briefly, an equal volume of Folin-Ciocalteu's phenol
reagent and two volumes of ddH2O were added to the hydrophilic
extract. After 6 min, Na2CO3 was added (7% final concentration). After
90 min the absorbance was read at 760 nm. A standard curve was
obtained by using gallic acid in the range 0–70 μg/mL. The total
phenolic content was expressed as mg of gallic acid equivalents
(GAE)/100 g dry weight (DW) of açai. Three independent analyses
Table 1
Total phenolic acids, total flavonoids and hydrophilic antioxidant activity in açai
extract.
Açai antioxidant determination Value
Total phenols (mg/100 g DW) 192.41 ± 10.78
Total flavonoid (mg/100 g DW) 159.67 ± 7.65
HAA (mmol TE/100 g DW) 2.1 ± 0.17
Fig. 1. Effect of açai extracts on the viability of BALB/3T3 fibroblasts. Dose-response
curve of BALB/3T3 cells after 48 h incubation with increasing concentrations of açai
extracts. Cell viability was assessed by the MTT assay and expressed as described in
Materials and Methods section. Values are given as means ± S.D. (n≥ 3).
Fig. 2. ROS production, GSH oxidation and lipid peroxidation in BALB/3T3 cells irradiated by UV-A in the presence of açai extracts. Cells were pre-incubated in the presence of 10 mg/mL
açai extract (grey bars) for 2 h and then irradiated by UV-A (100 J/cm2). A, intracellular ROS levels were determined by DCFDA assay; B, intracellular GSH levels determined by DTNB
assay; C, lipid peroxidation levels determined by TBARS assay. Values are expressed as fold increase with respect to control (i.e. untreated) cells. Data shown are the means± S.D. of three
independent experiments. * indicates p < 0.01; ** indicates p < 0.001.
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were carried out.
Total flavonoids were estimated by the aluminum chloride colori-
metric assay reported by Marinova et al. [32] with modifications
reported by Raiola et al. [33]. Briefly, NaNO2 (5%) was added to
methanolic extract and, after 5 min incubation, AlCl3 (10% w/v) was
added. After 6 min, NaOH (1 M) was added and the absorbance
measured at 510 nm. A standard curve was obtained by using quercetin
in the range 0–100 μg/mL. Total flavonoids content was expressed as
mg quercetin equivalents (QE)/100 g DW. Three independent analyses
were carried out.
HAA was evaluated in the water-soluble fraction using the protocol
described by Miller et al. [34] with modifications reported by Del
Giudice et al. [35]. Briefly, methanolic extracts were allowed to react
with an ABTS•+ solution for 2.5 min, and then the absorbance was
measured at 734 nm using a spectrophotometer. A standard curve,
obtained by using Trolox, was linear between 0 and 20 μM Trolox.
Values were expressed as mmol TE/kg DW of açai. Three separate
analyses were carried out with each sample.
2.3. Cell Culture and MTT Assay
BALB/3T3 fibroblasts (clone A31, from ATCC) were cultured in
Dulbecco's Modified Eagle's Medium (Sigma-Aldrich, St Louis, Mo,
USA), supplemented with 10% foetal bovine serum (HyClone), 2 mM
L-glutamine and antibiotics, all from Sigma-Aldrich, in a 5% CO2
humidified atmosphere at 37 °C.
Cells were seeded in 96-well plates (100 μL/well) at a density of
5 × 103/well. For dose-dependent cytotoxicity assays, 24 h after seed-
ing, increasing volumes of açai methanolic extracts were added to the
cells, to reach a final concentration ranging from 0.2 to 100 mg/mL.
After 48 h incubation, cell viability was assessed by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, as de-
scribed by Monti et al. [36]. Cell survival was expressed as the
percentage of viable cells in the presence of extract compared to that
of control samples. Two groups of cells were used as control, i.e. cells
untreated with the extract and cells supplemented with identical
volumes of DMSO. Each sample was tested in three independent
analyses, each carried out in triplicates.
2.4. Oxidative Stress
To analyze oxidative stress, cells were plated at a density of
4 × 104 cells/cm2. 24 h after seeding, cells were incubated for 2 h in
the presence or absence of 10 mg/mL of açai extract, or equivalent
amount of each isolated fraction, and then irradiated for 10 min with
UV-A light (100 J/cm2) (treatment before injury). In a second group of
experiments, cells were irradiated for 10 min with UV-A (100 J/cm2)
and then incubated for 2 h in the presence or absence of açai extract or
equivalent amount of each isolated fraction (treatment after injury).
2.5. DCFDA Assay
To estimate ROS production, the protocol described in [13] was
followed. Briefly, at the end of incubation, cells were incubated with
2′,7′-dichlorodihydrofluorescein diacetate (H2-DCFDA, Sigma-Aldrich).
Fluorescence intensity was measured by a Perkin-Elmer LS50 spectro-
fluorimeter (525 nm emission wavelength, 488 nm excitation wave-
length, 300 nm/min scanning speed, 5 slit width for both excitation and
emission). ROS production was expressed as percentage of DCF
fluorescence intensity of the sample under test, with respect to the
untreated sample. Each value was assessed by three independent
experiments, each with three determinations.
2.6. DTNB Assay
To estimate intracellular glutathione levels, a procedure previously
described was followed [14]. Briefly, at the end of incubation, cells
were detached by trypsin, lysed and protein concentration was deter-
mined by the Bradford assay. Then, 50 μg of proteins were incubated
with 3 mM EDTA, 144 μM 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) in
Fig. 3. Effect of açai extracts on UV-A-induced oxidative stress markers in BALB/3T3
fibroblasts. Cells were incubated with 10 mg/mL açaiextract2h prior to UV-A irradiation
(100 J/cm2) and then cells were incubated for 90 min. Western blots show the
phosphorylation levels of p38 (A),MAPKAPK-2 (B) and HSP-27 (C), with the relative
densitometric analysis in the absence (black bars) or in the presence (grey bars) of açai
extract. GAPDH was used as internal standard. Data shown are the means ± S.D. of three
independent experiments. * indicates p < 0.01; ** indicates p < 0.001.
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30 mM TrisHCl pH 8.2, centrifuged at 14,000g for 5 min at 4 °C and the
absorbance of the supernatant was measured at 412 nm by using a
multiplate reader (Biorad). GSH levels were expressed as the percentage
of TNB absorbance in the sample under test with respect to the
untreated sample. Values are the mean of three independent experi-
ments, each with triplicate determinations.
2.7. Measurement of Lipid Peroxidation
The thiobarbituric acid reactive substances (TBARS) assay was
performed as described by Del Giudice et al. [13]. Briefly, after
irradiation with UV-A, cells were kept for 90 min at 37 °C, then
detached and suspended (5 × 104 cells) in 0.67% thiobarbituric acid
(TBA) and 20% trichloroacetic acid (1:1 v/v). After heating and
centrifugation at 3000g for 5 min at 4 °C, samples were read at
532 nm. Lipid peroxidation levels were expressed as the percentage of
the absorbance at 532 nm of the sample under test, with respect to
untreated cells (100%). Three independent experiments were carried
out, each one with three determinations.
2.8. Western Blot Analyses
Cells were plated at a density of 2 × 104 cells/cm2 in complete
medium for 24 h and then treated as described above (paragraph 2.4).
When açai extract was used before UV-A exposure, cells were incubated
for further 90 min at 37 °C. Alternatively, following the induction of
UV-A stress, cells were treated with the extract for 120 min at 37 °C.
Cell lysates were then analyzed by Western blotting performed as
reported by Galano et al. [37]. Phosphorylation levels of p38, MAP-
KAPK-2 or HSP-27 were detected by using specific antibodies purchased
from Cell Signal Technology (Danvers, MA, USA). To normalize protein
intensity levels, specific antibodies against internal standards were
used, i.e. anti-β-actin (Proteintech, Manchester, UK) or anti-GAPDH
(ThermoFisher, Rockford, IL, USA). The chemiluminescence detection
system (SuperSignal® West Pico) was from Thermo Fisher.
2.9. Reverse-phase HPLC Analysis
Methanol/water açai extract (2 g/mL, 1 mL) was fractionated by
reverse-phase HPLC on a Phenomenex Jupiter C18 column
(250 × 2.00 mm 5 μm, 300 Å pore size) (Phenomenex, Torrance,
California, USA) with a linear gradient from 5% to 95% acetonitrile
(Sigma Aldrich,Saint Louis, USA) in 0.1% trifluoroacetic acid (TFA)
(Carlo Erba Reagents S.r.l, Milan, Italy) over 40 min, at a flow rate of
200 μL/min; elution was monitored at 278 nm. The eluate was collected
manually in thirteen fractions (1 mL). Fractions were lyophilized and
dissolved in 5% DMSO in PBS, and their content identified by MALDI-
TOF (AB SCIEX, Milan, Italy) analysis.
2.10. Mass Spectrometry Analyses
Matrix-assisted laser desorption/ionization (MALDI) mass spectro-
metry (MS) experiments were performed on a 5800 MALDI-TOF-TOF
ABSciex equipped with a nitrogen laser (337 nm) (AB SCIEX, Milan,
Italy). Aliquots of açai HPLC fractions (0.5 μL) were mixed (1:1, v/v)
with 2.5 dihydroxybenzoic acid (10 mg/mL) (Sigma-Aldrich, Saint
Louis, USA) in acetonitrile:water (90:10) solution. Calibration was
performed by using AB SCIEX calibration mixture (Monoisotopic (M
+ nH)n+: 904.46 Da des-Arg-Bradykinin, 1296.68 Da Angiotensin I,
1570.67 Da Glu-Fibrinopeptide B, 2093.08 Da ACTH (clip 1–17),
2465.19 Da ACTH (clip 18–39), 3657.92 Da ACTH (clip 7–38)). For
polyphenols identification, MS and tandem mass (MSMS) spectra were
acquired using a mass (m/z) range of 100–4000 Da.
2.11. Statistical Analyses
In all the experiments samples were analyzed in triplicate.
Quantitative parameters were expressed as the mean value ± SD.
Significance was determined by Student's t-test at a significance level of
0.01. Differences among fractions were determined by using SPSS
(Statistical Package for Social Sciences) Package 6, version 15.0 (SSPS
Inc., Chicago, IL, USA). Significance was determined by Duncan's-test at
a significance level of 0.05.
Fig. 4. Fractional analysis of açai extract by reverse-phase HPLC. Reverse phase C18 column was used with a linear gradient from 5% to 95% in 0.1% trifluoroacetic acid; elution was
monitored at 278 nm. Thirteen fractions were manually collected.
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3. Results
3.1. Antioxidant Compounds Determination
We first characterized the methanol/water açai extract by measur-
ing its antioxidant compounds and determining the antioxidant activ-
ity. By colorimetric assays, the total phenol content was estimated to be
192.41 ± 10.78 mg GAE/100 g DW, whereas that of total flavonoids
was found to be 159.67 ± 7.65 mg QE/100g DW. The mean antiox-
idant activity was 2.1 ± 0.17 mmol TE/100 g DW. Data are reported
in Table 1.
3.2. Biocompatibility of Açai Extracts on Fibroblasts
The biocompatibility of the açai extract on BALB/3T3 fibroblasts
was tested by a dose-response test, in a range from 0.2 to 100 mg/mL of
extract. As shown in Fig. 1, cell viability was not affected up to 40 mg/
mL, whereas at the highest concentration tested (100 mg/mL) a 50%
reduction of cell viability was observed. On the basis of these results,
subsequent experiments were carried out at 10 mg/mL of açai extract,
corresponding to a flavonoid content of 0.16 mg QE/mL and to a
phenolic content of 0.19 mg GAE/mL.
3.3. Pretreatment With Açai Extracts Inhibits UV-A-Induced Damage in
BALB/3T3 Fibroblasts
In all the experiments reported below, BALB/3T3 fibroblasts were
pretreated with açai extract for 2 h before the induction of oxidative
stress by UV-A irradiation (100 J/cm2). Immediately after UV-A
irradiation, ROS production was determined by using H2DCF-DA (2,7-
Fig. 5. Analysis of the antioxidant activity of açai fractions. A, Hydrophilic antioxidant activity (mmol TE/kg DW) in fractions evaluated by ABTS test. Data shown are the means ± S.D.
of three independent experiments. Significance was determined by Duncan's-test at a significance level of 0.05. Values with different letters are significantly different. B, Changes in
intracellular GSH levels of cells before (−) and after (+) UV-A treatment. Cells were incubated with açai extract, or equivalent amount of fractions obtained by HPLC, for 2 h prior to UV-
A irradiation (100 J/cm2). Data shown are the means± S.D. of three independent experiments. Values with different letters are significantly different compared to untreated cells,
indicated by black bars (p < 0.05).
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dichlorofluorescin diacetate) (Fig. 2A). As expected, UV-A treatment
significantly increased DCF fluorescence intensity, compared to the
non-irradiated samples, whereas açai extract had no effect on ROS
levels. Interestingly, pretreatment of cells with açai extract prior to UV-
A exposure, resulted in the inhibition of ROS production. Moreover,
following UV-A-oxidative stress induction, we found that intracellular
GSH was significantly decreased with respect to untreated cells,
whereas no alteration in intracellular GSH levels was observed when
cells were pretreated with açai extract before being irradiated by UV-A
(Fig. 2B). The protective effect of açai extract was confirmed by
analyzing the lipid peroxidation levels after 90 min from irradiation.
Lipid peroxidation level was measured by thiobarbituric acid reactive
substances (TBARS). A significant increase in lipid peroxidation levels
after UV-A treatment was observed but, noteworthy, this effect was
abolished when cells were pretreated with açai extract. Again, pre-
treatment of cells with açai extract significantly counteracted the
increase of lipid peroxidation (Fig. 2C).
The protective effect of açai extract was further confirmed by
Western blot experiments, in which the phosphorylation levels of p38
and its direct target, MAPKAPK-2, were analyzed (Fig. 3). These
proteins are directly involved in signaling stress pathways induced by
UV-A [38]. When cells were UV-A irradiated, we observed a significant
increase in the phosphorylation levels of p38 and MAPKAPK-2, as
expected (Fig. 3A and B, third lane). Instead, although the treatment of
non-irradiated cells with açai extract slightly altered the phosphoryla-
tion level of p38 (Fig. 3A, second lane), when cells were exposed to açai
extract prior to UV-A treatment, the phosphorylation levels of p38 and
MAPKAPK-2 were similar to those observed in non-irradiated cells
(Fig. 3A and B, fourth lane). A similar trend was observed for HSP-27, a
heat shock protein whose phosphorylation is directly related to
oxidative stress [39,40] (Fig. 3C).
3.4. Antioxidant Activity of Açai Fractions
In order to identify which açai compounds were responsible for the
antioxidant activity observed in irradiated fibroblasts, the extract was
fractionated by HPLC on a reverse phase C18 column, from which the
profile shown in Fig. 4 was obtained. 13 HPLC fractions were collected,
as reported in the Figure, and their antioxidant activity was tested in
vitro. The HAA analysis (Fig. 5A) revealed that the highest antioxidant
activity was associated to fractions 7 and 8, for which the HAA mean
values of 4.13 mmol TE/kg DW and 5.85 mmol TE/kg DW, respectively,
were calculated. High antioxidant power was also identified in fractions
1 and 9, with HAA mean values of 3.92 and 3.49 mmol TE/kg DW,
respectively. Lower values were detected in the other fractions, ranging
from 0.72 mmol TE/kg DW (fraction 13) to 1.89 mmol TE/kg DW
(fraction 10).
Then, we analyzed the intracellular GSH levels in BALB/3T3 cells
pretreated with each HPLC fraction, before and after UV-A treatment.
As shown in Fig. 5B, fractions 7 and 8 were able to contrast the
detrimental effects of UV-A irradiation on GSH depletion, whereas
fraction 9 was less efficient, in agreement with the HAA analysis. By
contrast, fraction 1 did not show any protective effect from oxidative
stress. Western blot experiments confirmed the strong antioxidant
activity of fraction 7 and 8 on UV-A-stressed fibroblasts. In particular,
the increase in p38 and MAPKAPK phosphorylation levels induced by
UV-A irradiation was attenuated when cells were pretreated with açai
fractions 7 and 8, whose effect was found to be slightly, but signifi-
cantly, more pronounced than that of the whole extract (Fig. 6).
Noticeable, a lower decrement in p38 phosphorylation level was
observed when cells were pre-treated with fraction 9.
Fig. 6. Western blot analysis of UV-A-treated BALB/3T3 cells in the presence of HPLC fractions. Cells were incubated with different fractions for 2h prior to UV-A (100 J/cm2) irradiation
and then cells were incubated for further 90min at 37 °C. Representative western blots show the phosphorylation levels of p38 (A) and MAPKAPK-2 (B), with the relative densitometric
analysis in the absence (black bars) or in the presence (white bars) of extract. GAPDH was used as internal standard. Data shown are the means ± S.D. of three independent experiments.
* indicates p < 0.01, ** indicates p < 0.001.
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3.5. Malvidin and Cyanidin are Responsible for the Açai Antioxidant
Activity on Immortalized Fibroblasts
HPLC fractions 7 and 8 were submitted to MALDI-MS analysis, as
described in the Material and Method section. The different species
detected in the MALDI spectra (Fig. 7A-B) were identified on the basis
of MSMS MALDI TOTOF analysis and compared with literature data
[41]. Mass spectral identification is reported in Table 2. Qualitative and
semi-quantitative differences can be appreciated in the MALDI spectra
showing the presence of different flavonoids in açai fractions. Among
them, malvidin-petunidin-glucoside-epicatechin was found to be the
predominant compound in fraction 7, whereas cyanidin-3-O-(6-O-p-
coumaryl)-monoglucoside was found to be the most abundant species in
fraction 8. DCFDA assay indicated that malvidin and cyanidin enriched
fractions were able to mitigate ROS production as well as the whole
extract (Fig. 8A). However, the TBARS assay (Fig. 8B) revealed that the
activity of malvidin enriched fraction was comparable to that of the
whole extract, whereas cyanidin enriched fraction was lower.
Finally, to evaluate if malvidin and cyanidin derivatives protect
cells after UV-A injury and to avoid any sunscreen effect, fibroblasts
were first irradiated by UV-A (100 J/cm2), and afterwards incubated for
2h with either açai extract or its fractions and then ROS, GSH levels and
the phosphorylation levels of p38 were evaluated (Fig. 9). Interestingly,
UV-A induced ROS production was mitigated by the presence of either
açai extract or its active fractions. Furthermore, no alteration in
intracellular GSH levels was measured and a significant decrease in
the phosphorylation levels of p38 was also observed.
4. Discussion
Among the most severe environmental injuries to which humans are
exposed, UV-A radiations are known to be the main cause of different
Fig. 7. MALDI-MS analysis of selected HPLC fractions from açai extract. The MALDIMS spectra of fractions 7 and 8 are reported in panels A and B, respectively. The attributions are
reported.
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detrimental effects on the skin, such as inflammation, premature skin
aging and development of skin cancer [42,43]. In recent years, an
increasing body of research has focused on antioxidants since they are
able to counteract oxidative stress-induced pathological conditions.
However, studies are usually conducted on commercial molecules,
supposed to have antioxidant activity [43–45].
Here, we analyzed hydrophilic extracts from açai berries to evaluate
their dermato-protective properties against UV-A irradiation. Açai is the
name commonly used for the tree Euterpe oleracea Martius, a South
American palm [25,46], whose berry is largely consumed since it shows
several beneficial activities, including anti-inflammatory and antiox-
idant properties. These activities are mainly due to açai high content in
polyphenol content, especially anthocyanins and flavones [20–25].
Immortalized fibroblasts, exposed to UV-A radiations, showed
increased levels of intracellular ROS and lipid peroxidation, and
decreased levels of intracellular GSH. Noteworthy, we found that a
pre-treatment of cells with açai extracts clearly inhibited the detri-
mental effect of oxidative stress, since ROS generation, lipid peroxida-
tion, intracellular GSH levels and p38 phosphorylation levels were all
found to be almost unaltered with respect to UV-A unexposed cells. It is
interesting to notice that the açai extract is able to efficiently protect
immortalized, non-cancer cells from the deleterious effects of UV-A
irradiation when tested at concentrations compatible with cell viability,
i.e. non associated to any cytotoxicity. Moreover, we demonstrated that
the protective effect of açai extract is not due to a sunscreen effect, as
the extract was able to protect cells also after UV-A induced damage.
Mass spectrometry analyses of HPLC fractionated extract led us to
the identification of the main agents responsible for the potent
antioxidant activity of açai extracts on fibroblasts. These are two
flavonoids, cyanidin and malvidin, both endowed with strong antiox-
idant activity, with malvidin the most active.
Cyanidin is considered the widest spread anthocyanin in the plant
kingdom and it is known to be a strong natural antioxidant. Amorini
and colleagues [47] demonstrated that cyanidin-3-glucoside, also
known as kuromanin, has a remarkable antioxidant capacity in the
model of Cu2+-mediated human low density lipoprotein oxidation,
even higher than resveratrol and ascorbic acid and independent from
pH variations (from 4 to 7.4). In addition, it is reported that cyanidin-3-
glucoside may attenuate obesity-associated insulin resistance and
hepatic steatosis in high-fat diet-fed mice via the transcription factor
FoxO1 [48].
Malvidin, normally present at high concentration in red wine and
black rice, and responsible for their color, plays an important role in
protecting plants from UV irradiation [49,50]. Accordingly, it has been
reported that malvidin has antioxidant activity in vitro [51], as well as
in neuronal and in endothelial cells [52,53]. Recently, it has been
demonstrated that malvidin is also able to inhibit aging by attenuating
oxidative stress in human diploid fibroblasts [54]. Moreover, several
authors have shown that malvidin inhibits the growth of different
tumor cell lines in vitro or in vivo [55–57].
Polyphenols are known to inhibit free radicals' production by
donating hydrogen atoms, which break oxidation chains and chelate
transition metal ions. Açai polyphenols may upregulate antioxidant
enzymes by activating the Nrf2/Keap1 pathway [58], downregulate the
expression of the pro-inflammatory transcription factor NF-kB, which in
turn targets pro-inflammatory cytokines, and reduces the accumulation
of intracellular lipids in differentiated adipocytes by downregulating
the expression of adipogenic genes transcription factors [59]. Addition-
ally, different studies performed on healthy women, which consumed
200 g/day of açai pulp for 4 weeks, revealed that some antioxidant
enzymes, i.e. superoxide dismutase, catalase and glutathione, were
increased [59–61].
Our findings now reveal that açai extract protects BALB/3T3 cells
against UV-A irradiation by neutralizing the negative effects of stress
induced by UV-A, as it interferes with ROS generation and keeps
intracellular GSH and lipid peroxidation close to the normal cellular
levels. This work reveals, for the first time, that malvidin present in açai
Table 2
MALDI mass spectral analysis of açai fractions after reverse-phase HPLC. The identified
species and the relative percentages are reported (G = glucose).
Compound m/z Main M2
fragments m/z
Fraction 7 Fraction 8
Petunidin-3-acetyl 365.10 305, 203 20% 43%
Peonidin-3-O-acetyl
monoglucoside
527.19 467, 365, 203 32% 38%
Cyanidin-3-O-(6-O-P-
coumaryl)-
monoglucoside + Na
617.20 455, 287 10% 100%
Petunidin-3-acetyl
diglucoside
689.23 527, 629 22% 20%
Malvidin-3-acetylglucose-
ethil-catechin/
Petunidin-3-acetil
triglucoside
851.31 791, 689 20% 17%
Petunidin-3-acetyl
tetraglucoside
1013.35 952, 851 20% 14%
Malvidin-petunidin-
glucoside-epicatechin
1097.68 1037, 796,
466, 809
100% 5%
Petunidin-3-acetyl + 5G 1175.42 1115, 1013 16% 8%
Petunidin-3-acetyl + 6G 1337.48 1277,1175 12% 5%
Petunidin-3-acetyl + 7G 1499.54 1439, 1337 8% 3%
Petunidin-3-acetyl + 8G 1661.6 1601, 1499 6% 3%
Petunidin-3-acetyl + 9G 1823.65 1763, 1661 6% 2%
Petunidin-3-acetyl + 10G 1985.71 1925, 1823 4% 1%
Petunidin-3-acetyl + 11G 2147.78 2087, 1985 2% 1%
Fig. 8. ROS production and lipid peroxidation in UV-A-treated BALB/3T3 fibroblasts in the presence of açai fractions. Cells were pre-incubated with açai extract (dark grey bars), fraction
7 (white bars) and fraction 8 (light grey bars) for 2h and then irradiated by UV-A (100 J/cm2). A, intracellular ROS levels; B, lipid peroxidation levels. Values are expressed as fold
increase with respect to control (i.e. untreated) cells. Data shown are the means ± S.D. of three independent experiments. * indicates p < 0.01; ** indicates p < 0.05.
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extract can be considered as a good and safe candidate for dietary
intervention in the prevention of age related diseases, since the use of
anthocyanins as food additives (indicated as “E163”) has been already
approved in the European Union, Australia, and New Zealand [62].
Author contribution
G.P. and D.M.M. conceived, performed and analyzed cell biology
experiments; A.R. and M.M.R. performed in vitro experiments; R.D.G.
performed spectrophluorimetric experiments; A.A and A.I. conceived,
performed and analyzed the HPLC and MS experiments; R.P. analyzed
and discussed the data; D.M.M. wrote the paper with the contribution of
all the authors.
Conflict of interest
The authors declare no competing financial interest.
Acknowledgement
The authors thank Dr. Carla Damiano for the work done during her
master thesis.
References
[1] R. Thanan, S. Oikawa, Y. Hiraku, S. Ohnishi, N. Ma, S. Pinlaor, et al., Oxidative
stress and its significant roles in neurodegenerative diseases and cancer, Int. J. Mol.
Sci. 16 (2014) 193–217.
[2] D.R. Bickers, M. Athar, Oxidative stress in the pathogenesis of skin disease, J.
Invest. Dermatol. 126 (2006) 2565–2575.
[3] S. Briganti, M. Picardo, Antioxidant activity, lipid peroxidation and skin diseases.
What's new, J. Eur. Acad. Dermatol. Venereol. 17 (2003) 663–669.
[4] J. Cadet, R. Teoule, Comparative study of oxidation of nucleic acid components by
hydroxyl radicals, singlet oxygen and superoxide anion radicals, Photochem.
Photobiol. 28 (1978) 661–665.
[5] J.L. Ravanat, C. Saint-Pierre, P. Di Mascio, G.R. Martinez, M.H.G. Medeiros,
J. Cadet, Damage to isolated DNA mediated by singlet oxygen, Helv. Chim. Acta 84
(2001) 3702–3709.
[6] T. Douki, A. Reynaud-Angelin, J. Cadet, E. Sage, Bipyrimidine photoproducts rather
than oxidative lesions are the main type of DNA damage, Biochemistry 42 (2003)
9221–9226.
[7] S. Raha, B.H. Robinson, Mitochondria, oxygen free radicals, disease and ageing,
Trends Biochem. Sci. 25 (2000) 502–508.
[8] L.A. Pham-Huy, H. He, C. Pham-Huy, Free radicals, antioxidants in disease and
health, Int. J. Biomed. Sci. 4 (2008) 89.
[9] L. Gil del Valle, Oxidative stress in aging: theoretical outcomes and clinical
evidences in humans, Biomed. Aging Pathol. 1 (2011) 1–7.
[10] A. Scalbert, I.T. Johnson, M. Saltmarsh, Polyphenols: antioxidants and beyond, Am.
J. Clin. Nutr. 81 (2005) 215S–217S.
[11] B.E. van Wyk, M. Wink, Phytomedicines, Herbal Drugs, and Poisons, first ed.,
(2015) (Chicago, IL).
[12] M. Wink, Modes of action of herbal medicines and plant secondary metabolites,
Fortschr. Med. 2 (2015) 251–286.
[13] R. Del Giudice, G. Petruk, A. Raiola, A. Barone, D.M. Monti, M.M. Rigano,
Carotenoids in fresh and processed tomato (Solanum lycopersicum) fruits protect
cells from oxidative stress injury, J. Sci. Food Agric. 97 (2017) 1616–1623, http://
dx.doi.org/10.1002/jsfa.7910.
[14] G. Petruk, A. Raiola, R. Del Giudice, A. Barone, L. Frusciante, M.M. Rigano,
D.M. Monti, An ascorbic acid-enriched tomato genotype to fight UV-A-induced
oxidative stress in normal human keratinocytes, J. Photochem. Photobiol. B 163
(2016) 284–289.
[15] H. Rogez, Açai: Preparo, Composicao e Melhoramento da Conservacao, first ed.,
EDUFPA, Brazil, 2000.
[16] M.S.M. Rufino, J. Perez-Jimenez, S. Arranz, R.E. Alves, E.S. de Brito, M.S. Oliveira,
F. Saura-Calixto, Açai (Euterpe oleracea)‘BRS Para’: a tropical fruit source of
antioxidant dietary fiber and high antioxidant capacity oil, Food Res. Int. 44 (2011)
2100–2106.
[17] J. Holderness, I.A. Schepetkin, B. Freedman, L.N. Kirpotina, M.T. Quinn,
J.F. Hedges, M.A. Jutila, Polysaccharides isolated from Açai fruit induce innate
immune responses, PLoS One 6 (2011) e17301.
[18] H. Peixoto, M. Roxo, S. Krstin, T. Röhrig, E. Richling, M. Wink, An Anthocyanin-rich
extract of açai (Euterpe precatoria Mart.) increases stress resistance and retards
aging-related markers in Caenorhabditis elegans, J. Agric. Food Chem. 64 (2016)
1283–1290.
[19] M.M. dos Santos Dias, H.S.D. Martino, G. Noratto, A. Roque-Andrade,
P.C. Stringheta, S. Talcott, A.M. Ramos, S.U. Mertens-Talcott, Anti-inflammatory
activity of polyphenolics from açai (Euterpe oleracea Martius) in intestinal myofi-
broblasts CCD-18Co cells, Food Funct. 6 (2015) 3249–3256.
[20] R. Lichtenthaler, R.B. Rodrigues, J.G.S. Maia, M. Papagiannopoulos, H. Fabricius,
F. Marx, Total oxidant scavenging capacities of Euterpe oleracea Mart.(Açai) fruits,
Int. J. Food Sci. Nutr. 56 (2005) 53–64.
[21] S.U. Mertens-Talcott, J. Rios, P. Jilma-Stohlawetz, L.A. Pacheco-Palencia,
B. Meibohm, S.T. Talcott, H. Derendorf, Pharmacokinetics of anthocyanins and
antioxidant effects after the consumption of anthocyanin-rich açai juice and pulp
(Euterpe oleracea Mart.) in human healthy volunteers, J. Agric. Food Chem. 56
(2008) 7796–7802.
[22] J. Kang, C. Xie, Z. Li, S. Nagarajan, A.G. Schauss, T. Wu, X. Wu, Flavonoids from
açai (Euterpe oleracea Mart.) pulp and their antioxidant and anti-inflammatory
activities, Food Chem. 128 (2011) 152–157.
[23] J. Kang, K.M. Thakali, C. Xie, M. Kondo, Y. Tong, B. Ou, G. Jensen, M.B. Medina,
Fig. 9. Analysis of oxidative stress in BALB/3T3 fibroblasts incubated in the presence of
açai fractions after UV-A treatment. Cells were irradiated by UV-A (100 J/cm2) and then
incubated with açai extract, fraction 7 or fraction 8 for 2h. A, intracellular ROS levels; B,
intracellular GSH levels; C, Western blotting of the phosphorylation levels of p38 and
MAPKAPK-2, with the relative densitometric analysis. GAPDH was used as internal
standard. In all panels, untreated cells (named c in western blotting analysis) are
represented by black bars, cells incubated with açai extract by dark grey bars, with
fraction 7 by white bars and with fraction 8 by light grey bars. Values are expressed as
fold increase with respect to control (i.e. untreated) cells. Data shown are the
means ± S.D. of three independent experiments. * indicates p < 0.05; ** indicates
p < 0.01.
G. Petruk et al. Journal of Photochemistry & Photobiology, B: Biology 172 (2017) 42–51
50
A.G. Schauss, X. Wu, Bioactivities of açai (Euterpe precatoria Mart.) fruit pulp,
superior antioxidant and anti-inflammatory properties to Euterpe oleracea Mart,
Food Chem. 133 (2012) 671–677.
[24] H.A. Favacho, B.R. Oliveira, K.C. Santos, B.J. Medeiros, P.J. Sousa, F.F. Perazzo,
J.C.T. Carvalho, Anti-inflammatory and antinociceptive activities of Euterpe oleracea
Mart., Arecaceae, oil, Rev. Bras 21 (2011) 105–114.
[25] A.G. Schauss, X. Wu, R.L. Prior, B. Ou, D. Huang, J. Owens, A. Agarwal, G.S. Jensen,
A.N. Hart, E. Shanbrom, Antioxidant capacity and other bioactivities of the freeze-
dried Amazonian palm berry, Euterpe oleracea Mart. (açai), J. Agric. Food Chem. 54
(2006) 8604–8610.
[26] G.D. Noratto, G. Angel-Morales, S.T. Talcott, S.U. Mertens-Talcott, Polyphenolics
from açai (Euterpe oleracea Mart.) and red muscadine grape (Vitis rotundifolia)
protect human umbilical vascular Endothelial cells (HUVEC)from glucose and
lipopolysaccharide (LPS)-induced inflammation and target micro RN A-126, J.
Agric. Food Chem. 59 (2011) 7999–8012.
[27] G.D. Stoner, L.S. Wang, C. Seguin, C. Rocha, K. Stoner, S. Chiu, A.D. Kinghorn,
Multiple berry types prevent N-nitrosomethylbenzylamine-induced esophageal
cancer in rats, Pharm. Res. 27 (2010) 1138–1145.
[28] M. Oliveira de Souza, M. Silva, M.E. Silva, R. de Paula Oliveira, M.L. Pedrosa, Diet
supplementation with açai (Euterpe oleracea Mart.) pulp improves biomarkers of
oxidative stress and the serum lipid profile in rats, Nutrition 26 (2010) 804–810.
[29] J.F. Ferreira da Costa Guerra, C.L. Lopes de Brito Magalhaes, D.C. Costa, M.E. Silva,
M.L. Pedrosa, Dietary açai modulates ROS production by neutrophils and gene
expression of liver antioxidant enzymes in rats, J. Clin. Biochem. Nutr. 49 (2011)
188–194.
[30] M.M. Rigano, A. Raiola, G.C. Tenore, D.M. Monti, R. Del Giudice, L. Frusciante,
A. Barone, Quantitative trait loci pyramiding can improve the nutritional potential
of tomato (Solanum lycopersicum) fruits, J. Agric. Food Chem. 62 (2014)
11519–11527.
[31] V.L. Singleton, J.A. Rossi, Colorimetry of total phenolics with phosphomolybdic-
phosphotungstic acid reagents, Am. J. Enol. Vitic. 16 (1965) 144–158.
[32] D. Marinova, F. Ribarova, M. Atanassova, Total phenolics and total flavonoids in
bulagrian fruits and vegetables, J. Univ. Chem. Technol. Metall. 40 (2005)
255–260.
[33] A. Raiola, R. Del Giudice, D.M. Monti, G.C. Tenore, A. Barone, M.M. Rigano,
Bioactive compound content and cytotoxic effect on human cancer cells of fresh and
processed yellow tomatoes, Molecules 21 (2016) 33.
[34] J.N. Miller, C.A. Rice-Evans, Factors influencing the antioxidant activity determined
by the ABTS•+ radical cation assay, Free Radic. Res. 26 (1997) 195–199.
[35] R. Del Giudice, A. Raiola, G.C. Tenore, L. Frusciante, A. Barone, D.M. Monti,
M.M. Rigano, Antioxidant bioactive compounds in tomato fruits at different
ripening stages and their effects on normal and cancer cells, J. Funct. Foods 18
(2015) 83–94.
[36] D.M. Monti, D. Guarnieri, G. Napolitano, R. Piccoli, P. Netti, S. Fusco, A. Arciello,
Biocompatibility, uptake and endocytosis pathways of polystyrene nanoparticles in
primary human renal epithelial cells, J. Biotechnol. 10 (2015) 3–10.
[37] E. Galano, A. Arciello, R. Piccoli, D.M. Monti, A. Amoresano, A proteomic approach
to investigate the effects of cadmium and lead on human primary renal cells,
Metallomics 6 (2014) 587–597.
[38] L.O. Klotz, C. Pellieux, K. Briviba, C. Pierlot, J.M. Aubry, H. Sies, Mitogen-activated
protein kinase (p38-, JNK-, ERK-) activation pattern induced by extracellular and
intracellular singlet oxygen and UV-A, Eur. J. Biochem. 260 (1999) 917–922.
[39] W.R. Swindell, Heat shock proteins in long-lived worms and mice with insulin/
insulin-like signaling mutations, Aging 1 (2009) 573.
[40] A. Strayer, Z. Wu, Y. Christen, C.D. Link, Y. Luo, Expression of the small heat-shock
protein Hsp16−2 in Caenorhabditiselegans is suppressed by Ginkgo biloba extract
EGb 761, FASEB J. 17 (2003) 2305–2307.
[41] R. Flamini, Mass spectrometry in grape and wine chemistry. Part I: polyphenols,
Mass Spectrom. Rev. 22 (2003) 218–250.
[42] D. Kulms, T. Schwarz, Molecular mechanisms of UV-induced apoptosis,
Photodermatol. Photoimmunol. Photomed. 16 (2000) 195–201.
[43] Y.-C. Hseu, C.W. Chou, K.J. Senthil Kumar, K.T. Fu, H.M. Wang, L.S. Hsu, Y.H. Kuo,
C.R. Wu, S.C. Chen, H.L. Yang, Ellagic acid protects human keratinocyte (HaCaT)
cells against UV-A-induced oxidative stress and apoptosis through the upregulation
of the HO-1 and Nrf-2 antioxidant genes, Food Chem. Toxicol. 50 (2012)
1245–1255.
[44] Y.-C. Hseu, H.W. Lo, M. Korivi, Y.C. Tsai, M.J. Tang, H.L. Yang, Dermato-protective
properties of ergothioneine through induction of Nrf2/ARE-mediated antioxidant
genes in UV-A-irradiated human keratinocytes, Free Radic. Biol. Med. 86 (2015)
102–117.
[45] I.F. Almeida, A.S. Pinto, C. Monteiro, H. Monteiro, L. Belo, J. Fernandes, A.R. Bento,
T.L. Duarte, J. Garrido, M.F. Bahia, J.M. Sousa Lobo, P.C. Costa, Protective effect of
C. sativa leaf extract against UV mediated-DNA damage in a human keratinocyte
cell line, J. Photochem. Photobiol. B 144 (2015) 28–34.
[46] A.G.V. Costa, D.F. Garcia-Diaz, P. Jimenez, P.I. Silva, Bioactive compounds and
health benefits of exotic tropical red–black berries, J. Funct. Foods 5 (2013)
539–549.
[47] A.M. Amorini, G. Fazzina, G. Lazzarino, B. Tavazzi, D. Di Pierro, R. Santucci,
F. Sinibaldi, F. Galvano, G. Galvano, Activity and mechanism of the antioxidant
properties of cyanidin-3-O-βglucopyranoside, Free Radic. Res. 35 (2001) 953–966.
[48] H. Guo, M. Xia, T. Zou, W. Ling, R. Zhong, W. Zhang, Cyanidin 3-glucoside
attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat
diet-fed and db/db mice via the transcription factor FoxO1, J. Nutr. Biochem. 23
(2012) 349–360.
[49] U. Matern, B. Grimmig, Polyphenols in plant pathology, Polyphenolic Phenomena.
Paris: INRA Editions, 1993, pp. 143–147.
[50] E. Bognar, Z. Sarszegi, A. Szabo, B. Debreceni, N. Kalman, Z. Tucsek, B. Sumegi,
F. GallyasJr, Antioxidant and anti-inflammatory effects in RAW264. 7 macrophages
of malvidin, a major red wine polyphenol, PLoS One 8 (2013) e65355.
[51] R. Pop, M.N. Stefanut, A. Cata, C. Tanasie, M. Medeleanu, Ab initio study regarding
the evaluation of the antioxidant character of cyanidin, delphinidin and malvidin,
Cent. Eur. J. Chem. 10 (2012) 180–186.
[52] N. Matsunaga, S. Imai, Y. Inokuchi, M. Shimazawa, S. Yokota, Y. Araki, H. Hara,
Bilberry and its main constituents have neuroprotective effects against retinal
neuronal damage in vitro and in vivo, Mol. Nutr. Food Res. 53 (2009) 869–877.
[53] W. Huang, Y. Zhu, C. Li, Z. Sui, W. Min, Effect of blueberry Anthocyanins Malvidin
and glycosides on the antioxidant properties in endothelial cells, Oxidative Med.
Cell. Longev. (2016), http://dx.doi.org/10.1155/2016/1591803.
[54] H.R. Seo, M.J. Choi, J.M. Choi, J.C. Ko, J.Y. Ko, E.J. Cho, Malvidin protects WI-38
human fibroblast cells against stress-induced premature senescence, Eur. J. Cancer
Prev. 21 (2016) 32–40.
[55] J.W. Hyun, H.S. Chung, Cyanidin and malvidin from Oryza sativa cv. Heugjinjubyeo
mediate cytotoxicity against human monocytic leukemia cells by arrest of G2/M
phase and induction of apoptosis, J. Agric. Food Chem. 52 (2004) 2213–2217.
[56] P.H. Shih, C.T. Yeh, G.C. Yen, Effects of anthocyanidin on the inhibition of
proliferation and induction of apoptosis in human gastric adenocarcinoma cells,
Food Chem. Toxicol. 43 (2005) 1557–1566.
[57] S.J. Patterson, J.G. Fischer, R.V. Dulebohn, DNA damage in HT-29 colon cancer
cells is enhanced by high concentrations of the anthocyanin malvidin, FASEB J. 22
(2008) 890–900.
[58] W. Li, Y. Guo, C. Zhang, R. Wu, A.Y. Yang, J. Gaspar, A.N. Kong, Dietary
phytochemicals and cancer chemoprevention: a perspective on oxidative stress,
inflammation, and epigenetics, Chem. Res. Toxicol. 29 (2016) 2071–2095.
[59] H.S.D. Martino, M.M. dos Santos Dias, G. Noratto, S. Talcott, S.U. Mertens-Talcott,
Anti-lipidaemic and anti-inflammatory effect of açai (Euterpe oleracea Martius)
polyphenols on 3T3-L1 adipocytes, J. Funct. Foods 23 (2016) 432–443.
[60] P.O. Barbosa, D. Pala, C.T. Silva, M.O. de Souza, J.F. do Amaral, R.A.L. Vieira,
G.A. Folly, A.C. Volp, R.N. de Freitas, Açai (Euterpe oleracea Mart.) pulp dietary
intake improves cellular antioxidant enzymes and biomarkers of serum in healthy
women, Nutrition 32 (2016) 674–680.
[61] D. Pala, P.O. Barbosa, C.T. Silva, M.O. de Souza, F.R. Freitas, A.C. Volp,
R.C. Maranhão, R.N. Freitas, Açai (Euterpe oleracea Mart.) dietary intake affects
plasma lipids, apolipoproteins, cholesteryl ester transfer to high-density lipoprotein
and redox metabolism: a prospective study in women, Clin. Nutr. (2017), http://dx.
doi.org/10.1016/j.clnu.2017.02.001.
[62] C.K. Singh, I.A. Siddiqui, S. El-Abd, H. Mukhtar, N. Ahmad, Combination
chemoprevention with grape antioxidants, Mol. Nutr. Food Res. 60 (2016)
1406–1415.
G. Petruk et al. Journal of Photochemistry & Photobiology, B: Biology 172 (2017) 42–51
51
Contents lists available at ScienceDirect
Algal Research
journal homepage: www.elsevier.com/locate/algal
Simultaneous production of antioxidants and starch from the microalga
Chlorella sorokiniana
Ganna Petruka, Imma Gifunib, Anna Illianoa, Mariana Roxoc, Gabriella Pintoa,
Angela Amoresanoa, Antonio Marzocchellab, Renata Piccolia,d, Michael Winkc,
Giuseppe Olivierib,e,⁎, Daria Maria Montia,d,⁎⁎
a Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte Sant'Angelo, via Cinthia 4, 80126 Naples, Italy
bDipartimento di Ingegneria Chimica, dei Materiali e della Produzione Industriale, Università degli Studi di Napoli Federico II, Piazzale Tecchio, 80, Naples, Italy
c Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, INF 364, 69120 Heidelberg, Germany
d Istituto Nazionale di Biostrutture e Biosistemi (INBB), Rome, Italy
e Bioprocess Engineering Group, Wageningen University and Research, Droevendaalsesteeg 1, 6700AA Wageningen, the Netherlands
A R T I C L E I N F O
Keywords:
Antioxidants
Chlorella sorokiniana
Eukaryotic cells
Microalgae
C. elegans
A B S T R A C T
In recent years, microalgae have gained considerable importance as potential source of biofuels and bioplastics.
However, these markets are still developing, as the high costs of cultivation ask for exploiting microalgae into
new areas and with a biorefinery approach towards a multicomponent cascade extraction process. Here, a se-
quential processing strategy was used to extract starch with high yield from Chlorella sorokiniana under bio-
compatible conditions. The extract residue was then tested as a potential source of antioxidants. We found a
strong protective activity of the extract residue towards oxidative stress in vitro on human colon cancer cells and
in vivo on Caenorhabditis elegans nematodes, by inhibiting ROS production and activating DAF-16/FOXO tran-
scription factor pathway. A pool of molecules from three different classes (fatty acids, photosynthetic pigments
and carotenoids) was identified as responsible for the antioxidant activity. To our knowledge, this is the first
report on the obtainment, from a “waste” fraction, of high value products endowed with antioxidant activity
tested in cell-based models and in vivo.
1. Introduction
The circular bioeconomy, based on the biorefinery approach, seems
to be a good and long-term solution to harmonise the use of natural
resources to sustain economic growth, ensure human wellness, reduce
the increase of CO2 concentration in the atmosphere and reduce waste
production. Microalgae have been often regarded as a potential can-
didate for biorefinery as they are an incredible reservoir of compounds
endowed with biological activities that could be used in different fields
[1].
Microalgal biomass is renewable, as CO2 and sun light energy are
both required for their growth. As no competition exists with food
culture for the use of arable land, many recent studies have been fo-
cused on the exploitation of various microalgal components in order to
obtain the maximum economic benefit, as the conversion of biomass
into different products produces minimal waste to the environment.
Currently, the research is mainly focused on the use of microalgae as
sources of lipids for biodiesel production [2], carbohydrates for me-
thane production via anaerobic fermentation [3], proteins for animal
nutrition [4] and food additives. Several process alternatives have been
proposed to exploit microalgal components in a multi-product bior-
efinery approach [5]. However, most of these fractions have been tested
only as raw fractions, not characterized in their single components to
validate them.
In our experimental system, we found that C. sorokiniana, requires,
for starch accumulation, nitrogen depletion [6]. This stressful condi-
tion, in turn, can be exploited to obtain pigments endowed with anti-
oxidant activity. In principle, the cultivation conditions (light intensity
and nutrient supply strategy) must be selected to optimize the accu-
mulation of all the main products to be extracted within the biorefinery.
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It is known that microalgae, when exposed to high oxygen and ra-
dical stress in their natural environment, develop several efficient
protective systems against reactive oxygen species (ROS) and free ra-
dicals [7], by producing pigments, such as chlorophylls, carotenoids,
xanthophylls and phycobiliproteins [8]. In particular, astaxanthin, β-
carotene, zeaxanthin and lutein possess antioxidant activity exceeding
that of α-tocopherol [9] and are required from food, cosmetic, nu-
traceutical and pharmaceutical industries. Thus, the obtainment of an
active pigment fraction can significantly influence the economic bal-
ance of the whole process (cultivation plus biorefinery).
The main objective of this contribution was to obtain a second high-
value class of molecules, such as antioxidants, starting from the dis-
carded fraction after starch extraction [6]. Moreover, we identified the
antioxidants obtained and validated their activity in a real applicative
environment, i.e. both in cell-based models and in vivo on a C. elegans
model, which is widely used in this context [10]. This contribution
provides a clear validation of the feasibility of a multiproduct bior-
efinery applied to C. sorokiniana at lab-scale.
2. Materials and methods
2.1. Microalgal strain and culture conditions
Chlorella sorokiniana Shihiraet Krauss strain ACUF 318 (http://
www.acuf.net) is a fresh water terrestrial alga. The culture medium
used was Bold's Basal Medium (BBM) containing NaNO3 as nitrogen
source at concentration of 0.25 g L−1. The growth was carried out in
inclined square bubble column photobioreactors, as reported by
Olivieri et al. [11]. The culture was continuously irradiated with white
fluorescent lamps on the front side of the reactors with a light intensity
of 300 μmol m−2 s−1. Aeration and mixing was provided by feeding air
supplemented with 2% of CO2. Gas flow rate was set at 0.2 vvm. The
temperature was maintained at 25 °C by air-conditioning system. Ni-
trogen depletion was reached after the regular uptake of NaNO3 for
biomass growth and the biomass was harvested in the second day of
nitrogen depletion, optimal condition for starch accumulation and
productivity [12].
2.2. Pigment extraction
A conventional solvent extraction method was carried out to obtain
starch and antioxidants from C. sorokiniana. Pure ethanol (99.8%,
Sigma-Aldrich) was used as solvent. The extraction protocol follows
that reported by Aremu et al. [13] with some modifications. Briefly, the
microalgal biomass was dried and ground to 0.150mm powder. 200mg
of microalgal powder were suspended in 2mL of ethanol and disrupted
in bead beater (2000 g for 3 cycles of 1min space out with 2min breaks
in ice) equipped with 0.5 mm glass beads. The disrupted biomass was
moved to dark flasks and the beads were washed twice with ethanol and
the final volume was led to 20mL. The mixture was shaken for 24 h at
250 rpm in the dark on a magnetic stirrer. Then the mixture was cen-
trifuged at 12000g for 10min. The supernatant was dried by using N2
stream, and represents the ethanol extract (EE), which was solubilized
in 1mL of DMSO for further analysis on a cell-based model and in vivo.
The recovered pellet (EP) was dried to recover starch.
2.3. Biochemical composition
Initial microalgal biomass, EE and EP were characterized in terms of
lipids, proteins, total sugars, starch and pigments. Lipids were extracted
according to the protocol proposed by Breuer et al. [14] followed by
gravimetric quantification of the chloroform extract, previously dried at
100 °C for 1 h.
Proteins were assayed by BCA Protein Assay Kit (Thermo Scientific).
10 mg of sample (biomass or dried pellet) was dissolved in 1mL of lysis
buffer (60mM Tris, 2% SDS) and disrupted in a bead beater (700 g for
3 cycles of 4min space out with 1min breaks in ice) equipped with
0.5 mm glass beads. The samples were incubated at 100 °C for 30min
for the extraction of membrane proteins and then centrifuged at 2500g
for 10min. Supernatants were analyzed by BCA Kit. Total sugars con-
centration was measured by spectrophotometric method of Anthrone
modified with respect to that described by Chen and Vaidyanathan
[15]. In particular, the disruption of the biomass and of the pellet was
carried out according to the procedure described for proteins. Starch
was measured using Total Starch kit by Megazyme (Wicklow, Ireland)
and according the manufacture's protocol with some modifications. The
mass of sample was set at 10mg and the cells disruption was carried out
in the bead beater, as previously reported [16]. Pigments were directly
measured by spectrophotometric measurements at 663, 646 and
470 nm. chlorophyll a, b and carotenoids concentration were calculated
according to Wellburn [17].
Analyses were performed in triplicates. Simple sugars are calculated
as difference between total sugars concentration and starch con-
centration. The recovery yields of the biomolecules were calculated
according to mass balances. The recovery yield (Y, %) was defined as
reported in the following formula:
= ∙Y m
m
100x EP
x initial
where mx EP is the mass (mg) of the compound x (proteins, lipids, total
sugars, starch) in EP and mx initial is the mass (mg) of the compound x in
the initial biomass.
2.4. Cell culture and cell survival assay
Human epithelial colorectal adenocarcinoma cells (LoVo) and
human immortalized keratinocytes (HaCaT) were obtained from ATCC
and cultured in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich),
supplemented with 10% foetal bovine serum (HyClone), 2 mM L-gluta-
mine and antibiotics, all from Sigma-Aldrich, in a 5% CO2 humidified
atmosphere at 37 °C. Every 3–4 days the culture medium was removed
and cells were rinsed with PBS, detached with trypsinEDTA and diluted
in fresh complete growth medium for sub-culturing.
For dose-dependent survival assays cells were seeded in 96-well
plates (100 μL/well) at a density of 4× 104 cells per cm2. 24 h after
seeding, increasing amount of microalgae extract (from 20 μgmL−1 to
2mgmL−1) were added to the cells for 24–48 h. At the end of treat-
ment, cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl tetrazolium bromide (MTT) reagent and the cells were in-
cubated for 4 h at 37 °C in a humidified 5% CO2 incubator. At the end of
the incubation, medium was removed and the converted dye was so-
lubilized with isopropanol containing 0.01mol L−1 HCl (100 μL per
well). Absorbance was measured at a wavelength of 570 nm using an
automatic plate reader (Microbeta Wallac 1420, PerkinElmer,
Waltham, MA, USA). Cell survival was expressed as percentage of vi-
able cells in the presence of the microalgae extract under test compared
with control cells grown in the absence of the extract. The assay was
carried out in triplicates for at least 3 times. Control experiments were
performed either by growing cells in the absence of the extract or by
adding to the cell cultures identical volumes of DMSO. The method used
avoids any possibility of a DMSO effect on the final results.
2.5. Oxidative stress
To analyze if EE was able to protect cells from oxidative stress, LoVo
cells were plated at a density of 4× 104 cells per cm2. 24 h after
seeding, cells were incubated for different length of time (24 or 48 h) in
the presence or absence of EE (200 μgmL−1), and then incubated in the
presence of 300 μM SA for 45min at 37 °C. At the end of treatment, cell
viability was assessed by the MTT assay as reported above.
To detect the minimal pre-treatment time, cells were plated as re-
ported above and then incubated for different length of time
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(5–120min) with EE (200 μgmL−1). Then, cells were exposed to oxi-
dative stress as reported above and a DTNB assay was performed (de-
scribed more in detail in paragraph 2.6). The result of the experiment is
documented in Fig. S1.
Once defined the minimum pre-treatment, in all further experiments
cells were pre-treated with EE for 30min and then exposed to SA for
45min. After incubation, different assays were performed, as reported
below.
2.6. Measurement of intracellular total GSH levels
Total reduced glutathione levels were estimated by using the pro-
cedure previously described [18]. Briefly, at the end of incubation, cells
were detached by trypsin, lysed and protein concentration was de-
termined by the Bradford assay. Then, 50 μg of proteins were incubated
with 3mM EDTA, 144 μM 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) in
30mM TrisHCl pH 8.2, centrifuged at 14,000g for 5min at 4 °C and the
absorbance of the supernatant was measured at 412 nm by using a
multiplate reader (Biorad). GSH levels were expressed as the percentage
of TNB absorbance in the sample under test with respect to the un-
treated sample. Values are the mean of three independent experiments,
each with triplicate determinations.
2.7. Measurement of intracellular ROS levels in cells
ROS intracellular levels were evaluated by using a cells permeable
probe, 2′,7′-dichlorodihydrofluorescein diacetate (H2-DCFDA, Sigma-
Aldrich). In particular the protocol described in [19] was followed.
Briefly, at the end of incubation cells were incubated with the non-
fluorescent H2DCFDA becomes fluorescent product, 2′,7′-dichloro-
fluorescein (DCF), in the presence of different species of ROS. Fluor-
escence intensity was measured by a Perkin-Elmer LS50 spectro-
fluorimeter (525 nm emission wavelength, 488 nm excitation
wavelength, 300 nm/min scanning speed, 5 slit width for both excita-
tion and emission). ROS production was expressed as percentage of DCF
fluorescence intensity of the sample under test, with respect to the
untreated sample. Each value was assessed by three independent ex-
periments, each with three determinations.
2.8. Western blot analyses
LoVo cells were plated at a density of 4×104 cells per cm2 in
complete medium for 24 h and then treated as described above (para-
graph 4.5). After treatment time, cells were detached and lysed in
100mM Tris-HCl, 300mM sucrose with addiction of inhibitors of pro-
teases and phosphatases. These lysates were analyzed by Western
blotting as reported by Del Giudice et al. [20]. Phosphorylation levels of
p38 and MAPKAPK-2 were detected by using specific antibodies pur-
chased from Cell Signal Technology (Danvers, MA, USA). To normalize
protein intensity levels, a specific antibody against anti-GAPDH
(ThermoFisher, Rockford, IL, USA) was used. The chemiluminescence
detection system (SuperSignal® West Pico) was from Thermo Fisher.
2.9. Caenorhabditis elegans strains and culture conditions
Nematode strains were obtained from the Caenorhabditis Genetic
Center (CGC). All C. elegans strains were cultured on solid nematode
growth media (NGM) plates fed with living E. coli OP50 and maintained
at 20 °C in a temperature-controlled incubator. Prior to each assay eggs
were isolated to obtain age synchronized cultures and kept in M9 buffer
(3 g KH2PO4, 6 g Na2HPO4, 5 g NaCl, 1 mL 1M MgSO4, H2O to 1 L) for
hatching, as described by Stiernagle [21].
2.10. Brood size
Synchronized N2 worms at L4 stage were sorted and placed one by
one on individual NGM agar plates. In the treatment group, the bac-
terial lawn was supplemented with microalgae extract (200 μgmL−1).
100 μgmL−1 of epigallocatechin gallate (EGCG, Sigma-Aldrich GmbH,
Steinheim, Germany) was used as positive control, whereas DMSO was
used to verify that buffer was not responsible for side effects. Adult
worms were transferred daily to fresh medium to separate them from
their progeny. Eggs were counted every day for 5 days using a dis-
secting microscope. The results are presented as mean brood size.
2.11. Caenorhabditis elegans survival assay under oxidative stress
24 h after bleaching, N2 wild-type worms and transgenic worms
(CF1038, GR1307), in L1 larval stage, were pre-treated with
200 μgmL−1 EE and maintained 48 h at 20 °C. EGCG and DMSO were
used as indicated above. In the adult stage, worms were transferred to
fresh media and grouped in populations of approximately 80 in-
dividuals and treated with 80 μM juglone (5-hydroxy-1,4-naphthale-
nedione) [22]. After 24 h, dead and live worms were counted. The
worms were scored dead when they did not respond to a gentle touch
stimulus. The results are expressed as percentage of living worms.
2.12. Intracellular ROS accumulation in Caenorhabditis elegans
Synchronized N2 worms at L1 larval stage were pre-treated with
200 μgmL−1 EE and maintained 48 h at 20 °C. EGCG and DMSO were
used as indicated above. At the end of the treatment, worms were
washed with M9 buffer and then incubated with 50 μM H2DCFDA so-
lution for 1 h at 20 °C. Worms were then mounted on a glass slide with a
drop of 10mM sodium azide (used to paralyze them) and photographed
by the BIOREVO BZ-9000 fluorescent microscope (Keyence
Deutschland 200 GmbH, Neu-Isenburg, Germany) equipped with a
mercury lamp. Images were taken for at least 30 worms at constant
exposure time (λ Ex 480/20 nm; λ Em 510/38 nm) using a 10 X ob-
jective lens. The relative fluorescence of the whole body was de-
termined densitometrically by using ImageJ software 6.01. The results
are expressed as percentage of fluorescence intensity of the worms
under test compared to untreated worms.
2.13. Quantification of hsp-16.2::GFP expression
The expression of hsp-16.2p::GFP construct was quantified in the
strain TJ375. Worms at larval stage L1 were pre-treated with
200 μgmL−1 EE and maintained 72 h at 20 °C. EGCG (50 μgmL−1) and
DMSO were used as indicated above. Then, worms were exposed to
20 μM juglone for 24 h and analyzed as described above.
2.14. Quantification of sod-3::GFP expression
The worms of transgenic strain CF1553 at larval stage L1 were pre-
treated with 200 μgmL−1 EE and maintained 72 h at 20 °C. EGCG
(100 μgmL−1) was used as positive control, whereas DMSO was used as
negative control. After treatment, the worms were analyzed as de-
scribed above.
2.15. Quantification of daf-16::GFP localization
The nematode worms of transgenic strain TJ356 at larval stage L1
were pre-treated with EE (200 μgmL−1) and maintained 24 h at 20 °C
and analyzed as described above. EGCG and DMSO were used as in-
dicated above.
2.16. Reverse-phase HPLC analyses
Metabolites from ethanol extracts were separated by reverse-phase
HPLC on a Phenomenex Jupiter C18 column (250× 2.00mm 5 μm,
300 Å pore size) (Phenomenex, Torrance, California, USA) at a flow rate
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of 200 μLmin−1. A linear gradient from 5% to 95% acetonitrile in 0.1%
formic acid (Sigma Aldrich, Milan, Italy) was used over a time of 40min
and a wavelength of 278 nm was used for monitoring the elution. The
eluate was collected in thirteen fractions to be directly analyzed by
MALDI-TOF and LC-MS.
2.17. Mass spectrometry analyses
Matrix-assisted laser desorption/ionization (MALDI) mass spectro-
metry (MS) experiments were performed on a 5800 MALDI-TOF-TOF
ABSciex equipped with a nitrogen laser (337 nm) (AB SCIEX, Milan,
Italy). Aliquots of HPLC fractions (0.5 μL) were mixed (1:1, v/v) with a
solution of 2.5 dihydroxybenzoic acid (DHB, Sigma Aldrich, Milan,
Italy) at a concentration of 10mgmL−1 in acetonitrile:water (90:10)
solution. Standards Kit for Calibration of AB SCIEX MALDI-TOF was
from AB SCIEX calibration mixture. For metabolite identification, MS
and tandem mass (MSMS) spectra were acquired in reflector positive
mode, by using a mass (m/z) range of 100–4000 Da. Laser power was
set to 3500 V for MS spectra acquisition. Each spectrum represents the
sum of 3000 laser pulses from randomly chosen spots per sample po-
sition. For CID experiments, ambient air was used as collision gas with
medium pressure of 10−6 Torr. The data were reported as monoisotopic
masses. LCMS analyses were performed by LC-MS equipped by an
Agilent HPLC system (1260 Series) on a reverse-phase C18 column
(Agilent Life Sciences Extend-C18, 2.1× 50mm, 1.8 μm) coupled to an
Agilent 6230 TOF mass spectrometer. The HPLC separation was carried
out by using water and acetonitrile as mobile phases A and B, respec-
tively, both acidified with 0.1% formic acid. A linear gradient was
employed over 40min (0–2min: 2% B, 2–8min: 2–40% B, 8–20min:
40%–60% B, 20–30min: 60–80%, 30–40min, 80–95) at a flow rate of
0.3 mLmin−1. The injection volume was 20 μL and the MS source was
an electrospray ionization (ESI) interface in the positive ion mode with
capillary voltage of 3000 V, gas temperature at 325 °C, dry gas (N2)
flow at 5 Lmin−1 and the nebulizer pressure at 35 psi. The MS spectra
were acquired in a mass range of 150–1000m/z with a rate of 1 spec-
trum/s, time of 1000ms/spectrum and transient/spectrum of 9961.
2.18. Statistical analyses
In all the experiments, samples were analyzed in triplicate. The
results are presented as mean of results obtained after three in-
dependent experiments (mean ± SD) and compared by one-way
ANOVA according to the Bonferroni's method (posthoc) using
Graphpad Prism for Windows, version 6.01.
3. Results
Recently, Gifuni and colleagues reported a purification protocol
addressed to primarily recover starch from C. sorokiniana [6]. Authors
highlighted the need of removing pigments form the microalgal bio-
mass before recovering starch. It must be underlined that in a bior-
efinery perspective each component of the microalgae should be va-
lorized. The extraction of pigments from the biomass was performed
not to obtain the highest amount of these molecules, but with the aim of
extracting interesting antioxidant compounds without damaging, or
drastically reducing, the starch recovery yield. For the same reason,
ethanol, which does not damage starch, was used as a solvent. More-
over, ethanol belongs to the permitted solvents exploitable for the ex-
traction of compounds used in food industries (law 2009/32/CE),
which would allow the use of the extracted antioxidants, or the mole-
cules recovered from the pellet, also as food additives. Finally, ethanol
has a low evaporation temperature (78 °C) and it may be easily re-
covered by evaporation at low specific energetic request.
3.1. Pigment extraction
The microalgal biomass was produced in photobioreactors [12],
harvested at the onset of nitrogen depletion, and dried. Pigment ex-
traction was performed by using ethanol from the dried biomass, as
reported in Materials and Methods section. The composition in starch,
simple sugars, proteins and lipids was assessed for the raw biomass and
for the extracted biomass pellet (herein denoted as EP). Results are
reported in Table 1. The microalgal biomass contained starch
(39.2 ± 1.0%), proteins (29.1 ± 1.1%), lipids (19.8 ± 0.4%) and
simple sugars (10.0 ± 0.3%). After pigments extraction, the weight
loss of the EP was about 35%, with respect to the initial biomass. The
EP composition revealed a starch content of 26.4 ± 0.6%,
18.5 ± 0.1% of proteins, 13.7 ± 0.4% of simple sugars and
4.1 ± 0.1% of lipids, thus indicating that lipids were almost com-
pletely extracted by the solvent. With this established extraction pro-
tocol, it was possible to recover 82.9% of the initial starch, and a sig-
nificant amount of proteins (78.3%). Only 17.0% of the initial lipid
content remained in the pellet after the extraction. Therefore, starch
recovery was considered satisfying. Simple sugars seemed to increase in
the pellet with respect to the untreated biomass, probably because part
of the initial starch is reduced in simple sugars during the treatment.
The composition in proteins and lipids of EP suggests applications as
feedstock for bioplastics or as feed or food complements without further
treatments. By introducing further separation steps, all the components
of the pellet could be separated and exploited as biochemicals in dif-
ferent industrial fields with higher profit.
When the ethanol extracted fraction (herein denoted as EE) was
analyzed, besides the presence of lipids (29.5 ± 3.6mg), proteins
(12.5 ± 1.3mg) and sugars (4.9 ± 0.8mg), carotenoids, chlorophyll
a and b were detected (0.17 ± 0.23mg, 0.79 ± 0.11mg and
0.66 ± 0.09mg, respectively). Thus, the EE was selected to test a pu-
tative antioxidant activity on human cells against oxidative stress in-
jury.
3.2. In vitro biocompatibility and antioxidant activity of the ethanol extract
from microalgae
Human cancer colon cells (LoVo) were chosen to study the protec-
tive effects of EE as a proof of concept. For this reason, we first eval-
uated the biocompatibility of EE by treating cells for 24 and 48 h with
increasing amounts (from 20 μgmL−1 to 2mgmL−1) of the extract and
the results are reported in Fig. 1A. In particular, no toxicity was ob-
served up to 200 μgmL1 of microalgal extract at any time point ana-
lyzed, whereas, at higher concentrations (1 and 2mgmL−1), cell via-
bility was found to be significantly reduced in a dose- and time-
dependent manner. These results are in line with literature data, as it
has been reported that low doses of antioxidants may have a protective
effect on cancer cells, whereas toxicity is observed at high concentra-
tion [23, 24].
Based on these results, we selected 200 μgmL−1 microalgal extract
Table 1
Total composition of biomass, of the extracted biomass pellet (EP) and of
ethanol extracted fraction (EE).
Biomass composition
(%DW)
EP composition (%
DW)
EE composition
(mg)
Simple sugars 10.0 ± 0.3 13.7 ± 0.4 4.9 ± 0.8
Starch 39.2 ± 1.0 26.4 ± 0.6 –
Proteins 29.1 ± 1.1 18.5 ± 0.1 50.2 ± 1.3
Lipids 18.8 ± 0.4 4.1 ± 0.1 65.8 ± 3.6
Weight loss 0 35 –
Chl a – 0 0.79 ± 0.23
Chl b – 0 0.66 ± 0.11
Carotenoids – 0 0.17 ± 0.09
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Fig. 1. In vitro antioxidant activity of microalgal ethanol extract.
A, LoVo cells were treated with increasing concentrations of EE (from 20 to 2000 μgmL−1) for 24 (black bars) and 48 h (grey bars). Cell viability was assessed by the
MTT assay. B, C, LoVo cells were pre-incubated with 200 μgmL−1 EE (grey bars) for 24 (B) and 48 h (C) and then treated with 300 μM SA for 45min. Cell viability
was assessed by the MTT assay. D, E, LoVo cells were incubated with 200 μgmL−1 EE prior to be stressed by 300 μM sodium arsenite (SA) for 45min at 37 °C. D,
Intracellular ROS levels were determined by DCFDA assay. Values are expressed as fold increase with respect to control (i.e. untreated) cells. E, intracellular GSH
levels determined by DTNB assay. F, Representative images of Western blots of cells incubated with EE. Cells were treated as described above and, after SA-treatment,
incubated for 90min at 37 °C. In Western blots the phosphorylation level of P-p38 and P-MAPKAPK-2 is reported. GAPDH was used as internal standard. In B, C, D, E,
G histograms, black bars refer to control cells, grey bars refer to cells pre-treated with EE, untreated (−) or treated with SA (+).
Values are expressed as fold increase with respect to control (i.e. untreated) cells. Data shown are the means ± S.D. of three independent experiments. ⁎⁎ indicates
p < 0.005; ⁎⁎⁎ indicates p < 0.001; ⁎⁎⁎⁎ indicates p < 0.0001.
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as the optimal concentration to analyze the ability of the extract to
protect cells from oxidative stress induced by sodium arsenite (SA).
Cells were pre-treated with 200 μgmL−1 EE for 24 h (Fig. 1B, grey bars)
or 48 h (Fig. 1C, grey bars) in the presence or absence of 300 μM SA
(45min incubation) and then cell viability was measured. Cells in-
cubated in the presence of SA, showed a low survival rate (67 and 61%
after 24 and 48 h, respectively) when compared to untreated cells
(Fig. 1B and C, black bars). Interestingly, the pre-treatment of cells with
EE before inducing oxidative stress was able to maintain unaltered cell
viability, comparable to that of untreated cells (Fig. 1B and C, grey
bars).
As it is well documented that SA induces high ROS production and
consequently GSH oxidation in eukaryotic cells [25, 26], we analyzed
EE ability to maintain unaltered intracellular ROS and GSH levels. As
shown in Fig. 1D, the pre-treatment of LoVo cells with the extract
reduced ROS levels of about 3.5 times with respect to cells exposed to
SA. Similarly, total intracellular GSH levels were significantly higher
(about 40%) in cells pre-treated with microalgal extract, compared to
cells exposed to SA (Fig. 1E). The protective effects of EE against oxi-
dative stress were further confirmed by using human immortalized
keratinocytes (HaCaT cells) stressed by SA. Indeed, SA is known to
induce oxidative stress also on these cells [27]. By using the same ex-
perimental procedure used for LoVo cells, we found that ROS and GSH
levels were kept at physiological levels, as reported in Fig. S2.
Finally, we analyzed the phosphorylation levels of p38 and its direct
target MAPKAPK-2 (Fig. 1F–G). These proteins belong to the family of
mitogen-activated protein kinases (MAPK) and are directly involved in
oxidative signaling stress pathways [18]. Consistently with the results
reported above, we observed a significant increase in the phosphor-
ylation level of both proteins after oxidative stress (Fig. 1F, third lane).
Fig. 2. In vivo antioxidant activity of microalgal ethanol extract.
A, wild type N2 worms were treated with 200 μgmL−1 EE extract for 48 h and then exposed to lethal dose of juglone (80 μM). After 24 h, alive and dead worms were
counted and survival rate were reported in histograms. B, wild type N2 worms were treated with 200 μgmL−1 EE extract for 48 h and then incubated with DCF
fluorescent probe. After 1 h incubation, accumulation of intracellular ROS levels was evaluated. On the top, representative images of DCF fluorescence in untreated
worms and in worms treated with EE or EGCG; on the bottom, quantification of the fluorescence intensity of the whole body determined densitometrically by using
ImageJ software. C, transgenic TJ375 worms were treated with 200 μgmL−1 EE extract for 72 h and then exposed to juglone (20 μM). After 24 h, the expression of
GFP::hsp-16.2 was evaluated. On the top, representative images of GFP fluorescence in untreated worms and in worms treated with extract or EGCG; On the bottom,
the relative fluorescence of the heads determined densitometrically by using ImageJ software. D, transgenic CF1553 worms were treated with 200 μgmL−1 EE extract
for 72 h and then the expression of GFP::sod-3 was evaluated. On the top, representative images of GFP fluorescence in untreated worms and in worms treated with
EE or EGCG; on the bottom, the relative fluorescence of the tails determined densitometrically by using ImageJ software. In the Figure, black bars refer to control
worms, light grey bars refer to worms treated with EE, white bars refer to worms treated with EGCG (used as positive control), whereas dark grey bars refer to worms
treated with buffer (DMSO). In B, C and D histograms data are presented as percentage of the mean pixel intensity of each treatment, with respect to control worms
(mean ± SD, n=40, replicated at least 3 times). Images were taken with BZ9000 from Keyence, scale bar= 100 μm. ⁎⁎⁎ indicates p < 0.001, ⁎⁎⁎⁎ indicates
p < 0.0001, compared to the untreated worms by one-way ANOVA followed by Bonferroni (post-hoc).
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On the other hand, the pre-treatment of cells with the microalgal ex-
tract prior to SA resulted in the inhibition of the phosphorylation of the
above mentioned markers (Fig. 1F, fourth lanes). It is worth to notice
that, in all the experiments described, the microalgal extract alone did
not induce oxidative stress.
3.3. In vivo biocompatibility and antioxidant activity of the ethanol extract
from microalgae
The protective activity of EE against oxidative stress was further
evaluated in an in vivo system, i.e. Caenorhabditis elegans. We first
analyzed the variation of brood size, widely accepted as a toxicity
marker [28], after treatment with the microalgal extract, and we did
not find any significant difference with respect to untreated worms
(169 ± 7 vs 177 ± 6 offspring, respectively).
Then, the antioxidant activity of EE was evaluated by treating N2
wild-type worms, in the L1 larval stage, with EE (200 μgmL−1), for 48 h
at 20 °C. The antioxidant epigallocatechin-3-gallate (EGCG), from green
tea (100 μgmL−1) was used as a positive control [22], whereas DMSO
was used to verify that buffer was not responsible for side effects.
As showed in Fig. 2A, worms pre-treated with EE showed a sig-
nificantly higher survival rate (46 ± 7 worms, light grey bar) with
respect to worms treated with juglone (23 ± 4 worms, black bar) or
juglone and DMSO (25 ± 4 worms, dark grey bar).
In the next step, the ability of EE to counteract ROS production was
evaluated. As reported in the histograms of Fig. 2B, a significant lower
Fig. 3. The DAF-16 pathway activated by EE in C. elegans.
A, transgenic TJ356 worms were treated with 200 μgmL−1 EE extract for 24 h and then GFP::daf-16 localization was evaluated. On the top, representative images of
different GFP localization. Below, histograms reporting the percentage of worms exhibiting a DAF-16 sub-cellular localization pattern, namely cytosolic (white bars),
intermediate (checked bars) and nuclear (black bars). Data are presented as mean ± SD (n=40, replicated at least 3 times). Images were taken with BZ9000 from
Keyence, scale bar= 100 μm. ⁎⁎⁎⁎ indicates p < 0.0001, compared to the untreated worms by one-way ANOVA followed by Bonferroni (post-hoc). B–C, a daf-16 null
mutant (GR1307) and daf-16 loss-of-function mutant (CF1038) worms were treated with 200 μgmL−1 EE extract (light grey bars) for 48 h and then exposed to lethal
dose of juglone (80 μM). After 24 h, alive and dead worms were counted and the survival rate was reported. Data are presented as mean ± SD (n=40, replicated 3
times).
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fluorescence intensity was observed in nematodes (N2 strain) treated
with EE (about 50%, light grey bar) with respect to the untreated
control group (black and darker grey bars).
Subsequently, the expression of heat shock protein hsp-16.2 was
evaluated. The family of HSPs proteins is found in almost all living
organisms and its expression is mainly induced by heat shock or oxi-
dative stress [29]. For this purpose, the mutant strain TJ375, which has
a hsp-16.2 promoter fused with a GFP reporter, was incubated with EE
(72 h) in the presence of 20 μM juglone (24 h). Worms pre-treated with
the extract showed extremely low expression of hsp-16.2 (about 60%,
Fig. 3C, light grey bar) when compared to stressed worms (Fig. 2C,
black and dark grey bars).
As SOD is a known first line defense enzyme in the elimination of
ROS, the effect of EE (72 h) on sod-3 expression was analyzed by using
the mutant strain CF1553, which has a sod-3 promoter fused to a GFP
reporter. A significant higher expression of sod-3::GFP was detected in
worms treated with EE (about 42% increase, Fig. 2D, light grey bar) in
comparison with control worms (Fig. 2D, black and dark grey bars).
Therefore, these results indicate that EE extract exerts its anti-
oxidant activity not only by scavenging ROS, but also by modulating
the expression of stress response genes, such as sod-3 and hsp-16.2.
Finally, we analyzed the subcellular localization of DAF-16/FOXO,
which is the main transcription factor involved in the regulation of
stress response genes. Under physiological conditions, DAF-16/FOXO
remains inactive in the cytosol, whereas, some environmental or stress
conditions can stimulate its translocation to the nucleus, where it in-
duces the expression of different genes involved in stress response,
metabolism and longevity.
The mutant strain TJ356 has a daf-16 fused to a GFP reporter and
was used to detect daf-16 localization. As shown in Fig. 3A, worms
pretreated with EE (24 h) showed a higher percentage of daf-16::GFP
nuclear localization (about 70%), with respect to untreated worms
(12%). This pathway was further confirmed by performing survival
assays with a daf-16 loss-of-function mutant (CF1038) and a daf-16 null
mutant (GR1307) grown in the presence of EE (48 h). In both cases, the
extract had no effect on the survival rate of the worms (Fig. 3B and C,
light grey bars), in contrast to the results obtained with N2 worms
(Fig. 2A).
Fig. 4. Characterization of EE.
A, HPLC chromatogram of EE, in which eluted fractions are marked in the profile. B, Analysis of the antioxidant activity of microalgae fractions by DTNB assay. LoVo
cells were pre-incubated in the presence of 200 μgmL−1 EE or equivalent amount of each fraction after HPLC for 120min and then cells were stressed by SA
treatment (300 μM) for 45min and intracellular GSH levels determined, as described in Materials and Methods section. Values are reported as % of untreated cells.
C–F, TIC chromatogram of the fractions with the highest biological activity.
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Table 2
Identification of each peak of TIC chromatogram with relative retention time and relative abundance.
Species Measured m/z Detected ion MALDI-TOF/TOF fragments Rt (min) Relative abundance (%)
8 9 11 12
Fatty acid C18:3 278.2 M%+ 15.4 1.5 3.1 2.4 2.5
Dimeric form of C18:3 555.5 [M+H]+
Fatty acid C19:2 294.2 M%+ 16.2/16.7 3.1 3.7 3.6 2.8
Dimeric form of fatty acid C19:2 587.4
609.3
[M+H]+,
[M+Na]+
Dimeric form of C19:0 595.5
617.5
MH+
[M+Na]+
17.1 1.9 1.7 0.7 1.8
Fatty acid C19:1 296.2 M%+ 18.6 0.8 2.4 1.4 0.3
Dimeric form of fatty acid C19:1 591.5 [M+H]+,
[M+Na]+
Fatty acid C18:3 279.3 [M+H]+ 18.9 0.4 n.d. n.d. n.d.
S Porphyrin (SEt) 611.3 [M+H]+ 567.4 Da, 547.3 Da, 537.3 Da, 493.3 da,
465.3 Da
19.4 1.7 n.d. 1.4 n.d.
Luteolin dihexoside 611.4 [M+H]+ 579.4 Da, 565.4 Da
Delphinidine 3-O p-coumaroyl-monoglucoside 611.4 [M+H]+ 519.3 Da, 465.31, 493.3 (malvidine 3–0
monoglucoside)
Fatty acid C18:4 277.2 [M+H]+ 19.9 0.4 n.d. 1.4 n.d.
Fatty acid C19:2 295.2 [M+H]+
Fatty acid C22:5 330.2 M%+
S-Porphyrin (SEt) 611.4 [M+H]+ 567.4 Da, 547.3 Da, 537.3 Da, 493.3 da,
465.3 Da
Luteolin dihexoside 611.4 [M+H]+ 579.4 Da, 565.4 Da
Delphinidine 3-O p-coumaroyl-monoglucoside 611.4 [M+H]+ 519.3 Da, 465.31, 493.3 (malvidine 3–0
monoglucoside)
Fatty acid C19:0 298.2 M%+ 20.3 0.5 1.9 1.1 1.3
Dimeric form of fatty acid C19:0 595.5
617.5
[M+H]+
[M+Na]+
Fatty acid C14:0 228.2 M%+ 21.9 0.3 0.3 0.3 2.3
Dimeric form of C14:0 455.4 [M+H]+
Fatty acid C16:1 254.2
M%+
M%+ 23.4 0.3 0.4 0.6 1.9
Fatty acid C22:4 332.2 M%+
Dimeric form of C16:1 507.5 [M+H]+
Fatty acid C18:2 280.2 M%+ 24.8
25.4
26.2
2.3
5.2
2.4
4.8
8.6
3.7
4.3
8.7
4.0
5.2
9.6
5.2
Dimeric form of C18:2 559.5 [M+H]+
[M+Na]+
Fatty acid C16:0 256.3 M%+ 27.5 7.7 7.3 8.5 9.7
Dimeric form of C16:0 511.5
533.5
[M+H]+
[M+Na]+
Fatty acid C18:1 282.3 M%+ 28.3
29.0
32.0
20.3
27.6
16.6
28.5
20.9
23.2
18.6Dimeric form of C18:1 563.5
585.5
[M+H]+
[M+Na]+
Fatty acid C17:0 270.3 M%+ 32.6 n.d. n.d. n.d. 0.7
Dimeric form of C17:0 539.5
561.5
[M+H]+
[M+Na]+
Quercetin 3-(2″-p-hydroxybenzoyl-4″-p-
coumarylrhamnoside)
715.3 [M+H]+ 699.1 Da, 669.1 Da, 561.1 Da, 311.4 Da,
283.4 Da
30.9 0.4 n.d. n.d. n.d.
Chlorophyll c2 609.3 [M+H]+ 579.4 Da, 549.4 Da, 455.3 Da, 429.05 Da 31.1 5.7 0.5 n.d. 1.3
Pheophorbide a 593.3 [M+H]+ 533.3 Da, 459.3 Da 32.8
33.8
n.d. n.d. n.d. 0.7
0.3
Fatty acid C18:0 284.4 M%+ 32.7 6.4 5.8 4.8 3.2
Dimeric form of C18:0 567.6
589.5
[M+H]+
[M+Na]+
Fatty acid C20:1 310.3 M%+ 33.2 3.7 4.2 n.d. 2.8
Pheophorbide a 593.3 [M+H]+ 533.3 Da, 459.3 Da
Dimeric form of C20:1 619.6
641.6
[M+H]+
[M+Na]+
Pheophytin a′ 871.2 [M+H]+ 593.2 Da, 714.9 Da
Hydroxylated chlorophyll a 908.9 [M+H]+ 752.9 Da, 311.3 Da, 283.2 Da
Fatty acid C20:1 310.3 M%+ 34.0 0.4 0.6 0.4 0.9
Astaxanthin 596.4 [M+H]+
Dimeric form of C20:1 619.6
641.6
[M+H]+
[M+Na]+
TG(16:0/18:1(9Z)/18:2 874.7 [M+NH4]+ 35.5 n.d. 1.9 n.d. n.d.
TG(18:1(9Z)/18:1(9Z)/18:1(9Z) 902.7 [M+NH4]+
Fatty acid C22:1 338.3 M%+ 38.0 0.8 1.9 1.6 1.8
Dimeric form of C22:1 675.7
697.5
[M+H]+
[M+Na]+
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3.4. Identification of active compounds
EE was then fractionated by HPLC and the elution profile is shown
in Fig. 4A. Thirteen fractions were manually collected and tested for
antioxidant activity in LoVo cells by measuring intracellular GSH in the
presence or absence of oxidative stress (300 μM SA). As shown in
Fig. 4B, fractions 8, 9, 11 and 12 had no effect on GSH levels when
tested alone, but showed a high protective effect against oxidative
stress. To verify the occurrence of additive effects, the active fractions
were combined and tested on LoVo cells, in the presence or absence of
SA damage, and the results, shown in Fig. 4B, suggested the presence of
additive effects.
The active fractions were further analyzed by LC-MS and MALDI-
TOF/TOF for the identification of the main agents responsible for their
bioactivity. The LC-MS TIC chromatogram of each fraction is reported
in Fig. 4C–F. A similar profile for the four fractions was observed, al-
though relevant differences in their relative abundance were recorded.
The base peak chromatogram of an ethanol extract with the identifi-
cation of the most abundant peaks is reported in the Supporting in-
formation (Fig. S3) while mass spectral identification of each peak is
reported in Table 2. The assignment of species to each mass peak is
based on the interpretation of MALDI-TOF/TOF spectra and on the
comparison with literature data [30–33]. By LC-TOF analysis, we found
several saturated and polyunsaturated chain fatty acids, consisting of
their radical species, dimeric forms and sodium adducts (Table 2), as
shown as an example in Fig. S4.
Besides FAs, different antioxidant molecules, well documented in
the literature, were identified by LC-TOF analysis and confirmed by
tandem MS. In particular, carotenoids, such as astaxanthin and its so-
dium salt (596.4 Da,), and porphyrins, as chlorophyll c2 (609.3 Da),
pheophorbide a (593.3 Da) and thioether porphyrin (611.4 Da) were
found to be present [10, 34]. A MALDI-TOF/TOF spectrum is reported
for chlorophyll C2, with the structures drawn for the most intense
fragments (Fig. S5). Interestingly, the chlorophylls were esterified with
unsaturated long chain fatty acid, e.g. pheophytin a′ (871.2 Da, Fig. S6)
and hydroxylated chlorophyll a (908.9 Da, Fig. S7), were detected only
by MALDI.
The other fragmentation spectra were documented in Supporting
information (Figs. S8–11). Finally, a derivate of the flavonoid quercetin
and some triacylglycerols were found exclusively in fractions 8 and 9,
respectively.
4. Discussion and conclusions
A new strategy for a sequential recovery of starch and antioxidants
was proposed and validated. We found that, after starch extraction from
C. sorokiniana, the waste product was able to counteract oxidative
stress, both on cell-based models and in vivo, as many carotenoids,
chlorophylls and FAs are present. Although a variable content of pro-
teins and lipids depending on the specific algal strain and growth
conditions was detected in microalgae [35], lipids are always present at
high levels [36]. Recently, Wang and Wink reported the beneficial ef-
fect of chlorophyll in C. elegans, demonstrating that this antioxidant
molecule is absorbed by worms, thus becoming bioavailable and pro-
moting longevity [10]. In general, the antioxidant activity of car-
otenoids is well documented; instead, the literature is still quiescent on
the FAs antioxidant activity. However, some studies are reported on the
impact of polyunsaturated fatty acids (PUFAs) intake on oxidative
stress, as omega-3 PUFAs have been shown to reduce lipoperoxidation
levels, advance glycation end products, increase SOD/CAT enzymatic
ratio in the liver of diabetic rats fed with a high fat thermolyzed diet
(rich in advanced glycation end-products) [37, 38]. These properties,
together with the reported inhibition of hepatic lipogenesis afforded by
EPA and DHA [39], suggest a multifaceted healthful activity of omega-3
fatty acids supplementation in liver disorders. We assume that chlor-
ophylls and carotenoids, which are known antioxidants, are important
in EE. We still do not know whether additional substances of EE have
antioxidant activity, or if there is a synergistic effect among them.
Further analysis will be performed to shed light on this issue. It has to
be taken into account, however, that, to date, papers claim the multi-
product biorefinery of algae, but no cascade or validation of the ob-
tained products are reported [5, 40, 41]. The physico-chemical char-
acterization of the starch granules, extracted with the method here
reported, was already carried out [6] and its properties suggest inter-
esting industrial applications: emulsifier for food and pharmaceuticals,
bioplastics, textiles and paper preservation. The novelty of the present
work concerns the proved feasibility of the cascade approach to isolate
two different high value products: starch and antioxidants.
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ABSTRACT: The discovery of extended catalytic versatilities is
of great importance in both the chemistry and biotechnology
fields. Fatty acid amide hydrolase (FAAH) belongs to the
amidase signature superfamily and is a major endocannabinoid
inactivating enzyme using an atypical catalytic mechanism involv-
ing hydrolysis of amide and occasionally ester bonds. FAAH
inhibitors are efficacious in experimental models of neuropathic
pain, inflammation, and anxiety, among others. We report a new
multitarget drug, AGN220653, containing a carboxyamide-4-
oxazole moiety and endowed with efficacious analgesic and anti-
inflammatory activities, which are partly due to its capability of
achieving inhibition of FAAH, and subsequently increasing the
tissue concentrations of the endocannabinoid anandamide. This
inhibitor behaves as a noncompetitive, slowly reversible inhibitor. Autoradiography of purified FAAH incubated with
AGN220653, opportunely radiolabeled, indicated covalent binding followed by fragmentation of the molecule. Molecular
docking suggested a possible nucleophilic attack by FAAH-Ser241 on the carbonyl group of the carboxyamide-4-oxazole moiety,
resulting in the cleavage of the C−C bond between the oxazole and the carboxyamide moieties, instead of either of the two
available amide bonds. MRM-MS analyses only detected the Ser241-assisted formation of the carbamate intermediate, thus
confirming the cleavage of the aforementioned C−C bond. Quantum mechanics calculations were fully consistent with this
mechanism. The study exemplifies how FAAH structural features and mechanism of action may override the binding and
reactivity propensities of substrates. This unpredicted mechanism could pave the way to the future development of a completely
new class of amidase inhibitors, of potential use against pain, inflammation, and mood disorders.
KEYWORDS: FAAH mechanism, C−C bond cleavage, multitarget inhibitors
■ INTRODUCTION
Fatty acid amide hydrolase (FAAH) is an atypical serine hydro-
lase, which embodies a catalytic mechanism for the hydrolysis of
amide and ester substrates. As the enzyme responsible for the
hydrolysis of the endocannabinoid N-arachidonoyl-ethanol-
amine (anandamide, AEA) and related anti-inflammatory
molecules,1 FAAH has been proposed as a therapeutic target
for the treatment of neuropathic pain, inflammation, and mood
disorders. Indeed, AEA, via different mechanisms including
peripheral and/or spinal activation of cannabinoid CB1 and
CB2 receptors, or activation and/or desensitization of transient
receptor potential vanilloid type-1 (TRPV1) channels, exerts
antinociceptive and antihyperalgesic actions in various animal
models of inflammatory and neuropathic pain.2 Furthermore,
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AEA also inhibits anxiety and depression in experimental
models.3 Accordingly, selective FAAH inhibitors have been
developed as potential analgesics, anxiolytics and antidepres-
sants.4 However, when tested in phase II clinical trials, an
irreversible FAAH inhibitor failed to alleviate pain in patients
with osteoarthritis.5 Recently, new strategies focusing on tar-
geted antagonism of selected prostanoid receptors have been
developed6,7 resulting in efficacious compounds acting through
the simultaneous blockade of the action of proinflammatory
prostanoids at DP1, DP2, EP1, EP4, FP, and TP receptors, while
sparing the more benign EP2, EP3, and IP receptors. Based on
this background, and on the increasing demand for rationally
designed multitarget drugs, we aimed at including the chemical
requirements for FAAH inhibition into the aforementioned
prostanoid pan-antagonists through their progressive chemical
modification. Having achieved this aim, we discovered, using
molecular modeling, biochemistry, quantum mechanics, and
mass spectrometry approaches, that these new multitarget mol-
ecules inhibit FAAH by favoring an unprecedented catalytic
behavior. This unique mechanism may now open previously
unexplored avenues in the fields of biochemistry and medicinal
and physical chemistry, with potential impact on therapeutic
drug development.
■ RESULTS AND DISCUSSION
Rational Design of Combined Pan-PG Antagonists
Hosting the Capability of Inhibiting FAAH in a Slowly
Reversible Manner.We previously patented8 and reported7 a
novel scaffold (AGN211377) with a unique polypharmacology
and therapeutically ideal prostanoid receptor pan-antagonism
profile at FP, TP, DP, EP1, and EP2 receptors that spares EP2,
EP3, and IP receptors.
6
This compound (AGN211377) possesses relatively weak FAAH
inhibitory activity (medium μmolar range), which however could
be significantly improved by the introduction of amide substituents
in the molecule. AGN220653 (IC50 = 93.6 nM against rat brain
FAAH, Tables S1 and S2) was thus identified as a mixed
prostanoid pan-antagonist/FAAH inhibitor, which produced
analgesic activity in vivo via the expected molecular targets
(Figures 1a−d and S1a-b). Our efforts were next directed to
understanding AGN220653 selectivity and mode of action.
First, we verified, using an affinity-based proteomic profiling
assay, that AGN220653 does not hit several “off-target” serine
hydrolases present in a mouse brain proteome (Figure 1e,f).
Furthermore, unlike some other previously reported FAAH
inhibitors, AGN220653, up to 10 μM, showed little affinity for
CB1 and CB2 cannabinoid receptors and did not activate nor
antagonize TRPV1 channels (Table S3). Next, we assessed
whether or not AGN220653 acts via a slowly reversible mecha-
nism, by comparing it to other well-known FAAH irreversible
inhibitors (URB579 and MAFP) incubated with rat brain mem-
branes for up to 24 h. A gradual reduction of AGN220653
potency was found over time with a corresponding recovery of
enzyme activity. Instead, as previously reported,9,10 MAFP
retained its activity for up to 24 h, while the effect of URB597
was comparable with that of AGN220653 but showed a
reduction of its inhibition potency only at the latest time point
measured, suggesting a difference in the type of interaction with
the enzyme (Figures S1c−e and S2).
Mechanistic Characterization of FAAH Inhibition by
AGN220653.Next, the following questions were addressed: on
which of the two carbonyl groups of AGN220653 does the
nucleophilic attack by Ser241 (one of the residues of the unusual
FAAH catalytic triad) occur? Is the nucleophilic attack followed
by elimination of a leaving group? Which of the two expected
leaving groups (the acyl-sulfonamine or the cyclohexyl-butyl-
amine) is preferentially eliminated? To address these questions,
we radiolabeled either of the two putative leaving groups of
AGN220653. Furthermore, AGN220346, an analogue with
comparable activity at FAAH but presenting an isopropyl sulfon-
amide group instead of the phenyl sulfonamide moiety, was also
utilized. Both compounds were [14C]-radiolabeled at the
1-position of the cyclohexyl-butyl amine portion. Alternatively,
the 1-position of the isopropyl group in AGN220346, and the
phenyl group in AGN220653, of the sulfonamide were [14C]-
radiolabeled. The [14C]-AGN compounds (75 000 cpm; 30 μM)
were then incubated with custom highly purified humanized
FAAH (0.2 μg; Medicilon Ltd., Shangai, China) at pH 9 in the
presence and absence of an excess of the corresponding non-
radiolabeled AGN compounds (700 μM).
The denatured protein was electrophoresed through a 10%
SDS polyacrylamide gel before exposing the films. Only when
labeled on their cyclohexyl-butyl amine portion did the
inhibitors also label full length FAAH, with a signal that was
displaced by the initial coincubation of the enzyme with the
corresponding nonradiolabeled compounds (Figure 2). These
results supported a mechanism involving the elimination of the
acyl sulfonamide group, with Ser241 attacking the “upper”
carbonyl that is adjacent to this group.
However, molecular docking suggested a completely different
scenario. In fact, on the basis of the representative poses, i.e.,
those forming the best ligand-protein polar interactions and
endowed with the most favorable binding energies, both
AGN220653 and AGN220346 share a similar energetically
favored pose within the FAAH binding site (Figure 3a). In this
pose, the carbonyl group is close to Ser241 and the group inter-
acting with the oxyanion hole is, instead, the carboamide, that is,
the one in the “lower” chain of the compounds.
As shown in Figure 3b, neither the cis nor the trans confor-
mations of the sulfonamide group affect the overall arrangement
of the two ligands, supporting the binding mode prediction.
Accordingly, the cyclohexyl-butyl chain and the oxazole moiety
were hosted in the acyl-binding pocket (ABP) and in the cyto-
solic port (CP), respectively, and the sulfonamide group pro-
truded toward the protein surface, thus being too distant from
the active site. Intriguingly, the only potential cleavage site on
the inhibitor that is compatible with such orientation is, quite
unexpectedly, the bond between the carbonyl group and the
oxazole moiety. The attack by Ser241 on this carbonyl group and
the subsequent, and quite unexpected, cleavage of the C−C
bond instead of the “upper” amide bond, would still explain the
autoradiography results.
Mass Spectrometric Characterization of the AGN220653
Moiety Covalently Binding to FAAH. To gain experimental
evidence in favor of this unexpected mechanism for FAAH
reaction with AGN220653, we first verified the formation of
the hypothesized adduct between Ser241 and the inhibitor
by means of MALDI mass spectrometry analyses. MALDI
mapping of purified humanized FAAH-AGN220653 tryptic
hydrolysate covered more than 82.4% of the amino acid
sequence. This, most interestingly, included a signal occurring
at m/z 2851.87, corresponding to the FAAH peptide including
the 213−243 amino acids (and containing Ser241), bound
with the cyclohexyl-butyl-carbonyl group (Δ = 181.17), as
compared to the expected value Δ = 181.27), as shown in
Figure 4).
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This finding confirmed the cleavage of AGN220653 according
to the new mechanism. It is worth noting that a signal at m/z
2670.70, corresponding to the unmodified tryptic peptide, was also
identified, whereas the putative adduct resulting from the
“classical” cleavage mechanisms, corresponding to the elimination
of the acyl sulfonamide group and the labeling of the 213−243
FAAH peptide with the remainder of the molecule (m/z =
3182.75), was undetectable (Figure S3). In order to unequivocally
detect the modified Ser241, a multiple reaction monitoring
(MRM) tandemmass spectrometry experiment, using an ion spray
source operated in positive mode, was set up to monitor the
modified 213−243 FAAH peptide. Selected transitions and pre-
cursor ion-daughter ions for the 213−243 FAAH-AGN220653
peptide were obtained using the Skyline software. MRM analysis
revealed the presence of the adduct between the enzyme and the
cyclohexyl-butyl-carboxyamide portion at the level of Ser241
(Figure 5). These findings confirm the unprecedented C−C bond
cleavage by FAAH subsequent to the enzyme nucleophilic attack
on the carbonyl group adjacent to the oxazole moiety.
AGN220653 Interaction with FAAH Reveals a Non-
amidase Mechanism of Action for the Enzyme. Since the
mechanism suggested by the above experiments implies the
cleavage of a theoretically very stable C−C bond, further sup-
port of this hypothesis was sought from computational techniques.
Because of the varied catalytic behavior and inhibition mecha-
nisms of FAAH and the number of enzyme residues affecting
it,1,4,11 several methodological approximations and simplifications
are mandatory to successfully apply computational methods to
this complex protein and its complexes. As a consequence, many
different approaches have been developed and applied12 to
optimally target specific structural or functional features of the
studied systems.
In the case of the FAAH-AGN220653 complex, we sought for
a Quantum Mechanical (QM) computational approach (I)
Figure 1. (a) AEA levels (pmol/g of wet tissue) in mouse brains treated with AGN220653 (3 mg/kg, i.p.) for different time points (30 min, 1 h, 4 h,
and 24 h). Data are expressed as mean± SEM (n = 4 per group). Student’s t test *p < 0.5; **p = 0.0079 was performed for treated vs untreated samples
at each time point. (b,c) Effect of AGN220653 (1, 2, and 3mg/kg, i.p.) alone or in combination, at the dose of 3 mg/kg, with AM251 (1mg/kg, i.p.) or
AM630 (1 mg/kg, i.p.) in formalin-injected mice. The total time of the nociceptive response was measured every 5 min and expressed as the total time
of the nociceptive responses in minutes. Results are mean ± SEM (n = 6−8 for each group). (d) Effect on spontaneous pain behavior after
subcutaneous injection of PGE2 (10 μg/20 μL/paw) or PGD2 (150 μg/20 μL/paw) or selective DP1 receptor agonist BW245C (200 μg/20 μL/paw)
in the presence of vehicle (0.5% DMSO in saline, i.p.) or AGN220653 (3 mg/kg i.p.). The total time of the nociceptive response was measured within
20 min and expressed as percentage of PG-induced effects (100%). Results are mean ± SEM (n = 6−8 for each group). Plus signs (+) denote
statistically significant differences (P < 0.05) vs vehicle, and asterisks (*) denote statistically significant differences (P < 0.05) between each group and
relative control (one-way ANOVA, Tukey’s post hoc). (e) Selectivity profiles of AGN220653 (0.01−0.1−1−10−30−50 μM), as judged by
competitive ABPP analysis in the rat brain membrane proteome. (f) Bars represent densitometric analysis of band intensity for AGN220653 effect (0−
50 μM) on FAAH activity in the rat brain membrane proteome. Results represent the average values ± SEM of three independent experiments.
Student’s t test (*p < 0.05; **p < 0.001) was performed for inhibitor versus vehicle (DMSO) treated samples.
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providing a satisfying structural description of a model system
comparable to that under investigation; (II) reproducing the
functional behavior of the model system; (III) correctly
predicting the lack of C−C bond cleavage in a negative control
system similar to the complex under investigation; and (IV)
providing results substantially independent upon the exact
choice of QM methods/setups within a reasonable range of
conditions, with the latter being another important criterion to
evaluate the results on a new, unexpected mechanism.
The first step in the choice of the methods and the definition
of the systems to be simulated is the selection of a system to be
used to guide and validate the system setup according to the
above-defined criteria (I)-(III). AGN220653 arrangement in
FAAH active site, as assessed in docking experiments, closely
resembles that found in PDB entry 2WJ1 for the complex
between FAAH and α-ketooxazole inhibitor (therein named
“S99”), where a slowly reversible covalently bound tetrahedral
intermediate (TI) is formed.13 However, while bearing an
oxazole moiety like AGN220653, S99 features a simple carbonyl
instead of an amide group, with a different attachment to the
oxazole ring (C2 atom vs C4 in AGN220653). In this view,
the FAAH-S99 complex, in addition to guide the choice of the
computational methods and opportunely size the system to be
studied, was also employed to validate the computational
approach and study the structure−activity relationships of these
compounds. In particular, since no C−C bond cleavage is
experimentally observed for FAAH-S99 complex, we reasoned
that this can also represent the proper “negative control”
necessary to test possible biases of the selected computational
protocol toward C−C bond cleavage (criterion III).
To derive aQMmodel,we subdivided the ligand in four regions,
including atoms: a) contacting FAAH residues substantially con-
tributing to enzyme activity in experimental/computational
studies11 (labeled in bold magenta in Figure 6a); b) forming
interactions rigidly or semirigidly anchoring the ligand to the
protein in regions adjacent to a); c) contacting the protein in
points distant from a) region; d) forming week or no interaction
with FAAH. Only ligand atoms in regions a) and b) were
retained (Figure 6b), together with the corresponding con-
tacting residues or side chains, shown in Figure 6a. The selected
Figure 2. SDS-PAGE of purified humanized FAAH (Medicilon, Ltd., Shangai, China) incubated with AGN220653 or AGN220346 showing
14C-radiolabeling of cyclohexyl-butyl amine (@) and sulfonamide (#) groups. Purified FAAH incubated either with or without radiolabeled compound
in the absence or presence of nonradiolabeled compound and subjected to SDS-PAGE before exposure to the radiographic film. Protein ladder (left),
the position of FAAH, and unbound radiolabeled compound (free probe) are indicated.
Figure 3. (a) Representative docking model of the FAAH (gray ribbons)-AGN220653cis complex (stick ligand, ligand-contacting (<4 Å) side chain
and oxyanion-hole backbone bonds, with green C atoms and other elements in standard colors). C atoms colored cyan/magenta/pink for catalytic-
triad/oxanionic-hole/other residues. (b) Ligand superposition from FAAH complexes of AGN220653cis (green), AGN220653trans (light-green),
AGN220346cis (pink), and AGN220346trans (dark magenta).
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protein residues include all the FAAH residues identified by
Chudyk et al.11 as critical or relevant for FAAH activity. A notice-
able feature is that Ser193, the only (moderately) important
residue in ref 11 not forming relevant contacts with S99, will show
its importance for the C−C bond cleavage in FAAH-
AGN220653. The only significant exception to this set is
represented by Arg243, critical to ensure the proper charge and
orientation of Asp237, in turn required to obtain the right
structure and reasonable energies for ligands in the oxanionic
hole (Ile238-Gly239-Gly240-Ser241). This feature was also
Figure 4. Partial MALDI-MS spectrum of th e tryptic digest of rhFAAH incubated with AGN220653 highlighting the peptides corresponding to the
unbound (a) and bound (b) state.
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confirmed by preliminary calculations on either the nonbonded,
or the covalently bonded form of the FAAH-S99 complex (not
shown). In both cases, the ligand carbonyl oxygen atom was
unable to assume the right position inside the oxanionic hole
when Asp237 was omitted, misoriented, or set in its charged
form in the absence of Arg243. These calculations showed that
the electronic and geometrical effects of the Arg residue can be
recovered by adopting a protonated form for Asp237 side chain
and restraining its torsional degrees of freedom (four dihedral
constraints, with ending atoms enclosed in a yellow area in
Figure 6a). In this view, Arg243 and Asn498 were deleted from
the truncated protein model (named FAAHT). FAAHT forms
exhibiting neutral Lys142/Ser241 or protonated Lys142/
deprotonated Ser241, i.e., corresponding to the end states of
the FAAH catalytic proton relay, are indicated as nFAAHT
and cFAAHT, respectively. Further details on the models are
described in Methods. The “truncated” model of the S99 ligand
from PDB: 2WJ1 was named S99T. FAAHT-S99T included 262
atoms (124 heavy atoms, see Figure 6c). Similarly, a reduced
model of the ligand was named AGN220653T. The FAAHT-
AGN220653T complex included 270 atoms (126 heavy atoms).
The large size of the QM systems to be simulated required
some compromise between the QM level adopted to describe
the atoms and the completeness of the approach used to sample
the potential energy surface of the systems. In this case, because
of the four criteria described above, and in the absence of quanti-
tative data on energetics and kinetics of FAAH-AGN220653, we
decided to maximize the QM level, while employing simple
unidimensional (and limited bidimensional) adiabatic mapping
(AM) scans of the main degrees of freedom of the three reaction
steps under investigation: Ser241 → Ser217 → Lys142 proton
transfer; Ser241 Oγ → AGN220653 carbonyl-C nucleophilic
attack with tetrahedral covalent intermediate (TCI) formation;
and AGN220653(C4) protonation by Ser217(Hγ) with
simultaneous AGN220653 C4-carbonyl C bond-breaking and
final carbamate formation. This choice limited the number of
degrees of freedom systematically explored, the characterization
of their couplings and the completion of such explorations.
Figure 6. QM model of FAAH-complexes: truncated FAAH (FAAHT, panel a), AGN220653 (AGN220653T, panel b), and S99 (S99T, panel c)
structures used in QM calculations are shown omitting nonpolar hydrogen atoms. FAAH residues substantially contributing to enzyme activity in
experimental/computational studies are labeled in bold magenta. Cyan and green lines delimit atoms described by “improved” and “maximum” basis
set functions, respectively. The area enclosing Asp237 side chain atoms with restrained torsional angles is colored in yellow. Positionally restrained C
atoms are marked with magenta circles, when also the three dihedral angles ending on the three H atoms adjacent to the marked atom are restrained, or
dark green squares, when only the position of the C atom is fixed.
Figure 5.Multiple reactionmonitoring tandemmass spectrometry analysis performedon the trypsin digest of FAAH incubatedwithAGN.The transitions
and the mass spectral parameters used for the selective isolation of modified FAAH peptide 213−243 are reported in the inset. The MRM current
corresponding to the transitions detected for the peptide 213−243 carrying the AGNmoiety at level of Ser241 and coeluting at r.t. for 2.80min is reported.
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In this view, no dynamic study of the system was attempted, and
only an approximation to the “real” energy barriers and intrinsic
reaction coordinates was obtained. The implications of such
approach for the different degrees of freedom involved in the
three steps are discussed in the “Quantum Mechanics (QM)
Calculations” section of the Supporting Information (page S8).
While the exact QM setups for the different methods and
protocols are described in Methods, a noticeable feature of our
models is the adoption of three levels of basis set functions in
DFT+D3 calculations: “standard”, for atoms only contributing
to the overall system stability and ligand orientation within the
site; “improved”, for atoms forming relevant polar protein−ligand
interactions; and “maximum”, with inclusion of diffuse func-
tions, for atoms potentially involved in the reaction mechanism,
possibly bearing at some stage a negative charge surplus. The
assignment of the different protein and ligand atoms to the three
groups is shown in Figure 6 where cyan and green lines delimit
atoms described by “improved” and “maximum” sets, respectively,
and listed in Methods, where the different basis sets are also
described. Note that for S99 complexes, atoms from oxazole and
the adjacent 2-pyridyl group were included in the “maximum” set.
The reference calculations fully validated the required features
of the computational approach of the system both functionally
and structurally. Functionally (criteria II and III): in fact, S99T,
in perfect agreement with available data, easily produces a
covalent unreactive complex with FAAH, whose formation
already starts at the end of the relay protein transfer stage of the
FAAH catalytic mechanism. In particular, AM calculations on
the nFAAHT-S99T complex showed an intramolecular proton
transfer to cFAAHT associated with a very small energy barrier
(1−2 kcal mol−1) and, already before the end point, a barrierless
addition of the nascent−O−moiety of S241 to the S99T carbonyl
C atom. This process led to the formation of the experimentally
observed tetrahedral covalent adduct,13 characterized by an
oxyanion O ligand atom stabilized by its interaction with the
protein oxyanion hole. The exploration by AM of a possible
further step in FAAH-S99 reaction involving cleavage of the C−C
bond between the ligand oxazole ring and carbonyl group resulted
in a high estimated barrier (about 45 kcal mol−1) and a final
dissociated system less stable than the covalent adduct (ΔE =
11.7 kcal mol−1 in MixBasSV/MixBasSV, 7.5 kcal mol−1 in
DLPNO−CCSD(T) cc-pVTZ/MixBasSV, see Table 1). Struc-
turally (criterion I): in fact, the final complex fits the
corresponding experimental structure (PDB: 2WJ1), with a
rmsd of less than 0.3 Å on all heavy atoms excluding side chain
atoms beyond Cβ of “frontier” residues Phe192 and Leu278 and
the last three atoms of the residual aliphatic chain of S99T (thus
including 114 heavy atoms out of 124). In addition, except for
two backbone oxygen atom (belonging to Gly239 and Gly268)
and protruding out the simulated region (pointing toward
FAAH counterparts missing in the truncated model), no atom in
the FAAHT selected set was distant more than 0.4 Å from its
FAAH counterpart.
Consequently, we applied the same AMprotocol to nFAAHT-
AGN220653T complex, adopting the “reaction coordinates”
described and illustrated in Figure 7 for the AM scans, obtaining
a substantially different picture of the evolution of the two
complexes. In fact, AGN220653T gives rise to an unstable TI
that undergoes dissociation of the carbonyl-4-oxazole bond,
producing a slowly hydrolyzable carbamate derivative of Ser241,
with elimination of the substituted oxazole ring (Figure 7).
In particular, the proton transfer, monitored using the Ser241
Hγ−Ser241 Oγ distance as reaction coordinate (distance d1 in
Figure 7a), exhibited a barrier of about 5 kcal mol−1. The
cFAAHT-AGN220653T minimum was about 3 kcal mol−1
higher in energy than the starting structure (Figure 7d) and
did not show any spontaneous tendency to evolve into the
covalent adduct (Figure 7e). The latter, in turn, as resulting from
AM scan of the Ser241 Oγ−AGN220653T carbonyl C distance
(distance d2 in Figure 7b), resulted about 9 kcal mol
−1 higher in
energy than the starting structure (and 4 kcal mol−1 higher than
cFAAHT-AGN220653T), with a barrier of about 10.5 kcal mol−1
over the starting structure (5.5 kcal mol−1 over cFAAHT-
AGN220653T). This marginally stable structure can either
revert to the nonbonded complex, or slowly evolve toward the
“dissociated” form (Figure 7f) hypothesized from isotopic
labeling experiments and docking, which is about 2 kcal mol−1
lower in energy than the starting nonbonded complex. The
dissociation occurs by protonation of the C4 oxazole atom of
AGN220653T by Ser241 Hγ, (distance d3 in Figure 7c) and
simultaneous breaking of the oxazole C4-amide C bond
(distance d4 in the same figure), accompanied by a back-transfer
of the proton from Lys142 to Ser217 (pink and magenta lines/
bonds in figures) and rotations of oxazole ring and the amide
moiety of the carbamate group resulting after dissociation. This
latter motion, in particular, results in the formation of a stabi-
lizing H-bond between ligand amide H and Ser193 backbone
O atoms (red dashed line in Figure 7f). This interaction
contributes by about 2−3 kcal mol−1 to the overall stability of
the dissociated form, as estimated by comparison with other AM
Table 1. Energetics of the Main Minima of FAAHT-AGN220653T and FAAHT-S99T Complex QM Modelsa
system QM setup
ΔE(MinNBneu)
(kcal mol−1)
ΔE(MinNBchg)
(kcal mol−1)
ΔE(MinCB)
(kcal mol−1)
ΔE(MinDis)
(kcal mol−1)
FAAHT-AGN220653T MB-SV/MB-SV 1.8 4.9 11 0
MB-TZ/MB-TZ 4.3 nc nc 0
EMBTZVPP/MB-SV 1.3 nc nc 0
EMBTZVPP/MBTZ 2.3 nc nc 0
DLPNO-CCSD(T) cc-pVTZ/
MB-SV
3.1 9.4 13.5 0
FAAHT-S99T MB-SV/MB-SV 15.6 uns 0 11.7
DLPNO-CCSD(T) cc-pVTZ/
MB-SV
16.5 uns 0 7.5
aEnergy differences (ΔE, in kcal mol−1) calculated from the minimum of each structure set for a given QM setup (energy calculation/geometry).
MB-SV and MB-TZ indicate “MixBasSV” and “MixBasTZ” setups, respectively. MinNBneu, MinNBchg, MinCB, and MinDis indicate nFAAHT-
LigT noncovalent, cFAAHT-LigT noncovalent, cFAAHT-LigT covalent, and nFAAHT-LigFragT covalent + LigLGT complexes, respectively (“Lig” =
“AGN220653” or “S99″, “LigFrag” = ligand fragment still covalently bonded to FAAH after elimination of the LigLG protonated leaving group),
nc = not calculated, uns = unstable.
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calculations ending with the ligand amide NH pointing toward
Met191 backbone O atom, with formation of a weaker,
suboptimal H-bond. Interestingly, this stabilizing interaction
for the final carbamate is also found in PDB entry 3LJ7, an
experimental structure featuring a carbamate adduct on FAAH
Ser241. However, the influence of this interaction on energy is
already seen during C−C bond cleavage, since it also reduces the
barrier of a comparable amount to that found on final minima in
comparison with the aforementioned calculations in which the
ligand amide moves toward Met191 backbone.
The upper limit to the energy barrier predicted for C−C
bond dissociation in TI (turquoise dashed line in Figure 7c),
amounts to about 25 kcal mol−1, but about one-third of it (i.e.
10 kcal mol−1) is just required to reduce the relatively large
distance between HO217 and C4 atoms (rHC) in the starting
structure (∼2.8 Å) to 2.0 Å, where they really start to interact.
Since we expected that, similarly to anandamide, this kind of
distance reduction14 or a distortion from planarity of the center
adjacent to the ligand carbonyl group15,16 could further reduce
the barrier, we investigated if overall protein motions at room
temperature could reduce rHC and/or decrease the planarity
around C4. These motions involve the whole (dimeric) protein,
depend on FAAH embedding into cell membrane, and occur on
a relatively large time scale (>10−9 s). Therefore, we recurred to
standard classical molecular dynamics (MD) of a covalently
bonded complex of the AGN220653 fragment used in QM
calculations with each monomer of FAAH dimer embedded in
membrane and solvated.
The MD trajectory resulted quite stable in terms of backbone
fluctuations both of the overall dimeric structure (Figure S3a) and
of each FAAHmonomer over itself (Figure S3b) or over the other
monomer (Figure S3c), as well as for the embedding of the
transmembrane helix in the lipid bilayer (Figure S3d). This result
shows that neither large interdomain relative motions, nor overall
major drifts or rearrangements occurred over the simulated time.
Figure 7. (a−c) QM reaction curves for Ser241→ Ser217→ Lys142 proton transfer (a), Ser241 Oγ→ AGN220653T carbonyl-C nucleophilic attack
(TCI formation) (b), protonation of AGN220653T(C4) by Ser217(Hγ), simultaneous AGN220653
T C4-carbonyl C bond-breaking and final
carbamate formation (c). Energy differences (kcal mol−1) calculated from the starting structure of eachmap. Themost-representative distances used as
“reaction coordinate”: Ser241(Hγ)−Ser241(Oγ) (d1, orange label/“springs”) (a), Ser241(Oγ)−AGN220653T(carbonyl C) (d2, dark-green label and
distance dashed-line plus transparent stick/opaque stick→ before/after full covalent-bond formation) (b), Ser217(Hγ)−AGN220653T(C4) (d3, dark-
blue label and distance dashed-line plus transparent stick/opaque stick → before/after full covalent-bond formation), plus AGN220653T(C4)−
(carbonyl C) (d4, green label, plot line and distance opaque stick/dashed-line plus transparent stick→ before/after full covalent-bond breaking), where
dashed-lines remark that no simple “reaction coordinate” exists for this step, the curves resulting from several one-/two-dimensional scans on d3 and/or
d4 (c). Other relevant distances: Lys142(Nζ)−(H) (pink), Lys142(NζH)−Ser217(Oγ) (magenta), Ser217(Oγ)−(H pointing toward
AGN220653T(C4)) (medium-blue). Ligand plus FAAH catalytic-triad side chains/other bonds shown as sticks/lines. Gray dash-and-dot/solid
lines show the QM energy vs d3/d4 vs d3 profiles for calculations started from the selected MD frame of the TCI complex. (d−f) detail of starting
noncovalent (d), the unstable TCI (e) and the final dissociated (f) complexes. Representation details: stick bonds (bold: ligand and water); ligand/
other C atoms colored cyan/very-light-blue; relevant distances, bonds and H atoms: see panels (a)−(c).
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However, local breathing motions are observed, also involving
the active site region. The resulting 400 ns MD trajectories show
that thesemotions also affect ligand-protein interatomic distances.
In particular, in∼10% of the sampled structures rHC is significantly
shorter (2.4−2.6 Å) than in our starting model, in ∼1% it is very
short (2.2−2.4 Å) and in ∼0.1% it is shorter than 2.2 Å. In addi-
tion, several structures with rHC < 2.2 Å also exhibit a significant
distortion (12°) of the planarity around C4 (Figure 8a,b). This
distortion can be attributed to the relative higher rigidity of the
residues involved in the oxyanion hole (Ile238-Gly239-Gly240-
Ser241), through a close contact between AGN220653T C4
atom and Ile238 side chain. When the site-shrinking motions of
the rest of the active site are propagated to the ligand, reducing
the rHC distance by up to 0.8 Å, AGN220653
T is unable to
further transmit the motion to the close-contacting side chain of
Ile238. The latter, in fact, is already at van der Waals distance
from C4 (maximum distance decrease of about 0.2 Å) and can
just undergo a limited rotation, which, however, only cyclically
permutes over time the specific Ile238 atom in closest contact
with AGN220653T C4 among CG1, CD1, and CG2, thus
preserving the steric interaction with C4 atom during the whole
MD simulation (Figure 8c,d). Globally, this stable interaction
determines a deformation of AGN220653T ring, Ile238 side
chain behaving like a rigid “anvil” and the rest of the site acting as
a “hammer” hitting AGN220653T oxazole ring at C4 atom, thus
distorting it from planarity.
QM energy minimization (EM) of the MD structure with the
shortest rHC distance confirmed the deformation of the oxazole
ring observed in MD (Figure 8). Application of the above
QM protocol to this EM structure reduced the barrier by
∼10 kcal mol−1 (Figure 7f) and confirmed that Ile238 side chain
facilitates C−C bond cleavage by pushing the oxazole ring
toward Ser217 HO atom and deforming it (Figure 8b).
EM and single-point calculations on the main FAAHT-
AGN220653T and FAAHT-S99T minima performed with larger
basis sets or higher levels of theory (Tables 1, S4, and S5) fully
supported the MixBasSV/MixBasSV results so far discussed,
showing a substantial independence of the overall predicted
behavior of AGN220653 and S99 from the specific QM setup,
thus satisfying criterion (IV) for the computational approach. In
particular, relative energies (Table 1) are very moderately (less
than 4 kcal mol−1), and geometries (Table S5) are only margin-
ally (less than 0.12 Å), affected by increasing basis set size, as
shown by the comparison of energies and atom rmsd values
between the MixBasSV/MixBasSV and MixBasTZ/MixBasTZ
calculations in Tables 1 and S5, or by energies between the
values calculated with EMBTZVPP basis sets on either
MixBasTZ or MixBasSV geometries. Even moving to higher
levels of theory, relative energies are still scarcely affected (less
than 4 kcal mol−1) (comparison of DFT+D3 with DLNPO-
CSSD(T) results). These results are confirmed by those on
FAAHT-S99T, where a difference of 3.4 kcal mol−1 is observed
for the relative stability of covalent vs nonbonded complexes.
Thus, the tendency of FAAHT-AGN220653T to dissociate
cannot be apparently ascribed to biases in the computational
procedures, since FAAHT-S99T, in perfect agreement with
experimental evidence, exhibits a considerable preference for the
TCI form vs the nonbonded complex and no tendency to
dissociate, and these trends are even more pronounced when
considering the results at the higher level of theory (CCSD(T)).
In summary, the overall picture of the reactive behavior of the
FAAH-AGN220653 complex emerging from the QM analysis
(Figure 9) is in agreement with the biochemical, docking, and
MS data presented above, and shows the initial formation of a
noncovalent protein−ligand interaction in the FAAH binding
site. As suggested by docking, the oxazole ring occupies a region
and exhibits an orientation in the cytosolic port similar to the
corresponding groups in ketone FAAH inhibitors OL-135/S99,
and the adjacent amide group and hydrophobic tail dock in the
acyl-binding pocket. This initial arrangement is rather stable, but
can slowly evolve toward dissociation according to a “substrate-
like” mechanism, albeit involving the atypical oxazole leaving
group. The instability of the “reversible-like” FAAH-AGN220653
tetrahedral covalent intermediate, in spite of the apparent strong
similarity with the structure observed in FAAH-S99, mainly
depends on the presence of an amide group. This implies the
destruction of the amide conjugation upon formation of the TCI,
associated with a high energetic cost, increased by minor con-
tributions from less-favorable steric interactions determined by
the different oxazole attachment between AGN220653 and S99.
Thus, the unstable TCI can dissociate with the assistance of
Ser217 (and the final contribution of Ser193 backbone O atom
described above), resulting in the prediction of an overall
energetically favorable process. It is noteworthy that these QM
results have been obtained in spite of the very conservative con-
ditions adopted in the computational approach. In particular,
favorable entropic and enthalpic effects expected after departure
of the dissociated substituted oxazole from the final QM
complex have not been accounted for, and the coupling between
the motions of the QM-simulated region and the overall enzyme
has been only partially characterized by MD plus QM
Figure 8. Influence of protein motions on the structure of FAAH-
AGN220653T TCI complex. Details of the structures of QM-refined
FAAH-AGN220653T TCI complexes obtained from the selected
docking model (a) and “shrunk-site” frame of MD simulation (b) show
the variation in distances between AGN220653T(C4) and either
Ser217(Hγ) or Ile238(Hγ21) atoms. The distortion of the planarity of
the oxazole ring at C4 on going from panel (a) to (b) is highlighted by
trasparent magenta discs enclosing the ring plus directly bonded atoms
except C4. Ser217, Ile238, and Ser 241 side chain bonds, the
corresponding Cα atoms, AGN220653
T bonds are represented as
thick sticks, spheres, and thin sticks, respectively. The constant presence
of a close contact between AGN220653T(C4) and Ile238 side chain is
shown by the time-series of the distances between AGN220653T(C4)
and either Ile238(Cδ1) (red), Ile238(Cγ1) (blue), or Ile238(Cγ2)
(green) atoms for FAAH A (c) and B (d) monomers from the MD
trajectory of the dimeric FAAH-AGN220653T covalent complex.
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calculations. This coupling typically helps the reactions by
“shrinking” the paths associated with the highest energy steps14
and/or decreasing the planarity of unsaturated groups therein
involved,15,16 thus decreasing the corresponding energy barriers.
■ CONCLUSIONS
The catalytic mechanism of FAAH is unique. Rather than the
more common serine−histidine−aspartate triad found in
classical serine hydrolases, it involves a catalytic triad consisting
of two serine residues and one lysine residue.1 Amultitarget drug
containing a carboxyamide-4-oxazole moiety was found here to
exhibit inhibition of FAAH by exploiting a novel catalytic
mechanism of this enzyme. Catalytic promiscuity, i.e., the ten-
dency to catalyze different reactions with the same machinery,
depends on (1) the ability to bind different substrates, (2) the
requirements of these substrates for different chemistry, and
(3) changes in hydrogen bond partners or Bronsted acids/bases
in the active sites, which create new binding pathways.17 From a
mechanistic point of view, the unique scaffold of AGN220653,
with its “swapped substrate” amide configuration, in which the
alkyl chain is bound to the amide nitrogen rather than the car-
bonyl atom as in FAAH substrates, resembles that of previously
reported carbamate or urea FAAH inhibitors. These compounds
also behave as slowly reversible inhibitors.18,19 However, in
AGN220653, the amide carbonyl group is also bound to a
carbon instead of the heteroatom (O or N) that provides a good
leaving group in the carbamylation step of the FAAH inhibition
mechanism followed by ureas or carbamates. The occurrence of
a CO-C bond in this “swapped substrate” motif also recalls
reversible ketone FAAH inhibitors, in which, however, the
carbonyl group is involved in two CO−C bonds.13 Thus, while
the new motif was likely to interact with FAAH, its mechanism
of action was not easily predictable in advance.
Indeed, the operating mechanism of FAAH on AGN220653
reported here following the use of a variety of biochemical,
computational, mass spectrometric, and quantum mechanics
methodologies is quite different from the one normally used by
the enzyme on its substrates or most of its inhibitors. We
propose that this difference is due to two main related reasons:
(1) the substrate exhibits an opposite orientation of its amide
bond within the site in comparison with conventional substrates;
and (2) as a consequence, the resulting mechanism now requires
the protonation of the oxazole C4 atom, an acceptor of the
Ser217 proton far less effective than the nitrogen atom typically
involved. These findings expand to a new level the already wide
array of catalytic capabilities of serine hydrolases and amidases,
particularly of an atypical one such as FAAH. They illustrate a
case in which the structural features and working mechanism of
the “enzyme machinery” override the binding and reactivity
propensities of the substrates, resulting in the unusual cleavage
of the C−C bond of the substrate-inhibitor. An alternative
interpretation from the “ligand’s point of view” is that, while
many inhibitors work by counteracting/blocking FAAH
catalytic mechanism at the early binding or covalent adduct
stages, AGN220653 instead acts by “seconding” it down to the
substrate protonation and dissociation step, albeit with a
noncanonical orientation within the binding site. This results
in the overall reduction/temporary block of FAAH activity
through the formation of a slowly hydrolyzable covalent final
derivative.
Serine hydrolases with “classical” serine−histidine−aspartate
catalytic triads are not new to catalyze the hydrolysis of C−C
bonds.17,20 Thus, it is perhaps not too surprising that FAAH,
although being characterized by an unusual catalytic triad, is also
able to use such a mechanism of action. Nevertheless, given the
crucial role of this enzyme in controlling the levels of neuroactive
mediators such as the endocannabinoids, theN-acylethanolamines
Figure 9. FAAH-AGN220653 reaction scheme up to carbamate formation and detachment of the substituted oxazole. The relevant FAAH side chain/
backbone atoms and ligand AGN220653T fragment are shown. Lines represent FAAH oxyanion hole (blue) and active site walls before (magenta) and
after (purple) the site “shrinkage” recurring in MD simulations (pink-to-purple concentric lines).
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and other long chain fatty acid amides, including the recently
discoveredN-oleoyl-glycine,21 the present findings have obvious
implications for the development of new inhibitors of potential
therapeutic importance for the treatment of neuropathic pain
and neuropsychiatric and neurological disorders.
■ METHODS
Chemical Synthesis. Molecules were synthesized at Selcia
Laboratories (Ongar, Essex, United Kingdom) starting from the
oxabicycloheptane scaffold as previously described.8 Selcia Laborato-
ries also performed the [14C]-labeling of compounds. Further details on
chemical syntheses as well as compound characterization data by mass
spectrometry and NMR are available in the Supporting Information.
In Vitro Analyses of Inhibitor Potency on Different FAAH
Preparations. AEA hydrolysis was measured by incubating the
compounds with different enzyme preparations (10 000g membrane
fraction of rat brain [70 μg per sample], rat basophilic leukemia cells
[RBL-2H3, 100 μg per sample], ormice neuroblastoma cells [N18TG2,
100 μg per sample]). Two commercially available enzymatic sources,
the human recombinant FAAH (Cayman, 2 μg per sample) and the
custom and highly purified humanized FAAH (Medicilon, Ltd.,
Shangai, China 0.2 μg per sample) were tested. Compounds were
incubated with the enzyme in Tris−HCl 50 mM, at pH 9.5 at 37 °C for
30 min, with synthetic N-arachidonoyl-[14C]-ethanolamine (55mCi
per mmol, ARC St. Louis, MO) properly diluted with AEA (Tocris
Bioscience, Avonmouth, Bristol, UK). Reactions were blocked by
organic extraction with ice-cold chloroform/methanol (1:1, vol:vol),
and the aqueous phase containing [14C]-ethanolamine produced by
AEA hydrolysis was measured by scintillation counting. For time-
course experiments, compounds were preincubated 20 min with FAAH
(rat brain membrane) before the addition of the [14C]-substrate. After a
further 30 min incubation, AEA hydrolysis was measured as previously
described.22 In a different set of experiments rat brainmembrane (70 μg
per sample) was incubated in the presence and absence of increasing
concentrations of AGN220653, MAFP or URB-597 (10−50−100−
500−1000 nM) with N-arachidonoyl-[14C]-ethanolamine (55mCi
per mmol, ARC St. Louis, MO, USA) for different time points (0.5−
1−2−4−24 h). After each time point, the reaction was terminated by
organic extraction with ice-cold chloroform/methanol (1:1, vol:vol)
and the aqueous phase containing [14C]-ethanolamine was measured
by scintillation counting as above-mentioned. All data are expressed as
the concentration exerting 50% inhibition of [14C]-AEA hydrolysis
(IC50). Values indicate averages ± SD of three independent
experiments conducted in triplicate.
Competitive Activity-Based Protein Profiling (ABPP). Rat
brain membranes were prepared according to previously reported
methods23,24 and diluted to 1 mg/mL prior to use. Proteomes (50 μL)
were preincubated with either DMSO or 1−1000 nM concentrations
of inhibitor at 37 °C. After 20 min, fluorophosphonate-rhodamine
(FP-Rh) (1.0 μL, 50 μM in DMSO, a kind gift of Prof. Benjiamin
Cravatt) was added and the mixture was incubated for another 30 min
at 37 °C. Reactions were quenched with SDS loading buffer (12.5 μL,
5×) and run on SDS-PAGE. Following gel imaging, serine hydrolase
activity was determined by measuring fluorescent intensity of gel bands
corresponding to MAGL, ABHD6, and FAAH using ImageJ 1.43u
software.
Detection and Quantitation of Radiolabeled Complexes
between Inhibitors and Humanized FAAH by Autoradiogra-
phy. AGN 220653 and AGN 220346 were [14C]-radiolabeled as
above-described at the 1-position of the cyclohexyl-butyl amine
portion. The 1-position of the isopropyl group in AGN220346 and
phenyl group of the sulfonamide ring in AGN220653 were also [14C]-
radiolabeled. [14C]-AGNs (75000 cpm; 30 μM) with custom and
highly purified humanized FAAH (0.2 μg/s; Medicilon, Ltd., Shangai,
China, 5 min in 50 mM Tris-HCl buffer, pH 9.5) were incubated in the
presence and absence of an excess of the corresponding non-
radiolabeled AGNs (700 μM) in a final volume of 20 μL. Reactions
were terminated by boiling samples in SDS-sample buffer (5 min
95 °C). Denatured samples were next electrophoresed through a
10% SDS polyacrylamide gel and the gels were dyed with Comassie
Blue (45min) before a further incubation in a destaining-fixing solution
(Kodak; 45 min). In order to improve detection sensitivity, before
drying gels at room temperature, gels were exposed to Amplify
Fluorographic Reagent (GE Healthcare, Amersham; 30 min) and
finally to a radiographic film (Hyperfilm, Amersham) for 78 days at
−80 °C. Autoradiographic images were acquired by ChemiDoc (Bio-
Rad Laboratories).
Molecular Docking. Starting ligands geometries were built with
Ghemical 2.99.2,25 followed by energyminimization (EM) atmolecular
mechanics level first, using Tripos 5.2 force field parametrization,26 and
then at AM1 semiempirical level. For docking calculations, both cis
and trans conformations of the acyl sulfonamide group of AGN220346
and AGN220653 were taken into account. Docking studies were
performed with both AutoDock 4.227 and AutoDock Vina 1.1.228 by
using two crystallographic structures of FAAH, complexed with two
different inhibitors, namely, URB597 (PDB entry 3LJ7) and OL-135
isomer (PDB entry 2WJ1). UCSF Chimera 1.10.129 was used to add
hydrogens to protein structures, keeping the catalytic Lys142 in the
nonprotonated form. Both proteins and ligands were processed with
AutoDock Tools (ADT) package version 1.5.6rc1227 to merge non
polar hydrogens, calculate Gasteiger charges and select the rotatable
side-chain bonds. Protein side-chains of Phe192 and Met191 and all
rotatable bonds of both ligands weremade flexible. The grid for docking
evaluation with a spacing of 0.375 Å and 70 × 70 × 60 points, centered
on the catalytic site, was generated using the program AutoGrid 4.2
included in Autodock 4.2 distribution. A 100 molecular docking run
was performed adopting a Lamarckian Genetic Algorithm (LGA) and
the following associated parameters: 100 individuals in a population
with a maximum of 15 million energy evaluations and a maximum of
37 000 generations, followed by 300 iterations of Solis and Wets local
search. Default parameters were used for AutoDock Vina.
Quantum Mechanical (QM) Calculations. FAAH-Ligand
Reduced Complexes. To simulate the presence of the full protein
and to avoid end effects at the protein cut points, the position of the
terminal atoms of each sequence of the FAAHT model was rigidly
restrained. Thus, one positional (on C atom) plus three dihedral
(ending on the three H atoms) constraints were applied for each
terminal methyl group (magenta circles in Figure 6a), while only the
positional constraint was used for terminal methylene groups (dark
green squares in Figure 6a). The systems were completed by addition of
three water molecules from PDB 2WJ1, which are also conserved in
other FAAH-ligand complex experimental structures.
Setup and Protocol. QM calculations were run either at the DFT
+D3 level, i.e., DFT with inclusion of the DFT-D3 atom-pairwise dis-
persion correction according to the Becke−Johnson damping scheme
(D3BJ),30 or at the DLPNO-CCSD(T) level.31 The B3LYP func-
tional32,33 was used in DFT+D3. Calculations were run with ORCA
program (version 3.0.334 for DFT and 4.0.035 for DLPNO-CCSD(T)
calculations), and include single-point energy evaluation (DFT+D3 or
DLPNO-CCSD(T)), energy minimization (EM) (DFT+D3), and
adiabatic mapping (AM) approach of single geometric parameters with
full optimization of the remaining degrees of freedom, starting from
geometry and wave function of the previous scan point (DFT+D3).
DFT+D3 calculations were performed with different basis set
ensembles (Figure 6):
(i) “MixBasSV” featuring def2-SV(P)36−38 for “standard” hydrogen,
carbon, nitrogen, oxygen; def2-TZV(P)36,39 for “standard” sulfur; def2-
SVP39 for “improved” atoms (peptide −CONH− of Ser217, Ser218,
Thr236-Ile242, side chain−CH2OH of Ser218, side chain−COOH of
Asp237, side chain −CH2−NH2 of Lys142, βCH2 of Ser217 and
Ser241, βCH of Thr236); and ma-def2-SVP40 for the “maximum” set
(−OH of Ser217, Thr236, Ser241, AGN220653 amide −NHCO− and
oxazole atoms, and the water molecule H-bonded to Thr236).
(ii) “MixBasTZ” using the MixBasSV setup for “standard” atoms;
def2-TZV(d)36,39 for “improved”; and ma-def2-TZVP40 for “max-
imum” atom sets.
(iii) “EMBTZVPP”, ORCA 3.0.3 DefBas-3 (TZV(d) basis set)
setting36,39 for “standard” atoms; def2-TZVPP36,39,41 for “improved”;
and ma-def2-TZVPP40,41 for “maximum” atom sets.
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In DFT+D3 calculations, the RIJCOSX approximation42 was used to
the Hartree−Fock exchange term, employing the auxiliary basis sets
automatically set by ORCA.
For DLPNO-CCSD(T) calculations, since preliminary tests on
FAAH complexes performed at the “double-ζ” level with either
cc-pVDZ basis set43,44 alone or cc-pVDZ for “standard” and “improved”
atoms, plus aug-cc-pVDZ43,44 for the “maximum” set calculations
showed small differences between the results obtained with the two
setups, the final “triple-ζ” level calculations were run with the
cc-pVTZ43,44 set on all atoms.
For DLPNO-CCSD(T) calculations, only the resolution of identity
approximation for the resolution of MP2 integrals, mandatory in the
ORCA implementation of this method, was applied, using the corre-
sponding cc-pVnZ/C auxiliary basis set45 with n =D or T for double- or
triple-ζ functions.
The whole systems were “immersed” in a low polarity (chloroform)
implicit solvent bath, to simulate protein bulk effects. The COSMO46
and C-PCM47 implicit solvent implementations into ORCA were used
in DFT+D3 and CCSD(T) calculations, respectively.
Classic Molecular Dynamics (MD). System Preparation and
Parametrization. The modified residue (hereinafter termed SAG)
formed by truncated ligand AGN220653T covalently bonded to
catalytic Ser241 was fully optimized using the GAMESS program48 at
the Hartree−Fock level with STO-3G basis set and subjected to HF/6-
31G*/STO-3G single-point calculations to derive its partial atomic
charges by the RESP procedure.49 The dimeric X-ray structure 2WJ1
was completed with the residues encompassing the N-terminal
transmembrane helix (9−33) and the C-terminal residues (578−579)
by using the programModeller v9.15.50 The resulting protein complex,
after addition of all hydrogen atoms, underwent 500 steps of steepest
descent followed by 5000 steps of conjugate gradient EM, using ff14SB
version of AMBER51 force field for the protein and gaff parameters for
the ligand adduct.52 Then, the dimeric protein was embedded in a pre-
equilibrated POPC bilayer and solvated with TIP3Pwater molecules by
using the “Membrane Builder” plug-in available at the CHARMM-GUI
Web site (http://www.charmm-gui.org). Potassium and chloride ions
were added to ensure electric neutrality and to reproduce an ionic
strength of 0.15 M. Charmmlipid2amber.py script available in
AmberTools v16 was used to convert the resulting files to the Amber
Lipid14 force field naming convention.53
Setup and Protocol. StandardMD simulations were carried out with
Amber16 pmemd.cuda module.54−56 Temperature was controlled by a
Langevin thermostat using a coupling constant of 1.0 ps−1. Bonds
involving hydrogen were constrained using the SHAKE algorithm,57
thus allowing for a 2.0 fs time step. A 10.0 Å cutoff was adopted to
truncate van der Waals interactions. The particle mesh Ewald method
was used to evaluate electrostatic interactions. MD equilibration phase
was performed as follows: (i) 5000 steps of steepest descent followed
by 5000 steps of conjugate gradient EM with positional restraints
on protein complex using a force constant of 10 kcal mol−1 Å−2.
(ii) A heating phase from 0 to 100 K over 500 ps in the NVT ensemble
and from 100 to 300 K over 1 ns in NPT ensemble, harmonically
restraining the whole system (protein+lipid) using a force constant of
10 kcal mol−1 Å−2. The Langevin thermostat was used with the
Berendsen barostat58,59 with a target pressure of 1.0 bar and a relaxation
time of 1.0 ps. (iii) 25 ns NPT with positional restraints only on the
protein with a force constant of 5 kcal mol−1 Å−2, followed by 5 ns NPT
with positional restraints only on protein Cα atoms, to ensure the lipid
bilayer equilibration. MD production run was carried out in NPT
ensemble for 400 ns with the catalytic Lys142 in the protonated form.
Mass Spectrometric Analysis. PD-10 prepacked columnwas used
to desalt the solution, highly purified humanized FAAH (Medicilon,
Ltd., Shangai, China) labeled with AG220653, as described above, was
eluted in 10 mM AMBIC. Dried fractions containing protein were
dissolved in denaturation buffer: guanidine 6M, Tris HCl 0.3M, EDTA
10 mM at pH 8.0. Reduction was carried out by using a 10:1 DTT/
cysteine molar ratio. After incubation at 37 °C for 2 h, iodoacetamide
was added to perform carboamidomethylation using an excess of
alkylating agent of 5:1 with respect to the moles of thiol groups. The
mixture was then incubated in the dark at room temperature for 30 min.
The alkylation reaction was stopped by addition of formic acid, in order
to achieve an acidic pH. The product was purified by precipitation,
100 μL volume of sample was added with 400 μL of CH3OH, 100 μL of
CHCl3, and 300 μL of water. The resulting solution was centrifuged for
5 min at 12 000 rpm. The protein precipitated at the interface organic−
inorganic phases. The supernatant was removed, and 300 μL of
CH3OHwas added. The resulting solution was centrifuged for 5 min at
12 000 rpm, and the protein pellet it was clearly visible on the bottom of
the eppendorf. The supernatant was removed, and the sample was
dried. The samples were then diluted with ammonium bicarbonate
10 mM pH 7.5, and enzymatic digestion was carried out by addition of
trypsin at a 50:1 protein/enzyme mass ratio at 37 °C for 16 h. The
supernatants were then recovered by centrifugation, filtered on 0.22 μm
PVDF membrane (Millipore), concentrated, and purified using a
reverse-phase C18 Zip Tip pipet tip (Millipore). Peptides were eluted
with 20 μL of a solution made of 50% acetonitrile, 0.1% formic acid in
Milli-Q water and analyzed (1 μL) by matrix-assisted laser desorption/
ionization mass spectrometry (MALDI-MS). MALDI-MS was carried
out on a 4800 Plus MALDI TOF/TOF mass spectrometer (Applied
Biosystems, Framingham, MA) equipped with a nitrogen laser
(337 nm). The peptide mixture (1 mL) was mixed (1:1, v/v) with a
10 mg/mL solution of α-cyano-4-hydroxycinnamic acid in acetonitrile/
50mMcitrate buffer (70:30 v/v).Mass calibration was performed using
external peptide standards purchased fromApplied Biosystems. Spectra
were acquired using a mass (m/z) range of 400−4000 amu, and raw
data were analyzed using Data Explorer Software provided by the
manufacturer. Peptide mixtures were analyzed by MRM LC-MS/MS
analysis using a 4000 QTRAP system (AB SCIEX) equipped with a
HPLC EKsigent binary pump. For each run, 5 μL peptide mixture were
injected and separated on a HALO C18 column 2.7 μm, 90A, 1.0 ×
50mm(ABSCIEX,Milford,MA,) at 60 °Cwith a flow rate of 30 μL/min.
Peptides were eluted (starting 1 min after injection) with a linear
gradient consisting of eluent A (0.1% formic acid in water) and eluent B
(0.1% formic acid in 100%ACN) from 7% to 95% in 5min. The column
was re-equilibrated at initial conditions for 4 min with eluent A. MRM
mass spectrometry analyses were performed in positive ion mode.
Skyline Software drew the choice for the selection of virtual best
transitions and collision energy calculated to generate maximal
fragmentation intensities. The developed MRM method was used
with MRM detection window set to 0.5−1.6 min per peptide, the duty
cycle was set to automatic and dwell times were minimal 5 ms. Cone
voltage was set to 35 V. The mass spectral MRM parameters obtained
using software Skyline are reported in the Figure 5b.
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ABSTRACT: Knowledge of the nature of biofluids at a crime scene is just as important as DNA test to link the nature of the
biofluid, the criminal act, and the dynamics of the crime. Identification of methods currently used for each biological fluid (blood,
semen, saliva, urine) suffer from several limitations including instability of assayed biomolecules, and low selectivity and spec-
ificity; as an example of the latter issue, it is not possible to discriminate between alpha-amylase 1 (present in saliva) and alpha-
amylase 2 (present in semen and vaginal secretion. In this context, the aim of the work has been to provide a predictive protein
signature characteristic of each biofluid by the recognition of specific peptides unique for each protein in a single analysis. A panel
of four protein biomarkers for blood, four for saliva, five for semen, and two for urine has been monitored has been monitored by
using a single multiple reaction monitoring (MRM)-based method targeting concomitantly 46 different peptides. Then, The
optimized method allows four biological matrices to be identified when present on their own or in 50:50 mixture with another
biofluid. Finally, a valid strategy combining both DNA analysis and liquid chromatographic-tandem mass spectrometric multiple
reaction monitoring (LC-MS-MRM) identification of biofluids on the same sample has been demonstrated to be particularly effec-
tive in forensic investigation of real trace evidence collected at a crime scene.
In the last three decades the link between forensic inves-tigations and scientific disciplines, such as Chemistry and
Biology, has been enormously strengthened by the application of
new tools for a detailed characterization of the crime scene
starting from trace evidence. In particular, DNA testing is funda-
mental to identify the individuals involved in a crime often
leading the investigators to define a unique genetic profile.1
However, the detection and identification of the type and
origin of biofluids at a crime scene are just as important as DNA
test to link the nature of the biofluid, the criminal act and the
dynamics of the crime. For example, blood stains can indicate
some form of physical altercation, whereas detection of semen or
vaginal fluid can indicate the involvement of some form of sexual
encounter or assault. Moreover, identification of the specific fluid
or tissue from which the DNA sample was recovered is
fundamental in correctly reconstructing the criminal event and
the effective role of the donor.
The most common biofluids found at crime scenes are blood,
semen, and saliva, but others such as vaginal fluid, urine, and
sweat can also be found. Each of these fluids has one or more
presumptive tests that are initially used to give some indication as
to the identity of the substance; blood is quickly detected by
means of luminol or benzidine,2 whereas traces of semen, saliva,
sweat, urine, and other biological fluids are detected by ultraviolet
light or by other light sources at specific wavelengths.3 Confir-
matory tests, based on biochemical, spectroscopic, and
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microscopy methods, and immunochemical techniques, are
necessary to give a legal value to the trace evidence.4−9
However, these identification methods suffer from several
limitations including instability of assayed biomolecules and low
selectivity and specificity. As an example of the latter issue, it is
not possible to discriminate between α-amylase 1 (present in
saliva) and 2 (present in semen and vaginal secretion).10Moreover,
biochemical assays are specific only for one biological matrix and
several cascade tests might then be needed before the biological
nature of a certain stain is uncovered. This is even more chal-
lenging when the sample is a mixture of different biological matri-
ces thus greatly increasing the complexity, the cost and the time
of the analytical procedures. Finally, some confirmatory tests
very often cause sample loss and they are not compatible with
downstream individual identification by DNA analysis.
For all these issues, forensic science is looking for a universal
confirmatory test for the analysis of unknown stains which will be
able to unambiguously identify the type and nature of any bio-
fluids that might be present at a crime scene. The method should
be applicable to mixtures and, more importantly, should preserve
the samples for subsequent DNA analysis. Since biofluids have
evolved to perform different functions, they contain different
proteins, or different combinations of proteins, providing each
biological matrix with a unique protein signature that can be used
to distinguish among the various biofluids.11−13 Recently,
untargeted proteomics have been introduced for the determi-
nation of biological matrices in forensic science based on the
identification of the most prominent proteins present in
biofluids.11,14 However, these methods can give poor or uncer-
tain results when high amounts of non specific proteins occur in
the samples, i.e. when low amounts of a particular fluid are
present in combination with high amounts of other matrices or
when the sample is contaminated by other tissues.
This Article reports a universal method alternative and com-
plementary to “traditional” tests currently used in forensic
investigation to identify an unknown stain of biofluids occurring
at a crime scene. The method is based on a targeted proteomic
approach that makes use of tandem mass spectrometry in
multiple reaction monitoring (MRM) mode to selectively mon-
itor a number of specific peptides belonging to proteins biomark-
ers of individual biological fluids. First, the most prominent and
highly specific protein biomarkers for each biological matrix were
identified by both conventional LC-MS/MS analyses and com-
parison with literature data. Specific peptide markers of each
protein were then selected on the basis of their mass spectrom-
etric behavior together with their specific precursor ion-product
ion transitions as defined by their unique amino acid sequence.
Then, a single MRM method was devised to detect the occur-
rence of the target peptides within the sample leading to the
unambiguous discrimination among the different biological
matrices in a single analysis because of its high sensitivity,
selectivity and accuracy. The optimized method was tested and
validated on specimens consisting of four biological matrices
(blood, saliva, semen, and urine), or mixtures of matrices, spotted
on different substrates like cloth, wood, plastic, plaster, and
paper. Finally, a combined strategy allowing both DNA analysis
and biofluids identification on the same sample was developed
and demonstrated to be effective in forensic investigation by the
analysis of real specimens collected at a crime scene.
■ MATERIALS AND METHODS
Control biofluids (blood, saliva, urine, semen) were provided by
a private chemical laboratory. Guanidine, Tris(hydroxymethyl)
aminomethane hydrochloride, dithiothreitol (DTT), ethyl-
endiaminetetraacetate (EDTA), trypsin, iodoacetamide (IAM),
ammonium bicarbonate (AMBIC), trichloroacetic acid (TCA)
were purchased from Sigma-Aldrich. Bovine serum albumin
(BSA), formic acid (HCOOH), methanol, chloroform, and
acetonitrile (ACN) are from J.T. Baker. Bradford staining solu-
tion was from Bio-Rad. Pipette tips C18 (zip tip) and centrifugal
filter units were purchased from Merck Millipore.
In-Solution Digestion of Proteins from Biological
Matrices. Different protocols were performed to improve the
number of identified proteins and thus to provide the higher
sequence coverage for blood, urine, semen, and saliva. A protocol
of protein precipitation by using chloroform/methanol/water15
was carried out for each biofluids. After precipitation, protein
concentration was determined by Bradford assay using BSA as
standard.16 Samples were submitted to reduction, alkylation and
tryptic digestion. Samples were dissolved in denaturant buffer
(urea 6M, Tris 300mMpH8.0, EDTA 10mM) containing DTT
(10-fold molar excess on the Cys residues) at 37 °C for 2 h and
then iodoacetamide (IAM) was added to perform carboamido-
methylation using an excess of alkylating agent (5-fold molar
excess on thiol residues). The mixture was then incubated in the
dark at room temperature for 30 min. The product was purified
by chloroform/methanol/water precipitation. Supernatants were
removed and the pellets were dried. Digestion of proteins mix-
ture was carried out in AMBIC 10 mM using trypsin at a 50:1
protein/enzyme mass ratio. The samples were incubated at 37 °C
for 16 h and after acidification (10% HCOOH) they were dried.
To eliminate any impurities the samples were suspended in 200 μL
of AMBIC 100 mM, filtrated by centrifugal filter units (0.22 μm),
and dried in a speed-vacuum concentrator. Finally, samples were
suspended in 20 μL of HCOOH 1% and purified by reverse
phase chromatography using ZipTip C18 cartridges (Millipore).
Samples were evaporated and suspended in 10 μL of HCOOH
0.1% and analyzed by nanoLC-MS/MS and then by LC-MRM/MS
as described below.
To improve the number of identified proteins from blood by
LC-MS/MS, a step of depletion of abundant proteins was carried
out using ProteoPrepR 20 Plasma Immunodepletion KitProteo-
prep 20 Plasma Immunodepletion Kit (Sigma-Aldrich, Milan,
Italy) able to deplete 20 highly abundant proteins from human
plasma or serum. Dried extracted proteins were subjected to reduc-
tion, carboamidomethylation, chloroform/methanol/water precip-
itation protocol and tryptic hydrolysis as described above.
Protein precipitation from urine was also performed using cold
acetone followed by the same steps of tryptic digestion as
described above. Cold acetone at−20 °C (400 μL) was added to
urine (100 μL) and incubated at −20 °C for 2 h. After centri-
fugation at 12 000 rpm for 15 min the pellet was collected and
dried under vacuum.
Protein precipitation from semen was also carried out using
TCA. Semen was centrifuged (13 000 rpm, 30 min) to remove
cellularmaterial, and the proteins were precipitated (4 °C, 60min)
using an equal volume of cold TCA at final concentration of 10%.
Following further centrifugation (10 000 rpm, 30 min), the
supernatant was removed and the protein pellet washed with
cold acetone (three times) to remove residual TCA.
Therefore, a unique precipitation/sample preparation proce-
dure based on chloroform/methanol/water was adopted for all
the samples because the origin or matrix of casework samples.
Test Specimens. Twenty test forensic samples were
prepared by drying different biological fluids (100 μL) or
mixture of them on various substrates: cloth, wood, plastic,
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plaster and paper. Cloths were put directly in a plastic tube while
the samples on the other substrates were recovered by a cotton-
swab (Agilent Technologies, Palo Alto, CA). Samples were
collected in plastic tubes and 2mL of AMBIC 50mMwere added
for 16 h under gentle agitation. Samples were then sonicated
for 20min and submitted to chloroform/methanol/water precip-
itation. After precipitation, reduction, alkylation and tryptic
digestion were performed as previously described. The resulting
peptide mixtures were analyzed by LC-MRM/MS as described
below.
Analysis of Real Samples. Real samples consisting of traces
of unknown biological fluids on cloths, paper and stubs collected
at a crime scene (samples 1, 2, and 3) were provided by RIS
Laboratory in Rome. Samples were treated as described above
(see Test Specimens section) and submitted to tryptic digestion.
Then, gDNA was extracted from the samples using the robotic
platform Qiagen Biorobot EZ1 Advanced XL using the Qiagen
EZ1 DNA Investigator kit.17 The DNA was then washed and
eluted in water. DNA degradation and quantification level was
evaluated by multiplex RT-PCR using the Quantifiler Trio DNA
Quantification Kit (Applied Biosystems, CA, USA)18 on a 7500
Real-Time PCR System (Applied Biosystems). Results showed a
total DNA amount of 0.081 ng/μL for sample 1, 0.71 ng/μL for
sample 2, and 1.05 ng/μL for sample 3. Samples were also tested
for possible DNA degradation showing a good quality with a
degradation index of about 1.0 for all samples.
DNA profiling was obtained by multiple amplification of 17
polimorphic regions comprising the D3S1358, vWA, FGA,
D8S1179, D21S11, D18S51, TH01, D16S539, D2S1338,
D19S433, ACTBP2 (SE33), D1S1656, D2S441, D10S1248,
D12S391, D22S1045, and Amelogenin STR loci using the
Investigator ES Splex SE Plus Kit Qiagen (Qiagen, Hilden,
Germany).18 Amplified DNA was analyzed by automated DNA
sequencing on an Applied Biosystems 3500xL Genetic
Analyzer.19−21 Data were collected and elaborated using the
3500 Series Data Collection Software v. 2.0and the GeneMapper
ID-X Software v.1.4 (Life Technologies, Carlsbad, CA, USA).
LC-MS/MS Analysis. Peptide mixture were analyzed by
LC-MS/MS on a 6520 Accurate-Mass Q-TOF LC/MS system
(Agilent Technologies) equipped with a 1200 HPLC system and
a chip cube (Agilent Technologies). After loading, the peptide
mixture (1 μL) was concentrated and desalted at flow rate of
4 μL/min in a 40 nL enrichment column (Agilent Technologies
chip) with 0.1%HCOOHas eluent. The sample was then fraction-
ated on a C18 reverse phase capillary column (75 μm*43 mm in
the Agilent Technologies chip) at flow rate of 400 nL/min, with a
linear gradient of eluent B (0.1% HCOOH in 95% acetonitrile)
in A (0.1% HCOOH in 2% acetonitrile) from 5% to 80% in
50 min. Peptides analysis was performed using data-dependent
acquisition of one MS scan (mass range m/z 300−2400)
followed by MS/MS scan of the five most abundant ions in each
MS scan. MS/MS spectra were measured automatically when the
MS signal was greater than the threshold of 50000 counts.
Doubly- and triply- charged ions were preferably isolated and
fragmented over singly charged ions. Data were acquired through
Mass Hunter software (Agilent Technologies). The acquired
data, containing MS and MS/MS spectra, were transformed in
.mgf format and used for protein identification with a licensed
version of Mascot Software (www.matrixscience.com).
Mascot search parameters included: NCBInr as database;
trypsin as enzyme, allowed number of missed cleavage 3; Homo-
Sapiens as taxonomy; carbamidomethyl, C as fixed modifications;
oxidation of methionine (oxidation (M));, Gln pyro-Glu
(N-term Q) as variable modifications; 10 ppm MS tolerance,
0.6 Da MS/MS tolerance and peptide charge, from +2 to +3.
MRM Targeted Proteomic Approach. To build up a
targeted MRM method, Skyline software (3.7, 64 bit version
MacCoss Lab Software, University of Washington, USA) was
used for the in silico selection of peptides with unique sequence
for each selected protein. For each peptide, m/z precursor ion,
m/z product ions and relative collision energy were provided by
Skyline. Peptide mixture was analyzed by LC-MS/MS analysis
using a Xevo TQ-S (Waters) equipped with an IonKey UPLC
Microflow Source coupled to an UPLC Acquity System (Waters).
For each run, 1 μL peptide mixture was injected and separated on
a TS3 1.0 mm× 150 mm analytical RP column (Waters, Milford,
MA, USA) at 45 °C with flow rate of 3 μL/min using 0.1%
HCOOH inwater (LC-MS grade) as eluent A and 0.1%HCOOH
in ACN as eluent B. Peptides were eluted (starting 1 min after
injection) with a linear gradient of eluent B in A from 7% to 95%
in 55 min. The column was re-equilibrated at initial conditions
for 4 min. The MRM mass spectrometric analyses were
performed in positive ion mode using a MRM detection win-
dow of 0.5−1.6 min per peptide; the duty cycle was set to
automatic and dwell times were minimal 5 ms. Cone voltage was
set to 35 V.
■ RESULTS
Selection of Protein Biomarkers of Biological Matrices.
Four biological matrices, blood, saliva, urine, and semen, repre-
sentative of biofluids recovered at crime scenes, were analyzed to
identify specific protein biomarkers candidates for each matrix.
Different procedures for sample preparation were investigated
(Material and Methods section). As an example, results obtained
for blood with the only chloroform/methanol/water precip-
itation followed by tryptic hydrolysis, are shown in Table 1 where
GI number, the name of identified proteins, the number of pep-
tides and the corresponding sequence coverage are reported.
The unsatisfactory number of identified proteins in the orig-
inal assay severely limited the choice of specific protein bio-
markers for blood candidates for the MRM method because the
dominant abundance of unselective blood proteins. Thus, a differ-
ent sample preparation procedure was then explored by a deplet-
ion step from the most abundant proteins to improve protein
identification (Table 2). A significantly higher number of
Table 1. List of the Identified Proteins Following the
Chloroform/Methanol/Water Precipitation Protocol Applied
to Human Blood Sample
GI number identification MascotScore
number of
peptides
sequence
coverage (%)
gi|3212456 chain A, crystal structure
of human serum
albumin
1186 35 24
gi|
90108664
chain A, crystal structure
of lipid-free human
apolipoprotein A-I
602 18 22
gi|2765421 immunoglobulin kappa
heavy chain
192 4 34
gi|28637 alpha-1 antitrypsin 188 5 5
gi|386789 hemopexin precursor 178 7 10
gi|28810 β-2-glycoprotein
apolipoprotein H
160 6 1
gi|4557871 serotransferrin precursor 146 6 5
gi|38026 Zn-α2-glycoprotein 75 2 5
gi|112910 α-2-HS-glycoprotein 71 2 4
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peptides were identified for each protein leading to a much larger
sequence coverage.
Improved results were also obtained in saliva, semen, and urine
analysis by using the chloroform/methanol/water precipitation
protocol. Table S-1 reports the lists of the different proteins
identified for the other matrices, including the GI number, the
number of peptides and the Mascot score.
Proteins identified for each biofluids by LC-MS/MS were then
compared with literature data11 to eventually select the most
specific protein biomarkers for each biological matrix. Following
this procedure, proteins listed in Table S-2 were chosen as
representative for each biological fluid.
Development of MRM Methods Specific for Each
Biological Matrix and a Single MRM Method for All the
Matrices. A number of unique peptides belonging to the target
proteins characteristic of individual biological matrix were selected
by in silico analysis using the Skyline software that provided the
predicted best transitions and collision energy to generate
maximal fragment intensities. The in silico data of the selected
peptides were then compared with the experimental fragmenta-
tion spectra obtained by the LC-MS/MS analyses. Peptides
defined by Skyline analysis and showing the best signal-to-noise
ratio in the experimental fragmentation spectra were selected for
developing MRM methods for each biological fluid. These
methods contained all the precursor ion−product ions trans-
itions and collision energy associated with the selected peptides
from the defined target proteins constituting the protein
signature of each individual biofluids in Table S-2.
As an example, two peptides from α-globin, three from
β-globin and hemopexin, five from haptoglobin, and six from
α-2-macroglobulinfor a total of 25 peptides and 106 transitions
were selected to monitor the presence of blood and to build the
MRM method for this biological matrix.
The total ion current chromatogram (A) and the MRM TIC
analysis of the three peptides 132−143, 82−94, and 30−39 from
β-globin (B) are shown in Figure 1. Panel C displays the MRM
TIC chromatogram of the three transitions, m/z 409.72 to
507.29,m/z 409.72 to 604.34, andm/z 409.72 to 719.37, used to
monitor the α-globin (92−98) peptide. The different transitions
perfectly coeluted at a retention time of 5.24 min thus indicating
that they belong to the same precursor ion.
SimilarMRMmethods were developed for the other biological
matrices (Table S-2). For urine, as an example, Figure S-1 shows
the total ion current chromatogram (A) and the MRM TIC
analysis of the two peptides (507−605) and (204−211) from
uromodulin (B). Panel C displays the TIC chromatogram of the
three transitions for the uromodulin (204−211) peptide.
The different transitions perfectly coeluted at a retention time
of 2.99 min thus indicating that they all originated from the same
precursor ion.
Some of the MRM TIC chromatograms of the selected pep-
tides for the specific detection of proteins from saliva and semen
were reported in Supporting Information (Figures S-2 and S-3).
Once the optimized MRM methods were developed for each
individual biological fluid, the next step involved the develop-
ment of a single MRM method able to detect all the biological
fluids in a single analysis. For each selected protein biomarker,
all the selected peptide sequences, m/z precursor ion, m/z
product ions and the optimized collision energy were tabulated in
Table S-4.
As the mass spectrometer was able to handle a very large
number of transitions per run, the single MRMmethod was built
up by using a total of 46 peptides and 212 transitions.
Analysis of Test Specimens. For all the test specimen sam-
ples, the MRM chromatograms solely showed the mass tran-
sitions associated with the target peptides belonging to the
specific proteins constituting the unique signature of the defined
matrix. No transitions related to peptides from proteins
characteristic of other biological fluids were detected for all the
analyzed samples. As an example, Figure 2A shows the MRM
TIC chromatogram of the three transitions, m/z 637.86 to
687.35,m/z 637.86 to 850.42,m/z 637.86 to 949.49,m/z 637.86
to 1048.56, and m/z 637.86 to 1161.64 used to monitor the
β-globin (30−39) peptide form a blood sample spotted on plas-
ter. Panel B showed the corresponding MRM chromatogram for
the (1075−1086) peptide from mucin-6, a protein specific of
semen, illustrating the absence of any nonspecific transition of inter-
fering proteins. This result clearly demonstrates that the specific
signature of blood could be easily monitored whereas no
interference from cross transitions of peptides belonging to other
biological matrices was detected.
Similar results were obtained on all the other spotted samples
and are summarized in Table 3. Each biological matrix could be
unambiguously identified by the developed MRM method even
on different substrates. No cross transitions were observed what-
soever with the exception of urine where peptides from PSA and
PAP proteins, a specific signature of semen, was also detected.
However, the presence of seminal proteins in urine is somehow
expected and provides further information on the origin of the
sample that was obviously from a male donor.
To test the MRM optimized method capability to unam-
biguously define the occurrence of individual biofluids when
occurring in a 50:50 ratio mixture, blood−semen, blood−urine,
and semen−urine were spotted onto different substrates. The
negative controls, for a total of 5 sample, consisted of the exclu-
sive use of substrates: cloth, wood, plastic, plaster, and paper.
As shown in Table S-5, each individual component of the binary
mixture was unambiguously identified by the specific transitions
of the unique peptide signature; whenever urine was present,
specific peptides from semen proteins were also detected.
Analysis of Real Crime Scene Samples. The developed
procedure was then applied to real samples collected at a crime
scene by the RIS Laboratory in Rome. Samples were prepared
according to the procedure described above and following enzy-
matic hydrolysis, DNA was extracted from each sample
according to the normal procedure performed at the RIS
Table 2. List of the Identified Proteins Following the
Depletion Step Previous to the Chloroform/Methanol/Water
Precipitation Protocola
GI number identification MascotScore
number of
peptides
sequence
coverage (%)
gi|1431650 chain β of hemoglobin 156 6 20
gi|229751 chain α of hemoglobin 138 4 15
gi|3212456 chain A, crystal
structure of human
serum albumin
1995 48 34
gi|
194383506
serum transferrin 1012 34 29
gi|90108664 chain A, crystal
structure of lipid-free
human
apolipoprotein A-I
562 22 27
gi|177870 α-2-macroglobulin 485 17 7
gi|13787109 α-1-antitrypsin 337 12 14
aThe GI number, the number of peptides, the corresponding Mascot
score, and sequence coverage are reported for human blood sample.
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Laboratory. DNA extracts were quantified, the degradation level
was evaluated and the DNA profiling obtained as described in
Materials and Methods section. The resulting genotypic profile
of sample 1 is shown in Figure S-4 and was identified as a male
genotype profile called “Profile A”. The quality of the data
exceeded the minimum quality requirements established by
Figure 1. Identification of all the protein of blood fluid by LC-MS/MS analysis and MRM/MS data of the defined target proteins constituting the
protein signature of blood. Panel A: Total ion current (TIC) as a function of time (min.). LC-MS-MS analysis allowed the identification of protein
content on blood tryptic peptide mixture. Panel B: BPI Chromatograms for β-globin 132−143, 82−94, 30−39 peptides eluted at 6.18, 11.46, and 16.91 min,
respectively. Panel C: MRM TIC Chromatograms extracted for α-globin (92−98) peptide. The monitored transitions for this peptide: m/z 409.72 to
719.37, m/z 409.72 to 604.34, and m/z 409.72 to 507.29 are perfectly coeluted at 5.24 min as an unambiguous identification of blood detection.
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internal validation procedures for this Lab for comparative proce-
dures to be used for personal identification purposes.
Following DNA analysis, the remainder of the samples con-
taining the mixture of tryptic peptides was submitted to the
developed MRM analytical procedure. Figure 3 shows the TIC
analysis of the three peptides 30−39, 82−94, and 132−143 mon-
itored for the human β-globin and two peptides 92−98 and
127−138 monitored for the human α-globin (A). Panel B
displays the MRM TIC chromatogram corresponding to four
transitions, m/z 637.87 to 687.35, m/z 637.87 to 850.42, m/z
637.87 to 949.48, and m/z 637.87 to 1048.55, used to monitor
the β-globin (30−39) peptide. As shown in Table 4, the MRM
analysis was able to unambiguously define individual protein
component occurring in the different samples by their unique
peptide signature even after DNA extraction and analysis.
Therefore, this combined procedure led to both DNA profiling
analysis and the unambiguous identification of blood indicating
the biological fluid the DNA was collected from.
■ DISCUSSION
Knowledge of the nature of biofluid discovered at a crime scene
can influence the outcome of a case. Identification of a suspect’s
DNA on a victim is quite different if it comes from saliva, sug-
gesting intimate contact, wither consensual or forced, or from
blood or seminal fluid, indicating a physical struggle or a sexual
assault. However, this is not always an easy task, since many
biofluid stains are either invisible to the naked eye or similar in
appearance to other fluids or substances. Even when the identity
of a stain may seem obvious to a forensic investigator, absolute
confirmation is necessary to give a legal value to the trace
evidence to either prove or disprove a fact in a lawsuit. This is
especially important with the possible occurrence of mixtures as
single stain could contain multiple biofluids.
Most biochemical and immunologic tests which have been
used for presumptive or confirmatory methods suffer from several
limitations leading to sample destruction resulting in sample loss
for subsequent DNA analysis or to incompatibility with down-
stream individual identification assays, that is, DNA profiling.
Moreover, most of the current methods are designed to detect a
single biofluid forcing the investigators to decide which test to
perform in the presence of a limited amount of sample.
Contrary to DNA, proteins were rarely considered and
scarcely used as sources of useful biological traces in crime scene
investigations. Proteins tend to be less stable than DNA and are
easily degraded making their identification by immunological
methods unfeasible. Moreover, the amount of available samples
cannot be amplified by “PCR-like” procedures thus requiring the
use of analytical techniques with extremely high sensitivity.22
More recently, proteomics strategies have been applied to the
identification of biofluids that overcome most of the previous
difficulties. In proteomic approaches, proteins are identified by
their peptide fragments making the degradation no longer a
problem.Moreover, contrary to DNA, proteins are tissue-specific
providing a unique signature to identify biological tissues and
fluids. Finally, the tiny amount of trace evidence usually recov-
ered at a crime scene is matched by the extraordinary sensitivity
of modern mass spectrometers. Untargeted proteomic approaches
demonstrated to be effective in the definition of biofluids in
traces from crime scenes by identification of specific proteins
belonging to individual biological sample.5 However, severe limi-
tations in sensitivity, in the analysis of mixed traces and, more
important, in preserving the samples for subsequent DNA ana-
lysis still exist. A recent study has greatly overcome this drawback
by MALD IMS imaging directly on a blood fingermark leaving
the ridge detail completely preserved.10 Despite the fact that the
proposed method is as destructive as the other approaches, the
great compatibility between DNA extraction and MS strategy
protocols allows to limit the destruction of the entire trace
evidence. Indeed, a combined strategy to provide both DNA
analysis profiling by RIS laboratory and identification of the
Figure 2.MRM/MS analysis of test specimens: blood spotted on plaster. Panel A: MRMTIC Chromatograms extracted for β-globin (30−39) peptide.
The best five monitored transitions m/z 637.87 to 687.36, m/z 637.87 to 850.42, m/z 637.87 to 949.49, m/z 637.87 to 1048.56, and m/z 637.87 to
1161.64 are reported in figure eluted at 16.73 min. Panel B: MRM TIC chromatogram extracted for (1075−1086) peptide from mucin-6 a protein
specific of semen, illustrating the absence of any nonspecific transition (m/z 785.38 to 960.42, m/z 785.38 to 1057.48, m/z 785.38 to 1307.62).
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corresponding biological fluids on the same sample collected at
real crime scenes has been developed. Samples were deprotei-
nized by treatment with trypsin instead of the commonly used
nonspecific proteases, that is, Pronase, proteinase K, etc. DNA
was then extracted from the digested samples and analyzed
according to the usual procedure, yielding optimal DNA profiles.
Moreover, the proposed bottom-up approach makes this method
valid also on old traces that have undergone degradation. Another
advantage from the current approach is the unambiguous identi-
fication of all target proteins allowing us to unequivocally
Figure 3.MRM/MS analysis of real crime scene samples after DNA extraction. Panel A: BPI Chromatograms for α-globin 92−98 and 127−138 peptides
eluted at 5.26 and 14.91 min respectively and BPI Chromatograms for β-globin 132−143, 82−94, AND 30−39 peptides eluted at 11.40, 11.50, AND
16.62 min, respectively. Panel B: MRMTIC chromatogram corresponding to four transitions,m/z 637.87 to 687.35,m/z 637.87 to 850.42,m/z 637.87
to 949.48, and m/z 637.87 to 1048.55 perfectly coeluted at 16.59 min, used to monitor the β-globin (30−39) peptide.
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discriminate among the different fluids, even in mixture by a single
MRM run of less than 1 h.
Indeed, four proteins, α-globin, β-globin, haptoglobin, and
hemopexin have been selected for blood signature, four for saliva
(α-amylase 1, mucin-5, annexin A1, and cystatin S), five for
semen (semenogelin I and II, PSA, PAP, and mucin-6) and two
proteins determined for urine (uromodulin and osteopontin).
For each protein biomarker, a number of unique tryptic peptides
(proteotypics) has been selected with the use of bioinformatics
tools and the best precursor ion-fragments transitions employed
to set up a single MRM method able to identify any of the four
biofluids in unknown stains. The MRM LC-MS/MS analysis
recognizes the specific peptides by their unique transitions. The
identified proteotypic peptides have been correlated to each set
of selected protein biomarkers that in turn unambiguously
defined the biological fluids under investigation.
The MRM method optimized on pure samples of the four
matrices, blood, urine, semen and saliva, is resulted to have good
specificity and selectivity for each biofluid with no cross-
contamination observed whatsoever. A single contamination was
detected in the urine samples spotted on different surfaces that
showed the occurrence of small amount of seminal fluid.
Table 4. Identification of the Biomarker Proteins by MRM Analysis in Three Samples Obtained from RIS Laboratories after DNA
Extraction and Analysisa
peptide sample 1 sample 2 sample 3
blood α Hb K.VGAHAGEYGAEALER.M [16, 30] x
R.VDPVNFK.L [92, 98] x
K.FLASVSTVLTSK.Y[127, 138] x x
β Hb R.LLVVYPWTQR.F [30, 39] x x
K.GTFATLSELHCDK.L [82, 94] x
K.VVAGVANALAHK.Y [132, 143] x
hemopexin R.ELISER.W [82, 87] x
K.VDGALCMEK.S [401, 409] x
haptoglobin K.DIAPTLTLYVGK.K [156, 167] x
R.VMPICLPSK.D [202, 210] x
saliva α amylase R.WVDIALECER.Y [35, 44] x
K.SSDYFGNGR.V [258, 266] x
annexin 1 K.GVDEATIIDILTK.R [58, 70] x
R.SEIDMNDIK.A [303, 311] x
K.ILVALCGGN.- [337, 345] x
MUC 5AC K.GVQLSDWR.D [1335, 1342] x
R.AQAQPGVPLR.E [2999, 3008] x
cystatin S K.QLCSFEIYEVPWEDR.M [115, 129]
R.MSLVNSR.C [130, 136] x
semen MUC 6 K.VTNEFVSEEGK.F [182, 192] x
R.ETDPCSMSQLNK.V [573, 584] x
R.GVLLWGWR.S [646, 653] x
K.VYHLPYYEACVR.D [1075, 1086] x
SEM II K.GHYQNVVDVR.E [217, 226] x
K.DIFTTQDELLVYNK.N [251, 264]
K.ISYQSSSTEER.H [345, 355] x
K.QDLLSHEQK.G [534, 542] x
PSA R.IVGGWECEK.H [20, 28] x
K.HSQPWQVLVASR.G [29, 40] x
R.LSEPAELTDAVK.V [121, 132] x
K.FMLCAGR.W [190, 196] x
PAP R.SPIDTFPTDPIK.E [47, 58] x
K.DFIATLGK.L [185, 192] x
R.ELSELSLLSLYGIHK.Q [236, 250] x
SEM 1 R.LWVHGLSK.E [165, 172] x
K.VQTSLCPAHQDK.L [233, 244] x
K.DVSQSSIYSQTEEK.A [307, 320]
K.GESGQSTNR.E [404, 412] x
urine osteopontin K.QNLLAPQTLPSK.S [51, 62]
R.GDSVVYGLR.S [145, 153]
R.ISHELDSASSEV.- [287, 298]
uromodulin R.STEYGEGYACDTDLR.G [185, 199]
K.VFMYLSDSR.C [356, 364]
K.INFACSYPLDMK.V [420, 431]
R.VGGTGMFTVR.M [449, 458]
R.VLNLGPITR.K [597, 605]
aX is reported when the unique peptides belonging to the target proteins characteristic of individual biological matrix were identified by MRM analysis.
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However, this presence was somehow expected and contributed
to indicate a male donor. Then in a proof of concept, prepared
test samples consisting of different fluids spotted on various
substrates have been analyzed by using the single optimized
MRM method.
The current results demonstrated that the developed strategy
based on the MRM LC-MS/MS method could be a useful sub-
strate in forensic science due to its capability of providing a
universal approach for the identification of unknown stains recov-
ered at crime scenes with high selectivity and specificity.Moreover,
this approach can be carried out on the same samples used for
DNA profiling revealing the nature of the tissue or fluid the DNA
had been recovered from.
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A B S T R A C T
Identification of proteins in paintings and polychrome objects is a challenge, which requires the development of
tailored analytical approaches. In the present study, a targeted proteomics approach was developed for dis-
criminating among the three most common proteinaceous materials used as paint binders, i.e. milk, egg, and
animal glue. In this study a specific database of peptides was created based on tandem MS analyses of tryptic
digests of several paint samples collected from a variety of art objects of different ages and conservation con-
ditions. Specific peptide markers of each protein were then selected and monitored by LC-MSMS in Multiple
Reaction Monitoring (MRM) ion mode, together with their specific precursor ion-product ion transitions, as
defined by their unique amino acid sequence. The developed method enabled a sensitive and reliable detection
of the target peptides in a selection of case studies, leading to the unambiguous identification of the proteins
used as paint binders. The method showed greatly increased sensitivity compared to currently available stra-
tegies.
1. Introduction
The inherently multidisciplinary nature of proteomics has recently
led to its application to assorted areas that include the field of cultural
heritage [1] for the identification of protein-based materials in artworks
and polychromies, archaeological remains, and paleontological objects
[2].
The most up-to-date approaches for the characterization of protei-
naceous materials in artworks and polychromies, and in general when
dealing with ancient proteins, rely on mass spectrometry technologies
that are able to identify proteins from the MS analysis of their digested
peptides [2,3] (and references therein). Typically, MS-based proteomics
pipelines aimed at identifying proteins in ancient samples follow the
classical bottom up approach, where samples are enzymatically di-
gested to peptides, which are either analyzed by simple MS, or sepa-
rated by liquid chromatography and eventually analyzed by tandem
mass spectrometry. Peptides and thereof proteins are identified by
correlating experimental spectra to virtual ones in a protein sequence
database [4]. In the classical full scan operating mode (typical of LC-
MSMS analysis in discovery proteomics or shotgun proteomics, other-
wise named global profiling proteomics or untargeted proteomics), the
mass spectrometer continuously repeats the full scan mass spectrum
and selects and fragments the n (typically n=1–10) most abundant
ions (information-dependent acquisition, IDA).
So far, the applications to the cultural heritage field are untargeted,
discovery proteomics based experiments. The fascinating potential of
this operating mode lies in the possibility of uncovering proteins
without any “a priori” knowledge or hypothesis. It is therefore com-
patible with both well and poorly characterized systems in cultural
heritage, the only basic requirements being the actual presence of
proteins in the sample and the presence of the protein sequences or
homologous sequences in a properly selected database [2,3].
Since the first report of LC-MSMS in 2006 [5], despite the tre-
mendous success of these approaches in a wide range of works of art
https://doi.org/10.1016/j.microc.2018.09.021
Received 18 June 2018; Received in revised form 7 September 2018; Accepted 18 September 2018
⁎ Corresponding authors at: Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario di Monte S. Angelo, Via Cinthia, 80126
Naples, Italy.
1 These authors equally contributed to the paper.
E-mail addresses: angamor@unina.it (A. Amoresano), birolo@unina.it (L. Birolo).
Microchemical Journal 144 (2019) 319–328
Available online 19 September 2018
0026-265X/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
and archaeological remains [5–24] standard based proteomics strate-
gies keep being developed to address the field-specific analytical chal-
lenges in samples from cultural heritage, by improving the steps in the
standard proteomics protocols, from the solubilization step on
[20,21,25–28]. So far, the greatest attention was addressed to the
preparation of the sample, correctly considering the unusual nature/
state of the sample itself as the biggest challenge in the analysis.
However, as far as the mass spectrometric analysis itself is con-
cerned, some of the limits in the detection in a LC-MSMS analysis can
also arise from the automated peak selection and the linked in-
strument's bias towards repeatedly selecting and fragmenting the spe-
cies with the most intense MS signals. The complexity of these unusual
samples in works of art and archaeological remains, in terms of che-
mical composition, the unavoidable presence of contaminating protein-
based materials (even coming from the environmental dust), as well as
the high levels of molecular damage found in ancient samples, can
overwhelm even the most modern mass spectrometer [3,21,25],
sometime making the identification of protein components in these
samples extremely challenging. This because the mass spectrometer
might miss signals coming from important, relevant proteins, but in-
stead might “waste its time” on signals from uninformative con-
taminants, for instance. Searching for significative signals in a multi-
tude of untargeted signals might then become like looking for a needle
in a haystack with the naked eye.
There are cases, however, such as the identification of the protein-
based binders in paintings, where, in principle, the search could be
basically simplified to a discrimination between the most commonly
used materials, i.e., animal glues, egg, and milk casein. Therefore, the
analysis can be “targeted” towards a search for the protein components
of these materials, within a limited range of possibilities, in an alter-
native, focused approach that by selectively searching for a restricted
set of marker proteins, can eventually guarantee a higher sensitivity
and reduce the interference from contaminations as lowest as possible.
In these cases, a significant advance in the solution of the analytical
challenge can be the multiple reaction monitoring (MRM) ion mode, an
alternative mass spectrometric strategy, the actual gold standard in
mass spectrometric technique for selectivity and high signal-to-noise
ratio that selectively and non-redundantly search for specific ions of
one or, more desirably, a few peptides that will unequivocally con-
stitute protein markers to be identified as unique signatures for each
binder. The mass spectrometer will therefore focus on selected signals,
getting rid of the “noise” of the other ions from the background, thus
sensibly increasing sensitivity. Quoting the commentary on Nature
Methods on 2013 [29], MRM “can be thought of as the mass spectro-
metrist's ELISA. It targets proteins using a predetermined assay with
high sensitivity and selectivity [30]: molecular ions of a target peptide
are selected in the first mass analyzer, fragmented in the collision cell
and one or several of the fragment ions uniquely derived from the target
peptide are measured by the second analyzer. MRM is referred to as
targeted approach as only predetermined ions are measured, and mass
spectrometer acts as a mass filter selectively monitoring a specific
analyte molecular ion and one or several fragment ions generated from
the analyte. MRM has been first developed and applied for decades in
the pharmaceutical industry to quantify small molecules [31] and
evolved to be applied in the field of proteomics, to detect low abundant
proteins in complex matrices, to verify biomarker candidates, and has
proved to be successful in clinical settings [32–42].
Mass spectrometry-based strategies that search for specific peptides
as markers in the analyses of protein-based binders have been reported
[20,43–46]. However, in none of them, to the best of our knowledge,
has ever been used to discriminate between collagen-, milk- and egg-
based binders. We propose this technique as a probe to specifically
identify peptide markers of proteinaceous materials in paintings.
Herein, we developed and applied a method based on a targeted pro-
teomic approach that makes use of tandem mass spectrometry in mul-
tiple reaction monitoring (MRM) ion mode to selectively monitor a
number of specific peptides belonging to proteins markers of individual
proteinaceous binders in paintings. This alternative strategy, by selec-
tively and non-redundantly searching for specific signatures of the
proteinaceous binders, could represent a significative advance in the
solution of the analytical challenge set by ancient samples. Differently
from previously reported methods [20,43,44,46] that also search for
specific peptides but in untargeted, typical shotgun runs, where relative
abundance of the single peptide ions can still strongly affect the results,
MRM by its two-level mass filtering instrumental operating mode re-
sults in an increase of selectivity, and an incredibly high signal-to- noise
ratio for the target analytes, getting rid of most of the nuisances arising
from abundant contaminating proteins in the samples that can un-
avoidably affect, for instance, mass fingerprinting methods but also
standard LC-MSMS approach.
In this work, the most prominent and specific protein markers for
protein-based binder were chosen by screening a collection of LC-MSMS
analyses of a panel of paintings/test samples that had been carried out
during the years. Samples had different origin, had been prepared with
different procedures, with different pigments, in order to be as general
as possible in the selection of the target peptides, and provide a ver-
satile tool that could be applied to any painting sample. Specific peptide
markers of each protein were then selected on the basis of their fre-
quency of detection in the set of samples and of their mass spectro-
metric behavior together with their specific precursor ion-product ion
transitions as defined by their unique amino acid sequence. Then, a
single MRM method was constructed to detect all the target peptides in
a single analysis with high sensitivity, selectivity and accuracy, leading
to the unambiguous discrimination among the different proteinaceous
binders. The method was tested on a panel of samples of known com-
position and then successfully applied to a set of paint samples of un-
known composition.
Results presented here demonstrate the unique ability of MRM
method to selectively assess the nature of proteinaceous binders in
paintings, and its successful application to samples where standard LC-
MSMS analysis had failed, or to disclose previously undetected com-
ponents.
2. Materials and methods
2.1. Reagents
Ammonium hydrogen carbonate (AMBIC), Ethylenediaminetetraacetic
acid (EDTA); Tri(hydroxymethyl)aminomethane (TRIS), and TPCK-treated
trypsin were from Sigma; recombinant Peptide N-Glycosidase F (PNGaseF)
was from Roche. Formic acid and Acetonitrile (ACN) were purchased from
Baker. Deionized water was obtained from Millipore cartridge equipment.
2.2. Painting samples
The list and the characteristics of paint replicas and historical
samples used to build the database of selected peptides are reported in
Table S1. Historical samples were from collections that have been
published elsewhere [26,47–50], and criteria for sampling and de-
scription of the single cases are therein given.
Samples were motley analyzed in the course of the years, and were
generally treated in heterogeneous phase with trypsin with variations in
respect to the minimally [21] invasive protocol as reported in Table S1,
and the resulting peptide mixtures were analyzed by LC-MSMS, as de-
tailed in the therein indicated references [21,25,26,47–50]. For those
samples that were used in the setup of the database that have not been
published previously, digestion with trypsin, LC-MSMS analysis and
data analysis were carried out as described in detail in the Supple-
mentary information.
In order to build up the database, the proteins and the peptides most
frequently detected in standard global profiling experiments were
screened regardless the treatment procedures they had undergone and
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the mass spectrometer that was used in the specific analysis. A rela-
tional database was designed on PivotTables (https://support.office.
com) to simplify the data processing.
2.3. LC-MSMS analysis in multiple reaction monitoring ion mode
In MRM mode, two steps of mass filtering are used on a triple quad
mass spectrometer. The technique is more sensitive than full scan
MSMS because both Q1 and Q3 are parked on a single m/z ion, with
both mass analyzers dwelling on a single ion.
In a typical MRM workflow, the targets must be selected. MRM-
based assay usually starts with the selection of a signal providing op-
timal signal intensity and discriminating the target peptide from the
other species. The predicted best transitions and collision energy to
generate the maximal fragment intensities are then provided by in silico
analysis by using Skyline software [51]. These data are then used for
MRM method construction. The detailed information of the herein used
MRM method is reported as follows.
Peptide mixtures were analyzed by LC-MSMS analysis using a Xevo
TQ-S (Waters) with an UPLC Microflow Source coupled to an UPLC
Acquity System (Waters) using an IonKey (Advion) device. For each
run, 1 μl peptide mixture was injected and separated on a TS3
1.0 mm×150mm analytical RP column (Waters, Milford, MA, USA) at
60 °C with flow rate of 3 μl/min. Peptides were eluted (starting 1min
after injection) with a linear gradient of eluent B (0.1% Formic acid in
100% ACN) in A (0.1% Formic acid in water (LC–MS grade)) from 7%
to 95% in 55min. The column was re-equilibrated at initial conditions
for 4min with eluent A. MRM mass spectrometry analyses were per-
formed in positive ion mode. Skyline Software drew the choice for the
selection of virtual best transitions and collision energy calculated to
generate maximal fragmentation intensities for each analyte. The de-
veloped MRM method was used with MRM detection window set to
0.5–1.6 min per peptide, the duty cycle was set to automatic and dwell
times were minimal 5ms. Cone voltage was set to 35 V. The mass
spectral MRM parameters are reported in Table S2.
3. Results
3.1. Database setup and selection of the binder specific proteins
Results from LC-MSMS analyses of a collection of 105 samples from
artistic and archaeological samples (Table S1), which had showed to
contain milk, animal glue and egg, were screened to identify specific
protein biomarker candidates for each material. Milk proteins were
found in 43 samples, animal glue in 29 samples and egg in 43 samples.
Table S3 shows the details of the identifications for all the samples that
were inserted in of the database that had not been published elsewhere.
Fig. 1 reports the summary of the results relative to the samples that
contained milk. Whenever milk was detected, alpha S1 casein was al-
ways identified, while beta casein was identified in 32 samples out of
43, and alpha S2 casein observed in 30 samples (Details in Table S4).
Similarly, in the animal glue containing samples, as expected, two
collagen proteins were detected in almost all samples, collagen alpha-
1(I) identified in all samples and collagen alpha-2(I) in 28 out of 29
samples (Fig. S1, and details in Table S5).
The case of egg binder was more complex since artists could alter-
natively use either albumen or yolk or whole egg. Moreover, pure al-
bumen can be quite easily obtained from a whole egg whereas yolk is
very likely contaminated by egg white. Therefore, the results obtained
with the 43 egg containing samples were evaluated by dividing them
into two subgroups of samples, i.e. those containing only albumen (27
samples) and those containing yolk plus albumen (16 samples). No
sample was considered as a pure yolk. As expected (Fig. S2, and details
in Table S6), chicken ovalbumin, the main protein of egg white, was
identified in all samples containing only albumen (27 out of 27) and in
38 out of the total 43 samples including those containing also egg yolk.
Similarly, ovotransferrin was observed in 21 out of 27 albumen only
samples and in 8 of the samples containing yolk plus albumen, thus
accounting for 29 out of 43 total samples. Vitellogenin-1 and vitello-
genin-2 were the most frequently identified proteins from yolk, ob-
served in 12 and 14, out of 16 samples containing egg yolk.
From the results obtained, alpha S1 casein, alpha S2 casein and beta
casein were selected for the subsequent selection of the peptides to be
used for the identification of milk, collagen alpha-1(I) collagen alpha-
2(I) for animal glue, ovalbumin and ovotranferrin as generic re-
presentative of egg containing binders and vitellogenin-1 and vitello-
genin-2 specifically for yolk containing binders.
3.2. Selection of the target peptides
Unique peptides belonging to the target proteins characteristic of
each proteinaceous binder were thus selected to develop the MRM
assay. Specific peptides were chosen on the basis of their frequency of
observation and quality of fragmentation spectra in the LC-MSMS
analyses. As an example, Fig. 2 reports the frequency of observation of
the alpha S1 casein peptides in the milk containing samples. The pep-
tide YLGYLEQLLR encompassing the 106–115 region of the alpha S1
casein was observed in 77% of cases while the peptide FFVAPFPEVFGK,
encompassing the 38–49 sequence was identified in 74% of cases and
the peptide HQGLPQEVLNENLLR, position 23–37, in 53%. These three
peptides were recognised as the most recurrent in milk binder and were
thus selected as suitable targets for the development of the MRM
method. Similarly, four peptides from alpha S2 casein and two peptides
from beta casein were selected as the most frequently detected in the
LC-MSMS analyses (Fig. S3 and S4, in the Supplementary material).
These peptides were also considered to investigate whether they
could be used to discriminate among the different milk sources i.e.
either bovine or ovine milk. The biological origin of proteins in
samples from cultural heritage can be ascertained by identifying
species-specific peptides, and is an attractive and still challenging
problem [6,17,19,20,47] that can in principle be tackled by MRM
approach. Two of the selected peptides from alpha S1 casein and
three peptides from alpha S2 casein were demonstrated to be able to
discriminate bovine and ovine milk [47]. In particular, FFVAPFPE-
VFGK and HQGLPQEVLNENLLR are specific of bovine alpha S1
casein, and FALPQYLK, AMKPWIQPK and NAVPITPTLNR of bovine
alpha S2 casein, respectively. Similarly, the orthologues peptides
FVVAPFPEVFR and NAGPFTPTVNR that are specific to goat alpha S1
casein and goat alpha S2 casein, respectively, were also inserted in
the MRM method (Table S2).
Fig. 1. Graphical representation of proteins occurrence in 43 milk containing
samples. The occurrence has been reported as percentage of the analyzed
samples. The UniProt code is reported in brackets. Details of the proteins oc-
currence are shown in Table S4.
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Fig. 2. Frequency of alpha S1 casein detected peptides in
milk containing samples. On the main vertical axis the
percentage is reported as calculated in respect to the
number of samples in the milk containing samples data-
base The secondary vertical axis reports the actual
number of observations. In the statistical analysis, de-
tected peptides have been considered only once, regard-
less possible deamidation detection, while oxidated pep-
tides were considered separately. The sequence of the
selected peptides is also reported.
Table 1
Selected peptides: peptides selected upon the analysis of the occurrence in group of samples. The number of
times the peptide has been observed and the corresponding percentage in the group of samples is reported.
Position in the protein sequence is given as flanking apexes. For peptides from vitellogenin 1 and vitellogenin 2,
the percentage in the set of yolk and albumen samples is also shown.
Sample
group
(number of
samples)
Protein
(UniProt entry)
Peptide MH+
No.of
observa
tions
%
%
 in
 th
e 
yo
lk
 a
nd
 a
lb
um
en
 s
am
pl
es
(4
3)
Alpha S1 casein
(P02662)
106YLGYLEQLLR115 1267.70 33 77
38FFVAPFPEVFGK49 1384.73 32 74
23HQGLPQEVLNENLLR37 1759.95 23 53
Alpha S2 casein
(P02663)
189FALPQYLK196 979.56 24 56
130NAVPITPTLNR140 1195.68 22 51
204AMKPWIQPK212 1098.61 15 35
96ALNEINQFYQK106 1367.7 19 44
Beta casein
(P02666)
192AVPYPQR198 830.45 30 69
199DMPIQAFLLYQEPVLGPVR217 2186.17 19 44
199DMPIQAFLLYQEPVLGPVR217 + Oxi (M) 2202.16 23 39
Collagen alpha-
1(I) (P02453)
1062SGDRGETGPAGPAGPIGPVGAR1083 1975.99 23 79
1084GPAGPQGPR1092 836.44 17 59
958GVVGLPGQR966 + Hydroxy (P) 898.51 21 72
Collagen alpha-
2(I) (P02465)
326GIPGPVGAAGATGAR340 + Hydroxy (P) 1267.67 16 55
572GIPGEFGLPGPAGAR586 + 2 Hydroxy (P) 1427.73 19 65.5
1066IGQPGAVGPAGIR1078 1192.68 19 65.5
Ovalbumin
(P01012)
265LTEWTSSNVMEER277 1581.72 23 53
128GGLEPINFQTAADQAR143 1687.87 32 74
324ISQAVHAAHAEINEAGR340 1773.90 30 70
144ELINSWVESQTNGIIR159 1858.97 32 74
Ovotransferrin
(P02789)
595ANVMDYR601 868.40 21 49
120GTEFTVNDLQGK131 1308.64 23 53
289AQSDFGVDTK298 1067.50 23 53
275DDNKVEDIWSFLSK288 1695.82 26 60
155GAIEWEGIESGSVEQAVAK173 1959.96 26 60
141SAGWNIPIGTLLHR154 1534.85 25 58
Vitellogenin-1
(P87498)
831LTELLNSNVR840 1158.65 4 9 25
472SNIEEVLLALK482 1228.71 4 9 25
315LQDLVETTYEQLPSDAPAK333 2118.06 4 9 25
813VAGNVQAQITPSPR826 1437.78 6 14 37.5
Vitellogenin-2
(P02845)
1515MVVALTSPR1523 973.55 10 23 62.5
456EALQPIHDLADEAISR471 1777.91 10 23 62.5
260QQLTLVEVR268 1085.63 13 30 81
642VGATGEIFVVNSPR655 1445.77 12 28 75
226QSDSGTLITDVSSR239 1465.71 11 26 69
240QVYQISPFNEPTGVAVMEAR259 2236.11 11 26 69
919NIGELGVEKR928 1114.62 7 16 44
1543LPLSLPVGPR1552 1048.65 8 19 50
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The analysis of peptides from animal glue samples lead to the se-
lection of three peptides for the definition of collagen alpha-1(I) and
three peptides for collagen alpha-2(I). Non-hydroxylated or un-
ambiguously singly hydroxylated peptides were preferred, since hy-
droxylation in different position within the same peptide leads to dif-
ferent ions upon fragmentation; however, a peptide of collagen alpha-
2(I) with multiple hydroxylation sites was also considered as a test, and
the transitions for the different possibilities were separately considered
(Tables 1 and S2).
Peptides identified in egg binder showed a larger distribution of
observation frequency, making the selection of the marker peptides
more complex. A higher number of peptides was therefore selected for
ovoalbumin, ovotransferrin, vitellogenin-1 and vitellogenin-2 (four, six,
four and eight peptides respectively), in order to maximise our prob-
ability of detecting egg in the MRM analysis of samples of unknown
composition.
Table 1 reports the ultimate list of the selected peptides with the
frequency of observation in the set of paintings/test samples analyzed.
To design the MRMmethod, the selected peptides were thus analyzed in
silico using the Skyline software to determine the predicted best tran-
sitions and collision energy to generate maximal fragmentation in-
tensities. Table S2 reports the full list of defined peptides for each single
target protein of the various proteinaceous binders, with the specific
transitions and collision energy that have been used to develop the
MRM method.
3.3. MRM analysis
A single MRM method able to detect in a single run the presence of
egg, animal glue and milk proteins in samples from cultural heritage
was thus developed. This method contains all the precursor ion-
daughter ions transitions associated with the selected target peptides
constituting the protein signature of each individual proteinaceous
binder (see Table S2).
As a preliminary check of the developed assay, some samples with
known composition, (containing either milk, animal glue or egg as
single proteinaceous component, as well as some combinations of
them), were used as test and were analyzed by using the newly set-up
MRM method. As an example, Fig. 3 shows the MRM TIC chromato-
grams for the transitions selected for the peptide 106–115 of bovine
alpha S1 casein. All the signals were recorded at the same retention
time, thus confirming that the transitions were originated by the same
peptide. Table S7 reports the transitions detected in the MRM analyses
of the test samples with known composition. The method showed the
transitions associated to the target peptides leading to the unambiguous
identification of the specific protein and thus to the assessment of the
individual proteinaceous binder. Moreover, in the test sample E17 four
peptides from collagen proteins and in the test sample G9 three pep-
tides from vitellogenin-2 could be clearly detected indicating the pre-
sence of contaminating material besides the expected binders, con-
tamination possibly occurring during the preparation of the painting
tests themselves.
3.4. Analysis of historical samples
The developed MRM approach was thus applied to a sample from
the paintings of the Monumental Cemetery of Pisa that had previously
been examined by a standard proteomic approach [48]. Several tran-
sitions that were ascribed to peptides from caseins and collagens could
be detected, thus confirming the occurrence of milk and animal glue
(Table S8). Moreover, most interestingly, MRM transitions of peptides
from ovalbumin, ovotransferrin and vitellogenin 2 could also be clearly
observed indicating the presence of egg within the sample (Fig. 4). It
should be underlined that no egg proteins were identified in previous
experiments carried out by the standard LC-MSMS procedure [48], thus
confirming the higher sensitivity achieved with the MRM assay. Fur-
thermore, when the MRM analysis was carried out on a second sample
from the Monumental Cemetery painting that had been previously
submitted to a deglycosylating pretreatment with N-Glycosidase F, an
even higher number of peptides from egg proteins were detected (Table
S8), accordingly with the observation that such a step improves ac-
cessibility to protease of the polypeptidic chain of egg proteins [26]. It
is worth mentioning, however, that even after the deglycosylation step,
no egg proteins were detected in untargeted LC-MSMS analysis carried
out on another aliquot of the same sample, possibly because of the
overwhelming presence of milk and animal glue proteins. The presence
of egg in these samples is not surprising, as it has been previously
shown, by means of GC/MS based approaches, that egg was often
present in samples collected from the Monumental Cemetery paintings,
as it was used as paint binder in other selected areas of the mural
paintings [52–54].
Paint samples from the polychromies of the giant Buddha statues
from the Baymian valley in Afghanistan that had already been analyzed
by standard LC-MSMS procedure [47] were also subject to the devel-
oped MRM assay. The detection of several mass transitions associated to
the specific peptides from caseins confirmed the presence of milk in the
binder, as already assessed by previous analyses [47] (Table S8). The
greatly improved performances of MRM procedure were demonstrated
by the analysis of some samples from the Buddha statues for which
untargeted LC-MSMS analysis provided no results. Fig. S3 shows the
MRM analysis of the fragments from the Western Buddha 22-1 [47]
clearly displaying the occurrence of several transitions associated to
two peptides from bovine alpha S1 and one from alpha S2 caseins, thus
confirming the presence of milk also in this sample. Similarly, the MRM
approach was able to detect and identify the binder in other three
Buddha samples that were negative in the standard LC-MSMS analyses
[47] (Table S8). Moreover, since we have previously demonstrated that
a mixture of bovine and ovine milks was used as binder in the dec-
oration of the Buddha statues [47], we took advantage of this ob-
servation to test the capability of our MRM methods to distinguish
highly similar protein sequences even in ancient samples, and even-
tually provide a tool that could be useful in the challenging problem of
identifying organism species. We therefore introduced in the MRM
method the transitions for two peptides from alpha S1 and alpha S2
casein from Capra hircus, that are homologous to two peptides in the
corresponding alpha S1 and alpha S2 casein from Bos taurus (Table S2).
The concomitant detection of the peptides from ovine and bovine
caseins in the MRM analyses confirmed that a mixture of bovine and
ovine milks was used as binder [47]. Accordingly, the MRM chroma-
tograms of the sample 214-2 [47] (Fig. 5) clearly displayed the specific
Fig. 3. Test specimen MRM analysis. MRM TIC chromatograms for the best four
transitions (634.35 > 1104.64, 634.35 > 991.56, 634.35 > 934.53,
634.35 > 771.47) related to 106YLGYLEQLLR115 peptide belonging to alpha S1
casein from Bos taurus. The perfect co-elution of the monitored transitions for
the selected peptide, at 18.6 confirmed the presence of milk in the analyzed
sample and the high selectivity and specificity of the developed method.
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mass transitions for the FFVAPFPEVFGK (Fig. 5A) and FVVAPFPEVFR
(Fig. 5B) peptides from bovine and ovine caseins, respectively.
These results clearly demonstrated that the targeted proteomic ap-
proach was able to identify proteins that were not detected with a
standard proteomics approach, that is capable of identifying proteins in
complex mixtures, and distinguish homologous peptides.
4. Discussion
The field of diagnosis in cultural heritage is continuously in search
for more and more reliable and alternative methods to identify the
materials used in a work of art while preserving as much as possible the
artistic object itself [55]. While fully noninvasive techniques will al-
ways be preferred as first choice, the development of very sensitive
methodologies will greatly reduce the impact of minimal invasive
procedures. Identification of proteinaceous binders in paintings was
successfully addressed by proteomics approaches providing informative
results on precious and irreplaceable samples ([2] and references
therein). This paper reports an evolution of this process turning from an
untargeted to a targeted proteomics strategy in which only specific
peptides representative of selected, relevant proteins, are searched to
discriminate between the three most common typologies of protein-
based binders in paintings.
Once defined the list of specific proteins most commonly detected in
each binder-milk, animal glue and egg based- the selection of diagnostic
peptides and the corresponding set of suitable mass transitions needed
to develop the MRM method constitutes the critical step. Predictive
models based on experimental data [56] have proven to be extremely
powerful in the selection of proteotypic peptides in targeted pro-
teomics, and several software packages exist that facilitate this step of
the assay development [57]. However, among the factors that could
affect the effective detection of peptides in this specific application, the
peculiar, solid and aged nature of the samples was considered, and a
more empirical approach to the selection of target peptides was herein
used.
As a large cohort of painting samples had already been examined
during the years in our laboratory by standard LC-MSMS analyses, we
screened the results in search for peptides most frequently detected in
these untargeted experiments for the three classes of protein-based
binders. Discriminative peptides of caseins and collagen that could be
considered as representatives of milk and animal glue binders were
easily selected. Moreover, an appropriate selection of casein peptides
was also used as test to distinguish the animal origin of milk, a specific
request in case of milk binders.
Selection of peptides representative of egg binders was more chal-
lenging for a number of reasons. First, as stated above, artists used ei-
ther albumen or yolk or the whole egg and often yolk was contaminated
by albumen. Moreover, it has been demonstrated that the extensive
glycosylation of egg proteins results in a poor production of suitable
peptides and that the confidence of identification can be improved by
the introduction of a deglycosylation step before trypsin digestion [26].
The molecular signature of egg binders was eventually defined by se-
lecting ovoalbumin and ovotransferrin as generic representative of the
presence of egg and vitellogenin 1 and vitellogenin 2 as specific mar-
kers of yolk binders.
The method was validated by analyzing model samples of known
composition and was then used to characterize samples from ancient
paintings and polychromies: the Monumental Cemetery in Pisa and the
Giant Buddha statues in the Baymian valley in Afghanistan. These
samples had already been analyzed by standard LC-MSMS procedure,
and MRM analyses confirmed previous positive results, and provided
successful identification in cases where untargeted procedures had
failed, demonstrating the higher sensitivity and selectivity of this tar-
geted approach. As an example, the overabundant milk and animal glue
used in the restorations of the mural paintings of the Monumental
Cemetery in Pisa prevented the identification of egg in standard LC-
MSMS analyses [48], while the MRM analysis unambiguously revealed
the presence of egg-derived peptides, possibly revealing the original
binder, covered then by overabundant layers of materials used in re-
storations.
The higher sensitivity of the MRM procedure also allowed the
identification of traces of milk proteins in some of the samples from the
Giant Buddha statues for which the untargeted approach had failed
[47]. Moreover, the specific case of the Giant Buddha statues was the
test case to investigate the potentiality of MRM to distinguish highly
similar protein sequences even in the case of ancient samples. This
positive result can be considered as the preliminary test paving the way
to the exploitation of the MRM assay in the challenging field of species
identification. The biological origin of proteins by identification of
species-specific peptides is an extremely challenging problem in several
fields of the cultural heritage analysis [6,17,19,20,47] that could thus
be faced by MRM approach, as we demonstrated by the specific case of
distinguishing the animal origin of the milk.
In conclusion, we demonstrated that a targeted, MRM analysis can
be successful in samples such as those from ancient objects. Searching
for specific signals in a multitude of untargeted signals might be like
looking for a needle in a haystack with the naked eye, while mass
spectrometer working in a targeted mode could be considered as the use
of a magnet in this search.
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